/*! For license information please see main.2d932019.js.LICENSE.txt */
!function(){var e={76:function(e,t,n){"use strict";n.d(t,{Z:function(){return ae}});var r=function(){function e(e){var t=this;this._insertTag=function(e){var n;n=0===t.tags.length?t.insertionPoint?t.insertionPoint.nextSibling:t.prepend?t.container.firstChild:t.before:t.tags[t.tags.length-1].nextSibling,t.container.insertBefore(e,n),t.tags.push(e)},this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.prepend=e.prepend,this.insertionPoint=e.insertionPoint,this.before=null}var t=e.prototype;return t.hydrate=function(e){e.forEach(this._insertTag)},t.insert=function(e){this.ctr%(this.isSpeedy?65e3:1)===0&&this._insertTag(function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t.setAttribute("data-s",""),t}(this));var t=this.tags[this.tags.length-1];if(this.isSpeedy){var n=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(t);try{n.insertRule(e,n.cssRules.length)}catch(r){0}}else t.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode&&e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}(),a=Math.abs,o=String.fromCharCode,i=Object.assign;function s(e){return e.trim()}function l(e,t,n){return e.replace(t,n)}function u(e,t){return e.indexOf(t)}function c(e,t){return 0|e.charCodeAt(t)}function d(e,t,n){return e.slice(t,n)}function p(e){return e.length}function f(e){return e.length}function m(e,t){return t.push(e),e}var h=1,v=1,y=0,b=0,g=0,_="";function w(e,t,n,r,a,o,i){return{value:e,root:t,parent:n,type:r,props:a,children:o,line:h,column:v,length:i,return:""}}function S(e,t){return i(w("",null,null,"",null,null,0),e,{length:-e.length},t)}function k(){return g=b>0?c(_,--b):0,v--,10===g&&(v=1,h--),g}function C(){return g=b<y?c(_,b++):0,v++,10===g&&(v=1,h++),g}function T(){return c(_,b)}function x(){return b}function P(e,t){return d(_,e,t)}function E(e){switch(e){case 0:case 9:case 10:case 13:case 32:return 5;case 33:case 43:case 44:case 47:case 62:case 64:case 126:case 59:case 123:case 125:return 4;case 58:return 3;case 34:case 39:case 40:case 91:return 2;case 41:case 93:return 1}return 0}function A(e){return h=v=1,y=p(_=e),b=0,[]}function N(e){return _="",e}function F(e){return s(P(b-1,D(91===e?e+2:40===e?e+1:e)))}function O(e){for(;(g=T())&&g<33;)C();return E(e)>2||E(g)>3?"":" "}function R(e,t){for(;--t&&C()&&!(g<48||g>102||g>57&&g<65||g>70&&g<97););return P(e,x()+(t<6&&32==T()&&32==C()))}function D(e){for(;C();)switch(g){case e:return b;case 34:case 39:34!==e&&39!==e&&D(g);break;case 40:41===e&&D(e);break;case 92:C()}return b}function M(e,t){for(;C()&&e+g!==57&&(e+g!==84||47!==T()););return"/*"+P(t,b-1)+"*"+o(47===e?e:C())}function I(e){for(;!E(T());)C();return P(e,b)}var z="-ms-",L="-moz-",Z="-webkit-",j="comm",B="rule",W="decl",J="@keyframes";function V(e,t){for(var n="",r=f(e),a=0;a<r;a++)n+=t(e[a],a,e,t)||"";return n}function U(e,t,n,r){switch(e.type){case"@import":case W:return e.return=e.return||e.value;case j:return"";case J:return e.return=e.value+"{"+V(e.children,r)+"}";case B:e.value=e.props.join(",")}return p(n=V(e.children,r))?e.return=e.value+"{"+n+"}":""}function $(e,t){switch(function(e,t){return(((t<<2^c(e,0))<<2^c(e,1))<<2^c(e,2))<<2^c(e,3)}(e,t)){case 5103:return Z+"print-"+e+e;case 5737:case 4201:case 3177:case 3433:case 1641:case 4457:case 2921:case 5572:case 6356:case 5844:case 3191:case 6645:case 3005:case 6391:case 5879:case 5623:case 6135:case 4599:case 4855:case 4215:case 6389:case 5109:case 5365:case 5621:case 3829:return Z+e+e;case 5349:case 4246:case 4810:case 6968:case 2756:return Z+e+L+e+z+e+e;case 6828:case 4268:return Z+e+z+e+e;case 6165:return Z+e+z+"flex-"+e+e;case 5187:return Z+e+l(e,/(\w+).+(:[^]+)/,"-webkit-box-$1$2-ms-flex-$1$2")+e;case 5443:return Z+e+z+"flex-item-"+l(e,/flex-|-self/,"")+e;case 4675:return Z+e+z+"flex-line-pack"+l(e,/align-content|flex-|-self/,"")+e;case 5548:return Z+e+z+l(e,"shrink","negative")+e;case 5292:return Z+e+z+l(e,"basis","preferred-size")+e;case 6060:return Z+"box-"+l(e,"-grow","")+Z+e+z+l(e,"grow","positive")+e;case 4554:return Z+l(e,/([^-])(transform)/g,"$1-webkit-$2")+e;case 6187:return l(l(l(e,/(zoom-|grab)/,Z+"$1"),/(image-set)/,Z+"$1"),e,"")+e;case 5495:case 3959:return l(e,/(image-set\([^]*)/,Z+"$1$`$1");case 4968:return l(l(e,/(.+:)(flex-)?(.*)/,"-webkit-box-pack:$3-ms-flex-pack:$3"),/s.+-b[^;]+/,"justify")+Z+e+e;case 4095:case 3583:case 4068:case 2532:return l(e,/(.+)-inline(.+)/,Z+"$1$2")+e;case 8116:case 7059:case 5753:case 5535:case 5445:case 5701:case 4933:case 4677:case 5533:case 5789:case 5021:case 4765:if(p(e)-1-t>6)switch(c(e,t+1)){case 109:if(45!==c(e,t+4))break;case 102:return l(e,/(.+:)(.+)-([^]+)/,"$1-webkit-$2-$3$1"+L+(108==c(e,t+3)?"$3":"$2-$3"))+e;case 115:return~u(e,"stretch")?$(l(e,"stretch","fill-available"),t)+e:e}break;case 4949:if(115!==c(e,t+1))break;case 6444:switch(c(e,p(e)-3-(~u(e,"!important")&&10))){case 107:return l(e,":",":"+Z)+e;case 101:return l(e,/(.+:)([^;!]+)(;|!.+)?/,"$1"+Z+(45===c(e,14)?"inline-":"")+"box$3$1"+Z+"$2$3$1"+z+"$2box$3")+e}break;case 5936:switch(c(e,t+11)){case 114:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb")+e;case 108:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"tb-rl")+e;case 45:return Z+e+z+l(e,/[svh]\w+-[tblr]{2}/,"lr")+e}return Z+e+z+e+e}return e}function G(e){return N(H("",null,null,null,[""],e=A(e),0,[0],e))}function H(e,t,n,r,a,i,s,c,d){for(var f=0,h=0,v=s,y=0,b=0,g=0,_=1,w=1,S=1,P=0,E="",A=a,N=i,D=r,z=E;w;)switch(g=P,P=C()){case 40:if(108!=g&&58==z.charCodeAt(v-1)){-1!=u(z+=l(F(P),"&","&\f"),"&\f")&&(S=-1);break}case 34:case 39:case 91:z+=F(P);break;case 9:case 10:case 13:case 32:z+=O(g);break;case 92:z+=R(x()-1,7);continue;case 47:switch(T()){case 42:case 47:m(K(M(C(),x()),t,n),d);break;default:z+="/"}break;case 123*_:c[f++]=p(z)*S;case 125*_:case 59:case 0:switch(P){case 0:case 125:w=0;case 59+h:b>0&&p(z)-v&&m(b>32?Q(z+";",r,n,v-1):Q(l(z," ","")+";",r,n,v-2),d);break;case 59:z+=";";default:if(m(D=q(z,t,n,f,h,a,c,E,A=[],N=[],v),i),123===P)if(0===h)H(z,t,D,D,A,i,v,c,N);else switch(y){case 100:case 109:case 115:H(e,D,D,r&&m(q(e,D,D,0,0,a,c,E,a,A=[],v),N),a,N,v,c,r?A:N);break;default:H(z,D,D,D,[""],N,0,c,N)}}f=h=b=0,_=S=1,E=z="",v=s;break;case 58:v=1+p(z),b=g;default:if(_<1)if(123==P)--_;else if(125==P&&0==_++&&125==k())continue;switch(z+=o(P),P*_){case 38:S=h>0?1:(z+="\f",-1);break;case 44:c[f++]=(p(z)-1)*S,S=1;break;case 64:45===T()&&(z+=F(C())),y=T(),h=v=p(E=z+=I(x())),P++;break;case 45:45===g&&2==p(z)&&(_=0)}}return i}function q(e,t,n,r,o,i,u,c,p,m,h){for(var v=o-1,y=0===o?i:[""],b=f(y),g=0,_=0,S=0;g<r;++g)for(var k=0,C=d(e,v+1,v=a(_=u[g])),T=e;k<b;++k)(T=s(_>0?y[k]+" "+C:l(C,/&\f/g,y[k])))&&(p[S++]=T);return w(e,t,n,0===o?B:c,p,m,h)}function K(e,t,n){return w(e,t,n,j,o(g),d(e,2,-2),0)}function Q(e,t,n,r){return w(e,t,n,W,d(e,0,r),d(e,r+1,-1),r)}var Y=function(e,t,n){for(var r=0,a=0;r=a,a=T(),38===r&&12===a&&(t[n]=1),!E(a);)C();return P(e,b)},X=function(e,t){return N(function(e,t){var n=-1,r=44;do{switch(E(r)){case 0:38===r&&12===T()&&(t[n]=1),e[n]+=Y(b-1,t,n);break;case 2:e[n]+=F(r);break;case 4:if(44===r){e[++n]=58===T()?"&\f":"",t[n]=e[n].length;break}default:e[n]+=o(r)}}while(r=C());return e}(A(e),t))},ee=new WeakMap,te=function(e){if("rule"===e.type&&e.parent&&!(e.length<1)){for(var t=e.value,n=e.parent,r=e.column===n.column&&e.line===n.line;"rule"!==n.type;)if(!(n=n.parent))return;if((1!==e.props.length||58===t.charCodeAt(0)||ee.get(n))&&!r){ee.set(e,!0);for(var a=[],o=X(t,a),i=n.props,s=0,l=0;s<o.length;s++)for(var u=0;u<i.length;u++,l++)e.props[l]=a[s]?o[s].replace(/&\f/g,i[u]):i[u]+" "+o[s]}}},ne=function(e){if("decl"===e.type){var t=e.value;108===t.charCodeAt(0)&&98===t.charCodeAt(2)&&(e.return="",e.value="")}},re=[function(e,t,n,r){if(e.length>-1&&!e.return)switch(e.type){case W:e.return=$(e.value,e.length);break;case J:return V([S(e,{value:l(e.value,"@","@"+Z)})],r);case B:if(e.length)return function(e,t){return e.map(t).join("")}(e.props,(function(t){switch(function(e,t){return(e=t.exec(e))?e[0]:e}(t,/(::plac\w+|:read-\w+)/)){case":read-only":case":read-write":return V([S(e,{props:[l(t,/:(read-\w+)/,":-moz-$1")]})],r);case"::placeholder":return V([S(e,{props:[l(t,/:(plac\w+)/,":-webkit-input-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,":-moz-$1")]}),S(e,{props:[l(t,/:(plac\w+)/,z+"input-$1")]})],r)}return""}))}}],ae=function(e){var t=e.key;if("css"===t){var n=document.querySelectorAll("style[data-emotion]:not([data-s])");Array.prototype.forEach.call(n,(function(e){-1!==e.getAttribute("data-emotion").indexOf(" ")&&(document.head.appendChild(e),e.setAttribute("data-s",""))}))}var a=e.stylisPlugins||re;var o,i,s={},l=[];o=e.container||document.head,Array.prototype.forEach.call(document.querySelectorAll('style[data-emotion^="'+t+' "]'),(function(e){for(var t=e.getAttribute("data-emotion").split(" "),n=1;n<t.length;n++)s[t[n]]=!0;l.push(e)}));var u,c,d=[U,(c=function(e){u.insert(e)},function(e){e.root||(e=e.return)&&c(e)})],p=function(e){var t=f(e);return function(n,r,a,o){for(var i="",s=0;s<t;s++)i+=e[s](n,r,a,o)||"";return i}}([te,ne].concat(a,d));i=function(e,t,n,r){u=n,V(G(e?e+"{"+t.styles+"}":t.styles),p),r&&(m.inserted[t.name]=!0)};var m={key:t,sheet:new r({key:t,container:o,nonce:e.nonce,speedy:e.speedy,prepend:e.prepend,insertionPoint:e.insertionPoint}),nonce:e.nonce,inserted:s,registered:{},insert:i};return m.sheet.hydrate(l),m}},9797:function(e,t){"use strict";t.Z=function(e){var t=Object.create(null);return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}},9886:function(e,t,n){"use strict";n.d(t,{T:function(){return s},w:function(){return i}});var r=n(2791),a=n(76),o=(n(9140),n(2561),(0,r.createContext)("undefined"!==typeof HTMLElement?(0,a.Z)({key:"css"}):null));o.Provider;var i=function(e){return(0,r.forwardRef)((function(t,n){var a=(0,r.useContext)(o);return e(t,a,n)}))},s=(0,r.createContext)({})},9140:function(e,t,n){"use strict";n.d(t,{O:function(){return h}});var r=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},a={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1},o=n(9797),i=/[A-Z]|^ms/g,s=/_EMO_([^_]+?)_([^]*?)_EMO_/g,l=function(e){return 45===e.charCodeAt(1)},u=function(e){return null!=e&&"boolean"!==typeof e},c=(0,o.Z)((function(e){return l(e)?e:e.replace(i,"-$&").toLowerCase()})),d=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(s,(function(e,t,n){return f={name:t,styles:n,next:f},t}))}return 1===a[e]||l(e)||"number"!==typeof t||0===t?t:t+"px"};function p(e,t,n){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return f={name:n.name,styles:n.styles,next:f},n.name;if(void 0!==n.styles){var r=n.next;if(void 0!==r)for(;void 0!==r;)f={name:r.name,styles:r.styles,next:f},r=r.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=p(e,t,n[a])+";";else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":u(i)&&(r+=c(o)+":"+d(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=p(e,t,i);switch(o){case"animation":case"animationName":r+=c(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)u(i[l])&&(r+=c(o)+":"+d(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var a=f,o=n(e);return f=a,p(e,t,o)}}if(null==t)return n;var i=t[n];return void 0!==i?i:n}var f,m=/label:\s*([^\s;\n{]+)\s*(;|$)/g;var h=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var a=!0,o="";f=void 0;var i=e[0];null==i||void 0===i.raw?(a=!1,o+=p(n,t,i)):o+=i[0];for(var s=1;s<e.length;s++)o+=p(n,t,e[s]),a&&(o+=i[s]);m.lastIndex=0;for(var l,u="";null!==(l=m.exec(o));)u+="-"+l[1];return{name:r(o)+u,styles:o,next:f}}},2561:function(e,t,n){"use strict";var r;n.d(t,{L:function(){return i},j:function(){return s}});var a=n(2791),o=!!(r||(r=n.t(a,2))).useInsertionEffect&&(r||(r=n.t(a,2))).useInsertionEffect,i=o||function(e){return e()},s=o||a.useLayoutEffect},5438:function(e,t,n){"use strict";n.d(t,{My:function(){return o},fp:function(){return r},hC:function(){return a}});function r(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]+";"):r+=n+" "})),r}var a=function(e,t,n){var r=e.key+"-"+t.name;!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles)},o=function(e,t,n){a(e,t,n);var r=e.key+"-"+t.name;if(void 0===e.inserted[t.name]){var o=t;do{e.insert(t===o?"."+r:"",o,e.sheet,!0);o=o.next}while(void 0!==o)}}},2156:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M15.41 7.41 14 6l-6 6 6 6 1.41-1.41L10.83 12z"}),"NavigateBefore");t.Z=i},5129:function(e,t,n){"use strict";var r=n(4836);t.Z=void 0;var a=r(n(5649)),o=n(184),i=(0,a.default)((0,o.jsx)("path",{d:"M10 6 8.59 7.41 13.17 12l-4.58 4.59L10 18l6-6z"}),"NavigateNext");t.Z=i},5649:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),Object.defineProperty(t,"default",{enumerable:!0,get:function(){return r.createSvgIcon}});var r=n(3111)},4360:function(e,t,n){"use strict";n.d(t,{Z:function(){return Z}});var r=n(7462),a=n(3366),o=n(6189),i=n(2466),s=n(5080),l=n(4942);function u(e,t){var n;return(0,r.Z)({toolbar:(n={minHeight:56},(0,l.Z)(n,e.up("xs"),{"@media (orientation: landscape)":{minHeight:48}}),(0,l.Z)(n,e.up("sm"),{minHeight:64}),n)},t)}var c=n(2065),d={black:"#000",white:"#fff"},p={50:"#fafafa",100:"#f5f5f5",200:"#eeeeee",300:"#e0e0e0",400:"#bdbdbd",500:"#9e9e9e",600:"#757575",700:"#616161",800:"#424242",900:"#212121",A100:"#f5f5f5",A200:"#eeeeee",A400:"#bdbdbd",A700:"#616161"},f={50:"#f3e5f5",100:"#e1bee7",200:"#ce93d8",300:"#ba68c8",400:"#ab47bc",500:"#9c27b0",600:"#8e24aa",700:"#7b1fa2",800:"#6a1b9a",900:"#4a148c",A100:"#ea80fc",A200:"#e040fb",A400:"#d500f9",A700:"#aa00ff"},m={50:"#ffebee",100:"#ffcdd2",200:"#ef9a9a",300:"#e57373",400:"#ef5350",500:"#f44336",600:"#e53935",700:"#d32f2f",800:"#c62828",900:"#b71c1c",A100:"#ff8a80",A200:"#ff5252",A400:"#ff1744",A700:"#d50000"},h={50:"#fff3e0",100:"#ffe0b2",200:"#ffcc80",300:"#ffb74d",400:"#ffa726",500:"#ff9800",600:"#fb8c00",700:"#f57c00",800:"#ef6c00",900:"#e65100",A100:"#ffd180",A200:"#ffab40",A400:"#ff9100",A700:"#ff6d00"},v={50:"#e3f2fd",100:"#bbdefb",200:"#90caf9",300:"#64b5f6",400:"#42a5f5",500:"#2196f3",600:"#1e88e5",700:"#1976d2",800:"#1565c0",900:"#0d47a1",A100:"#82b1ff",A200:"#448aff",A400:"#2979ff",A700:"#2962ff"},y={50:"#e1f5fe",100:"#b3e5fc",200:"#81d4fa",300:"#4fc3f7",400:"#29b6f6",500:"#03a9f4",600:"#039be5",700:"#0288d1",800:"#0277bd",900:"#01579b",A100:"#80d8ff",A200:"#40c4ff",A400:"#00b0ff",A700:"#0091ea"},b={50:"#e8f5e9",100:"#c8e6c9",200:"#a5d6a7",300:"#81c784",400:"#66bb6a",500:"#4caf50",600:"#43a047",700:"#388e3c",800:"#2e7d32",900:"#1b5e20",A100:"#b9f6ca",A200:"#69f0ae",A400:"#00e676",A700:"#00c853"},g=["mode","contrastThreshold","tonalOffset"],_={text:{primary:"rgba(0, 0, 0, 0.87)",secondary:"rgba(0, 0, 0, 0.6)",disabled:"rgba(0, 0, 0, 0.38)"},divider:"rgba(0, 0, 0, 0.12)",background:{paper:d.white,default:d.white},action:{active:"rgba(0, 0, 0, 0.54)",hover:"rgba(0, 0, 0, 0.04)",hoverOpacity:.04,selected:"rgba(0, 0, 0, 0.08)",selectedOpacity:.08,disabled:"rgba(0, 0, 0, 0.26)",disabledBackground:"rgba(0, 0, 0, 0.12)",disabledOpacity:.38,focus:"rgba(0, 0, 0, 0.12)",focusOpacity:.12,activatedOpacity:.12}},w={text:{primary:d.white,secondary:"rgba(255, 255, 255, 0.7)",disabled:"rgba(255, 255, 255, 0.5)",icon:"rgba(255, 255, 255, 0.5)"},divider:"rgba(255, 255, 255, 0.12)",background:{paper:"#121212",default:"#121212"},action:{active:d.white,hover:"rgba(255, 255, 255, 0.08)",hoverOpacity:.08,selected:"rgba(255, 255, 255, 0.16)",selectedOpacity:.16,disabled:"rgba(255, 255, 255, 0.3)",disabledBackground:"rgba(255, 255, 255, 0.12)",disabledOpacity:.38,focus:"rgba(255, 255, 255, 0.12)",focusOpacity:.12,activatedOpacity:.24}};function S(e,t,n,r){var a=r.light||r,o=r.dark||1.5*r;e[t]||(e.hasOwnProperty(n)?e[t]=e[n]:"light"===t?e.light=(0,c.$n)(e.main,a):"dark"===t&&(e.dark=(0,c._j)(e.main,o)))}function k(e){var t=e.mode,n=void 0===t?"light":t,s=e.contrastThreshold,l=void 0===s?3:s,u=e.tonalOffset,k=void 0===u?.2:u,C=(0,a.Z)(e,g),T=e.primary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:v[200],light:v[50],dark:v[400]}:{main:v[700],light:v[400],dark:v[800]}}(n),x=e.secondary||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:f[200],light:f[50],dark:f[400]}:{main:f[500],light:f[300],dark:f[700]}}(n),P=e.error||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:m[500],light:m[300],dark:m[700]}:{main:m[700],light:m[400],dark:m[800]}}(n),E=e.info||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:y[400],light:y[300],dark:y[700]}:{main:y[700],light:y[500],dark:y[900]}}(n),A=e.success||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:b[400],light:b[300],dark:b[700]}:{main:b[800],light:b[500],dark:b[900]}}(n),N=e.warning||function(){return"dark"===(arguments.length>0&&void 0!==arguments[0]?arguments[0]:"light")?{main:h[400],light:h[300],dark:h[700]}:{main:"#ed6c02",light:h[500],dark:h[900]}}(n);function F(e){return(0,c.mi)(e,w.text.primary)>=l?w.text.primary:_.text.primary}var O=function(e){var t=e.color,n=e.name,a=e.mainShade,i=void 0===a?500:a,s=e.lightShade,l=void 0===s?300:s,u=e.darkShade,c=void 0===u?700:u;if(!(t=(0,r.Z)({},t)).main&&t[i]&&(t.main=t[i]),!t.hasOwnProperty("main"))throw new Error((0,o.Z)(11,n?" (".concat(n,")"):"",i));if("string"!==typeof t.main)throw new Error((0,o.Z)(12,n?" (".concat(n,")"):"",JSON.stringify(t.main)));return S(t,"light",l,k),S(t,"dark",c,k),t.contrastText||(t.contrastText=F(t.main)),t},R={dark:w,light:_};return(0,i.Z)((0,r.Z)({common:(0,r.Z)({},d),mode:n,primary:O({color:T,name:"primary"}),secondary:O({color:x,name:"secondary",mainShade:"A400",lightShade:"A200",darkShade:"A700"}),error:O({color:P,name:"error"}),warning:O({color:N,name:"warning"}),info:O({color:E,name:"info"}),success:O({color:A,name:"success"}),grey:p,contrastThreshold:l,getContrastText:F,augmentColor:O,tonalOffset:k},R[n]),C)}var C=["fontFamily","fontSize","fontWeightLight","fontWeightRegular","fontWeightMedium","fontWeightBold","htmlFontSize","allVariants","pxToRem"];var T={textTransform:"uppercase"},x='"Roboto", "Helvetica", "Arial", sans-serif';function P(e,t){var n="function"===typeof t?t(e):t,o=n.fontFamily,s=void 0===o?x:o,l=n.fontSize,u=void 0===l?14:l,c=n.fontWeightLight,d=void 0===c?300:c,p=n.fontWeightRegular,f=void 0===p?400:p,m=n.fontWeightMedium,h=void 0===m?500:m,v=n.fontWeightBold,y=void 0===v?700:v,b=n.htmlFontSize,g=void 0===b?16:b,_=n.allVariants,w=n.pxToRem,S=(0,a.Z)(n,C);var k=u/14,P=w||function(e){return"".concat(e/g*k,"rem")},E=function(e,t,n,a,o){return(0,r.Z)({fontFamily:s,fontWeight:e,fontSize:P(t),lineHeight:n},s===x?{letterSpacing:"".concat((i=a/t,Math.round(1e5*i)/1e5),"em")}:{},o,_);var i},A={h1:E(d,96,1.167,-1.5),h2:E(d,60,1.2,-.5),h3:E(f,48,1.167,0),h4:E(f,34,1.235,.25),h5:E(f,24,1.334,0),h6:E(h,20,1.6,.15),subtitle1:E(f,16,1.75,.15),subtitle2:E(h,14,1.57,.1),body1:E(f,16,1.5,.15),body2:E(f,14,1.43,.15),button:E(h,14,1.75,.4,T),caption:E(f,12,1.66,.4),overline:E(f,12,2.66,1,T)};return(0,i.Z)((0,r.Z)({htmlFontSize:g,pxToRem:P,fontFamily:s,fontSize:u,fontWeightLight:d,fontWeightRegular:f,fontWeightMedium:h,fontWeightBold:y},A),S,{clone:!1})}function E(){return["".concat(arguments.length<=0?void 0:arguments[0],"px ").concat(arguments.length<=1?void 0:arguments[1],"px ").concat(arguments.length<=2?void 0:arguments[2],"px ").concat(arguments.length<=3?void 0:arguments[3],"px rgba(0,0,0,").concat(.2,")"),"".concat(arguments.length<=4?void 0:arguments[4],"px ").concat(arguments.length<=5?void 0:arguments[5],"px ").concat(arguments.length<=6?void 0:arguments[6],"px ").concat(arguments.length<=7?void 0:arguments[7],"px rgba(0,0,0,").concat(.14,")"),"".concat(arguments.length<=8?void 0:arguments[8],"px ").concat(arguments.length<=9?void 0:arguments[9],"px ").concat(arguments.length<=10?void 0:arguments[10],"px ").concat(arguments.length<=11?void 0:arguments[11],"px rgba(0,0,0,").concat(.12,")")].join(",")}var A=["none",E(0,2,1,-1,0,1,1,0,0,1,3,0),E(0,3,1,-2,0,2,2,0,0,1,5,0),E(0,3,3,-2,0,3,4,0,0,1,8,0),E(0,2,4,-1,0,4,5,0,0,1,10,0),E(0,3,5,-1,0,5,8,0,0,1,14,0),E(0,3,5,-1,0,6,10,0,0,1,18,0),E(0,4,5,-2,0,7,10,1,0,2,16,1),E(0,5,5,-3,0,8,10,1,0,3,14,2),E(0,5,6,-3,0,9,12,1,0,3,16,2),E(0,6,6,-3,0,10,14,1,0,4,18,3),E(0,6,7,-4,0,11,15,1,0,4,20,3),E(0,7,8,-4,0,12,17,2,0,5,22,4),E(0,7,8,-4,0,13,19,2,0,5,24,4),E(0,7,9,-4,0,14,21,2,0,5,26,4),E(0,8,9,-5,0,15,22,2,0,6,28,5),E(0,8,10,-5,0,16,24,2,0,6,30,5),E(0,8,11,-5,0,17,26,2,0,6,32,5),E(0,9,11,-5,0,18,28,2,0,7,34,6),E(0,9,12,-6,0,19,29,2,0,7,36,6),E(0,10,13,-6,0,20,31,3,0,8,38,7),E(0,10,13,-6,0,21,33,3,0,8,40,7),E(0,10,14,-6,0,22,35,3,0,8,42,7),E(0,11,14,-7,0,23,36,3,0,9,44,8),E(0,11,15,-7,0,24,38,3,0,9,46,8)],N=["duration","easing","delay"],F={easeInOut:"cubic-bezier(0.4, 0, 0.2, 1)",easeOut:"cubic-bezier(0.0, 0, 0.2, 1)",easeIn:"cubic-bezier(0.4, 0, 1, 1)",sharp:"cubic-bezier(0.4, 0, 0.6, 1)"},O={shortest:150,shorter:200,short:250,standard:300,complex:375,enteringScreen:225,leavingScreen:195};function R(e){return"".concat(Math.round(e),"ms")}function D(e){if(!e)return 0;var t=e/36;return Math.round(10*(4+15*Math.pow(t,.25)+t/5))}function M(e){var t=(0,r.Z)({},F,e.easing),n=(0,r.Z)({},O,e.duration);return(0,r.Z)({getAutoHeightDuration:D,create:function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:["all"],r=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},o=r.duration,i=void 0===o?n.standard:o,s=r.easing,l=void 0===s?t.easeInOut:s,u=r.delay,c=void 0===u?0:u;(0,a.Z)(r,N);return(Array.isArray(e)?e:[e]).map((function(e){return"".concat(e," ").concat("string"===typeof i?i:R(i)," ").concat(l," ").concat("string"===typeof c?c:R(c))})).join(",")}},e,{easing:t,duration:n})}var I={mobileStepper:1e3,fab:1050,speedDial:1050,appBar:1100,drawer:1200,modal:1300,snackbar:1400,tooltip:1500},z=["breakpoints","mixins","spacing","palette","transitions","typography","shape"];function L(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.mixins,n=void 0===t?{}:t,l=e.palette,c=void 0===l?{}:l,d=e.transitions,p=void 0===d?{}:d,f=e.typography,m=void 0===f?{}:f,h=(0,a.Z)(e,z);if(e.vars)throw new Error((0,o.Z)(18));var v=k(c),y=(0,s.Z)(e),b=(0,i.Z)(y,{mixins:u(y.breakpoints,n),palette:v,shadows:A.slice(),typography:P(v,m),transitions:M(p),zIndex:(0,r.Z)({},I)});b=(0,i.Z)(b,h);for(var g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,i.Z)(e,t)}),b)}var Z=L},4205:function(e,t,n){"use strict";var r=(0,n(4360).Z)();t.Z=r},277:function(e,t,n){"use strict";var r=n(4046),a=n(4205),o=(0,r.ZP)({defaultTheme:a.Z,rootShouldForwardProp:function(e){return(0,r.x9)(e)&&"classes"!==e}});t.ZP=o},5513:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(8691),a=n(4205);function o(e){var t=e.props,n=e.name;return(0,r.Z)({props:t,name:n,defaultTheme:a.Z})}},9853:function(e,t,n){"use strict";var r=n(7312);t.Z=r.Z},3111:function(e,t,n){"use strict";n.r(t),n.d(t,{capitalize:function(){return a.Z},createChainedFunction:function(){return o},createSvgIcon:function(){return w},debounce:function(){return S},deprecatedPropType:function(){return k},isMuiElement:function(){return C},ownerDocument:function(){return x},ownerWindow:function(){return P},requirePropFactory:function(){return E},setRef:function(){return A},unstable_ClassNameGenerator:function(){return j},unstable_useEnhancedEffect:function(){return N},unstable_useId:function(){return D},unsupportedProp:function(){return M},useControlled:function(){return I},useEventCallback:function(){return z.Z},useForkRef:function(){return L.Z},useIsFocusVisible:function(){return Z.Z}});var r=n(5902),a=n(9853);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return t.reduce((function(e,t){return null==t?e:function(){for(var n=arguments.length,r=new Array(n),a=0;a<n;a++)r[a]=arguments[a];e.apply(this,r),t.apply(this,r)}}),(function(){}))},i=n(7462),s=n(2791),l=n.t(s,2),u=n(3366),c=n(8182),d=n(4419),p=n(5513),f=n(277),m=n(1217);function h(e){return(0,m.Z)("MuiSvgIcon",e)}(0,n(5878).Z)("MuiSvgIcon",["root","colorPrimary","colorSecondary","colorAction","colorError","colorDisabled","fontSizeInherit","fontSizeSmall","fontSizeMedium","fontSizeLarge"]);var v=n(184),y=["children","className","color","component","fontSize","htmlColor","inheritViewBox","titleAccess","viewBox"],b=(0,f.ZP)("svg",{name:"MuiSvgIcon",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"inherit"!==n.color&&t["color".concat((0,a.Z)(n.color))],t["fontSize".concat((0,a.Z)(n.fontSize))]]}})((function(e){var t,n,r,a,o,i,s,l,u,c,d,p,f,m,h,v,y,b=e.theme,g=e.ownerState;return{userSelect:"none",width:"1em",height:"1em",display:"inline-block",fill:"currentColor",flexShrink:0,transition:null==(t=b.transitions)||null==(n=t.create)?void 0:n.call(t,"fill",{duration:null==(r=b.transitions)||null==(a=r.duration)?void 0:a.shorter}),fontSize:{inherit:"inherit",small:(null==(o=b.typography)||null==(i=o.pxToRem)?void 0:i.call(o,20))||"1.25rem",medium:(null==(s=b.typography)||null==(l=s.pxToRem)?void 0:l.call(s,24))||"1.5rem",large:(null==(u=b.typography)||null==(c=u.pxToRem)?void 0:c.call(u,35))||"2.1875rem"}[g.fontSize],color:null!=(d=null==(p=(b.vars||b).palette)||null==(f=p[g.color])?void 0:f.main)?d:{action:null==(m=(b.vars||b).palette)||null==(h=m.action)?void 0:h.active,disabled:null==(v=(b.vars||b).palette)||null==(y=v.action)?void 0:y.disabled,inherit:void 0}[g.color]}})),g=s.forwardRef((function(e,t){var n=(0,p.Z)({props:e,name:"MuiSvgIcon"}),r=n.children,o=n.className,s=n.color,l=void 0===s?"inherit":s,f=n.component,m=void 0===f?"svg":f,g=n.fontSize,_=void 0===g?"medium":g,w=n.htmlColor,S=n.inheritViewBox,k=void 0!==S&&S,C=n.titleAccess,T=n.viewBox,x=void 0===T?"0 0 24 24":T,P=(0,u.Z)(n,y),E=(0,i.Z)({},n,{color:l,component:m,fontSize:_,instanceFontSize:e.fontSize,inheritViewBox:k,viewBox:x}),A={};k||(A.viewBox=x);var N=function(e){var t=e.color,n=e.fontSize,r=e.classes,o={root:["root","inherit"!==t&&"color".concat((0,a.Z)(t)),"fontSize".concat((0,a.Z)(n))]};return(0,d.Z)(o,h,r)}(E);return(0,v.jsxs)(b,(0,i.Z)({as:m,className:(0,c.Z)(N.root,o),focusable:"false",color:w,"aria-hidden":!C||void 0,role:C?"img":void 0,ref:t},A,P,{ownerState:E,children:[r,C?(0,v.jsx)("title",{children:C}):null]}))}));g.muiName="SvgIcon";var _=g;function w(e,t){var n=function(n,r){return(0,v.jsx)(_,(0,i.Z)({"data-testid":"".concat(t,"Icon"),ref:r},n,{children:e}))};return n.muiName=_.muiName,s.memo(s.forwardRef(n))}var S=function(e){var t,n=arguments.length>1&&void 0!==arguments[1]?arguments[1]:166;function r(){for(var r=this,a=arguments.length,o=new Array(a),i=0;i<a;i++)o[i]=arguments[i];var s=function(){e.apply(r,o)};clearTimeout(t),t=setTimeout(s,n)}return r.clear=function(){clearTimeout(t)},r};var k=function(e,t){return function(){return null}};var C=function(e,t){return s.isValidElement(e)&&-1!==t.indexOf(e.type.muiName)};function T(e){return e&&e.ownerDocument||document}var x=T;var P=function(e){return T(e).defaultView||window};var E=function(e,t){return function(){return null}},A=n(2971).Z,N=n(5721).Z,F=n(885),O=0;var R=l.useId;var D=function(e){if(void 0!==R){var t=R();return null!=e?e:t}return function(e){var t=s.useState(e),n=(0,F.Z)(t,2),r=n[0],a=n[1],o=e||r;return s.useEffect((function(){null==r&&a("mui-".concat(O+=1))}),[r]),o}(e)};var M=function(e,t,n,r,a){return null};var I=function(e){var t=e.controlled,n=e.default,r=(e.name,e.state,s.useRef(void 0!==t).current),a=s.useState(n),o=(0,F.Z)(a,2),i=o[0],l=o[1];return[r?t:i,s.useCallback((function(e){r||l(e)}),[])]},z=n(6702),L=n(792),Z=n(2763),j={configure:function(e){console.warn(["MUI: `ClassNameGenerator` import from `@mui/material/utils` is outdated and might cause unexpected issues.","","You should use `import { unstable_ClassNameGenerator } from '@mui/material/className'` instead","","The detail of the issue: https://github.com/mui/material-ui/issues/30011#issuecomment-1024993401","","The updated documentation: https://mui.com/guides/classname-generator/"].join("\n")),r.Z.configure(e)}}},6702:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(5721);var o=function(e){var t=r.useRef(e);return(0,a.Z)((function(){t.current=e})),r.useCallback((function(){return t.current.apply(void 0,arguments)}),[])}},792:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(2791),a=n(2971);var o=function(e,t){return r.useMemo((function(){return null==e&&null==t?null:function(n){(0,a.Z)(e,n),(0,a.Z)(t,n)}}),[e,t])}},2763:function(e,t,n){"use strict";n.d(t,{Z:function(){return p}});var r,a=n(2791),o=!0,i=!1,s={text:!0,search:!0,url:!0,tel:!0,email:!0,password:!0,number:!0,date:!0,month:!0,week:!0,time:!0,datetime:!0,"datetime-local":!0};function l(e){e.metaKey||e.altKey||e.ctrlKey||(o=!0)}function u(){o=!1}function c(){"hidden"===this.visibilityState&&i&&(o=!0)}function d(e){var t=e.target;try{return t.matches(":focus-visible")}catch(n){}return o||function(e){var t=e.type,n=e.tagName;return!("INPUT"!==n||!s[t]||e.readOnly)||"TEXTAREA"===n&&!e.readOnly||!!e.isContentEditable}(t)}var p=function(){var e=a.useCallback((function(e){var t;null!=e&&((t=e.ownerDocument).addEventListener("keydown",l,!0),t.addEventListener("mousedown",u,!0),t.addEventListener("pointerdown",u,!0),t.addEventListener("touchstart",u,!0),t.addEventListener("visibilitychange",c,!0))}),[]),t=a.useRef(!1);return{isFocusVisibleRef:t,onFocus:function(e){return!!d(e)&&(t.current=!0,!0)},onBlur:function(){return!!t.current&&(i=!0,window.clearTimeout(r),r=window.setTimeout((function(){i=!1}),100),t.current=!1,!0)},ref:e}}},2421:function(e,t,n){"use strict";n.d(t,{ZP:function(){return _},Co:function(){return w}});var r=n(2791),a=n(7462),o=n(9797),i=/^((children|dangerouslySetInnerHTML|key|ref|autoFocus|defaultValue|defaultChecked|innerHTML|suppressContentEditableWarning|suppressHydrationWarning|valueLink|abbr|accept|acceptCharset|accessKey|action|allow|allowUserMedia|allowPaymentRequest|allowFullScreen|allowTransparency|alt|async|autoComplete|autoPlay|capture|cellPadding|cellSpacing|challenge|charSet|checked|cite|classID|className|cols|colSpan|content|contentEditable|contextMenu|controls|controlsList|coords|crossOrigin|data|dateTime|decoding|default|defer|dir|disabled|disablePictureInPicture|download|draggable|encType|enterKeyHint|form|formAction|formEncType|formMethod|formNoValidate|formTarget|frameBorder|headers|height|hidden|high|href|hrefLang|htmlFor|httpEquiv|id|inputMode|integrity|is|keyParams|keyType|kind|label|lang|list|loading|loop|low|marginHeight|marginWidth|max|maxLength|media|mediaGroup|method|min|minLength|multiple|muted|name|nonce|noValidate|open|optimum|pattern|placeholder|playsInline|poster|preload|profile|radioGroup|readOnly|referrerPolicy|rel|required|reversed|role|rows|rowSpan|sandbox|scope|scoped|scrolling|seamless|selected|shape|size|sizes|slot|span|spellCheck|src|srcDoc|srcLang|srcSet|start|step|style|summary|tabIndex|target|title|translate|type|useMap|value|width|wmode|wrap|about|datatype|inlist|prefix|property|resource|typeof|vocab|autoCapitalize|autoCorrect|autoSave|color|incremental|fallback|inert|itemProp|itemScope|itemType|itemID|itemRef|on|option|results|security|unselectable|accentHeight|accumulate|additive|alignmentBaseline|allowReorder|alphabetic|amplitude|arabicForm|ascent|attributeName|attributeType|autoReverse|azimuth|baseFrequency|baselineShift|baseProfile|bbox|begin|bias|by|calcMode|capHeight|clip|clipPathUnits|clipPath|clipRule|colorInterpolation|colorInterpolationFilters|colorProfile|colorRendering|contentScriptType|contentStyleType|cursor|cx|cy|d|decelerate|descent|diffuseConstant|direction|display|divisor|dominantBaseline|dur|dx|dy|edgeMode|elevation|enableBackground|end|exponent|externalResourcesRequired|fill|fillOpacity|fillRule|filter|filterRes|filterUnits|floodColor|floodOpacity|focusable|fontFamily|fontSize|fontSizeAdjust|fontStretch|fontStyle|fontVariant|fontWeight|format|from|fr|fx|fy|g1|g2|glyphName|glyphOrientationHorizontal|glyphOrientationVertical|glyphRef|gradientTransform|gradientUnits|hanging|horizAdvX|horizOriginX|ideographic|imageRendering|in|in2|intercept|k|k1|k2|k3|k4|kernelMatrix|kernelUnitLength|kerning|keyPoints|keySplines|keyTimes|lengthAdjust|letterSpacing|lightingColor|limitingConeAngle|local|markerEnd|markerMid|markerStart|markerHeight|markerUnits|markerWidth|mask|maskContentUnits|maskUnits|mathematical|mode|numOctaves|offset|opacity|operator|order|orient|orientation|origin|overflow|overlinePosition|overlineThickness|panose1|paintOrder|pathLength|patternContentUnits|patternTransform|patternUnits|pointerEvents|points|pointsAtX|pointsAtY|pointsAtZ|preserveAlpha|preserveAspectRatio|primitiveUnits|r|radius|refX|refY|renderingIntent|repeatCount|repeatDur|requiredExtensions|requiredFeatures|restart|result|rotate|rx|ry|scale|seed|shapeRendering|slope|spacing|specularConstant|specularExponent|speed|spreadMethod|startOffset|stdDeviation|stemh|stemv|stitchTiles|stopColor|stopOpacity|strikethroughPosition|strikethroughThickness|string|stroke|strokeDasharray|strokeDashoffset|strokeLinecap|strokeLinejoin|strokeMiterlimit|strokeOpacity|strokeWidth|surfaceScale|systemLanguage|tableValues|targetX|targetY|textAnchor|textDecoration|textRendering|textLength|to|transform|u1|u2|underlinePosition|underlineThickness|unicode|unicodeBidi|unicodeRange|unitsPerEm|vAlphabetic|vHanging|vIdeographic|vMathematical|values|vectorEffect|version|vertAdvY|vertOriginX|vertOriginY|viewBox|viewTarget|visibility|widths|wordSpacing|writingMode|x|xHeight|x1|x2|xChannelSelector|xlinkActuate|xlinkArcrole|xlinkHref|xlinkRole|xlinkShow|xlinkTitle|xlinkType|xmlBase|xmlns|xmlnsXlink|xmlLang|xmlSpace|y|y1|y2|yChannelSelector|z|zoomAndPan|for|class|autofocus)|(([Dd][Aa][Tt][Aa]|[Aa][Rr][Ii][Aa]|x)-.*))$/,s=(0,o.Z)((function(e){return i.test(e)||111===e.charCodeAt(0)&&110===e.charCodeAt(1)&&e.charCodeAt(2)<91})),l=n(9886),u=n(5438),c=n(9140),d=n(2561),p=s,f=function(e){return"theme"!==e},m=function(e){return"string"===typeof e&&e.charCodeAt(0)>96?p:f},h=function(e,t,n){var r;if(t){var a=t.shouldForwardProp;r=e.__emotion_forwardProp&&a?function(t){return e.__emotion_forwardProp(t)&&a(t)}:a}return"function"!==typeof r&&n&&(r=e.__emotion_forwardProp),r},v=function(e){var t=e.cache,n=e.serialized,r=e.isStringTag;(0,u.hC)(t,n,r);(0,d.L)((function(){return(0,u.My)(t,n,r)}));return null},y=function e(t,n){var o,i,s=t.__emotion_real===t,d=s&&t.__emotion_base||t;void 0!==n&&(o=n.label,i=n.target);var p=h(t,n,s),f=p||m(d),y=!f("as");return function(){var b=arguments,g=s&&void 0!==t.__emotion_styles?t.__emotion_styles.slice(0):[];if(void 0!==o&&g.push("label:"+o+";"),null==b[0]||void 0===b[0].raw)g.push.apply(g,b);else{0,g.push(b[0][0]);for(var _=b.length,w=1;w<_;w++)g.push(b[w],b[0][w])}var S=(0,l.w)((function(e,t,n){var a=y&&e.as||d,o="",s=[],h=e;if(null==e.theme){for(var b in h={},e)h[b]=e[b];h.theme=(0,r.useContext)(l.T)}"string"===typeof e.className?o=(0,u.fp)(t.registered,s,e.className):null!=e.className&&(o=e.className+" ");var _=(0,c.O)(g.concat(s),t.registered,h);o+=t.key+"-"+_.name,void 0!==i&&(o+=" "+i);var w=y&&void 0===p?m(a):f,S={};for(var k in e)y&&"as"===k||w(k)&&(S[k]=e[k]);return S.className=o,S.ref=n,(0,r.createElement)(r.Fragment,null,(0,r.createElement)(v,{cache:t,serialized:_,isStringTag:"string"===typeof a}),(0,r.createElement)(a,S))}));return S.displayName=void 0!==o?o:"Styled("+("string"===typeof d?d:d.displayName||d.name||"Component")+")",S.defaultProps=t.defaultProps,S.__emotion_real=S,S.__emotion_base=d,S.__emotion_styles=g,S.__emotion_forwardProp=p,Object.defineProperty(S,"toString",{value:function(){return"."+i}}),S.withComponent=function(t,r){return e(t,(0,a.Z)({},n,r,{shouldForwardProp:h(S,r,!0)})).apply(void 0,g)},S}},b=y.bind();["a","abbr","address","area","article","aside","audio","b","base","bdi","bdo","big","blockquote","body","br","button","canvas","caption","cite","code","col","colgroup","data","datalist","dd","del","details","dfn","dialog","div","dl","dt","em","embed","fieldset","figcaption","figure","footer","form","h1","h2","h3","h4","h5","h6","head","header","hgroup","hr","html","i","iframe","img","input","ins","kbd","keygen","label","legend","li","link","main","map","mark","marquee","menu","menuitem","meta","meter","nav","noscript","object","ol","optgroup","option","output","p","param","picture","pre","progress","q","rp","rt","ruby","s","samp","script","section","select","small","source","span","strong","style","sub","summary","sup","table","tbody","td","textarea","tfoot","th","thead","time","title","tr","track","u","ul","var","video","wbr","circle","clipPath","defs","ellipse","foreignObject","g","image","line","linearGradient","mask","path","pattern","polygon","polyline","radialGradient","rect","stop","svg","text","tspan"].forEach((function(e){b[e]=b(e)}));var g=b;function _(e,t){return g(e,t)}var w=function(e,t){Array.isArray(e.__emotion_styles)&&(e.__emotion_styles=t(e.__emotion_styles))}},1184:function(e,t,n){"use strict";n.d(t,{L7:function(){return l},P$:function(){return c},VO:function(){return a},W8:function(){return s},dt:function(){return u},k9:function(){return i}});var r=n(2466),a={xs:0,sm:600,md:900,lg:1200,xl:1536},o={keys:["xs","sm","md","lg","xl"],up:function(e){return"@media (min-width:".concat(a[e],"px)")}};function i(e,t,n){var r=e.theme||{};if(Array.isArray(t)){var i=r.breakpoints||o;return t.reduce((function(e,r,a){return e[i.up(i.keys[a])]=n(t[a]),e}),{})}if("object"===typeof t){var s=r.breakpoints||o;return Object.keys(t).reduce((function(e,r){if(-1!==Object.keys(s.values||a).indexOf(r)){e[s.up(r)]=n(t[r],r)}else{var o=r;e[o]=t[o]}return e}),{})}return n(t)}function s(){var e,t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=null==(e=t.keys)?void 0:e.reduce((function(e,n){return e[t.up(n)]={},e}),{});return n||{}}function l(e,t){return e.reduce((function(e,t){var n=e[t];return(!n||0===Object.keys(n).length)&&delete e[t],e}),t)}function u(e){for(var t=s(e),n=arguments.length,a=new Array(n>1?n-1:0),o=1;o<n;o++)a[o-1]=arguments[o];var i=[t].concat(a).reduce((function(e,t){return(0,r.Z)(e,t)}),{});return l(Object.keys(t),i)}function c(e){var t,n=e.values,r=e.breakpoints,a=e.base||function(e,t){if("object"!==typeof e)return{};var n={},r=Object.keys(t);return Array.isArray(e)?r.forEach((function(t,r){r<e.length&&(n[t]=!0)})):r.forEach((function(t){null!=e[t]&&(n[t]=!0)})),n}(n,r),o=Object.keys(a);return 0===o.length?n:o.reduce((function(e,r,a){return Array.isArray(n)?(e[r]=null!=n[a]?n[a]:n[t],t=a):"object"===typeof n?(e[r]=null!=n[r]?n[r]:n[t],t=r):e[r]=n,e}),{})}},2065:function(e,t,n){"use strict";n.d(t,{$n:function(){return d},Fq:function(){return u},_j:function(){return c},mi:function(){return l}});var r=n(6189);function a(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:0,n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:1;return Math.min(Math.max(t,e),n)}function o(e){if(e.type)return e;if("#"===e.charAt(0))return o(function(e){e=e.slice(1);var t=new RegExp(".{1,".concat(e.length>=6?2:1,"}"),"g"),n=e.match(t);return n&&1===n[0].length&&(n=n.map((function(e){return e+e}))),n?"rgb".concat(4===n.length?"a":"","(").concat(n.map((function(e,t){return t<3?parseInt(e,16):Math.round(parseInt(e,16)/255*1e3)/1e3})).join(", "),")"):""}(e));var t=e.indexOf("("),n=e.substring(0,t);if(-1===["rgb","rgba","hsl","hsla","color"].indexOf(n))throw new Error((0,r.Z)(9,e));var a,i=e.substring(t+1,e.length-1);if("color"===n){if(a=(i=i.split(" ")).shift(),4===i.length&&"/"===i[3].charAt(0)&&(i[3]=i[3].slice(1)),-1===["srgb","display-p3","a98-rgb","prophoto-rgb","rec-2020"].indexOf(a))throw new Error((0,r.Z)(10,a))}else i=i.split(",");return{type:n,values:i=i.map((function(e){return parseFloat(e)})),colorSpace:a}}function i(e){var t=e.type,n=e.colorSpace,r=e.values;return-1!==t.indexOf("rgb")?r=r.map((function(e,t){return t<3?parseInt(e,10):e})):-1!==t.indexOf("hsl")&&(r[1]="".concat(r[1],"%"),r[2]="".concat(r[2],"%")),r=-1!==t.indexOf("color")?"".concat(n," ").concat(r.join(" ")):"".concat(r.join(", ")),"".concat(t,"(").concat(r,")")}function s(e){var t="hsl"===(e=o(e)).type||"hsla"===e.type?o(function(e){var t=(e=o(e)).values,n=t[0],r=t[1]/100,a=t[2]/100,s=r*Math.min(a,1-a),l=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(e+n/30)%12;return a-s*Math.max(Math.min(t-3,9-t,1),-1)},u="rgb",c=[Math.round(255*l(0)),Math.round(255*l(8)),Math.round(255*l(4))];return"hsla"===e.type&&(u+="a",c.push(t[3])),i({type:u,values:c})}(e)).values:e.values;return t=t.map((function(t){return"color"!==e.type&&(t/=255),t<=.03928?t/12.92:Math.pow((t+.055)/1.055,2.4)})),Number((.2126*t[0]+.7152*t[1]+.0722*t[2]).toFixed(3))}function l(e,t){var n=s(e),r=s(t);return(Math.max(n,r)+.05)/(Math.min(n,r)+.05)}function u(e,t){return e=o(e),t=a(t),"rgb"!==e.type&&"hsl"!==e.type||(e.type+="a"),"color"===e.type?e.values[3]="/".concat(t):e.values[3]=t,i(e)}function c(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]*=1-t;else if(-1!==e.type.indexOf("rgb")||-1!==e.type.indexOf("color"))for(var n=0;n<3;n+=1)e.values[n]*=1-t;return i(e)}function d(e,t){if(e=o(e),t=a(t),-1!==e.type.indexOf("hsl"))e.values[2]+=(100-e.values[2])*t;else if(-1!==e.type.indexOf("rgb"))for(var n=0;n<3;n+=1)e.values[n]+=(255-e.values[n])*t;else if(-1!==e.type.indexOf("color"))for(var r=0;r<3;r+=1)e.values[r]+=(1-e.values[r])*t;return i(e)}},4046:function(e,t,n){"use strict";n.d(t,{ZP:function(){return C},x9:function(){return S}});var r=n(2982),a=n(885),o=n(3366),i=n(7462),s=n(2421),l=n(5080),u=n(7312),c=["variant"];function d(e){return 0===e.length}function p(e){var t=e.variant,n=(0,o.Z)(e,c),r=t||"";return Object.keys(n).sort().forEach((function(t){r+="color"===t?d(r)?e[t]:(0,u.Z)(e[t]):"".concat(d(r)?t:(0,u.Z)(t)).concat((0,u.Z)(e[t].toString()))})),r}var f=n(104),m=["name","slot","skipVariantsResolver","skipSx","overridesResolver"],h=["theme"],v=["theme"];function y(e){return 0===Object.keys(e).length}function b(e){return"string"===typeof e&&e.charCodeAt(0)>96}var g=function(e,t){return t.components&&t.components[e]&&t.components[e].styleOverrides?t.components[e].styleOverrides:null},_=function(e,t){var n=[];t&&t.components&&t.components[e]&&t.components[e].variants&&(n=t.components[e].variants);var r={};return n.forEach((function(e){var t=p(e.props);r[t]=e.style})),r},w=function(e,t,n,r){var a,o,i=e.ownerState,s=void 0===i?{}:i,l=[],u=null==n||null==(a=n.components)||null==(o=a[r])?void 0:o.variants;return u&&u.forEach((function(n){var r=!0;Object.keys(n.props).forEach((function(t){s[t]!==n.props[t]&&e[t]!==n.props[t]&&(r=!1)})),r&&l.push(t[p(n.props)])})),l};function S(e){return"ownerState"!==e&&"theme"!==e&&"sx"!==e&&"as"!==e}var k=(0,l.Z)();function C(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.defaultTheme,n=void 0===t?k:t,l=e.rootShouldForwardProp,u=void 0===l?S:l,c=e.slotShouldForwardProp,d=void 0===c?S:c,p=e.styleFunctionSx,C=void 0===p?f.Z:p,T=function(e){var t=y(e.theme)?n:e.theme;return C((0,i.Z)({},e,{theme:t}))};return T.__mui_systemSx=!0,function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{};(0,s.Co)(e,(function(e){return e.filter((function(e){return!(null!=e&&e.__mui_systemSx)}))}));var l,c=t.name,p=t.slot,f=t.skipVariantsResolver,k=t.skipSx,C=t.overridesResolver,x=(0,o.Z)(t,m),P=void 0!==f?f:p&&"Root"!==p||!1,E=k||!1;var A=S;"Root"===p?A=u:p?A=d:b(e)&&(A=void 0);var N=(0,s.ZP)(e,(0,i.Z)({shouldForwardProp:A,label:l},x)),F=function(e){for(var t=arguments.length,s=new Array(t>1?t-1:0),l=1;l<t;l++)s[l-1]=arguments[l];var u=s?s.map((function(e){return"function"===typeof e&&e.__emotion_real!==e?function(t){var r=t.theme,a=(0,o.Z)(t,h);return e((0,i.Z)({theme:y(r)?n:r},a))}:e})):[],d=e;c&&C&&u.push((function(e){var t=y(e.theme)?n:e.theme,r=g(c,t);if(r){var o={};return Object.entries(r).forEach((function(n){var r=(0,a.Z)(n,2),s=r[0],l=r[1];o[s]="function"===typeof l?l((0,i.Z)({},e,{theme:t})):l})),C(e,o)}return null})),c&&!P&&u.push((function(e){var t=y(e.theme)?n:e.theme;return w(e,_(c,t),t,c)})),E||u.push(T);var p=u.length-s.length;if(Array.isArray(e)&&p>0){var f=new Array(p).fill("");(d=[].concat((0,r.Z)(e),(0,r.Z)(f))).raw=[].concat((0,r.Z)(e.raw),(0,r.Z)(f))}else"function"===typeof e&&e.__emotion_real!==e&&(d=function(t){var r=t.theme,a=(0,o.Z)(t,v);return e((0,i.Z)({theme:y(r)?n:r},a))});var m=N.apply(void 0,[d].concat((0,r.Z)(u)));return m};return N.withConfig&&(F.withConfig=N.withConfig),F}}},5080:function(e,t,n){"use strict";n.d(t,{Z:function(){return f}});var r=n(7462),a=n(3366),o=n(2466),i=n(4942),s=["values","unit","step"];function l(e){var t=e.values,n=void 0===t?{xs:0,sm:600,md:900,lg:1200,xl:1536}:t,o=e.unit,l=void 0===o?"px":o,u=e.step,c=void 0===u?5:u,d=(0,a.Z)(e,s),p=function(e){var t=Object.keys(e).map((function(t){return{key:t,val:e[t]}}))||[];return t.sort((function(e,t){return e.val-t.val})),t.reduce((function(e,t){return(0,r.Z)({},e,(0,i.Z)({},t.key,t.val))}),{})}(n),f=Object.keys(p);function m(e){var t="number"===typeof n[e]?n[e]:e;return"@media (min-width:".concat(t).concat(l,")")}function h(e){var t="number"===typeof n[e]?n[e]:e;return"@media (max-width:".concat(t-c/100).concat(l,")")}function v(e,t){var r=f.indexOf(t);return"@media (min-width:".concat("number"===typeof n[e]?n[e]:e).concat(l,") and ")+"(max-width:".concat((-1!==r&&"number"===typeof n[f[r]]?n[f[r]]:t)-c/100).concat(l,")")}return(0,r.Z)({keys:f,values:p,up:m,down:h,between:v,only:function(e){return f.indexOf(e)+1<f.length?v(e,f[f.indexOf(e)+1]):m(e)},not:function(e){var t=f.indexOf(e);return 0===t?m(f[1]):t===f.length-1?h(f[t]):v(e,f[f.indexOf(e)+1]).replace("@media","@media not all and")},unit:l},d)}var u={borderRadius:4},c=n(5682);function d(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:8;if(e.mui)return e;var t=(0,c.hB)({spacing:e}),n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=0===n.length?[1]:n;return a.map((function(e){var n=t(e);return"number"===typeof n?"".concat(n,"px"):n})).join(" ")};return n.mui=!0,n}var p=["breakpoints","palette","spacing","shape"];var f=function(){for(var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=e.breakpoints,n=void 0===t?{}:t,i=e.palette,s=void 0===i?{}:i,c=e.spacing,f=e.shape,m=void 0===f?{}:f,h=(0,a.Z)(e,p),v=l(n),y=d(c),b=(0,o.Z)({breakpoints:v,direction:"ltr",components:{},palette:(0,r.Z)({mode:"light"},s),spacing:y,shape:(0,r.Z)({},u,m)},h),g=arguments.length,_=new Array(g>1?g-1:0),w=1;w<g;w++)_[w-1]=arguments[w];return b=_.reduce((function(e,t){return(0,o.Z)(e,t)}),b)}},114:function(e,t,n){"use strict";n.d(t,{Gc:function(){return q},G$:function(){return H}});var r=n(8529),a=n(8247);var o=function(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return t.filterProps.forEach((function(n){e[n]=t})),e}),{}),o=function(e){return Object.keys(e).reduce((function(t,n){return r[n]?(0,a.Z)(t,r[n](e)):t}),{})};return o.propTypes={},o.filterProps=t.reduce((function(e,t){return e.concat(t.filterProps)}),[]),o},i=n(5682),s=n(1184);function l(e){return"number"!==typeof e?e:"".concat(e,"px solid")}var u=(0,r.Z)({prop:"border",themeKey:"borders",transform:l}),c=(0,r.Z)({prop:"borderTop",themeKey:"borders",transform:l}),d=(0,r.Z)({prop:"borderRight",themeKey:"borders",transform:l}),p=(0,r.Z)({prop:"borderBottom",themeKey:"borders",transform:l}),f=(0,r.Z)({prop:"borderLeft",themeKey:"borders",transform:l}),m=(0,r.Z)({prop:"borderColor",themeKey:"palette"}),h=(0,r.Z)({prop:"borderTopColor",themeKey:"palette"}),v=(0,r.Z)({prop:"borderRightColor",themeKey:"palette"}),y=(0,r.Z)({prop:"borderBottomColor",themeKey:"palette"}),b=(0,r.Z)({prop:"borderLeftColor",themeKey:"palette"}),g=function(e){if(void 0!==e.borderRadius&&null!==e.borderRadius){var t=(0,i.eI)(e.theme,"shape.borderRadius",4,"borderRadius");return(0,s.k9)(e,e.borderRadius,(function(e){return{borderRadius:(0,i.NA)(t,e)}}))}return null};g.propTypes={},g.filterProps=["borderRadius"];var _=o(u,c,d,p,f,m,h,v,y,b,g),w=o((0,r.Z)({prop:"displayPrint",cssProperty:!1,transform:function(e){return{"@media print":{display:e}}}}),(0,r.Z)({prop:"display"}),(0,r.Z)({prop:"overflow"}),(0,r.Z)({prop:"textOverflow"}),(0,r.Z)({prop:"visibility"}),(0,r.Z)({prop:"whiteSpace"})),S=o((0,r.Z)({prop:"flexBasis"}),(0,r.Z)({prop:"flexDirection"}),(0,r.Z)({prop:"flexWrap"}),(0,r.Z)({prop:"justifyContent"}),(0,r.Z)({prop:"alignItems"}),(0,r.Z)({prop:"alignContent"}),(0,r.Z)({prop:"order"}),(0,r.Z)({prop:"flex"}),(0,r.Z)({prop:"flexGrow"}),(0,r.Z)({prop:"flexShrink"}),(0,r.Z)({prop:"alignSelf"}),(0,r.Z)({prop:"justifyItems"}),(0,r.Z)({prop:"justifySelf"})),k=function(e){if(void 0!==e.gap&&null!==e.gap){var t=(0,i.eI)(e.theme,"spacing",8,"gap");return(0,s.k9)(e,e.gap,(function(e){return{gap:(0,i.NA)(t,e)}}))}return null};k.propTypes={},k.filterProps=["gap"];var C=function(e){if(void 0!==e.columnGap&&null!==e.columnGap){var t=(0,i.eI)(e.theme,"spacing",8,"columnGap");return(0,s.k9)(e,e.columnGap,(function(e){return{columnGap:(0,i.NA)(t,e)}}))}return null};C.propTypes={},C.filterProps=["columnGap"];var T=function(e){if(void 0!==e.rowGap&&null!==e.rowGap){var t=(0,i.eI)(e.theme,"spacing",8,"rowGap");return(0,s.k9)(e,e.rowGap,(function(e){return{rowGap:(0,i.NA)(t,e)}}))}return null};T.propTypes={},T.filterProps=["rowGap"];var x=o(k,C,T,(0,r.Z)({prop:"gridColumn"}),(0,r.Z)({prop:"gridRow"}),(0,r.Z)({prop:"gridAutoFlow"}),(0,r.Z)({prop:"gridAutoColumns"}),(0,r.Z)({prop:"gridAutoRows"}),(0,r.Z)({prop:"gridTemplateColumns"}),(0,r.Z)({prop:"gridTemplateRows"}),(0,r.Z)({prop:"gridTemplateAreas"}),(0,r.Z)({prop:"gridArea"})),P=o((0,r.Z)({prop:"position"}),(0,r.Z)({prop:"zIndex",themeKey:"zIndex"}),(0,r.Z)({prop:"top"}),(0,r.Z)({prop:"right"}),(0,r.Z)({prop:"bottom"}),(0,r.Z)({prop:"left"})),E=o((0,r.Z)({prop:"color",themeKey:"palette"}),(0,r.Z)({prop:"bgcolor",cssProperty:"backgroundColor",themeKey:"palette"}),(0,r.Z)({prop:"backgroundColor",themeKey:"palette"})),A=(0,r.Z)({prop:"boxShadow",themeKey:"shadows"});function N(e){return e<=1&&0!==e?"".concat(100*e,"%"):e}var F=(0,r.Z)({prop:"width",transform:N}),O=function(e){if(void 0!==e.maxWidth&&null!==e.maxWidth){return(0,s.k9)(e,e.maxWidth,(function(t){var n,r,a;return{maxWidth:(null==(n=e.theme)||null==(r=n.breakpoints)||null==(a=r.values)?void 0:a[t])||s.VO[t]||N(t)}}))}return null};O.filterProps=["maxWidth"];var R=(0,r.Z)({prop:"minWidth",transform:N}),D=(0,r.Z)({prop:"height",transform:N}),M=(0,r.Z)({prop:"maxHeight",transform:N}),I=(0,r.Z)({prop:"minHeight",transform:N}),z=((0,r.Z)({prop:"size",cssProperty:"width",transform:N}),(0,r.Z)({prop:"size",cssProperty:"height",transform:N}),o(F,O,R,D,M,I,(0,r.Z)({prop:"boxSizing"}))),L=(0,r.Z)({prop:"fontFamily",themeKey:"typography"}),Z=(0,r.Z)({prop:"fontSize",themeKey:"typography"}),j=(0,r.Z)({prop:"fontStyle",themeKey:"typography"}),B=(0,r.Z)({prop:"fontWeight",themeKey:"typography"}),W=(0,r.Z)({prop:"letterSpacing"}),J=(0,r.Z)({prop:"textTransform"}),V=(0,r.Z)({prop:"lineHeight"}),U=(0,r.Z)({prop:"textAlign"}),$=o((0,r.Z)({prop:"typography",cssProperty:!1,themeKey:"typography"}),L,Z,j,B,W,V,U,J),G={borders:_.filterProps,display:w.filterProps,flexbox:S.filterProps,grid:x.filterProps,positions:P.filterProps,palette:E.filterProps,shadows:A.filterProps,sizing:z.filterProps,spacing:i.ZP.filterProps,typography:$.filterProps},H={borders:_,display:w,flexbox:S,grid:x,positions:P,palette:E,shadows:A,sizing:z,spacing:i.ZP,typography:$},q=Object.keys(G).reduce((function(e,t){return G[t].forEach((function(n){e[n]=H[t]})),e}),{})},8247:function(e,t,n){"use strict";var r=n(2466);t.Z=function(e,t){return t?(0,r.Z)(e,t,{clone:!1}):e}},5682:function(e,t,n){"use strict";n.d(t,{hB:function(){return h},eI:function(){return m},ZP:function(){return S},NA:function(){return v}});var r=n(885),a=n(1184),o=n(8529),i=n(8247);var s={m:"margin",p:"padding"},l={t:"Top",r:"Right",b:"Bottom",l:"Left",x:["Left","Right"],y:["Top","Bottom"]},u={marginX:"mx",marginY:"my",paddingX:"px",paddingY:"py"},c=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}}((function(e){if(e.length>2){if(!u[e])return[e];e=u[e]}var t=e.split(""),n=(0,r.Z)(t,2),a=n[0],o=n[1],i=s[a],c=l[o]||"";return Array.isArray(c)?c.map((function(e){return i+e})):[i+c]})),d=["m","mt","mr","mb","ml","mx","my","margin","marginTop","marginRight","marginBottom","marginLeft","marginX","marginY","marginInline","marginInlineStart","marginInlineEnd","marginBlock","marginBlockStart","marginBlockEnd"],p=["p","pt","pr","pb","pl","px","py","padding","paddingTop","paddingRight","paddingBottom","paddingLeft","paddingX","paddingY","paddingInline","paddingInlineStart","paddingInlineEnd","paddingBlock","paddingBlockStart","paddingBlockEnd"],f=[].concat(d,p);function m(e,t,n,r){var a,i=null!=(a=(0,o.D)(e,t,!1))?a:n;return"number"===typeof i?function(e){return"string"===typeof e?e:i*e}:Array.isArray(i)?function(e){return"string"===typeof e?e:i[e]}:"function"===typeof i?i:function(){}}function h(e){return m(e,"spacing",8)}function v(e,t){if("string"===typeof t||null==t)return t;var n=e(Math.abs(t));return t>=0?n:"number"===typeof n?-n:"-".concat(n)}function y(e,t,n,r){if(-1===t.indexOf(n))return null;var o=function(e,t){return function(n){return e.reduce((function(e,r){return e[r]=v(t,n),e}),{})}}(c(n),r),i=e[n];return(0,a.k9)(e,i,o)}function b(e,t){var n=h(e.theme);return Object.keys(e).map((function(r){return y(e,t,r,n)})).reduce(i.Z,{})}function g(e){return b(e,d)}function _(e){return b(e,p)}function w(e){return b(e,f)}g.propTypes={},g.filterProps=d,_.propTypes={},_.filterProps=p,w.propTypes={},w.filterProps=f;var S=w},8529:function(e,t,n){"use strict";n.d(t,{D:function(){return i}});var r=n(4942),a=n(7312),o=n(1184);function i(e,t){var n=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(!t||"string"!==typeof t)return null;if(e&&e.vars&&n){var r="vars.".concat(t).split(".").reduce((function(e,t){return e&&e[t]?e[t]:null}),e);if(null!=r)return r}return t.split(".").reduce((function(e,t){return e&&null!=e[t]?e[t]:null}),e)}function s(e,t,n){var r,a=arguments.length>3&&void 0!==arguments[3]?arguments[3]:n;return r="function"===typeof e?e(n):Array.isArray(e)?e[n]||a:i(e,n)||a,t&&(r=t(r)),r}t.Z=function(e){var t=e.prop,n=e.cssProperty,l=void 0===n?e.prop:n,u=e.themeKey,c=e.transform,d=function(e){if(null==e[t])return null;var n=e[t],d=i(e.theme,u)||{};return(0,o.k9)(e,n,(function(e){var n=s(d,c,e);return e===n&&"string"===typeof e&&(n=s(d,c,"".concat(t).concat("default"===e?"":(0,a.Z)(e)),e)),!1===l?n:(0,r.Z)({},l,n)}))};return d.propTypes={},d.filterProps=[t],d}},104:function(e,t,n){"use strict";var r=n(4942),a=n(8247),o=n(114),i=n(1184);function s(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];var r=t.reduce((function(e,t){return e.concat(Object.keys(t))}),[]),a=new Set(r);return t.every((function(e){return a.size===Object.keys(e).length}))}function l(e,t){return"function"===typeof e?e(t):e}var u=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:o.G$,t=Object.keys(e).reduce((function(t,n){return e[n].filterProps.forEach((function(r){t[r]=e[n]})),t}),{});function n(e,n,a){var o,i=(o={},(0,r.Z)(o,e,n),(0,r.Z)(o,"theme",a),o),s=t[e];return s?s(i):(0,r.Z)({},e,n)}function u(e){var o=e||{},c=o.sx,d=o.theme,p=void 0===d?{}:d;if(!c)return null;function f(e){var o=e;if("function"===typeof e)o=e(p);else if("object"!==typeof e)return e;if(!o)return null;var c=(0,i.W8)(p.breakpoints),d=Object.keys(c),f=c;return Object.keys(o).forEach((function(e){var c=l(o[e],p);if(null!==c&&void 0!==c)if("object"===typeof c)if(t[e])f=(0,a.Z)(f,n(e,c,p));else{var d=(0,i.k9)({theme:p},c,(function(t){return(0,r.Z)({},e,t)}));s(d,c)?f[e]=u({sx:c,theme:p}):f=(0,a.Z)(f,d)}else f=(0,a.Z)(f,n(e,c,p))})),(0,i.L7)(d,f)}return Array.isArray(c)?c.map(f):f(c)}return u}();u.filterProps=["sx"],t.Z=u},886:function(e,t,n){"use strict";n.d(t,{Z:function(){return c}});var r=n(5080),a=n(2791);var o=a.createContext(null);function i(){return a.useContext(o)}function s(e){return 0===Object.keys(e).length}var l=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:null,t=i();return!t||s(t)?e:t},u=(0,r.Z)();var c=function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:u;return l(e)}},8691:function(e,t,n){"use strict";n.d(t,{Z:function(){return i}});var r=n(7462);function a(e){var t=e.theme,n=e.name,a=e.props;return t&&t.components&&t.components[n]&&t.components[n].defaultProps?function(e,t){var n=(0,r.Z)({},t);return Object.keys(e).forEach((function(t){void 0===n[t]&&(n[t]=e[t])})),n}(t.components[n].defaultProps,a):a}var o=n(886);function i(e){var t=e.props,n=e.name,r=e.defaultTheme;return a({theme:(0,o.Z)(r),name:n,props:t})}},5902:function(e,t){"use strict";var n=function(e){return e},r=function(){var e=n;return{configure:function(t){e=t},generate:function(t){return e(t)},reset:function(){e=n}}}();t.Z=r},7312:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(6189);function a(e){if("string"!==typeof e)throw new Error((0,r.Z)(7));return e.charAt(0).toUpperCase()+e.slice(1)}},4419:function(e,t,n){"use strict";function r(e,t,n){var r={};return Object.keys(e).forEach((function(a){r[a]=e[a].reduce((function(e,r){return r&&(e.push(t(r)),n&&n[r]&&e.push(n[r])),e}),[]).join(" ")})),r}n.d(t,{Z:function(){return r}})},2466:function(e,t,n){"use strict";n.d(t,{P:function(){return a},Z:function(){return o}});var r=n(7462);function a(e){return null!==e&&"object"===typeof e&&e.constructor===Object}function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{clone:!0},i=n.clone?(0,r.Z)({},e):e;return a(e)&&a(t)&&Object.keys(t).forEach((function(r){"__proto__"!==r&&(a(t[r])&&r in e&&a(e[r])?i[r]=o(e[r],t[r],n):i[r]=t[r])})),i}},6189:function(e,t,n){"use strict";function r(e){for(var t="https://mui.com/production-error/?code="+e,n=1;n<arguments.length;n+=1)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified MUI error #"+e+"; visit "+t+" for the full message."}n.d(t,{Z:function(){return r}})},1217:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(5902),a={active:"active",checked:"checked",completed:"completed",disabled:"disabled",error:"error",expanded:"expanded",focused:"focused",focusVisible:"focusVisible",required:"required",selected:"selected"};function o(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",o=a[t];return o?"".concat(n,"-").concat(o):"".concat(r.Z.generate(e),"-").concat(t)}},5878:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(1217);function a(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:"Mui",a={};return t.forEach((function(t){a[t]=(0,r.Z)(e,t,n)})),a}},2971:function(e,t,n){"use strict";function r(e,t){"function"===typeof e?e(t):e&&(e.current=t)}n.d(t,{Z:function(){return r}})},5721:function(e,t,n){"use strict";var r=n(2791),a="undefined"!==typeof window?r.useLayoutEffect:r.useEffect;t.Z=a},1694:function(e,t){var n;!function(){"use strict";var r={}.hasOwnProperty;function a(){for(var e=[],t=0;t<arguments.length;t++){var n=arguments[t];if(n){var o=typeof n;if("string"===o||"number"===o)e.push(n);else if(Array.isArray(n)){if(n.length){var i=a.apply(null,n);i&&e.push(i)}}else if("object"===o){if(n.toString!==Object.prototype.toString&&!n.toString.toString().includes("[native code]")){e.push(n.toString());continue}for(var s in n)r.call(n,s)&&n[s]&&e.push(s)}}}return e.join(" ")}e.exports?(a.default=a,e.exports=a):void 0===(n=function(){return a}.apply(t,[]))||(e.exports=n)}()},8182:function(e,t,n){"use strict";function r(e){var t,n,a="";if("string"==typeof e||"number"==typeof e)a+=e;else if("object"==typeof e)if(Array.isArray(e))for(t=0;t<e.length;t++)e[t]&&(n=r(e[t]))&&(a&&(a+=" "),a+=n);else for(t in e)e[t]&&(a&&(a+=" "),a+=t);return a}t.Z=function(){for(var e,t,n=0,a="";n<arguments.length;)(e=arguments[n++])&&(t=r(e))&&(a&&(a+=" "),a+=t);return a}},4173:function(e,t){!function(e){"use strict";function t(){}function n(e,t,n,r,a){for(var o=0,i=t.length,s=0,l=0;o<i;o++){var u=t[o];if(u.removed){if(u.value=e.join(r.slice(l,l+u.count)),l+=u.count,o&&t[o-1].added){var c=t[o-1];t[o-1]=t[o],t[o]=c}}else{if(!u.added&&a){var d=n.slice(s,s+u.count);d=d.map((function(e,t){var n=r[l+t];return n.length>e.length?n:e})),u.value=e.join(d)}else u.value=e.join(n.slice(s,s+u.count));s+=u.count,u.added||(l+=u.count)}}var p=t[i-1];return i>1&&"string"===typeof p.value&&(p.added||p.removed)&&e.equals("",p.value)&&(t[i-2].value+=p.value,t.pop()),t}function r(e){return{newPos:e.newPos,components:e.components.slice(0)}}t.prototype={diff:function(e,t){var a=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{},o=a.callback;"function"===typeof a&&(o=a,a={}),this.options=a;var i=this;function s(e){return o?(setTimeout((function(){o(void 0,e)}),0),!0):e}e=this.castInput(e),t=this.castInput(t),e=this.removeEmpty(this.tokenize(e));var l=(t=this.removeEmpty(this.tokenize(t))).length,u=e.length,c=1,d=l+u,p=[{newPos:-1,components:[]}],f=this.extractCommon(p[0],t,e,0);if(p[0].newPos+1>=l&&f+1>=u)return s([{value:this.join(t),count:t.length}]);function m(){for(var a=-1*c;a<=c;a+=2){var o=void 0,d=p[a-1],f=p[a+1],m=(f?f.newPos:0)-a;d&&(p[a-1]=void 0);var h=d&&d.newPos+1<l,v=f&&0<=m&&m<u;if(h||v){if(!h||v&&d.newPos<f.newPos?(o=r(f),i.pushComponent(o.components,void 0,!0)):((o=d).newPos++,i.pushComponent(o.components,!0,void 0)),m=i.extractCommon(o,t,e,a),o.newPos+1>=l&&m+1>=u)return s(n(i,o.components,t,e,i.useLongestToken));p[a]=o}else p[a]=void 0}c++}if(o)!function e(){setTimeout((function(){if(c>d)return o();m()||e()}),0)}();else for(;c<=d;){var h=m();if(h)return h}},pushComponent:function(e,t,n){var r=e[e.length-1];r&&r.added===t&&r.removed===n?e[e.length-1]={count:r.count+1,added:t,removed:n}:e.push({count:1,added:t,removed:n})},extractCommon:function(e,t,n,r){for(var a=t.length,o=n.length,i=e.newPos,s=i-r,l=0;i+1<a&&s+1<o&&this.equals(t[i+1],n[s+1]);)i++,s++,l++;return l&&e.components.push({count:l}),e.newPos=i,s},equals:function(e,t){return this.options.comparator?this.options.comparator(e,t):e===t||this.options.ignoreCase&&e.toLowerCase()===t.toLowerCase()},removeEmpty:function(e){for(var t=[],n=0;n<e.length;n++)e[n]&&t.push(e[n]);return t},castInput:function(e){return e},tokenize:function(e){return e.split("")},join:function(e){return e.join("")}};var a=new t;function o(e,t,n){return a.diff(e,t,n)}function i(e,t){if("function"===typeof e)t.callback=e;else if(e)for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}var s=/^[A-Za-z\xC0-\u02C6\u02C8-\u02D7\u02DE-\u02FF\u1E00-\u1EFF]+$/,l=/\S/,u=new t;function c(e,t,n){return n=i(n,{ignoreWhitespace:!0}),u.diff(e,t,n)}function d(e,t,n){return u.diff(e,t,n)}u.equals=function(e,t){return this.options.ignoreCase&&(e=e.toLowerCase(),t=t.toLowerCase()),e===t||this.options.ignoreWhitespace&&!l.test(e)&&!l.test(t)},u.tokenize=function(e){for(var t=e.split(/(\s+|[()[\]{}'"]|\b)/),n=0;n<t.length-1;n++)!t[n+1]&&t[n+2]&&s.test(t[n])&&s.test(t[n+2])&&(t[n]+=t[n+2],t.splice(n+1,2),n--);return t};var p=new t;function f(e,t,n){return p.diff(e,t,n)}function m(e,t,n){var r=i(n,{ignoreWhitespace:!0});return p.diff(e,t,r)}p.tokenize=function(e){var t=[],n=e.split(/(\n|\r\n)/);n[n.length-1]||n.pop();for(var r=0;r<n.length;r++){var a=n[r];r%2&&!this.options.newlineIsToken?t[t.length-1]+=a:(this.options.ignoreWhitespace&&(a=a.trim()),t.push(a))}return t};var h=new t;function v(e,t,n){return h.diff(e,t,n)}h.tokenize=function(e){return e.split(/(\S.+?[.!?])(?=\s+|$)/)};var y=new t;function b(e,t,n){return y.diff(e,t,n)}function g(e){return g="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e},g(e)}function _(e){return w(e)||S(e)||k()}function w(e){if(Array.isArray(e)){for(var t=0,n=new Array(e.length);t<e.length;t++)n[t]=e[t];return n}}function S(e){if(Symbol.iterator in Object(e)||"[object Arguments]"===Object.prototype.toString.call(e))return Array.from(e)}function k(){throw new TypeError("Invalid attempt to spread non-iterable instance")}y.tokenize=function(e){return e.split(/([{}:;,]|\s+)/)};var C=Object.prototype.toString,T=new t;function x(e,t,n){return T.diff(e,t,n)}function P(e,t,n,r,a){var o,i;for(t=t||[],n=n||[],r&&(e=r(a,e)),o=0;o<t.length;o+=1)if(t[o]===e)return n[o];if("[object Array]"===C.call(e)){for(t.push(e),i=new Array(e.length),n.push(i),o=0;o<e.length;o+=1)i[o]=P(e[o],t,n,r,a);return t.pop(),n.pop(),i}if(e&&e.toJSON&&(e=e.toJSON()),"object"===g(e)&&null!==e){t.push(e),i={},n.push(i);var s,l=[];for(s in e)e.hasOwnProperty(s)&&l.push(s);for(l.sort(),o=0;o<l.length;o+=1)i[s=l[o]]=P(e[s],t,n,r,s);t.pop(),n.pop()}else i=e;return i}T.useLongestToken=!0,T.tokenize=p.tokenize,T.castInput=function(e){var t=this.options,n=t.undefinedReplacement,r=t.stringifyReplacer,a=void 0===r?function(e,t){return"undefined"===typeof t?n:t}:r;return"string"===typeof e?e:JSON.stringify(P(e,null,null,a),a,"  ")},T.equals=function(e,n){return t.prototype.equals.call(T,e.replace(/,([\r\n])/g,"$1"),n.replace(/,([\r\n])/g,"$1"))};var E=new t;function A(e,t,n){return E.diff(e,t,n)}function N(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=e.split(/\r\n|[\n\v\f\r\x85]/),r=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],a=[],o=0;function i(){var e={};for(a.push(e);o<n.length;){var r=n[o];if(/^(\-\-\-|\+\+\+|@@)\s/.test(r))break;var i=/^(?:Index:|diff(?: -r \w+)+)\s+(.+?)\s*$/.exec(r);i&&(e.index=i[1]),o++}for(s(e),s(e),e.hunks=[];o<n.length;){var u=n[o];if(/^(Index:|diff|\-\-\-|\+\+\+)\s/.test(u))break;if(/^@@/.test(u))e.hunks.push(l());else{if(u&&t.strict)throw new Error("Unknown line "+(o+1)+" "+JSON.stringify(u));o++}}}function s(e){var t=/^(---|\+\+\+)\s+(.*)$/.exec(n[o]);if(t){var r="---"===t[1]?"old":"new",a=t[2].split("\t",2),i=a[0].replace(/\\\\/g,"\\");/^".*"$/.test(i)&&(i=i.substr(1,i.length-2)),e[r+"FileName"]=i,e[r+"Header"]=(a[1]||"").trim(),o++}}function l(){for(var e=o,a=n[o++].split(/@@ -(\d+)(?:,(\d+))? \+(\d+)(?:,(\d+))? @@/),i={oldStart:+a[1],oldLines:+a[2]||1,newStart:+a[3],newLines:+a[4]||1,lines:[],linedelimiters:[]},s=0,l=0;o<n.length&&!(0===n[o].indexOf("--- ")&&o+2<n.length&&0===n[o+1].indexOf("+++ ")&&0===n[o+2].indexOf("@@"));o++){var u=0==n[o].length&&o!=n.length-1?" ":n[o][0];if("+"!==u&&"-"!==u&&" "!==u&&"\\"!==u)break;i.lines.push(n[o]),i.linedelimiters.push(r[o]||"\n"),"+"===u?s++:"-"===u?l++:" "===u&&(s++,l++)}if(s||1!==i.newLines||(i.newLines=0),l||1!==i.oldLines||(i.oldLines=0),t.strict){if(s!==i.newLines)throw new Error("Added line count did not match for hunk at line "+(e+1));if(l!==i.oldLines)throw new Error("Removed line count did not match for hunk at line "+(e+1))}return i}for(;o<n.length;)i();return a}function F(e,t,n){var r=!0,a=!1,o=!1,i=1;return function s(){if(r&&!o){if(a?i++:r=!1,e+i<=n)return i;o=!0}if(!a)return o||(r=!0),t<=e-i?-i++:(a=!0,s())}}function O(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if("string"===typeof t&&(t=N(t)),Array.isArray(t)){if(t.length>1)throw new Error("applyPatch only works with a single input.");t=t[0]}var r,a,o=e.split(/\r\n|[\n\v\f\r\x85]/),i=e.match(/\r\n|[\n\v\f\r\x85]/g)||[],s=t.hunks,l=n.compareLine||function(e,t,n,r){return t===r},u=0,c=n.fuzzFactor||0,d=0,p=0;function f(e,t){for(var n=0;n<e.lines.length;n++){var r=e.lines[n],a=r.length>0?r[0]:" ",i=r.length>0?r.substr(1):r;if(" "===a||"-"===a){if(!l(t+1,o[t],a,i)&&++u>c)return!1;t++}}return!0}for(var m=0;m<s.length;m++){for(var h=s[m],v=o.length-h.oldLines,y=0,b=p+h.oldStart-1,g=F(b,d,v);void 0!==y;y=g())if(f(h,b+y)){h.offset=p+=y;break}if(void 0===y)return!1;d=h.offset+h.oldStart+h.oldLines}for(var _=0,w=0;w<s.length;w++){var S=s[w],k=S.oldStart+S.offset+_-1;_+=S.newLines-S.oldLines,k<0&&(k=0);for(var C=0;C<S.lines.length;C++){var T=S.lines[C],x=T.length>0?T[0]:" ",P=T.length>0?T.substr(1):T,E=S.linedelimiters[C];if(" "===x)k++;else if("-"===x)o.splice(k,1),i.splice(k,1);else if("+"===x)o.splice(k,0,P),i.splice(k,0,E),k++;else if("\\"===x){var A=S.lines[C-1]?S.lines[C-1][0]:null;"+"===A?r=!0:"-"===A&&(a=!0)}}}if(r)for(;!o[o.length-1];)o.pop(),i.pop();else a&&(o.push(""),i.push("\n"));for(var O=0;O<o.length-1;O++)o[O]=o[O]+i[O];return o.join("")}function R(e,t){"string"===typeof e&&(e=N(e));var n=0;function r(){var a=e[n++];if(!a)return t.complete();t.loadFile(a,(function(e,n){if(e)return t.complete(e);var o=O(n,a,t);t.patched(a,o,(function(e){if(e)return t.complete(e);r()}))}))}r()}function D(e,t,n,r,a,o,i){i||(i={}),"undefined"===typeof i.context&&(i.context=4);var s=f(n,r,i);function l(e){return e.map((function(e){return" "+e}))}s.push({value:"",lines:[]});for(var u=[],c=0,d=0,p=[],m=1,h=1,v=function(e){var t=s[e],a=t.lines||t.value.replace(/\n$/,"").split("\n");if(t.lines=a,t.added||t.removed){var o;if(!c){var f=s[e-1];c=m,d=h,f&&(p=i.context>0?l(f.lines.slice(-i.context)):[],c-=p.length,d-=p.length)}(o=p).push.apply(o,_(a.map((function(e){return(t.added?"+":"-")+e})))),t.added?h+=a.length:m+=a.length}else{if(c)if(a.length<=2*i.context&&e<s.length-2){var v;(v=p).push.apply(v,_(l(a)))}else{var y,b=Math.min(a.length,i.context);(y=p).push.apply(y,_(l(a.slice(0,b))));var g={oldStart:c,oldLines:m-c+b,newStart:d,newLines:h-d+b,lines:p};if(e>=s.length-2&&a.length<=i.context){var w=/\n$/.test(n),S=/\n$/.test(r),k=0==a.length&&p.length>g.oldLines;!w&&k&&p.splice(g.oldLines,0,"\\ No newline at end of file"),(w||k)&&S||p.push("\\ No newline at end of file")}u.push(g),c=0,d=0,p=[]}m+=a.length,h+=a.length}},y=0;y<s.length;y++)v(y);return{oldFileName:e,newFileName:t,oldHeader:a,newHeader:o,hunks:u}}function M(e,t,n,r,a,o,i){var s=D(e,t,n,r,a,o,i),l=[];e==t&&l.push("Index: "+e),l.push("==================================================================="),l.push("--- "+s.oldFileName+("undefined"===typeof s.oldHeader?"":"\t"+s.oldHeader)),l.push("+++ "+s.newFileName+("undefined"===typeof s.newHeader?"":"\t"+s.newHeader));for(var u=0;u<s.hunks.length;u++){var c=s.hunks[u];l.push("@@ -"+c.oldStart+","+c.oldLines+" +"+c.newStart+","+c.newLines+" @@"),l.push.apply(l,c.lines)}return l.join("\n")+"\n"}function I(e,t,n,r,a,o){return M(e,e,t,n,r,a,o)}function z(e,t){return e.length===t.length&&L(e,t)}function L(e,t){if(t.length>e.length)return!1;for(var n=0;n<t.length;n++)if(t[n]!==e[n])return!1;return!0}function Z(e){var t=ne(e.lines),n=t.oldLines,r=t.newLines;void 0!==n?e.oldLines=n:delete e.oldLines,void 0!==r?e.newLines=r:delete e.newLines}function j(e,t,n){e=B(e,n),t=B(t,n);var r={};(e.index||t.index)&&(r.index=e.index||t.index),(e.newFileName||t.newFileName)&&(W(e)?W(t)?(r.oldFileName=J(r,e.oldFileName,t.oldFileName),r.newFileName=J(r,e.newFileName,t.newFileName),r.oldHeader=J(r,e.oldHeader,t.oldHeader),r.newHeader=J(r,e.newHeader,t.newHeader)):(r.oldFileName=e.oldFileName,r.newFileName=e.newFileName,r.oldHeader=e.oldHeader,r.newHeader=e.newHeader):(r.oldFileName=t.oldFileName||e.oldFileName,r.newFileName=t.newFileName||e.newFileName,r.oldHeader=t.oldHeader||e.oldHeader,r.newHeader=t.newHeader||e.newHeader)),r.hunks=[];for(var a=0,o=0,i=0,s=0;a<e.hunks.length||o<t.hunks.length;){var l=e.hunks[a]||{oldStart:1/0},u=t.hunks[o]||{oldStart:1/0};if(V(l,u))r.hunks.push(U(l,i)),a++,s+=l.newLines-l.oldLines;else if(V(u,l))r.hunks.push(U(u,s)),o++,i+=u.newLines-u.oldLines;else{var c={oldStart:Math.min(l.oldStart,u.oldStart),oldLines:0,newStart:Math.min(l.newStart+i,u.oldStart+s),newLines:0,lines:[]};$(c,l.oldStart,l.lines,u.oldStart,u.lines),o++,a++,r.hunks.push(c)}}return r}function B(e,t){if("string"===typeof e){if(/^@@/m.test(e)||/^Index:/m.test(e))return N(e)[0];if(!t)throw new Error("Must provide a base reference or pass in a patch");return D(void 0,void 0,t,e)}return e}function W(e){return e.newFileName&&e.newFileName!==e.oldFileName}function J(e,t,n){return t===n?t:(e.conflict=!0,{mine:t,theirs:n})}function V(e,t){return e.oldStart<t.oldStart&&e.oldStart+e.oldLines<t.oldStart}function U(e,t){return{oldStart:e.oldStart,oldLines:e.oldLines,newStart:e.newStart+t,newLines:e.newLines,lines:e.lines}}function $(e,t,n,r,a){var o={offset:t,lines:n,index:0},i={offset:r,lines:a,index:0};for(K(e,o,i),K(e,i,o);o.index<o.lines.length&&i.index<i.lines.length;){var s=o.lines[o.index],l=i.lines[i.index];if("-"!==s[0]&&"+"!==s[0]||"-"!==l[0]&&"+"!==l[0])if("+"===s[0]&&" "===l[0]){var u;(u=e.lines).push.apply(u,_(Y(o)))}else if("+"===l[0]&&" "===s[0]){var c;(c=e.lines).push.apply(c,_(Y(i)))}else"-"===s[0]&&" "===l[0]?H(e,o,i):"-"===l[0]&&" "===s[0]?H(e,i,o,!0):s===l?(e.lines.push(s),o.index++,i.index++):q(e,Y(o),Y(i));else G(e,o,i)}Q(e,o),Q(e,i),Z(e)}function G(e,t,n){var r=Y(t),a=Y(n);if(ee(r)&&ee(a)){var o,i;if(L(r,a)&&te(n,r,r.length-a.length))return void(o=e.lines).push.apply(o,_(r));if(L(a,r)&&te(t,a,a.length-r.length))return void(i=e.lines).push.apply(i,_(a))}else if(z(r,a)){var s;return void(s=e.lines).push.apply(s,_(r))}q(e,r,a)}function H(e,t,n,r){var a,o=Y(t),i=X(n,o);i.merged?(a=e.lines).push.apply(a,_(i.merged)):q(e,r?i:o,r?o:i)}function q(e,t,n){e.conflict=!0,e.lines.push({conflict:!0,mine:t,theirs:n})}function K(e,t,n){for(;t.offset<n.offset&&t.index<t.lines.length;){var r=t.lines[t.index++];e.lines.push(r),t.offset++}}function Q(e,t){for(;t.index<t.lines.length;){var n=t.lines[t.index++];e.lines.push(n)}}function Y(e){for(var t=[],n=e.lines[e.index][0];e.index<e.lines.length;){var r=e.lines[e.index];if("-"===n&&"+"===r[0]&&(n="+"),n!==r[0])break;t.push(r),e.index++}return t}function X(e,t){for(var n=[],r=[],a=0,o=!1,i=!1;a<t.length&&e.index<e.lines.length;){var s=e.lines[e.index],l=t[a];if("+"===l[0])break;if(o=o||" "!==s[0],r.push(l),a++,"+"===s[0])for(i=!0;"+"===s[0];)n.push(s),s=e.lines[++e.index];l.substr(1)===s.substr(1)?(n.push(s),e.index++):i=!0}if("+"===(t[a]||"")[0]&&o&&(i=!0),i)return n;for(;a<t.length;)r.push(t[a++]);return{merged:r,changes:n}}function ee(e){return e.reduce((function(e,t){return e&&"-"===t[0]}),!0)}function te(e,t,n){for(var r=0;r<n;r++){var a=t[t.length-n+r].substr(1);if(e.lines[e.index+r]!==" "+a)return!1}return e.index+=n,!0}function ne(e){var t=0,n=0;return e.forEach((function(e){if("string"!==typeof e){var r=ne(e.mine),a=ne(e.theirs);void 0!==t&&(r.oldLines===a.oldLines?t+=r.oldLines:t=void 0),void 0!==n&&(r.newLines===a.newLines?n+=r.newLines:n=void 0)}else void 0===n||"+"!==e[0]&&" "!==e[0]||n++,void 0===t||"-"!==e[0]&&" "!==e[0]||t++})),{oldLines:t,newLines:n}}function re(e){for(var t,n,r=[],a=0;a<e.length;a++)n=(t=e[a]).added?1:t.removed?-1:0,r.push([n,t.value]);return r}function ae(e){for(var t=[],n=0;n<e.length;n++){var r=e[n];r.added?t.push("<ins>"):r.removed&&t.push("<del>"),t.push(oe(r.value)),r.added?t.push("</ins>"):r.removed&&t.push("</del>")}return t.join("")}function oe(e){var t=e;return t=(t=(t=(t=t.replace(/&/g,"&amp;")).replace(/</g,"&lt;")).replace(/>/g,"&gt;")).replace(/"/g,"&quot;")}E.tokenize=function(e){return e.slice()},E.join=E.removeEmpty=function(e){return e},e.Diff=t,e.diffChars=o,e.diffWords=c,e.diffWordsWithSpace=d,e.diffLines=f,e.diffTrimmedLines=m,e.diffSentences=v,e.diffCss=b,e.diffJson=x,e.diffArrays=A,e.structuredPatch=D,e.createTwoFilesPatch=M,e.createPatch=I,e.applyPatch=O,e.applyPatches=R,e.parsePatch=N,e.merge=j,e.convertChangesToDMP=re,e.convertChangesToXML=ae,e.canonicalize=P,Object.defineProperty(e,"__esModule",{value:!0})}(t)},6025:function(e,t,n){"use strict";n.r(t),n.d(t,{cache:function(){return Z},css:function(){return z},cx:function(){return O},flush:function(){return N},getRegisteredStyles:function(){return D},hydrate:function(){return F},injectGlobal:function(){return M},keyframes:function(){return I},merge:function(){return R},sheet:function(){return L}});var r=function(){function e(e){this.isSpeedy=void 0===e.speedy||e.speedy,this.tags=[],this.ctr=0,this.nonce=e.nonce,this.key=e.key,this.container=e.container,this.before=null}var t=e.prototype;return t.insert=function(e){if(this.ctr%(this.isSpeedy?65e3:1)===0){var t,n=function(e){var t=document.createElement("style");return t.setAttribute("data-emotion",e.key),void 0!==e.nonce&&t.setAttribute("nonce",e.nonce),t.appendChild(document.createTextNode("")),t}(this);t=0===this.tags.length?this.before:this.tags[this.tags.length-1].nextSibling,this.container.insertBefore(n,t),this.tags.push(n)}var r=this.tags[this.tags.length-1];if(this.isSpeedy){var a=function(e){if(e.sheet)return e.sheet;for(var t=0;t<document.styleSheets.length;t++)if(document.styleSheets[t].ownerNode===e)return document.styleSheets[t]}(r);try{var o=105===e.charCodeAt(1)&&64===e.charCodeAt(0);a.insertRule(e,o?0:a.cssRules.length)}catch(i){0}}else r.appendChild(document.createTextNode(e));this.ctr++},t.flush=function(){this.tags.forEach((function(e){return e.parentNode.removeChild(e)})),this.tags=[],this.ctr=0},e}();var a=function(e){function t(e,r,l,u,p){for(var f,m,h,v,_,S=0,k=0,C=0,T=0,x=0,O=0,D=h=f=0,I=0,z=0,L=0,Z=0,j=l.length,B=j-1,W="",J="",V="",U="";I<j;){if(m=l.charCodeAt(I),I===B&&0!==k+T+C+S&&(0!==k&&(m=47===k?10:47),T=C=S=0,j++,B++),0===k+T+C+S){if(I===B&&(0<z&&(W=W.replace(d,"")),0<W.trim().length)){switch(m){case 32:case 9:case 59:case 13:case 10:break;default:W+=l.charAt(I)}m=59}switch(m){case 123:for(f=(W=W.trim()).charCodeAt(0),h=1,Z=++I;I<j;){switch(m=l.charCodeAt(I)){case 123:h++;break;case 125:h--;break;case 47:switch(m=l.charCodeAt(I+1)){case 42:case 47:e:{for(D=I+1;D<B;++D)switch(l.charCodeAt(D)){case 47:if(42===m&&42===l.charCodeAt(D-1)&&I+2!==D){I=D+1;break e}break;case 10:if(47===m){I=D+1;break e}}I=D}}break;case 91:m++;case 40:m++;case 34:case 39:for(;I++<B&&l.charCodeAt(I)!==m;);}if(0===h)break;I++}if(h=l.substring(Z,I),0===f&&(f=(W=W.replace(c,"").trim()).charCodeAt(0)),64===f){switch(0<z&&(W=W.replace(d,"")),m=W.charCodeAt(1)){case 100:case 109:case 115:case 45:z=r;break;default:z=F}if(Z=(h=t(r,z,h,m,p+1)).length,0<R&&(_=s(3,h,z=n(F,W,L),r,E,P,Z,m,p,u),W=z.join(""),void 0!==_&&0===(Z=(h=_.trim()).length)&&(m=0,h="")),0<Z)switch(m){case 115:W=W.replace(w,i);case 100:case 109:case 45:h=W+"{"+h+"}";break;case 107:h=(W=W.replace(y,"$1 $2"))+"{"+h+"}",h=1===N||2===N&&o("@"+h,3)?"@-webkit-"+h+"@"+h:"@"+h;break;default:h=W+h,112===u&&(J+=h,h="")}else h=""}else h=t(r,n(r,W,L),h,u,p+1);V+=h,h=L=z=D=f=0,W="",m=l.charCodeAt(++I);break;case 125:case 59:if(1<(Z=(W=(0<z?W.replace(d,""):W).trim()).length))switch(0===D&&(f=W.charCodeAt(0),45===f||96<f&&123>f)&&(Z=(W=W.replace(" ",":")).length),0<R&&void 0!==(_=s(1,W,r,e,E,P,J.length,u,p,u))&&0===(Z=(W=_.trim()).length)&&(W="\0\0"),f=W.charCodeAt(0),m=W.charCodeAt(1),f){case 0:break;case 64:if(105===m||99===m){U+=W+l.charAt(I);break}default:58!==W.charCodeAt(Z-1)&&(J+=a(W,f,m,W.charCodeAt(2)))}L=z=D=f=0,W="",m=l.charCodeAt(++I)}}switch(m){case 13:case 10:47===k?k=0:0===1+f&&107!==u&&0<W.length&&(z=1,W+="\0"),0<R*M&&s(0,W,r,e,E,P,J.length,u,p,u),P=1,E++;break;case 59:case 125:if(0===k+T+C+S){P++;break}default:switch(P++,v=l.charAt(I),m){case 9:case 32:if(0===T+S+k)switch(x){case 44:case 58:case 9:case 32:v="";break;default:32!==m&&(v=" ")}break;case 0:v="\\0";break;case 12:v="\\f";break;case 11:v="\\v";break;case 38:0===T+k+S&&(z=L=1,v="\f"+v);break;case 108:if(0===T+k+S+A&&0<D)switch(I-D){case 2:112===x&&58===l.charCodeAt(I-3)&&(A=x);case 8:111===O&&(A=O)}break;case 58:0===T+k+S&&(D=I);break;case 44:0===k+C+T+S&&(z=1,v+="\r");break;case 34:case 39:0===k&&(T=T===m?0:0===T?m:T);break;case 91:0===T+k+C&&S++;break;case 93:0===T+k+C&&S--;break;case 41:0===T+k+S&&C--;break;case 40:if(0===T+k+S){if(0===f)if(2*x+3*O===533);else f=1;C++}break;case 64:0===k+C+T+S+D+h&&(h=1);break;case 42:case 47:if(!(0<T+S+C))switch(k){case 0:switch(2*m+3*l.charCodeAt(I+1)){case 235:k=47;break;case 220:Z=I,k=42}break;case 42:47===m&&42===x&&Z+2!==I&&(33===l.charCodeAt(Z+2)&&(J+=l.substring(Z,I+1)),v="",k=0)}}0===k&&(W+=v)}O=x,x=m,I++}if(0<(Z=J.length)){if(z=r,0<R&&(void 0!==(_=s(2,J,z,e,E,P,Z,u,p,u))&&0===(J=_).length))return U+J+V;if(J=z.join(",")+"{"+J+"}",0!==N*A){switch(2!==N||o(J,2)||(A=0),A){case 111:J=J.replace(g,":-moz-$1")+J;break;case 112:J=J.replace(b,"::-webkit-input-$1")+J.replace(b,"::-moz-$1")+J.replace(b,":-ms-input-$1")+J}A=0}}return U+J+V}function n(e,t,n){var a=t.trim().split(h);t=a;var o=a.length,i=e.length;switch(i){case 0:case 1:var s=0;for(e=0===i?"":e[0]+" ";s<o;++s)t[s]=r(e,t[s],n).trim();break;default:var l=s=0;for(t=[];s<o;++s)for(var u=0;u<i;++u)t[l++]=r(e[u]+" ",a[s],n).trim()}return t}function r(e,t,n){var r=t.charCodeAt(0);switch(33>r&&(r=(t=t.trim()).charCodeAt(0)),r){case 38:return t.replace(v,"$1"+e.trim());case 58:return e.trim()+t.replace(v,"$1"+e.trim());default:if(0<1*n&&0<t.indexOf("\f"))return t.replace(v,(58===e.charCodeAt(0)?"":"$1")+e.trim())}return e+t}function a(e,t,n,r){var i=e+";",s=2*t+3*n+4*r;if(944===s){e=i.indexOf(":",9)+1;var l=i.substring(e,i.length-1).trim();return l=i.substring(0,e).trim()+l+";",1===N||2===N&&o(l,1)?"-webkit-"+l+l:l}if(0===N||2===N&&!o(i,1))return i;switch(s){case 1015:return 97===i.charCodeAt(10)?"-webkit-"+i+i:i;case 951:return 116===i.charCodeAt(3)?"-webkit-"+i+i:i;case 963:return 110===i.charCodeAt(5)?"-webkit-"+i+i:i;case 1009:if(100!==i.charCodeAt(4))break;case 969:case 942:return"-webkit-"+i+i;case 978:return"-webkit-"+i+"-moz-"+i+i;case 1019:case 983:return"-webkit-"+i+"-moz-"+i+"-ms-"+i+i;case 883:if(45===i.charCodeAt(8))return"-webkit-"+i+i;if(0<i.indexOf("image-set(",11))return i.replace(x,"$1-webkit-$2")+i;break;case 932:if(45===i.charCodeAt(4))switch(i.charCodeAt(5)){case 103:return"-webkit-box-"+i.replace("-grow","")+"-webkit-"+i+"-ms-"+i.replace("grow","positive")+i;case 115:return"-webkit-"+i+"-ms-"+i.replace("shrink","negative")+i;case 98:return"-webkit-"+i+"-ms-"+i.replace("basis","preferred-size")+i}return"-webkit-"+i+"-ms-"+i+i;case 964:return"-webkit-"+i+"-ms-flex-"+i+i;case 1023:if(99!==i.charCodeAt(8))break;return"-webkit-box-pack"+(l=i.substring(i.indexOf(":",15)).replace("flex-","").replace("space-between","justify"))+"-webkit-"+i+"-ms-flex-pack"+l+i;case 1005:return f.test(i)?i.replace(p,":-webkit-")+i.replace(p,":-moz-")+i:i;case 1e3:switch(t=(l=i.substring(13).trim()).indexOf("-")+1,l.charCodeAt(0)+l.charCodeAt(t)){case 226:l=i.replace(_,"tb");break;case 232:l=i.replace(_,"tb-rl");break;case 220:l=i.replace(_,"lr");break;default:return i}return"-webkit-"+i+"-ms-"+l+i;case 1017:if(-1===i.indexOf("sticky",9))break;case 975:switch(t=(i=e).length-10,s=(l=(33===i.charCodeAt(t)?i.substring(0,t):i).substring(e.indexOf(":",7)+1).trim()).charCodeAt(0)+(0|l.charCodeAt(7))){case 203:if(111>l.charCodeAt(8))break;case 115:i=i.replace(l,"-webkit-"+l)+";"+i;break;case 207:case 102:i=i.replace(l,"-webkit-"+(102<s?"inline-":"")+"box")+";"+i.replace(l,"-webkit-"+l)+";"+i.replace(l,"-ms-"+l+"box")+";"+i}return i+";";case 938:if(45===i.charCodeAt(5))switch(i.charCodeAt(6)){case 105:return l=i.replace("-items",""),"-webkit-"+i+"-webkit-box-"+l+"-ms-flex-"+l+i;case 115:return"-webkit-"+i+"-ms-flex-item-"+i.replace(k,"")+i;default:return"-webkit-"+i+"-ms-flex-line-pack"+i.replace("align-content","").replace(k,"")+i}break;case 973:case 989:if(45!==i.charCodeAt(3)||122===i.charCodeAt(4))break;case 931:case 953:if(!0===T.test(e))return 115===(l=e.substring(e.indexOf(":")+1)).charCodeAt(0)?a(e.replace("stretch","fill-available"),t,n,r).replace(":fill-available",":stretch"):i.replace(l,"-webkit-"+l)+i.replace(l,"-moz-"+l.replace("fill-",""))+i;break;case 962:if(i="-webkit-"+i+(102===i.charCodeAt(5)?"-ms-"+i:"")+i,211===n+r&&105===i.charCodeAt(13)&&0<i.indexOf("transform",10))return i.substring(0,i.indexOf(";",27)+1).replace(m,"$1-webkit-$2")+i}return i}function o(e,t){var n=e.indexOf(1===t?":":"{"),r=e.substring(0,3!==t?n:10);return n=e.substring(n+1,e.length-1),D(2!==t?r:r.replace(C,"$1"),n,t)}function i(e,t){var n=a(t,t.charCodeAt(0),t.charCodeAt(1),t.charCodeAt(2));return n!==t+";"?n.replace(S," or ($1)").substring(4):"("+t+")"}function s(e,t,n,r,a,o,i,s,l,c){for(var d,p=0,f=t;p<R;++p)switch(d=O[p].call(u,e,f,n,r,a,o,i,s,l,c)){case void 0:case!1:case!0:case null:break;default:f=d}if(f!==t)return f}function l(e){return void 0!==(e=e.prefix)&&(D=null,e?"function"!==typeof e?N=1:(N=2,D=e):N=0),l}function u(e,n){var r=e;if(33>r.charCodeAt(0)&&(r=r.trim()),r=[r],0<R){var a=s(-1,n,r,r,E,P,0,0,0,0);void 0!==a&&"string"===typeof a&&(n=a)}var o=t(F,r,n,0,0);return 0<R&&(void 0!==(a=s(-2,o,r,r,E,P,o.length,0,0,0))&&(o=a)),"",A=0,P=E=1,o}var c=/^\0+/g,d=/[\0\r\f]/g,p=/: */g,f=/zoo|gra/,m=/([,: ])(transform)/g,h=/,\r+?/g,v=/([\t\r\n ])*\f?&/g,y=/@(k\w+)\s*(\S*)\s*/,b=/::(place)/g,g=/:(read-only)/g,_=/[svh]\w+-[tblr]{2}/,w=/\(\s*(.*)\s*\)/g,S=/([\s\S]*?);/g,k=/-self|flex-/g,C=/[^]*?(:[rp][el]a[\w-]+)[^]*/,T=/stretch|:\s*\w+\-(?:conte|avail)/,x=/([^-])(image-set\()/,P=1,E=1,A=0,N=1,F=[],O=[],R=0,D=null,M=0;return u.use=function e(t){switch(t){case void 0:case null:R=O.length=0;break;default:if("function"===typeof t)O[R++]=t;else if("object"===typeof t)for(var n=0,r=t.length;n<r;++n)e(t[n]);else M=0|!!t}return e},u.set=l,void 0!==e&&l(e),u},o="/*|*/";function i(e){e&&s.current.insert(e+"}")}var s={current:null},l=function(e,t,n,r,a,l,u,c,d,p){switch(e){case 1:switch(t.charCodeAt(0)){case 64:return s.current.insert(t+";"),"";case 108:if(98===t.charCodeAt(2))return""}break;case 2:if(0===c)return t+o;break;case 3:switch(c){case 102:case 112:return s.current.insert(n[0]+t),"";default:return t+(0===p?o:"")}case-2:t.split("/*|*/}").forEach(i)}},u=function(e){void 0===e&&(e={});var t,n=e.key||"css";void 0!==e.prefix&&(t={prefix:e.prefix});var o=new a(t);var i,u={};i=e.container||document.head;var c,d=document.querySelectorAll("style[data-emotion-"+n+"]");Array.prototype.forEach.call(d,(function(e){e.getAttribute("data-emotion-"+n).split(" ").forEach((function(e){u[e]=!0})),e.parentNode!==i&&i.appendChild(e)})),o.use(e.stylisPlugins)(l),c=function(e,t,n,r){var a=t.name;s.current=n,o(e,t.styles),r&&(p.inserted[a]=!0)};var p={key:n,sheet:new r({key:n,container:i,nonce:e.nonce,speedy:e.speedy}),nonce:e.nonce,inserted:u,registered:{},insert:c};return p};var c=function(e){for(var t,n=0,r=0,a=e.length;a>=4;++r,a-=4)t=1540483477*(65535&(t=255&e.charCodeAt(r)|(255&e.charCodeAt(++r))<<8|(255&e.charCodeAt(++r))<<16|(255&e.charCodeAt(++r))<<24))+(59797*(t>>>16)<<16),n=1540483477*(65535&(t^=t>>>24))+(59797*(t>>>16)<<16)^1540483477*(65535&n)+(59797*(n>>>16)<<16);switch(a){case 3:n^=(255&e.charCodeAt(r+2))<<16;case 2:n^=(255&e.charCodeAt(r+1))<<8;case 1:n=1540483477*(65535&(n^=255&e.charCodeAt(r)))+(59797*(n>>>16)<<16)}return(((n=1540483477*(65535&(n^=n>>>13))+(59797*(n>>>16)<<16))^n>>>15)>>>0).toString(36)},d={animationIterationCount:1,borderImageOutset:1,borderImageSlice:1,borderImageWidth:1,boxFlex:1,boxFlexGroup:1,boxOrdinalGroup:1,columnCount:1,columns:1,flex:1,flexGrow:1,flexPositive:1,flexShrink:1,flexNegative:1,flexOrder:1,gridRow:1,gridRowEnd:1,gridRowSpan:1,gridRowStart:1,gridColumn:1,gridColumnEnd:1,gridColumnSpan:1,gridColumnStart:1,msGridRow:1,msGridRowSpan:1,msGridColumn:1,msGridColumnSpan:1,fontWeight:1,lineHeight:1,opacity:1,order:1,orphans:1,tabSize:1,widows:1,zIndex:1,zoom:1,WebkitLineClamp:1,fillOpacity:1,floodOpacity:1,stopOpacity:1,strokeDasharray:1,strokeDashoffset:1,strokeMiterlimit:1,strokeOpacity:1,strokeWidth:1};var p=function(e){var t={};return function(n){return void 0===t[n]&&(t[n]=e(n)),t[n]}},f=/[A-Z]|^ms/g,m=/_EMO_([^_]+?)_([^]*?)_EMO_/g,h=function(e){return 45===e.charCodeAt(1)},v=function(e){return null!=e&&"boolean"!==typeof e},y=p((function(e){return h(e)?e:e.replace(f,"-$&").toLowerCase()})),b=function(e,t){switch(e){case"animation":case"animationName":if("string"===typeof t)return t.replace(m,(function(e,t,n){return _={name:t,styles:n,next:_},t}))}return 1===d[e]||h(e)||"number"!==typeof t||0===t?t:t+"px"};function g(e,t,n,r){if(null==n)return"";if(void 0!==n.__emotion_styles)return n;switch(typeof n){case"boolean":return"";case"object":if(1===n.anim)return _={name:n.name,styles:n.styles,next:_},n.name;if(void 0!==n.styles){var a=n.next;if(void 0!==a)for(;void 0!==a;)_={name:a.name,styles:a.styles,next:_},a=a.next;return n.styles+";"}return function(e,t,n){var r="";if(Array.isArray(n))for(var a=0;a<n.length;a++)r+=g(e,t,n[a],!1);else for(var o in n){var i=n[o];if("object"!==typeof i)null!=t&&void 0!==t[i]?r+=o+"{"+t[i]+"}":v(i)&&(r+=y(o)+":"+b(o,i)+";");else if(!Array.isArray(i)||"string"!==typeof i[0]||null!=t&&void 0!==t[i[0]]){var s=g(e,t,i,!1);switch(o){case"animation":case"animationName":r+=y(o)+":"+s+";";break;default:r+=o+"{"+s+"}"}}else for(var l=0;l<i.length;l++)v(i[l])&&(r+=y(o)+":"+b(o,i[l])+";")}return r}(e,t,n);case"function":if(void 0!==e){var o=_,i=n(e);return _=o,g(e,t,i,r)}}if(null==t)return n;var s=t[n];return void 0===s||r?n:s}var _,w=/label:\s*([^\s;\n{]+)\s*;/g;var S=function(e,t,n){if(1===e.length&&"object"===typeof e[0]&&null!==e[0]&&void 0!==e[0].styles)return e[0];var r=!0,a="";_=void 0;var o=e[0];null==o||void 0===o.raw?(r=!1,a+=g(n,t,o,!1)):a+=o[0];for(var i=1;i<e.length;i++)a+=g(n,t,e[i],46===a.charCodeAt(a.length-1)),r&&(a+=o[i]);w.lastIndex=0;for(var s,l="";null!==(s=w.exec(a));)l+="-"+s[1];return{name:c(a)+l,styles:a,next:_}};function k(e,t,n){var r="";return n.split(" ").forEach((function(n){void 0!==e[n]?t.push(e[n]):r+=n+" "})),r}var C=function(e,t,n){var r=e.key+"-"+t.name;if(!1===n&&void 0===e.registered[r]&&(e.registered[r]=t.styles),void 0===e.inserted[t.name]){var a=t;do{e.insert("."+r,a,e.sheet,!0);a=a.next}while(void 0!==a)}};function T(e,t){if(void 0===e.inserted[t.name])return e.insert("",t,e.sheet,!0)}function x(e,t,n){var r=[],a=k(e,r,n);return r.length<2?n:a+t(r)}var P=function e(t){for(var n="",r=0;r<t.length;r++){var a=t[r];if(null!=a){var o=void 0;switch(typeof a){case"boolean":break;case"object":if(Array.isArray(a))o=e(a);else for(var i in o="",a)a[i]&&i&&(o&&(o+=" "),o+=i);break;default:o=a}o&&(n&&(n+=" "),n+=o)}}return n},E=function(e){var t=u(e);t.sheet.speedy=function(e){this.isSpeedy=e},t.compat=!0;var n=function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered,void 0);return C(t,a,!1),t.key+"-"+a.name};return{css:n,cx:function(){for(var e=arguments.length,r=new Array(e),a=0;a<e;a++)r[a]=arguments[a];return x(t.registered,n,P(r))},injectGlobal:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered);T(t,a)},keyframes:function(){for(var e=arguments.length,n=new Array(e),r=0;r<e;r++)n[r]=arguments[r];var a=S(n,t.registered),o="animation-"+a.name;return T(t,{name:a.name,styles:"@keyframes "+o+"{"+a.styles+"}"}),o},hydrate:function(e){e.forEach((function(e){t.inserted[e]=!0}))},flush:function(){t.registered={},t.inserted={},t.sheet.flush()},sheet:t.sheet,cache:t,getRegisteredStyles:k.bind(null,t.registered),merge:x.bind(null,t.registered,n)}},A=E(),N=A.flush,F=A.hydrate,O=A.cx,R=A.merge,D=A.getRegisteredStyles,M=A.injectGlobal,I=A.keyframes,z=A.css,L=A.sheet,Z=A.cache},2110:function(e,t,n){"use strict";var r=n(8309),a={childContextTypes:!0,contextType:!0,contextTypes:!0,defaultProps:!0,displayName:!0,getDefaultProps:!0,getDerivedStateFromError:!0,getDerivedStateFromProps:!0,mixins:!0,propTypes:!0,type:!0},o={name:!0,length:!0,prototype:!0,caller:!0,callee:!0,arguments:!0,arity:!0},i={$$typeof:!0,compare:!0,defaultProps:!0,displayName:!0,propTypes:!0,type:!0},s={};function l(e){return r.isMemo(e)?i:s[e.$$typeof]||a}s[r.ForwardRef]={$$typeof:!0,render:!0,defaultProps:!0,displayName:!0,propTypes:!0},s[r.Memo]=i;var u=Object.defineProperty,c=Object.getOwnPropertyNames,d=Object.getOwnPropertySymbols,p=Object.getOwnPropertyDescriptor,f=Object.getPrototypeOf,m=Object.prototype;e.exports=function e(t,n,r){if("string"!==typeof n){if(m){var a=f(n);a&&a!==m&&e(t,a,r)}var i=c(n);d&&(i=i.concat(d(n)));for(var s=l(t),h=l(n),v=0;v<i.length;++v){var y=i[v];if(!o[y]&&(!r||!r[y])&&(!h||!h[y])&&(!s||!s[y])){var b=p(n,y);try{u(t,y,b)}catch(g){}}}}return t}},746:function(e,t){"use strict";var n="function"===typeof Symbol&&Symbol.for,r=n?Symbol.for("react.element"):60103,a=n?Symbol.for("react.portal"):60106,o=n?Symbol.for("react.fragment"):60107,i=n?Symbol.for("react.strict_mode"):60108,s=n?Symbol.for("react.profiler"):60114,l=n?Symbol.for("react.provider"):60109,u=n?Symbol.for("react.context"):60110,c=n?Symbol.for("react.async_mode"):60111,d=n?Symbol.for("react.concurrent_mode"):60111,p=n?Symbol.for("react.forward_ref"):60112,f=n?Symbol.for("react.suspense"):60113,m=n?Symbol.for("react.suspense_list"):60120,h=n?Symbol.for("react.memo"):60115,v=n?Symbol.for("react.lazy"):60116,y=n?Symbol.for("react.block"):60121,b=n?Symbol.for("react.fundamental"):60117,g=n?Symbol.for("react.responder"):60118,_=n?Symbol.for("react.scope"):60119;function w(e){if("object"===typeof e&&null!==e){var t=e.$$typeof;switch(t){case r:switch(e=e.type){case c:case d:case o:case s:case i:case f:return e;default:switch(e=e&&e.$$typeof){case u:case p:case v:case h:case l:return e;default:return t}}case a:return t}}}function S(e){return w(e)===d}t.AsyncMode=c,t.ConcurrentMode=d,t.ContextConsumer=u,t.ContextProvider=l,t.Element=r,t.ForwardRef=p,t.Fragment=o,t.Lazy=v,t.Memo=h,t.Portal=a,t.Profiler=s,t.StrictMode=i,t.Suspense=f,t.isAsyncMode=function(e){return S(e)||w(e)===c},t.isConcurrentMode=S,t.isContextConsumer=function(e){return w(e)===u},t.isContextProvider=function(e){return w(e)===l},t.isElement=function(e){return"object"===typeof e&&null!==e&&e.$$typeof===r},t.isForwardRef=function(e){return w(e)===p},t.isFragment=function(e){return w(e)===o},t.isLazy=function(e){return w(e)===v},t.isMemo=function(e){return w(e)===h},t.isPortal=function(e){return w(e)===a},t.isProfiler=function(e){return w(e)===s},t.isStrictMode=function(e){return w(e)===i},t.isSuspense=function(e){return w(e)===f},t.isValidElementType=function(e){return"string"===typeof e||"function"===typeof e||e===o||e===d||e===s||e===i||e===f||e===m||"object"===typeof e&&null!==e&&(e.$$typeof===v||e.$$typeof===h||e.$$typeof===l||e.$$typeof===u||e.$$typeof===p||e.$$typeof===b||e.$$typeof===g||e.$$typeof===_||e.$$typeof===y)},t.typeOf=w},8309:function(e,t,n){"use strict";e.exports=n(746)},5781:function(e,t,n){"use strict";n.r(t);var r=Number.isNaN||function(e){return"number"===typeof e&&e!==e};function a(e,t){if(e.length!==t.length)return!1;for(var n=0;n<e.length;n++)if(a=e[n],o=t[n],!(a===o||r(a)&&r(o)))return!1;var a,o;return!0}t.default=function(e,t){var n;void 0===t&&(t=a);var r,o=[],i=!1;return function(){for(var a=[],s=0;s<arguments.length;s++)a[s]=arguments[s];return i&&n===this&&t(a,o)||(r=e.apply(this,a),i=!0,n=this,o=a),r}}},888:function(e,t,n){"use strict";var r=n(9047);function a(){}function o(){}o.resetWarningCache=a,e.exports=function(){function e(e,t,n,a,o,i){if(i!==r){var s=new Error("Calling PropTypes validators directly is not supported by the `prop-types` package. Use PropTypes.checkPropTypes() to call them. Read more at http://fb.me/use-check-prop-types");throw s.name="Invariant Violation",s}}function t(){return e}e.isRequired=e;var n={array:e,bigint:e,bool:e,func:e,number:e,object:e,string:e,symbol:e,any:e,arrayOf:t,element:e,elementType:e,instanceOf:t,node:e,objectOf:t,oneOf:t,oneOfType:t,shape:t,exact:t,checkPropTypes:o,resetWarningCache:a};return n.PropTypes=n,n}},2007:function(e,t,n){e.exports=n(888)()},9047:function(e){"use strict";e.exports="SECRET_DO_NOT_PASS_THIS_OR_YOU_WILL_BE_FIRED"},8472:function(e,t,n){n(3561)},8015:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),o=n(2791),i=(r=o)&&r.__esModule?r:{default:r},s=n(1509),l=n(8333);var u=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.state={},n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),a(t,[{key:"buildURI",value:function(){return s.buildURI.apply(void 0,arguments)}},{key:"componentDidMount",value:function(){var e=this.props,t=e.data,n=e.headers,r=e.separator,a=e.enclosingCharacter,o=e.uFEFF,i=e.target,s=e.specs,l=e.replace;this.state.page=window.open(this.buildURI(t,o,n,r,a),i,s,l)}},{key:"getWindow",value:function(){return this.state.page}},{key:"render",value:function(){return null}}]),t}(i.default.Component);u.defaultProps=Object.assign(l.defaultProps,{target:"_blank"}),u.propTypes=l.propTypes,t.default=u},9088:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var r,a=Object.assign||function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},o=function(){function e(e,t){for(var n=0;n<t.length;n++){var r=t[n];r.enumerable=r.enumerable||!1,r.configurable=!0,"value"in r&&(r.writable=!0),Object.defineProperty(e,r.key,r)}}return function(t,n,r){return n&&e(t.prototype,n),r&&e(t,r),t}}(),i=n(2791),s=(r=i)&&r.__esModule?r:{default:r},l=n(1509),u=n(8333);var c=function(e){function t(e){!function(e,t){if(!(e instanceof t))throw new TypeError("Cannot call a class as a function")}(this,t);var n=function(e,t){if(!e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return!t||"object"!==typeof t&&"function"!==typeof t?e:t}(this,(t.__proto__||Object.getPrototypeOf(t)).call(this,e));return n.buildURI=n.buildURI.bind(n),n}return function(e,t){if("function"!==typeof t&&null!==t)throw new TypeError("Super expression must either be null or a function, not "+typeof t);e.prototype=Object.create(t&&t.prototype,{constructor:{value:e,enumerable:!1,writable:!0,configurable:!0}}),t&&(Object.setPrototypeOf?Object.setPrototypeOf(e,t):e.__proto__=t)}(t,e),o(t,[{key:"buildURI",value:function(){return l.buildURI.apply(void 0,arguments)}},{key:"handleLegacy",value:function(e){var t=arguments.length>1&&void 0!==arguments[1]&&arguments[1];if(window.navigator.msSaveOrOpenBlob){e.preventDefault();var n=this.props,r=n.data,a=n.headers,o=n.separator,i=n.filename,s=n.enclosingCharacter,u=n.uFEFF,c=t&&"function"===typeof r?r():r,d=new Blob([u?"\ufeff":"",(0,l.toCSV)(c,a,o,s)]);return window.navigator.msSaveBlob(d,i),!1}}},{key:"handleAsyncClick",value:function(e){var t=this;this.props.onClick(e,(function(n){!1!==n?t.handleLegacy(e,!0):e.preventDefault()}))}},{key:"handleSyncClick",value:function(e){!1===this.props.onClick(e)?e.preventDefault():this.handleLegacy(e)}},{key:"handleClick",value:function(){var e=this;return function(t){if("function"===typeof e.props.onClick)return e.props.asyncOnClick?e.handleAsyncClick(t):e.handleSyncClick(t);e.handleLegacy(t)}}},{key:"render",value:function(){var e=this,t=this.props,n=t.data,r=t.headers,o=t.separator,i=t.filename,l=t.uFEFF,u=t.children,c=(t.onClick,t.asyncOnClick,t.enclosingCharacter),d=function(e,t){var n={};for(var r in e)t.indexOf(r)>=0||Object.prototype.hasOwnProperty.call(e,r)&&(n[r]=e[r]);return n}(t,["data","headers","separator","filename","uFEFF","children","onClick","asyncOnClick","enclosingCharacter"]),p="undefined"===typeof window?"":this.buildURI(n,l,r,o,c);return s.default.createElement("a",a({download:i},d,{ref:function(t){return e.link=t},target:"_self",href:p,onClick:this.handleClick()}),u)}}]),t}(s.default.Component);c.defaultProps=u.defaultProps,c.propTypes=u.propTypes,t.default=c},1509:function(e,t){"use strict";Object.defineProperty(t,"__esModule",{value:!0});var n="function"===typeof Symbol&&"symbol"===typeof Symbol.iterator?function(e){return typeof e}:function(e){return e&&"function"===typeof Symbol&&e.constructor===Symbol&&e!==Symbol.prototype?"symbol":typeof e};function r(e){if(Array.isArray(e)){for(var t=0,n=Array(e.length);t<e.length;t++)n[t]=e[t];return n}return Array.from(e)}var a=t.isSafari=function(){return/^((?!chrome|android).)*safari/i.test(navigator.userAgent)},o=t.isJsons=function(e){return Array.isArray(e)&&e.every((function(e){return"object"===("undefined"===typeof e?"undefined":n(e))&&!(e instanceof Array)}))},i=t.isArrays=function(e){return Array.isArray(e)&&e.every((function(e){return Array.isArray(e)}))},s=t.jsonsHeaders=function(e){return Array.from(e.map((function(e){return Object.keys(e)})).reduce((function(e,t){return new Set([].concat(r(e),r(t)))}),[]))},l=t.jsons2arrays=function(e,t){var n=t=t||s(e),a=t;o(t)&&(n=t.map((function(e){return e.label})),a=t.map((function(e){return e.key})));var i=e.map((function(e){return a.map((function(t){return u(t,e)}))}));return[n].concat(r(i))},u=t.getHeaderValue=function(e,t){var n=e.replace(/\[([^\]]+)]/g,".$1").split(".").reduce((function(e,t,n,r){var a=e[t];if(void 0!==a&&null!==a)return a;r.splice(1)}),t);return void 0===n?e in t?t[e]:"":n},c=t.elementOrEmpty=function(e){return"undefined"===typeof e||null===e?"":e},d=t.joiner=function(e){var t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:",",n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:'"';return e.filter((function(e){return e})).map((function(e){return e.map((function(e){return c(e)})).map((function(e){return""+n+e+n})).join(t)})).join("\n")},p=t.arrays2csv=function(e,t,n,a){return d(t?[t].concat(r(e)):e,n,a)},f=t.jsons2csv=function(e,t,n,r){return d(l(e,t),n,r)},m=t.string2csv=function(e,t,n,r){return t?t.join(n)+"\n"+e:e.replace(/"/g,'""')},h=t.toCSV=function(e,t,n,r){if(o(e))return f(e,t,n,r);if(i(e))return p(e,t,n,r);if("string"===typeof e)return m(e,t,n);throw new TypeError('Data should be a "String", "Array of arrays" OR "Array of objects" ')};t.buildURI=function(e,t,n,r,o){var i=h(e,n,r,o),s=a()?"application/csv":"text/csv",l=new Blob([t?"\ufeff":"",i],{type:s}),u="data:"+s+";charset=utf-8,"+(t?"\ufeff":"")+i,c=window.URL||window.webkitURL;return"undefined"===typeof c.createObjectURL?u:c.createObjectURL(l)}},3561:function(e,t,n){"use strict";var r=o(n(8015)),a=o(n(9088));function o(e){return e&&e.__esModule?e:{default:e}}r.default,a.default},8333:function(e,t,n){"use strict";Object.defineProperty(t,"__esModule",{value:!0}),t.PropsNotForwarded=t.defaultProps=t.propTypes=void 0;var r,a=n(2791),o=((r=a)&&r.__esModule,n(2007));t.propTypes={data:(0,o.oneOfType)([o.string,o.array,o.func]).isRequired,headers:o.array,target:o.string,separator:o.string,filename:o.string,uFEFF:o.bool,onClick:o.func,asyncOnClick:o.bool,enclosingCharacter:o.string},t.defaultProps={separator:",",filename:"generatedBy_react-csv.csv",uFEFF:!0,asyncOnClick:!1,enclosingCharacter:'"'},t.PropsNotForwarded=["data","headers"]},7786:function(e,t,n){"use strict";var r=this&&this.__read||function(e,t){var n="function"===typeof Symbol&&e[Symbol.iterator];if(!n)return e;var r,a,o=n.call(e),i=[];try{for(;(void 0===t||t-- >0)&&!(r=o.next()).done;)i.push(r.value)}catch(s){a={error:s}}finally{try{r&&!r.done&&(n=o.return)&&n.call(o)}finally{if(a)throw a.error}}return i},a=this&&this.__spread||function(){for(var e=[],t=0;t<arguments.length;t++)e=e.concat(r(arguments[t]));return e};Object.defineProperty(t,"__esModule",{value:!0});var o,i,s=n(4173),l=s;!function(e){e[e.DEFAULT=0]="DEFAULT",e[e.ADDED=1]="ADDED",e[e.REMOVED=2]="REMOVED"}(o=t.DiffType||(t.DiffType={})),function(e){e.CHARS="diffChars",e.WORDS="diffWords",e.WORDS_WITH_SPACE="diffWordsWithSpace",e.LINES="diffLines",e.TRIMMED_LINES="diffTrimmedLines",e.SENTENCES="diffSentences",e.CSS="diffCss"}(i=t.DiffMethod||(t.DiffMethod={}));var u=function(e){var t=e.split("\n");if(t.every((function(e){return!e})))return 2===t.length?[]:(t.pop(),t);var n=t[t.length-1],r=t[0];return n||t.pop(),r||t.shift(),t};t.computeLineInformation=function(e,t,n,r,c){void 0===n&&(n=!1),void 0===r&&(r=i.CHARS),void 0===c&&(c=0);var d=s.diffLines(e.trimRight(),t.trimRight(),{newlineIsToken:!0,ignoreWhitespace:!1,ignoreCase:!1}),p=c,f=c,m=[],h=0,v=[],y=[],b=function e(t,a,s,c,m){return u(t).map((function(t,b){var g={},_={};if(!(y.includes(a+"-"+b)||m&&0!==b)){if(s||c)if(v.includes(h)||v.push(h),c){f+=1,g.lineNumber=f,g.type=o.REMOVED,g.value=t||" ";var w=d[a+1];if(w&&w.added)if(u(w.value)[b]){var S=e(w.value,a,!0,!1,!0)[0].right,k=S.value,C=S.lineNumber,T=S.type;if(y.push(a+1+"-"+b),_.lineNumber=C,_.type=T,n)_.value=k;else{var x=function(e,t,n){void 0===n&&(n=i.CHARS);var r=l[n](e,t),a={left:[],right:[]};return r.forEach((function(e){var t=e.added,n=e.removed,r=e.value,i={};return t&&(i.type=o.ADDED,i.value=r,a.right.push(i)),n&&(i.type=o.REMOVED,i.value=r,a.left.push(i)),n||t||(i.type=o.DEFAULT,i.value=r,a.right.push(i),a.left.push(i)),i})),a}(t,k,r);_.value=x.right,g.value=x.left}}}else p+=1,_.lineNumber=p,_.type=o.ADDED,_.value=t;else f+=1,p+=1,g.lineNumber=f,g.type=o.DEFAULT,g.value=t,_.lineNumber=p,_.type=o.DEFAULT,_.value=t;return h+=1,{right:_,left:g}}})).filter(Boolean)};return d.forEach((function(e,t){var n=e.added,r=e.removed,o=e.value;m=a(m,b(o,t,n,r))})),{lineInformation:m,diffLines:v}}},1774:function(e,t,n){"use strict";var r=this&&this.__extends||function(){var e=function(t,n){return e=Object.setPrototypeOf||{__proto__:[]}instanceof Array&&function(e,t){e.__proto__=t}||function(e,t){for(var n in t)t.hasOwnProperty(n)&&(e[n]=t[n])},e(t,n)};return function(t,n){function r(){this.constructor=t}e(t,n),t.prototype=null===n?Object.create(n):(r.prototype=n.prototype,new r)}}();Object.defineProperty(t,"__esModule",{value:!0});var a=n(2791),o=n(2007),i=n(1694),s=n(7786);t.DiffMethod=s.DiffMethod;var l,u=n(2813),c=n(5781),d=c.default||c;!function(e){e.LEFT="L",e.RIGHT="R"}(l=t.LineNumberPrefix||(t.LineNumberPrefix={}));var p=function(e){function t(t){var n=e.call(this,t)||this;return n.resetCodeBlocks=function(){return n.state.expandedBlocks.length>0&&(n.setState({expandedBlocks:[]}),!0)},n.onBlockExpand=function(e){var t=n.state.expandedBlocks.slice();t.push(e),n.setState({expandedBlocks:t})},n.computeStyles=d(u.default),n.onLineNumberClickProxy=function(e){return n.props.onLineNumberClick?function(t){return n.props.onLineNumberClick(e,t)}:function(){}},n.renderWordDiff=function(e,t){return e.map((function(e,r){var o;return a.createElement("span",{key:r,className:i.default(n.styles.wordDiff,(o={},o[n.styles.wordAdded]=e.type===s.DiffType.ADDED,o[n.styles.wordRemoved]=e.type===s.DiffType.REMOVED,o))},t?t(e.value):e.value)}))},n.renderLine=function(e,t,r,o,l,u){var c,d,p,f,m,h=r+"-"+e,v=u+"-"+l,y=n.props.highlightLines.includes(h)||n.props.highlightLines.includes(v),b=t===s.DiffType.ADDED,g=t===s.DiffType.REMOVED;return m=Array.isArray(o)?n.renderWordDiff(o,n.props.renderContent):n.props.renderContent?n.props.renderContent(o):o,a.createElement(a.Fragment,null,!n.props.hideLineNumbers&&a.createElement("td",{onClick:e&&n.onLineNumberClickProxy(h),className:i.default(n.styles.gutter,(c={},c[n.styles.emptyGutter]=!e,c[n.styles.diffAdded]=b,c[n.styles.diffRemoved]=g,c[n.styles.highlightedGutter]=y,c))},a.createElement("pre",{className:n.styles.lineNumber},e)),!n.props.splitView&&!n.props.hideLineNumbers&&a.createElement("td",{onClick:l&&n.onLineNumberClickProxy(v),className:i.default(n.styles.gutter,(d={},d[n.styles.emptyGutter]=!l,d[n.styles.diffAdded]=b,d[n.styles.diffRemoved]=g,d[n.styles.highlightedGutter]=y,d))},a.createElement("pre",{className:n.styles.lineNumber},l)),a.createElement("td",{className:i.default(n.styles.marker,(p={},p[n.styles.emptyLine]=!m,p[n.styles.diffAdded]=b,p[n.styles.diffRemoved]=g,p[n.styles.highlightedLine]=y,p))},a.createElement("pre",null,b&&"+",g&&"-")),a.createElement("td",{className:i.default(n.styles.content,(f={},f[n.styles.emptyLine]=!m,f[n.styles.diffAdded]=b,f[n.styles.diffRemoved]=g,f[n.styles.highlightedLine]=y,f))},a.createElement("pre",{className:n.styles.contentText},m)))},n.renderSplitView=function(e,t){var r=e.left,o=e.right;return a.createElement("tr",{key:t,className:n.styles.line},n.renderLine(r.lineNumber,r.type,l.LEFT,r.value),n.renderLine(o.lineNumber,o.type,l.RIGHT,o.value))},n.renderInlineView=function(e,t){var r,o=e.left,i=e.right;return o.type===s.DiffType.REMOVED&&i.type===s.DiffType.ADDED?a.createElement(a.Fragment,{key:t},a.createElement("tr",{className:n.styles.line},n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),a.createElement("tr",{className:n.styles.line},n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber))):(o.type===s.DiffType.REMOVED&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,null)),o.type===s.DiffType.DEFAULT&&(r=n.renderLine(o.lineNumber,o.type,l.LEFT,o.value,i.lineNumber,l.RIGHT)),i.type===s.DiffType.ADDED&&(r=n.renderLine(null,i.type,l.RIGHT,i.value,i.lineNumber)),a.createElement("tr",{key:t,className:n.styles.line},r))},n.onBlockClickProxy=function(e){return function(){return n.onBlockExpand(e)}},n.renderSkippedLineIndicator=function(e,t,r,o){var s,l=n.props,u=l.hideLineNumbers,c=l.splitView,d=n.props.codeFoldMessageRenderer?n.props.codeFoldMessageRenderer(e,r,o):a.createElement("pre",{className:n.styles.codeFoldContent},"Expand ",e," lines ..."),p=a.createElement("td",null,a.createElement("a",{onClick:n.onBlockClickProxy(t),tabIndex:0},d)),f=!c&&!u;return a.createElement("tr",{key:r+"-"+o,className:n.styles.codeFold},!u&&a.createElement("td",{className:n.styles.codeFoldGutter}),a.createElement("td",{className:i.default((s={},s[n.styles.codeFoldGutter]=f,s))}),f?a.createElement(a.Fragment,null,a.createElement("td",null),p):a.createElement(a.Fragment,null,p,a.createElement("td",null)),a.createElement("td",null),a.createElement("td",null))},n.renderDiff=function(){var e=n.props,t=e.oldValue,r=e.newValue,o=e.splitView,i=e.disableWordDiff,l=e.compareMethod,u=e.linesOffset,c=s.computeLineInformation(t,r,i,l,u),d=c.lineInformation,p=c.diffLines,f=n.props.extraLinesSurroundingDiff<0?0:n.props.extraLinesSurroundingDiff,m=[];return d.map((function(e,t){var r=p[0],i=r-t;if(n.props.showDiffOnly&&(i===-f&&(m=[],p.shift()),e.left.type===s.DiffType.DEFAULT&&(i>f||"undefined"===typeof r)&&!n.state.expandedBlocks.includes(r)))return m.push(t+1),t===d.length-1&&m.length>1?n.renderSkippedLineIndicator(m.length,r,e.left.lineNumber,e.right.lineNumber):null;var l=o?n.renderSplitView(e,t):n.renderInlineView(e,t);if(i===f&&m.length>0){var u=m.length;return m=[],a.createElement(a.Fragment,{key:t},n.renderSkippedLineIndicator(u,r,e.left.lineNumber,e.right.lineNumber),l)}return l}))},n.render=function(){var e,t=n.props,r=t.oldValue,o=t.newValue,s=t.useDarkTheme,l=t.leftTitle,u=t.rightTitle,c=t.splitView,d=t.hideLineNumbers;if("string"!==typeof r||"string"!==typeof o)throw Error('"oldValue" and "newValue" should be strings');n.styles=n.computeStyles(n.props.styles,s);var p=n.renderDiff(),f=d?2:3,m=d?2:4,h=(l||u)&&a.createElement("tr",null,a.createElement("td",{colSpan:c?f:m,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},l)),c&&a.createElement("td",{colSpan:f,className:n.styles.titleBlock},a.createElement("pre",{className:n.styles.contentText},u)));return a.createElement("table",{className:i.default(n.styles.diffContainer,(e={},e[n.styles.splitView]=c,e))},a.createElement("tbody",null,h,p))},n.state={expandedBlocks:[]},n}return r(t,e),t.defaultProps={oldValue:"",newValue:"",splitView:!0,highlightLines:[],disableWordDiff:!1,compareMethod:s.DiffMethod.CHARS,styles:{},hideLineNumbers:!1,extraLinesSurroundingDiff:3,showDiffOnly:!0,useDarkTheme:!1,linesOffset:0},t.propTypes={oldValue:o.string.isRequired,newValue:o.string.isRequired,splitView:o.bool,disableWordDiff:o.bool,compareMethod:o.oneOf(Object.values(s.DiffMethod)),renderContent:o.func,onLineNumberClick:o.func,extraLinesSurroundingDiff:o.number,styles:o.object,hideLineNumbers:o.bool,showDiffOnly:o.bool,highlightLines:o.arrayOf(o.string),leftTitle:o.oneOfType([o.string,o.element]),rightTitle:o.oneOfType([o.string,o.element]),linesOffset:o.number},t}(a.Component);t.default=p},2813:function(e,t,n){"use strict";var r=this&&this.__assign||function(){return r=Object.assign||function(e){for(var t,n=1,r=arguments.length;n<r;n++)for(var a in t=arguments[n])Object.prototype.hasOwnProperty.call(t,a)&&(e[a]=t[a]);return e},r.apply(this,arguments)},a=this&&this.__rest||function(e,t){var n={};for(var r in e)Object.prototype.hasOwnProperty.call(e,r)&&t.indexOf(r)<0&&(n[r]=e[r]);if(null!=e&&"function"===typeof Object.getOwnPropertySymbols){var a=0;for(r=Object.getOwnPropertySymbols(e);a<r.length;a++)t.indexOf(r[a])<0&&Object.prototype.propertyIsEnumerable.call(e,r[a])&&(n[r[a]]=e[r[a]])}return n};Object.defineProperty(t,"__esModule",{value:!0});var o=n(6025);t.default=function(e,t){var n,i,s,l,u,c,d;void 0===t&&(t=!1);var p=e.variables,f=void 0===p?{}:p,m=a(e,["variables"]),h={light:r({diffViewerBackground:"#fff",diffViewerColor:"212529",addedBackground:"#e6ffed",addedColor:"#24292e",removedBackground:"#ffeef0",removedColor:"#24292e",wordAddedBackground:"#acf2bd",wordRemovedBackground:"#fdb8c0",addedGutterBackground:"#cdffd8",removedGutterBackground:"#ffdce0",gutterBackground:"#f7f7f7",gutterBackgroundDark:"#f3f1f1",highlightBackground:"#fffbdd",highlightGutterBackground:"#fff5b1",codeFoldGutterBackground:"#dbedff",codeFoldBackground:"#f1f8ff",emptyLineBackground:"#fafbfc",gutterColor:"#212529",addedGutterColor:"#212529",removedGutterColor:"#212529",codeFoldContentColor:"#212529",diffViewerTitleBackground:"#fafbfc",diffViewerTitleColor:"#212529",diffViewerTitleBorderColor:"#eee"},f.light||{}),dark:r({diffViewerBackground:"#2e303c",diffViewerColor:"#FFF",addedBackground:"#044B53",addedColor:"white",removedBackground:"#632F34",removedColor:"white",wordAddedBackground:"#055d67",wordRemovedBackground:"#7d383f",addedGutterBackground:"#034148",removedGutterBackground:"#632b30",gutterBackground:"#2c2f3a",gutterBackgroundDark:"#262933",highlightBackground:"#2a3967",highlightGutterBackground:"#2d4077",codeFoldGutterBackground:"#21232b",codeFoldBackground:"#262831",emptyLineBackground:"#363946",gutterColor:"#464c67",addedGutterColor:"#8c8c8c",removedGutterColor:"#8c8c8c",codeFoldContentColor:"#555a7b",diffViewerTitleBackground:"#2f323e",diffViewerTitleColor:"#555a7b",diffViewerTitleBorderColor:"#353846"},f.dark||{})},v=t?h.dark:h.light,y=o.css({width:"100%",label:"content"}),b=o.css(((n={})["."+y]={width:"50%"},n.label="split-view",n)),g=o.css({width:"100%",background:v.diffViewerBackground,pre:{margin:0,whiteSpace:"pre-wrap",lineHeight:"25px"},label:"diff-container",borderCollapse:"collapse"}),_=o.css({color:v.codeFoldContentColor,label:"code-fold-content"}),w=o.css({color:v.diffViewerColor,label:"content-text"}),S=o.css(((i={background:v.diffViewerTitleBackground,padding:10,borderBottom:"1px solid "+v.diffViewerTitleBorderColor,label:"title-block",":last-child":{borderLeft:"1px solid "+v.diffViewerTitleBorderColor}})["."+w]={color:v.diffViewerTitleColor},i)),k=o.css({color:v.gutterColor,label:"line-number"}),C=o.css(((s={background:v.removedBackground,color:v.removedColor,pre:{color:v.removedColor}})["."+k]={color:v.removedGutterColor},s.label="diff-removed",s)),T=o.css(((l={background:v.addedBackground,color:v.addedColor,pre:{color:v.addedColor}})["."+k]={color:v.addedGutterColor},l.label="diff-added",l)),x=o.css({padding:2,display:"inline-flex",borderRadius:1,label:"word-diff"}),P=o.css({background:v.wordAddedBackground,label:"word-added"}),E=o.css({background:v.wordRemovedBackground,label:"word-removed"}),A=o.css({backgroundColor:v.codeFoldGutterBackground,label:"code-fold-gutter"}),N=o.css({backgroundColor:v.codeFoldBackground,height:40,fontSize:14,fontWeight:700,label:"code-fold",a:{textDecoration:"underline !important",cursor:"pointer",pre:{display:"inline"}}}),F=o.css({backgroundColor:v.emptyLineBackground,label:"empty-line"}),O=o.css(((u={width:25,paddingLeft:10,paddingRight:10,userSelect:"none",label:"marker"})["&."+T]={pre:{color:v.addedColor}},u["&."+C]={pre:{color:v.removedColor}},u)),R=o.css(((c={background:v.highlightBackground,label:"highlighted-line"})["."+P+", ."+E]={backgroundColor:"initial"},c)),D=o.css({label:"highlighted-gutter"}),M=o.css(((d={userSelect:"none",minWidth:50,padding:"0 10px",label:"gutter",textAlign:"right",background:v.gutterBackground,"&:hover":{cursor:"pointer",background:v.gutterBackgroundDark,pre:{opacity:1}},pre:{opacity:.5}})["&."+T]={background:v.addedGutterBackground},d["&."+C]={background:v.removedGutterBackground},d["&."+D]={background:v.highlightGutterBackground,"&:hover":{background:v.highlightGutterBackground}},d)),I=o.css({"&:hover":{background:v.gutterBackground,cursor:"initial"},label:"empty-gutter"}),z={diffContainer:g,diffRemoved:C,diffAdded:T,splitView:b,marker:O,highlightedGutter:D,highlightedLine:R,gutter:M,line:o.css({verticalAlign:"baseline",label:"line"}),wordDiff:x,wordAdded:P,wordRemoved:E,codeFoldGutter:A,codeFold:N,emptyGutter:I,emptyLine:F,lineNumber:k,contentText:w,content:y,codeFoldContent:_,titleBlock:S},L=Object.keys(m).reduce((function(e,t){var n;return r({},e,((n={})[t]=o.css(m[t]),n))}),{});return Object.keys(z).reduce((function(e,t){var n;return r({},e,((n={})[t]=L[t]?o.cx(z[t],L[t]):z[t],n))}),{})}},4463:function(e,t,n){"use strict";var r=n(2791),a=n(5296);function o(e){for(var t="https://reactjs.org/docs/error-decoder.html?invariant="+e,n=1;n<arguments.length;n++)t+="&args[]="+encodeURIComponent(arguments[n]);return"Minified React error #"+e+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}var i=new Set,s={};function l(e,t){u(e,t),u(e+"Capture",t)}function u(e,t){for(s[e]=t,e=0;e<t.length;e++)i.add(t[e])}var c=!("undefined"===typeof window||"undefined"===typeof window.document||"undefined"===typeof window.document.createElement),d=Object.prototype.hasOwnProperty,p=/^[:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD][:A-Z_a-z\u00C0-\u00D6\u00D8-\u00F6\u00F8-\u02FF\u0370-\u037D\u037F-\u1FFF\u200C-\u200D\u2070-\u218F\u2C00-\u2FEF\u3001-\uD7FF\uF900-\uFDCF\uFDF0-\uFFFD\-.0-9\u00B7\u0300-\u036F\u203F-\u2040]*$/,f={},m={};function h(e,t,n,r,a,o,i){this.acceptsBooleans=2===t||3===t||4===t,this.attributeName=r,this.attributeNamespace=a,this.mustUseProperty=n,this.propertyName=e,this.type=t,this.sanitizeURL=o,this.removeEmptyString=i}var v={};"children dangerouslySetInnerHTML defaultValue defaultChecked innerHTML suppressContentEditableWarning suppressHydrationWarning style".split(" ").forEach((function(e){v[e]=new h(e,0,!1,e,null,!1,!1)})),[["acceptCharset","accept-charset"],["className","class"],["htmlFor","for"],["httpEquiv","http-equiv"]].forEach((function(e){var t=e[0];v[t]=new h(t,1,!1,e[1],null,!1,!1)})),["contentEditable","draggable","spellCheck","value"].forEach((function(e){v[e]=new h(e,2,!1,e.toLowerCase(),null,!1,!1)})),["autoReverse","externalResourcesRequired","focusable","preserveAlpha"].forEach((function(e){v[e]=new h(e,2,!1,e,null,!1,!1)})),"allowFullScreen async autoFocus autoPlay controls default defer disabled disablePictureInPicture disableRemotePlayback formNoValidate hidden loop noModule noValidate open playsInline readOnly required reversed scoped seamless itemScope".split(" ").forEach((function(e){v[e]=new h(e,3,!1,e.toLowerCase(),null,!1,!1)})),["checked","multiple","muted","selected"].forEach((function(e){v[e]=new h(e,3,!0,e,null,!1,!1)})),["capture","download"].forEach((function(e){v[e]=new h(e,4,!1,e,null,!1,!1)})),["cols","rows","size","span"].forEach((function(e){v[e]=new h(e,6,!1,e,null,!1,!1)})),["rowSpan","start"].forEach((function(e){v[e]=new h(e,5,!1,e.toLowerCase(),null,!1,!1)}));var y=/[\-:]([a-z])/g;function b(e){return e[1].toUpperCase()}function g(e,t,n,r){var a=v.hasOwnProperty(t)?v[t]:null;(null!==a?0!==a.type:r||!(2<t.length)||"o"!==t[0]&&"O"!==t[0]||"n"!==t[1]&&"N"!==t[1])&&(function(e,t,n,r){if(null===t||"undefined"===typeof t||function(e,t,n,r){if(null!==n&&0===n.type)return!1;switch(typeof t){case"function":case"symbol":return!0;case"boolean":return!r&&(null!==n?!n.acceptsBooleans:"data-"!==(e=e.toLowerCase().slice(0,5))&&"aria-"!==e);default:return!1}}(e,t,n,r))return!0;if(r)return!1;if(null!==n)switch(n.type){case 3:return!t;case 4:return!1===t;case 5:return isNaN(t);case 6:return isNaN(t)||1>t}return!1}(t,n,a,r)&&(n=null),r||null===a?function(e){return!!d.call(m,e)||!d.call(f,e)&&(p.test(e)?m[e]=!0:(f[e]=!0,!1))}(t)&&(null===n?e.removeAttribute(t):e.setAttribute(t,""+n)):a.mustUseProperty?e[a.propertyName]=null===n?3!==a.type&&"":n:(t=a.attributeName,r=a.attributeNamespace,null===n?e.removeAttribute(t):(n=3===(a=a.type)||4===a&&!0===n?"":""+n,r?e.setAttributeNS(r,t,n):e.setAttribute(t,n))))}"accent-height alignment-baseline arabic-form baseline-shift cap-height clip-path clip-rule color-interpolation color-interpolation-filters color-profile color-rendering dominant-baseline enable-background fill-opacity fill-rule flood-color flood-opacity font-family font-size font-size-adjust font-stretch font-style font-variant font-weight glyph-name glyph-orientation-horizontal glyph-orientation-vertical horiz-adv-x horiz-origin-x image-rendering letter-spacing lighting-color marker-end marker-mid marker-start overline-position overline-thickness paint-order panose-1 pointer-events rendering-intent shape-rendering stop-color stop-opacity strikethrough-position strikethrough-thickness stroke-dasharray stroke-dashoffset stroke-linecap stroke-linejoin stroke-miterlimit stroke-opacity stroke-width text-anchor text-decoration text-rendering underline-position underline-thickness unicode-bidi unicode-range units-per-em v-alphabetic v-hanging v-ideographic v-mathematical vector-effect vert-adv-y vert-origin-x vert-origin-y word-spacing writing-mode xmlns:xlink x-height".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,null,!1,!1)})),"xlink:actuate xlink:arcrole xlink:role xlink:show xlink:title xlink:type".split(" ").forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/1999/xlink",!1,!1)})),["xml:base","xml:lang","xml:space"].forEach((function(e){var t=e.replace(y,b);v[t]=new h(t,1,!1,e,"http://www.w3.org/XML/1998/namespace",!1,!1)})),["tabIndex","crossOrigin"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!1,!1)})),v.xlinkHref=new h("xlinkHref",1,!1,"xlink:href","http://www.w3.org/1999/xlink",!0,!1),["src","href","action","formAction"].forEach((function(e){v[e]=new h(e,1,!1,e.toLowerCase(),null,!0,!0)}));var _=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED,w=Symbol.for("react.element"),S=Symbol.for("react.portal"),k=Symbol.for("react.fragment"),C=Symbol.for("react.strict_mode"),T=Symbol.for("react.profiler"),x=Symbol.for("react.provider"),P=Symbol.for("react.context"),E=Symbol.for("react.forward_ref"),A=Symbol.for("react.suspense"),N=Symbol.for("react.suspense_list"),F=Symbol.for("react.memo"),O=Symbol.for("react.lazy");Symbol.for("react.scope"),Symbol.for("react.debug_trace_mode");var R=Symbol.for("react.offscreen");Symbol.for("react.legacy_hidden"),Symbol.for("react.cache"),Symbol.for("react.tracing_marker");var D=Symbol.iterator;function M(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=D&&e[D]||e["@@iterator"])?e:null}var I,z=Object.assign;function L(e){if(void 0===I)try{throw Error()}catch(n){var t=n.stack.trim().match(/\n( *(at )?)/);I=t&&t[1]||""}return"\n"+I+e}var Z=!1;function j(e,t){if(!e||Z)return"";Z=!0;var n=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{if(t)if(t=function(){throw Error()},Object.defineProperty(t.prototype,"props",{set:function(){throw Error()}}),"object"===typeof Reflect&&Reflect.construct){try{Reflect.construct(t,[])}catch(u){var r=u}Reflect.construct(e,[],t)}else{try{t.call()}catch(u){r=u}e.call(t.prototype)}else{try{throw Error()}catch(u){r=u}e()}}catch(u){if(u&&r&&"string"===typeof u.stack){for(var a=u.stack.split("\n"),o=r.stack.split("\n"),i=a.length-1,s=o.length-1;1<=i&&0<=s&&a[i]!==o[s];)s--;for(;1<=i&&0<=s;i--,s--)if(a[i]!==o[s]){if(1!==i||1!==s)do{if(i--,0>--s||a[i]!==o[s]){var l="\n"+a[i].replace(" at new "," at ");return e.displayName&&l.includes("<anonymous>")&&(l=l.replace("<anonymous>",e.displayName)),l}}while(1<=i&&0<=s);break}}}finally{Z=!1,Error.prepareStackTrace=n}return(e=e?e.displayName||e.name:"")?L(e):""}function B(e){switch(e.tag){case 5:return L(e.type);case 16:return L("Lazy");case 13:return L("Suspense");case 19:return L("SuspenseList");case 0:case 2:case 15:return e=j(e.type,!1);case 11:return e=j(e.type.render,!1);case 1:return e=j(e.type,!0);default:return""}}function W(e){if(null==e)return null;if("function"===typeof e)return e.displayName||e.name||null;if("string"===typeof e)return e;switch(e){case k:return"Fragment";case S:return"Portal";case T:return"Profiler";case C:return"StrictMode";case A:return"Suspense";case N:return"SuspenseList"}if("object"===typeof e)switch(e.$$typeof){case P:return(e.displayName||"Context")+".Consumer";case x:return(e._context.displayName||"Context")+".Provider";case E:var t=e.render;return(e=e.displayName)||(e=""!==(e=t.displayName||t.name||"")?"ForwardRef("+e+")":"ForwardRef"),e;case F:return null!==(t=e.displayName||null)?t:W(e.type)||"Memo";case O:t=e._payload,e=e._init;try{return W(e(t))}catch(n){}}return null}function J(e){var t=e.type;switch(e.tag){case 24:return"Cache";case 9:return(t.displayName||"Context")+".Consumer";case 10:return(t._context.displayName||"Context")+".Provider";case 18:return"DehydratedFragment";case 11:return e=(e=t.render).displayName||e.name||"",t.displayName||(""!==e?"ForwardRef("+e+")":"ForwardRef");case 7:return"Fragment";case 5:return t;case 4:return"Portal";case 3:return"Root";case 6:return"Text";case 16:return W(t);case 8:return t===C?"StrictMode":"Mode";case 22:return"Offscreen";case 12:return"Profiler";case 21:return"Scope";case 13:return"Suspense";case 19:return"SuspenseList";case 25:return"TracingMarker";case 1:case 0:case 17:case 2:case 14:case 15:if("function"===typeof t)return t.displayName||t.name||null;if("string"===typeof t)return t}return null}function V(e){switch(typeof e){case"boolean":case"number":case"string":case"undefined":case"object":return e;default:return""}}function U(e){var t=e.type;return(e=e.nodeName)&&"input"===e.toLowerCase()&&("checkbox"===t||"radio"===t)}function $(e){e._valueTracker||(e._valueTracker=function(e){var t=U(e)?"checked":"value",n=Object.getOwnPropertyDescriptor(e.constructor.prototype,t),r=""+e[t];if(!e.hasOwnProperty(t)&&"undefined"!==typeof n&&"function"===typeof n.get&&"function"===typeof n.set){var a=n.get,o=n.set;return Object.defineProperty(e,t,{configurable:!0,get:function(){return a.call(this)},set:function(e){r=""+e,o.call(this,e)}}),Object.defineProperty(e,t,{enumerable:n.enumerable}),{getValue:function(){return r},setValue:function(e){r=""+e},stopTracking:function(){e._valueTracker=null,delete e[t]}}}}(e))}function G(e){if(!e)return!1;var t=e._valueTracker;if(!t)return!0;var n=t.getValue(),r="";return e&&(r=U(e)?e.checked?"true":"false":e.value),(e=r)!==n&&(t.setValue(e),!0)}function H(e){if("undefined"===typeof(e=e||("undefined"!==typeof document?document:void 0)))return null;try{return e.activeElement||e.body}catch(t){return e.body}}function q(e,t){var n=t.checked;return z({},t,{defaultChecked:void 0,defaultValue:void 0,value:void 0,checked:null!=n?n:e._wrapperState.initialChecked})}function K(e,t){var n=null==t.defaultValue?"":t.defaultValue,r=null!=t.checked?t.checked:t.defaultChecked;n=V(null!=t.value?t.value:n),e._wrapperState={initialChecked:r,initialValue:n,controlled:"checkbox"===t.type||"radio"===t.type?null!=t.checked:null!=t.value}}function Q(e,t){null!=(t=t.checked)&&g(e,"checked",t,!1)}function Y(e,t){Q(e,t);var n=V(t.value),r=t.type;if(null!=n)"number"===r?(0===n&&""===e.value||e.value!=n)&&(e.value=""+n):e.value!==""+n&&(e.value=""+n);else if("submit"===r||"reset"===r)return void e.removeAttribute("value");t.hasOwnProperty("value")?ee(e,t.type,n):t.hasOwnProperty("defaultValue")&&ee(e,t.type,V(t.defaultValue)),null==t.checked&&null!=t.defaultChecked&&(e.defaultChecked=!!t.defaultChecked)}function X(e,t,n){if(t.hasOwnProperty("value")||t.hasOwnProperty("defaultValue")){var r=t.type;if(!("submit"!==r&&"reset"!==r||void 0!==t.value&&null!==t.value))return;t=""+e._wrapperState.initialValue,n||t===e.value||(e.value=t),e.defaultValue=t}""!==(n=e.name)&&(e.name=""),e.defaultChecked=!!e._wrapperState.initialChecked,""!==n&&(e.name=n)}function ee(e,t,n){"number"===t&&H(e.ownerDocument)===e||(null==n?e.defaultValue=""+e._wrapperState.initialValue:e.defaultValue!==""+n&&(e.defaultValue=""+n))}var te=Array.isArray;function ne(e,t,n,r){if(e=e.options,t){t={};for(var a=0;a<n.length;a++)t["$"+n[a]]=!0;for(n=0;n<e.length;n++)a=t.hasOwnProperty("$"+e[n].value),e[n].selected!==a&&(e[n].selected=a),a&&r&&(e[n].defaultSelected=!0)}else{for(n=""+V(n),t=null,a=0;a<e.length;a++){if(e[a].value===n)return e[a].selected=!0,void(r&&(e[a].defaultSelected=!0));null!==t||e[a].disabled||(t=e[a])}null!==t&&(t.selected=!0)}}function re(e,t){if(null!=t.dangerouslySetInnerHTML)throw Error(o(91));return z({},t,{value:void 0,defaultValue:void 0,children:""+e._wrapperState.initialValue})}function ae(e,t){var n=t.value;if(null==n){if(n=t.children,t=t.defaultValue,null!=n){if(null!=t)throw Error(o(92));if(te(n)){if(1<n.length)throw Error(o(93));n=n[0]}t=n}null==t&&(t=""),n=t}e._wrapperState={initialValue:V(n)}}function oe(e,t){var n=V(t.value),r=V(t.defaultValue);null!=n&&((n=""+n)!==e.value&&(e.value=n),null==t.defaultValue&&e.defaultValue!==n&&(e.defaultValue=n)),null!=r&&(e.defaultValue=""+r)}function ie(e){var t=e.textContent;t===e._wrapperState.initialValue&&""!==t&&null!==t&&(e.value=t)}function se(e){switch(e){case"svg":return"http://www.w3.org/2000/svg";case"math":return"http://www.w3.org/1998/Math/MathML";default:return"http://www.w3.org/1999/xhtml"}}function le(e,t){return null==e||"http://www.w3.org/1999/xhtml"===e?se(t):"http://www.w3.org/2000/svg"===e&&"foreignObject"===t?"http://www.w3.org/1999/xhtml":e}var ue,ce,de=(ce=function(e,t){if("http://www.w3.org/2000/svg"!==e.namespaceURI||"innerHTML"in e)e.innerHTML=t;else{for((ue=ue||document.createElement("div")).innerHTML="<svg>"+t.valueOf().toString()+"</svg>",t=ue.firstChild;e.firstChild;)e.removeChild(e.firstChild);for(;t.firstChild;)e.appendChild(t.firstChild)}},"undefined"!==typeof MSApp&&MSApp.execUnsafeLocalFunction?function(e,t,n,r){MSApp.execUnsafeLocalFunction((function(){return ce(e,t)}))}:ce);function pe(e,t){if(t){var n=e.firstChild;if(n&&n===e.lastChild&&3===n.nodeType)return void(n.nodeValue=t)}e.textContent=t}var fe={animationIterationCount:!0,aspectRatio:!0,borderImageOutset:!0,borderImageSlice:!0,borderImageWidth:!0,boxFlex:!0,boxFlexGroup:!0,boxOrdinalGroup:!0,columnCount:!0,columns:!0,flex:!0,flexGrow:!0,flexPositive:!0,flexShrink:!0,flexNegative:!0,flexOrder:!0,gridArea:!0,gridRow:!0,gridRowEnd:!0,gridRowSpan:!0,gridRowStart:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnSpan:!0,gridColumnStart:!0,fontWeight:!0,lineClamp:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,tabSize:!0,widows:!0,zIndex:!0,zoom:!0,fillOpacity:!0,floodOpacity:!0,stopOpacity:!0,strokeDasharray:!0,strokeDashoffset:!0,strokeMiterlimit:!0,strokeOpacity:!0,strokeWidth:!0},me=["Webkit","ms","Moz","O"];function he(e,t,n){return null==t||"boolean"===typeof t||""===t?"":n||"number"!==typeof t||0===t||fe.hasOwnProperty(e)&&fe[e]?(""+t).trim():t+"px"}function ve(e,t){for(var n in e=e.style,t)if(t.hasOwnProperty(n)){var r=0===n.indexOf("--"),a=he(n,t[n],r);"float"===n&&(n="cssFloat"),r?e.setProperty(n,a):e[n]=a}}Object.keys(fe).forEach((function(e){me.forEach((function(t){t=t+e.charAt(0).toUpperCase()+e.substring(1),fe[t]=fe[e]}))}));var ye=z({menuitem:!0},{area:!0,base:!0,br:!0,col:!0,embed:!0,hr:!0,img:!0,input:!0,keygen:!0,link:!0,meta:!0,param:!0,source:!0,track:!0,wbr:!0});function be(e,t){if(t){if(ye[e]&&(null!=t.children||null!=t.dangerouslySetInnerHTML))throw Error(o(137,e));if(null!=t.dangerouslySetInnerHTML){if(null!=t.children)throw Error(o(60));if("object"!==typeof t.dangerouslySetInnerHTML||!("__html"in t.dangerouslySetInnerHTML))throw Error(o(61))}if(null!=t.style&&"object"!==typeof t.style)throw Error(o(62))}}function ge(e,t){if(-1===e.indexOf("-"))return"string"===typeof t.is;switch(e){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var _e=null;function we(e){return(e=e.target||e.srcElement||window).correspondingUseElement&&(e=e.correspondingUseElement),3===e.nodeType?e.parentNode:e}var Se=null,ke=null,Ce=null;function Te(e){if(e=ga(e)){if("function"!==typeof Se)throw Error(o(280));var t=e.stateNode;t&&(t=wa(t),Se(e.stateNode,e.type,t))}}function xe(e){ke?Ce?Ce.push(e):Ce=[e]:ke=e}function Pe(){if(ke){var e=ke,t=Ce;if(Ce=ke=null,Te(e),t)for(e=0;e<t.length;e++)Te(t[e])}}function Ee(e,t){return e(t)}function Ae(){}var Ne=!1;function Fe(e,t,n){if(Ne)return e(t,n);Ne=!0;try{return Ee(e,t,n)}finally{Ne=!1,(null!==ke||null!==Ce)&&(Ae(),Pe())}}function Oe(e,t){var n=e.stateNode;if(null===n)return null;var r=wa(n);if(null===r)return null;n=r[t];e:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(r=!r.disabled)||(r=!("button"===(e=e.type)||"input"===e||"select"===e||"textarea"===e)),e=!r;break e;default:e=!1}if(e)return null;if(n&&"function"!==typeof n)throw Error(o(231,t,typeof n));return n}var Re=!1;if(c)try{var De={};Object.defineProperty(De,"passive",{get:function(){Re=!0}}),window.addEventListener("test",De,De),window.removeEventListener("test",De,De)}catch(ce){Re=!1}function Me(e,t,n,r,a,o,i,s,l){var u=Array.prototype.slice.call(arguments,3);try{t.apply(n,u)}catch(c){this.onError(c)}}var Ie=!1,ze=null,Le=!1,Ze=null,je={onError:function(e){Ie=!0,ze=e}};function Be(e,t,n,r,a,o,i,s,l){Ie=!1,ze=null,Me.apply(je,arguments)}function We(e){var t=e,n=e;if(e.alternate)for(;t.return;)t=t.return;else{e=t;do{0!==(4098&(t=e).flags)&&(n=t.return),e=t.return}while(e)}return 3===t.tag?n:null}function Je(e){if(13===e.tag){var t=e.memoizedState;if(null===t&&(null!==(e=e.alternate)&&(t=e.memoizedState)),null!==t)return t.dehydrated}return null}function Ve(e){if(We(e)!==e)throw Error(o(188))}function Ue(e){return null!==(e=function(e){var t=e.alternate;if(!t){if(null===(t=We(e)))throw Error(o(188));return t!==e?null:e}for(var n=e,r=t;;){var a=n.return;if(null===a)break;var i=a.alternate;if(null===i){if(null!==(r=a.return)){n=r;continue}break}if(a.child===i.child){for(i=a.child;i;){if(i===n)return Ve(a),e;if(i===r)return Ve(a),t;i=i.sibling}throw Error(o(188))}if(n.return!==r.return)n=a,r=i;else{for(var s=!1,l=a.child;l;){if(l===n){s=!0,n=a,r=i;break}if(l===r){s=!0,r=a,n=i;break}l=l.sibling}if(!s){for(l=i.child;l;){if(l===n){s=!0,n=i,r=a;break}if(l===r){s=!0,r=i,n=a;break}l=l.sibling}if(!s)throw Error(o(189))}}if(n.alternate!==r)throw Error(o(190))}if(3!==n.tag)throw Error(o(188));return n.stateNode.current===n?e:t}(e))?$e(e):null}function $e(e){if(5===e.tag||6===e.tag)return e;for(e=e.child;null!==e;){var t=$e(e);if(null!==t)return t;e=e.sibling}return null}var Ge=a.unstable_scheduleCallback,He=a.unstable_cancelCallback,qe=a.unstable_shouldYield,Ke=a.unstable_requestPaint,Qe=a.unstable_now,Ye=a.unstable_getCurrentPriorityLevel,Xe=a.unstable_ImmediatePriority,et=a.unstable_UserBlockingPriority,tt=a.unstable_NormalPriority,nt=a.unstable_LowPriority,rt=a.unstable_IdlePriority,at=null,ot=null;var it=Math.clz32?Math.clz32:function(e){return 0===(e>>>=0)?32:31-(st(e)/lt|0)|0},st=Math.log,lt=Math.LN2;var ut=64,ct=4194304;function dt(e){switch(e&-e){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return 4194240&e;case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:return 130023424&e;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 1073741824;default:return e}}function pt(e,t){var n=e.pendingLanes;if(0===n)return 0;var r=0,a=e.suspendedLanes,o=e.pingedLanes,i=268435455&n;if(0!==i){var s=i&~a;0!==s?r=dt(s):0!==(o&=i)&&(r=dt(o))}else 0!==(i=n&~a)?r=dt(i):0!==o&&(r=dt(o));if(0===r)return 0;if(0!==t&&t!==r&&0===(t&a)&&((a=r&-r)>=(o=t&-t)||16===a&&0!==(4194240&o)))return t;if(0!==(4&r)&&(r|=16&n),0!==(t=e.entangledLanes))for(e=e.entanglements,t&=r;0<t;)a=1<<(n=31-it(t)),r|=e[n],t&=~a;return r}function ft(e,t){switch(e){case 1:case 2:case 4:return t+250;case 8:case 16:case 32:case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;default:return-1}}function mt(e){return 0!==(e=-1073741825&e.pendingLanes)?e:1073741824&e?1073741824:0}function ht(){var e=ut;return 0===(4194240&(ut<<=1))&&(ut=64),e}function vt(e){for(var t=[],n=0;31>n;n++)t.push(e);return t}function yt(e,t,n){e.pendingLanes|=t,536870912!==t&&(e.suspendedLanes=0,e.pingedLanes=0),(e=e.eventTimes)[t=31-it(t)]=n}function bt(e,t){var n=e.entangledLanes|=t;for(e=e.entanglements;n;){var r=31-it(n),a=1<<r;a&t|e[r]&t&&(e[r]|=t),n&=~a}}var gt=0;function _t(e){return 1<(e&=-e)?4<e?0!==(268435455&e)?16:536870912:4:1}var wt,St,kt,Ct,Tt,xt=!1,Pt=[],Et=null,At=null,Nt=null,Ft=new Map,Ot=new Map,Rt=[],Dt="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset submit".split(" ");function Mt(e,t){switch(e){case"focusin":case"focusout":Et=null;break;case"dragenter":case"dragleave":At=null;break;case"mouseover":case"mouseout":Nt=null;break;case"pointerover":case"pointerout":Ft.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":Ot.delete(t.pointerId)}}function It(e,t,n,r,a,o){return null===e||e.nativeEvent!==o?(e={blockedOn:t,domEventName:n,eventSystemFlags:r,nativeEvent:o,targetContainers:[a]},null!==t&&(null!==(t=ga(t))&&St(t)),e):(e.eventSystemFlags|=r,t=e.targetContainers,null!==a&&-1===t.indexOf(a)&&t.push(a),e)}function zt(e){var t=ba(e.target);if(null!==t){var n=We(t);if(null!==n)if(13===(t=n.tag)){if(null!==(t=Je(n)))return e.blockedOn=t,void Tt(e.priority,(function(){kt(n)}))}else if(3===t&&n.stateNode.current.memoizedState.isDehydrated)return void(e.blockedOn=3===n.tag?n.stateNode.containerInfo:null)}e.blockedOn=null}function Lt(e){if(null!==e.blockedOn)return!1;for(var t=e.targetContainers;0<t.length;){var n=qt(e.domEventName,e.eventSystemFlags,t[0],e.nativeEvent);if(null!==n)return null!==(t=ga(n))&&St(t),e.blockedOn=n,!1;var r=new(n=e.nativeEvent).constructor(n.type,n);_e=r,n.target.dispatchEvent(r),_e=null,t.shift()}return!0}function Zt(e,t,n){Lt(e)&&n.delete(t)}function jt(){xt=!1,null!==Et&&Lt(Et)&&(Et=null),null!==At&&Lt(At)&&(At=null),null!==Nt&&Lt(Nt)&&(Nt=null),Ft.forEach(Zt),Ot.forEach(Zt)}function Bt(e,t){e.blockedOn===t&&(e.blockedOn=null,xt||(xt=!0,a.unstable_scheduleCallback(a.unstable_NormalPriority,jt)))}function Wt(e){function t(t){return Bt(t,e)}if(0<Pt.length){Bt(Pt[0],e);for(var n=1;n<Pt.length;n++){var r=Pt[n];r.blockedOn===e&&(r.blockedOn=null)}}for(null!==Et&&Bt(Et,e),null!==At&&Bt(At,e),null!==Nt&&Bt(Nt,e),Ft.forEach(t),Ot.forEach(t),n=0;n<Rt.length;n++)(r=Rt[n]).blockedOn===e&&(r.blockedOn=null);for(;0<Rt.length&&null===(n=Rt[0]).blockedOn;)zt(n),null===n.blockedOn&&Rt.shift()}var Jt=_.ReactCurrentBatchConfig,Vt=!0;function Ut(e,t,n,r){var a=gt,o=Jt.transition;Jt.transition=null;try{gt=1,Gt(e,t,n,r)}finally{gt=a,Jt.transition=o}}function $t(e,t,n,r){var a=gt,o=Jt.transition;Jt.transition=null;try{gt=4,Gt(e,t,n,r)}finally{gt=a,Jt.transition=o}}function Gt(e,t,n,r){if(Vt){var a=qt(e,t,n,r);if(null===a)Vr(e,t,r,Ht,n),Mt(e,r);else if(function(e,t,n,r,a){switch(t){case"focusin":return Et=It(Et,e,t,n,r,a),!0;case"dragenter":return At=It(At,e,t,n,r,a),!0;case"mouseover":return Nt=It(Nt,e,t,n,r,a),!0;case"pointerover":var o=a.pointerId;return Ft.set(o,It(Ft.get(o)||null,e,t,n,r,a)),!0;case"gotpointercapture":return o=a.pointerId,Ot.set(o,It(Ot.get(o)||null,e,t,n,r,a)),!0}return!1}(a,e,t,n,r))r.stopPropagation();else if(Mt(e,r),4&t&&-1<Dt.indexOf(e)){for(;null!==a;){var o=ga(a);if(null!==o&&wt(o),null===(o=qt(e,t,n,r))&&Vr(e,t,r,Ht,n),o===a)break;a=o}null!==a&&r.stopPropagation()}else Vr(e,t,r,null,n)}}var Ht=null;function qt(e,t,n,r){if(Ht=null,null!==(e=ba(e=we(r))))if(null===(t=We(e)))e=null;else if(13===(n=t.tag)){if(null!==(e=Je(t)))return e;e=null}else if(3===n){if(t.stateNode.current.memoizedState.isDehydrated)return 3===t.tag?t.stateNode.containerInfo:null;e=null}else t!==e&&(e=null);return Ht=e,null}function Kt(e){switch(e){case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 1;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"toggle":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 4;case"message":switch(Ye()){case Xe:return 1;case et:return 4;case tt:case nt:return 16;case rt:return 536870912;default:return 16}default:return 16}}var Qt=null,Yt=null,Xt=null;function en(){if(Xt)return Xt;var e,t,n=Yt,r=n.length,a="value"in Qt?Qt.value:Qt.textContent,o=a.length;for(e=0;e<r&&n[e]===a[e];e++);var i=r-e;for(t=1;t<=i&&n[r-t]===a[o-t];t++);return Xt=a.slice(e,1<t?1-t:void 0)}function tn(e){var t=e.keyCode;return"charCode"in e?0===(e=e.charCode)&&13===t&&(e=13):e=t,10===e&&(e=13),32<=e||13===e?e:0}function nn(){return!0}function rn(){return!1}function an(e){function t(t,n,r,a,o){for(var i in this._reactName=t,this._targetInst=r,this.type=n,this.nativeEvent=a,this.target=o,this.currentTarget=null,e)e.hasOwnProperty(i)&&(t=e[i],this[i]=t?t(a):a[i]);return this.isDefaultPrevented=(null!=a.defaultPrevented?a.defaultPrevented:!1===a.returnValue)?nn:rn,this.isPropagationStopped=rn,this}return z(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var e=this.nativeEvent;e&&(e.preventDefault?e.preventDefault():"unknown"!==typeof e.returnValue&&(e.returnValue=!1),this.isDefaultPrevented=nn)},stopPropagation:function(){var e=this.nativeEvent;e&&(e.stopPropagation?e.stopPropagation():"unknown"!==typeof e.cancelBubble&&(e.cancelBubble=!0),this.isPropagationStopped=nn)},persist:function(){},isPersistent:nn}),t}var on,sn,ln,un={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(e){return e.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},cn=an(un),dn=z({},un,{view:0,detail:0}),pn=an(dn),fn=z({},dn,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:Tn,button:0,buttons:0,relatedTarget:function(e){return void 0===e.relatedTarget?e.fromElement===e.srcElement?e.toElement:e.fromElement:e.relatedTarget},movementX:function(e){return"movementX"in e?e.movementX:(e!==ln&&(ln&&"mousemove"===e.type?(on=e.screenX-ln.screenX,sn=e.screenY-ln.screenY):sn=on=0,ln=e),on)},movementY:function(e){return"movementY"in e?e.movementY:sn}}),mn=an(fn),hn=an(z({},fn,{dataTransfer:0})),vn=an(z({},dn,{relatedTarget:0})),yn=an(z({},un,{animationName:0,elapsedTime:0,pseudoElement:0})),bn=z({},un,{clipboardData:function(e){return"clipboardData"in e?e.clipboardData:window.clipboardData}}),gn=an(bn),_n=an(z({},un,{data:0})),wn={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},Sn={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},kn={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Cn(e){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(e):!!(e=kn[e])&&!!t[e]}function Tn(){return Cn}var xn=z({},dn,{key:function(e){if(e.key){var t=wn[e.key]||e.key;if("Unidentified"!==t)return t}return"keypress"===e.type?13===(e=tn(e))?"Enter":String.fromCharCode(e):"keydown"===e.type||"keyup"===e.type?Sn[e.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:Tn,charCode:function(e){return"keypress"===e.type?tn(e):0},keyCode:function(e){return"keydown"===e.type||"keyup"===e.type?e.keyCode:0},which:function(e){return"keypress"===e.type?tn(e):"keydown"===e.type||"keyup"===e.type?e.keyCode:0}}),Pn=an(xn),En=an(z({},fn,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0})),An=an(z({},dn,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:Tn})),Nn=an(z({},un,{propertyName:0,elapsedTime:0,pseudoElement:0})),Fn=z({},fn,{deltaX:function(e){return"deltaX"in e?e.deltaX:"wheelDeltaX"in e?-e.wheelDeltaX:0},deltaY:function(e){return"deltaY"in e?e.deltaY:"wheelDeltaY"in e?-e.wheelDeltaY:"wheelDelta"in e?-e.wheelDelta:0},deltaZ:0,deltaMode:0}),On=an(Fn),Rn=[9,13,27,32],Dn=c&&"CompositionEvent"in window,Mn=null;c&&"documentMode"in document&&(Mn=document.documentMode);var In=c&&"TextEvent"in window&&!Mn,zn=c&&(!Dn||Mn&&8<Mn&&11>=Mn),Ln=String.fromCharCode(32),Zn=!1;function jn(e,t){switch(e){case"keyup":return-1!==Rn.indexOf(t.keyCode);case"keydown":return 229!==t.keyCode;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function Bn(e){return"object"===typeof(e=e.detail)&&"data"in e?e.data:null}var Wn=!1;var Jn={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function Vn(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return"input"===t?!!Jn[e.type]:"textarea"===t}function Un(e,t,n,r){xe(r),0<(t=$r(t,"onChange")).length&&(n=new cn("onChange","change",null,n,r),e.push({event:n,listeners:t}))}var $n=null,Gn=null;function Hn(e){Lr(e,0)}function qn(e){if(G(_a(e)))return e}function Kn(e,t){if("change"===e)return t}var Qn=!1;if(c){var Yn;if(c){var Xn="oninput"in document;if(!Xn){var er=document.createElement("div");er.setAttribute("oninput","return;"),Xn="function"===typeof er.oninput}Yn=Xn}else Yn=!1;Qn=Yn&&(!document.documentMode||9<document.documentMode)}function tr(){$n&&($n.detachEvent("onpropertychange",nr),Gn=$n=null)}function nr(e){if("value"===e.propertyName&&qn(Gn)){var t=[];Un(t,Gn,e,we(e)),Fe(Hn,t)}}function rr(e,t,n){"focusin"===e?(tr(),Gn=n,($n=t).attachEvent("onpropertychange",nr)):"focusout"===e&&tr()}function ar(e){if("selectionchange"===e||"keyup"===e||"keydown"===e)return qn(Gn)}function or(e,t){if("click"===e)return qn(t)}function ir(e,t){if("input"===e||"change"===e)return qn(t)}var sr="function"===typeof Object.is?Object.is:function(e,t){return e===t&&(0!==e||1/e===1/t)||e!==e&&t!==t};function lr(e,t){if(sr(e,t))return!0;if("object"!==typeof e||null===e||"object"!==typeof t||null===t)return!1;var n=Object.keys(e),r=Object.keys(t);if(n.length!==r.length)return!1;for(r=0;r<n.length;r++){var a=n[r];if(!d.call(t,a)||!sr(e[a],t[a]))return!1}return!0}function ur(e){for(;e&&e.firstChild;)e=e.firstChild;return e}function cr(e,t){var n,r=ur(e);for(e=0;r;){if(3===r.nodeType){if(n=e+r.textContent.length,e<=t&&n>=t)return{node:r,offset:t-e};e=n}e:{for(;r;){if(r.nextSibling){r=r.nextSibling;break e}r=r.parentNode}r=void 0}r=ur(r)}}function dr(e,t){return!(!e||!t)&&(e===t||(!e||3!==e.nodeType)&&(t&&3===t.nodeType?dr(e,t.parentNode):"contains"in e?e.contains(t):!!e.compareDocumentPosition&&!!(16&e.compareDocumentPosition(t))))}function pr(){for(var e=window,t=H();t instanceof e.HTMLIFrameElement;){try{var n="string"===typeof t.contentWindow.location.href}catch(r){n=!1}if(!n)break;t=H((e=t.contentWindow).document)}return t}function fr(e){var t=e&&e.nodeName&&e.nodeName.toLowerCase();return t&&("input"===t&&("text"===e.type||"search"===e.type||"tel"===e.type||"url"===e.type||"password"===e.type)||"textarea"===t||"true"===e.contentEditable)}function mr(e){var t=pr(),n=e.focusedElem,r=e.selectionRange;if(t!==n&&n&&n.ownerDocument&&dr(n.ownerDocument.documentElement,n)){if(null!==r&&fr(n))if(t=r.start,void 0===(e=r.end)&&(e=t),"selectionStart"in n)n.selectionStart=t,n.selectionEnd=Math.min(e,n.value.length);else if((e=(t=n.ownerDocument||document)&&t.defaultView||window).getSelection){e=e.getSelection();var a=n.textContent.length,o=Math.min(r.start,a);r=void 0===r.end?o:Math.min(r.end,a),!e.extend&&o>r&&(a=r,r=o,o=a),a=cr(n,o);var i=cr(n,r);a&&i&&(1!==e.rangeCount||e.anchorNode!==a.node||e.anchorOffset!==a.offset||e.focusNode!==i.node||e.focusOffset!==i.offset)&&((t=t.createRange()).setStart(a.node,a.offset),e.removeAllRanges(),o>r?(e.addRange(t),e.extend(i.node,i.offset)):(t.setEnd(i.node,i.offset),e.addRange(t)))}for(t=[],e=n;e=e.parentNode;)1===e.nodeType&&t.push({element:e,left:e.scrollLeft,top:e.scrollTop});for("function"===typeof n.focus&&n.focus(),n=0;n<t.length;n++)(e=t[n]).element.scrollLeft=e.left,e.element.scrollTop=e.top}}var hr=c&&"documentMode"in document&&11>=document.documentMode,vr=null,yr=null,br=null,gr=!1;function _r(e,t,n){var r=n.window===n?n.document:9===n.nodeType?n:n.ownerDocument;gr||null==vr||vr!==H(r)||("selectionStart"in(r=vr)&&fr(r)?r={start:r.selectionStart,end:r.selectionEnd}:r={anchorNode:(r=(r.ownerDocument&&r.ownerDocument.defaultView||window).getSelection()).anchorNode,anchorOffset:r.anchorOffset,focusNode:r.focusNode,focusOffset:r.focusOffset},br&&lr(br,r)||(br=r,0<(r=$r(yr,"onSelect")).length&&(t=new cn("onSelect","select",null,t,n),e.push({event:t,listeners:r}),t.target=vr)))}function wr(e,t){var n={};return n[e.toLowerCase()]=t.toLowerCase(),n["Webkit"+e]="webkit"+t,n["Moz"+e]="moz"+t,n}var Sr={animationend:wr("Animation","AnimationEnd"),animationiteration:wr("Animation","AnimationIteration"),animationstart:wr("Animation","AnimationStart"),transitionend:wr("Transition","TransitionEnd")},kr={},Cr={};function Tr(e){if(kr[e])return kr[e];if(!Sr[e])return e;var t,n=Sr[e];for(t in n)if(n.hasOwnProperty(t)&&t in Cr)return kr[e]=n[t];return e}c&&(Cr=document.createElement("div").style,"AnimationEvent"in window||(delete Sr.animationend.animation,delete Sr.animationiteration.animation,delete Sr.animationstart.animation),"TransitionEvent"in window||delete Sr.transitionend.transition);var xr=Tr("animationend"),Pr=Tr("animationiteration"),Er=Tr("animationstart"),Ar=Tr("transitionend"),Nr=new Map,Fr="abort auxClick cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");function Or(e,t){Nr.set(e,t),l(t,[e])}for(var Rr=0;Rr<Fr.length;Rr++){var Dr=Fr[Rr];Or(Dr.toLowerCase(),"on"+(Dr[0].toUpperCase()+Dr.slice(1)))}Or(xr,"onAnimationEnd"),Or(Pr,"onAnimationIteration"),Or(Er,"onAnimationStart"),Or("dblclick","onDoubleClick"),Or("focusin","onFocus"),Or("focusout","onBlur"),Or(Ar,"onTransitionEnd"),u("onMouseEnter",["mouseout","mouseover"]),u("onMouseLeave",["mouseout","mouseover"]),u("onPointerEnter",["pointerout","pointerover"]),u("onPointerLeave",["pointerout","pointerover"]),l("onChange","change click focusin focusout input keydown keyup selectionchange".split(" ")),l("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" ")),l("onBeforeInput",["compositionend","keypress","textInput","paste"]),l("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" ")),l("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var Mr="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Ir=new Set("cancel close invalid load scroll toggle".split(" ").concat(Mr));function zr(e,t,n){var r=e.type||"unknown-event";e.currentTarget=n,function(e,t,n,r,a,i,s,l,u){if(Be.apply(this,arguments),Ie){if(!Ie)throw Error(o(198));var c=ze;Ie=!1,ze=null,Le||(Le=!0,Ze=c)}}(r,t,void 0,e),e.currentTarget=null}function Lr(e,t){t=0!==(4&t);for(var n=0;n<e.length;n++){var r=e[n],a=r.event;r=r.listeners;e:{var o=void 0;if(t)for(var i=r.length-1;0<=i;i--){var s=r[i],l=s.instance,u=s.currentTarget;if(s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,u),o=l}else for(i=0;i<r.length;i++){if(l=(s=r[i]).instance,u=s.currentTarget,s=s.listener,l!==o&&a.isPropagationStopped())break e;zr(a,s,u),o=l}}}if(Le)throw e=Ze,Le=!1,Ze=null,e}function Zr(e,t){var n=t[ha];void 0===n&&(n=t[ha]=new Set);var r=e+"__bubble";n.has(r)||(Jr(t,e,2,!1),n.add(r))}function jr(e,t,n){var r=0;t&&(r|=4),Jr(n,e,r,t)}var Br="_reactListening"+Math.random().toString(36).slice(2);function Wr(e){if(!e[Br]){e[Br]=!0,i.forEach((function(t){"selectionchange"!==t&&(Ir.has(t)||jr(t,!1,e),jr(t,!0,e))}));var t=9===e.nodeType?e:e.ownerDocument;null===t||t[Br]||(t[Br]=!0,jr("selectionchange",!1,t))}}function Jr(e,t,n,r){switch(Kt(t)){case 1:var a=Ut;break;case 4:a=$t;break;default:a=Gt}n=a.bind(null,t,n,e),a=void 0,!Re||"touchstart"!==t&&"touchmove"!==t&&"wheel"!==t||(a=!0),r?void 0!==a?e.addEventListener(t,n,{capture:!0,passive:a}):e.addEventListener(t,n,!0):void 0!==a?e.addEventListener(t,n,{passive:a}):e.addEventListener(t,n,!1)}function Vr(e,t,n,r,a){var o=r;if(0===(1&t)&&0===(2&t)&&null!==r)e:for(;;){if(null===r)return;var i=r.tag;if(3===i||4===i){var s=r.stateNode.containerInfo;if(s===a||8===s.nodeType&&s.parentNode===a)break;if(4===i)for(i=r.return;null!==i;){var l=i.tag;if((3===l||4===l)&&((l=i.stateNode.containerInfo)===a||8===l.nodeType&&l.parentNode===a))return;i=i.return}for(;null!==s;){if(null===(i=ba(s)))return;if(5===(l=i.tag)||6===l){r=o=i;continue e}s=s.parentNode}}r=r.return}Fe((function(){var r=o,a=we(n),i=[];e:{var s=Nr.get(e);if(void 0!==s){var l=cn,u=e;switch(e){case"keypress":if(0===tn(n))break e;case"keydown":case"keyup":l=Pn;break;case"focusin":u="focus",l=vn;break;case"focusout":u="blur",l=vn;break;case"beforeblur":case"afterblur":l=vn;break;case"click":if(2===n.button)break e;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":l=mn;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":l=hn;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":l=An;break;case xr:case Pr:case Er:l=yn;break;case Ar:l=Nn;break;case"scroll":l=pn;break;case"wheel":l=On;break;case"copy":case"cut":case"paste":l=gn;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":l=En}var c=0!==(4&t),d=!c&&"scroll"===e,p=c?null!==s?s+"Capture":null:s;c=[];for(var f,m=r;null!==m;){var h=(f=m).stateNode;if(5===f.tag&&null!==h&&(f=h,null!==p&&(null!=(h=Oe(m,p))&&c.push(Ur(m,h,f)))),d)break;m=m.return}0<c.length&&(s=new l(s,u,null,n,a),i.push({event:s,listeners:c}))}}if(0===(7&t)){if(l="mouseout"===e||"pointerout"===e,(!(s="mouseover"===e||"pointerover"===e)||n===_e||!(u=n.relatedTarget||n.fromElement)||!ba(u)&&!u[ma])&&(l||s)&&(s=a.window===a?a:(s=a.ownerDocument)?s.defaultView||s.parentWindow:window,l?(l=r,null!==(u=(u=n.relatedTarget||n.toElement)?ba(u):null)&&(u!==(d=We(u))||5!==u.tag&&6!==u.tag)&&(u=null)):(l=null,u=r),l!==u)){if(c=mn,h="onMouseLeave",p="onMouseEnter",m="mouse","pointerout"!==e&&"pointerover"!==e||(c=En,h="onPointerLeave",p="onPointerEnter",m="pointer"),d=null==l?s:_a(l),f=null==u?s:_a(u),(s=new c(h,m+"leave",l,n,a)).target=d,s.relatedTarget=f,h=null,ba(a)===r&&((c=new c(p,m+"enter",u,n,a)).target=f,c.relatedTarget=d,h=c),d=h,l&&u)e:{for(p=u,m=0,f=c=l;f;f=Gr(f))m++;for(f=0,h=p;h;h=Gr(h))f++;for(;0<m-f;)c=Gr(c),m--;for(;0<f-m;)p=Gr(p),f--;for(;m--;){if(c===p||null!==p&&c===p.alternate)break e;c=Gr(c),p=Gr(p)}c=null}else c=null;null!==l&&Hr(i,s,l,c,!1),null!==u&&null!==d&&Hr(i,d,u,c,!0)}if("select"===(l=(s=r?_a(r):window).nodeName&&s.nodeName.toLowerCase())||"input"===l&&"file"===s.type)var v=Kn;else if(Vn(s))if(Qn)v=ir;else{v=ar;var y=rr}else(l=s.nodeName)&&"input"===l.toLowerCase()&&("checkbox"===s.type||"radio"===s.type)&&(v=or);switch(v&&(v=v(e,r))?Un(i,v,n,a):(y&&y(e,s,r),"focusout"===e&&(y=s._wrapperState)&&y.controlled&&"number"===s.type&&ee(s,"number",s.value)),y=r?_a(r):window,e){case"focusin":(Vn(y)||"true"===y.contentEditable)&&(vr=y,yr=r,br=null);break;case"focusout":br=yr=vr=null;break;case"mousedown":gr=!0;break;case"contextmenu":case"mouseup":case"dragend":gr=!1,_r(i,n,a);break;case"selectionchange":if(hr)break;case"keydown":case"keyup":_r(i,n,a)}var b;if(Dn)e:{switch(e){case"compositionstart":var g="onCompositionStart";break e;case"compositionend":g="onCompositionEnd";break e;case"compositionupdate":g="onCompositionUpdate";break e}g=void 0}else Wn?jn(e,n)&&(g="onCompositionEnd"):"keydown"===e&&229===n.keyCode&&(g="onCompositionStart");g&&(zn&&"ko"!==n.locale&&(Wn||"onCompositionStart"!==g?"onCompositionEnd"===g&&Wn&&(b=en()):(Yt="value"in(Qt=a)?Qt.value:Qt.textContent,Wn=!0)),0<(y=$r(r,g)).length&&(g=new _n(g,e,null,n,a),i.push({event:g,listeners:y}),b?g.data=b:null!==(b=Bn(n))&&(g.data=b))),(b=In?function(e,t){switch(e){case"compositionend":return Bn(t);case"keypress":return 32!==t.which?null:(Zn=!0,Ln);case"textInput":return(e=t.data)===Ln&&Zn?null:e;default:return null}}(e,n):function(e,t){if(Wn)return"compositionend"===e||!Dn&&jn(e,t)?(e=en(),Xt=Yt=Qt=null,Wn=!1,e):null;switch(e){case"paste":default:return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return zn&&"ko"!==t.locale?null:t.data}}(e,n))&&(0<(r=$r(r,"onBeforeInput")).length&&(a=new _n("onBeforeInput","beforeinput",null,n,a),i.push({event:a,listeners:r}),a.data=b))}Lr(i,t)}))}function Ur(e,t,n){return{instance:e,listener:t,currentTarget:n}}function $r(e,t){for(var n=t+"Capture",r=[];null!==e;){var a=e,o=a.stateNode;5===a.tag&&null!==o&&(a=o,null!=(o=Oe(e,n))&&r.unshift(Ur(e,o,a)),null!=(o=Oe(e,t))&&r.push(Ur(e,o,a))),e=e.return}return r}function Gr(e){if(null===e)return null;do{e=e.return}while(e&&5!==e.tag);return e||null}function Hr(e,t,n,r,a){for(var o=t._reactName,i=[];null!==n&&n!==r;){var s=n,l=s.alternate,u=s.stateNode;if(null!==l&&l===r)break;5===s.tag&&null!==u&&(s=u,a?null!=(l=Oe(n,o))&&i.unshift(Ur(n,l,s)):a||null!=(l=Oe(n,o))&&i.push(Ur(n,l,s))),n=n.return}0!==i.length&&e.push({event:t,listeners:i})}var qr=/\r\n?/g,Kr=/\u0000|\uFFFD/g;function Qr(e){return("string"===typeof e?e:""+e).replace(qr,"\n").replace(Kr,"")}function Yr(e,t,n){if(t=Qr(t),Qr(e)!==t&&n)throw Error(o(425))}function Xr(){}var ea=null,ta=null;function na(e,t){return"textarea"===e||"noscript"===e||"string"===typeof t.children||"number"===typeof t.children||"object"===typeof t.dangerouslySetInnerHTML&&null!==t.dangerouslySetInnerHTML&&null!=t.dangerouslySetInnerHTML.__html}var ra="function"===typeof setTimeout?setTimeout:void 0,aa="function"===typeof clearTimeout?clearTimeout:void 0,oa="function"===typeof Promise?Promise:void 0,ia="function"===typeof queueMicrotask?queueMicrotask:"undefined"!==typeof oa?function(e){return oa.resolve(null).then(e).catch(sa)}:ra;function sa(e){setTimeout((function(){throw e}))}function la(e,t){var n=t,r=0;do{var a=n.nextSibling;if(e.removeChild(n),a&&8===a.nodeType)if("/$"===(n=a.data)){if(0===r)return e.removeChild(a),void Wt(t);r--}else"$"!==n&&"$?"!==n&&"$!"!==n||r++;n=a}while(n);Wt(t)}function ua(e){for(;null!=e;e=e.nextSibling){var t=e.nodeType;if(1===t||3===t)break;if(8===t){if("$"===(t=e.data)||"$!"===t||"$?"===t)break;if("/$"===t)return null}}return e}function ca(e){e=e.previousSibling;for(var t=0;e;){if(8===e.nodeType){var n=e.data;if("$"===n||"$!"===n||"$?"===n){if(0===t)return e;t--}else"/$"===n&&t++}e=e.previousSibling}return null}var da=Math.random().toString(36).slice(2),pa="__reactFiber$"+da,fa="__reactProps$"+da,ma="__reactContainer$"+da,ha="__reactEvents$"+da,va="__reactListeners$"+da,ya="__reactHandles$"+da;function ba(e){var t=e[pa];if(t)return t;for(var n=e.parentNode;n;){if(t=n[ma]||n[pa]){if(n=t.alternate,null!==t.child||null!==n&&null!==n.child)for(e=ca(e);null!==e;){if(n=e[pa])return n;e=ca(e)}return t}n=(e=n).parentNode}return null}function ga(e){return!(e=e[pa]||e[ma])||5!==e.tag&&6!==e.tag&&13!==e.tag&&3!==e.tag?null:e}function _a(e){if(5===e.tag||6===e.tag)return e.stateNode;throw Error(o(33))}function wa(e){return e[fa]||null}var Sa=[],ka=-1;function Ca(e){return{current:e}}function Ta(e){0>ka||(e.current=Sa[ka],Sa[ka]=null,ka--)}function xa(e,t){ka++,Sa[ka]=e.current,e.current=t}var Pa={},Ea=Ca(Pa),Aa=Ca(!1),Na=Pa;function Fa(e,t){var n=e.type.contextTypes;if(!n)return Pa;var r=e.stateNode;if(r&&r.__reactInternalMemoizedUnmaskedChildContext===t)return r.__reactInternalMemoizedMaskedChildContext;var a,o={};for(a in n)o[a]=t[a];return r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=t,e.__reactInternalMemoizedMaskedChildContext=o),o}function Oa(e){return null!==(e=e.childContextTypes)&&void 0!==e}function Ra(){Ta(Aa),Ta(Ea)}function Da(e,t,n){if(Ea.current!==Pa)throw Error(o(168));xa(Ea,t),xa(Aa,n)}function Ma(e,t,n){var r=e.stateNode;if(t=t.childContextTypes,"function"!==typeof r.getChildContext)return n;for(var a in r=r.getChildContext())if(!(a in t))throw Error(o(108,J(e)||"Unknown",a));return z({},n,r)}function Ia(e){return e=(e=e.stateNode)&&e.__reactInternalMemoizedMergedChildContext||Pa,Na=Ea.current,xa(Ea,e),xa(Aa,Aa.current),!0}function za(e,t,n){var r=e.stateNode;if(!r)throw Error(o(169));n?(e=Ma(e,t,Na),r.__reactInternalMemoizedMergedChildContext=e,Ta(Aa),Ta(Ea),xa(Ea,e)):Ta(Aa),xa(Aa,n)}var La=null,Za=!1,ja=!1;function Ba(e){null===La?La=[e]:La.push(e)}function Wa(){if(!ja&&null!==La){ja=!0;var e=0,t=gt;try{var n=La;for(gt=1;e<n.length;e++){var r=n[e];do{r=r(!0)}while(null!==r)}La=null,Za=!1}catch(a){throw null!==La&&(La=La.slice(e+1)),Ge(Xe,Wa),a}finally{gt=t,ja=!1}}return null}var Ja=[],Va=0,Ua=null,$a=0,Ga=[],Ha=0,qa=null,Ka=1,Qa="";function Ya(e,t){Ja[Va++]=$a,Ja[Va++]=Ua,Ua=e,$a=t}function Xa(e,t,n){Ga[Ha++]=Ka,Ga[Ha++]=Qa,Ga[Ha++]=qa,qa=e;var r=Ka;e=Qa;var a=32-it(r)-1;r&=~(1<<a),n+=1;var o=32-it(t)+a;if(30<o){var i=a-a%5;o=(r&(1<<i)-1).toString(32),r>>=i,a-=i,Ka=1<<32-it(t)+a|n<<a|r,Qa=o+e}else Ka=1<<o|n<<a|r,Qa=e}function eo(e){null!==e.return&&(Ya(e,1),Xa(e,1,0))}function to(e){for(;e===Ua;)Ua=Ja[--Va],Ja[Va]=null,$a=Ja[--Va],Ja[Va]=null;for(;e===qa;)qa=Ga[--Ha],Ga[Ha]=null,Qa=Ga[--Ha],Ga[Ha]=null,Ka=Ga[--Ha],Ga[Ha]=null}var no=null,ro=null,ao=!1,oo=null;function io(e,t){var n=Fu(5,null,null,0);n.elementType="DELETED",n.stateNode=t,n.return=e,null===(t=e.deletions)?(e.deletions=[n],e.flags|=16):t.push(n)}function so(e,t){switch(e.tag){case 5:var n=e.type;return null!==(t=1!==t.nodeType||n.toLowerCase()!==t.nodeName.toLowerCase()?null:t)&&(e.stateNode=t,no=e,ro=ua(t.firstChild),!0);case 6:return null!==(t=""===e.pendingProps||3!==t.nodeType?null:t)&&(e.stateNode=t,no=e,ro=null,!0);case 13:return null!==(t=8!==t.nodeType?null:t)&&(n=null!==qa?{id:Ka,overflow:Qa}:null,e.memoizedState={dehydrated:t,treeContext:n,retryLane:1073741824},(n=Fu(18,null,null,0)).stateNode=t,n.return=e,e.child=n,no=e,ro=null,!0);default:return!1}}function lo(e){return 0!==(1&e.mode)&&0===(128&e.flags)}function uo(e){if(ao){var t=ro;if(t){var n=t;if(!so(e,t)){if(lo(e))throw Error(o(418));t=ua(n.nextSibling);var r=no;t&&so(e,t)?io(r,n):(e.flags=-4097&e.flags|2,ao=!1,no=e)}}else{if(lo(e))throw Error(o(418));e.flags=-4097&e.flags|2,ao=!1,no=e}}}function co(e){for(e=e.return;null!==e&&5!==e.tag&&3!==e.tag&&13!==e.tag;)e=e.return;no=e}function po(e){if(e!==no)return!1;if(!ao)return co(e),ao=!0,!1;var t;if((t=3!==e.tag)&&!(t=5!==e.tag)&&(t="head"!==(t=e.type)&&"body"!==t&&!na(e.type,e.memoizedProps)),t&&(t=ro)){if(lo(e))throw fo(),Error(o(418));for(;t;)io(e,t),t=ua(t.nextSibling)}if(co(e),13===e.tag){if(!(e=null!==(e=e.memoizedState)?e.dehydrated:null))throw Error(o(317));e:{for(e=e.nextSibling,t=0;e;){if(8===e.nodeType){var n=e.data;if("/$"===n){if(0===t){ro=ua(e.nextSibling);break e}t--}else"$"!==n&&"$!"!==n&&"$?"!==n||t++}e=e.nextSibling}ro=null}}else ro=no?ua(e.stateNode.nextSibling):null;return!0}function fo(){for(var e=ro;e;)e=ua(e.nextSibling)}function mo(){ro=no=null,ao=!1}function ho(e){null===oo?oo=[e]:oo.push(e)}var vo=_.ReactCurrentBatchConfig;function yo(e,t){if(e&&e.defaultProps){for(var n in t=z({},t),e=e.defaultProps)void 0===t[n]&&(t[n]=e[n]);return t}return t}var bo=Ca(null),go=null,_o=null,wo=null;function So(){wo=_o=go=null}function ko(e){var t=bo.current;Ta(bo),e._currentValue=t}function Co(e,t,n){for(;null!==e;){var r=e.alternate;if((e.childLanes&t)!==t?(e.childLanes|=t,null!==r&&(r.childLanes|=t)):null!==r&&(r.childLanes&t)!==t&&(r.childLanes|=t),e===n)break;e=e.return}}function To(e,t){go=e,wo=_o=null,null!==(e=e.dependencies)&&null!==e.firstContext&&(0!==(e.lanes&t)&&(_s=!0),e.firstContext=null)}function xo(e){var t=e._currentValue;if(wo!==e)if(e={context:e,memoizedValue:t,next:null},null===_o){if(null===go)throw Error(o(308));_o=e,go.dependencies={lanes:0,firstContext:e}}else _o=_o.next=e;return t}var Po=null;function Eo(e){null===Po?Po=[e]:Po.push(e)}function Ao(e,t,n,r){var a=t.interleaved;return null===a?(n.next=n,Eo(t)):(n.next=a.next,a.next=n),t.interleaved=n,No(e,r)}function No(e,t){e.lanes|=t;var n=e.alternate;for(null!==n&&(n.lanes|=t),n=e,e=e.return;null!==e;)e.childLanes|=t,null!==(n=e.alternate)&&(n.childLanes|=t),n=e,e=e.return;return 3===n.tag?n.stateNode:null}var Fo=!1;function Oo(e){e.updateQueue={baseState:e.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,interleaved:null,lanes:0},effects:null}}function Ro(e,t){e=e.updateQueue,t.updateQueue===e&&(t.updateQueue={baseState:e.baseState,firstBaseUpdate:e.firstBaseUpdate,lastBaseUpdate:e.lastBaseUpdate,shared:e.shared,effects:e.effects})}function Do(e,t){return{eventTime:e,lane:t,tag:0,payload:null,callback:null,next:null}}function Mo(e,t,n){var r=e.updateQueue;if(null===r)return null;if(r=r.shared,0!==(2&El)){var a=r.pending;return null===a?t.next=t:(t.next=a.next,a.next=t),r.pending=t,No(e,n)}return null===(a=r.interleaved)?(t.next=t,Eo(r)):(t.next=a.next,a.next=t),r.interleaved=t,No(e,n)}function Io(e,t,n){if(null!==(t=t.updateQueue)&&(t=t.shared,0!==(4194240&n))){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}function zo(e,t){var n=e.updateQueue,r=e.alternate;if(null!==r&&n===(r=r.updateQueue)){var a=null,o=null;if(null!==(n=n.firstBaseUpdate)){do{var i={eventTime:n.eventTime,lane:n.lane,tag:n.tag,payload:n.payload,callback:n.callback,next:null};null===o?a=o=i:o=o.next=i,n=n.next}while(null!==n);null===o?a=o=t:o=o.next=t}else a=o=t;return n={baseState:r.baseState,firstBaseUpdate:a,lastBaseUpdate:o,shared:r.shared,effects:r.effects},void(e.updateQueue=n)}null===(e=n.lastBaseUpdate)?n.firstBaseUpdate=t:e.next=t,n.lastBaseUpdate=t}function Lo(e,t,n,r){var a=e.updateQueue;Fo=!1;var o=a.firstBaseUpdate,i=a.lastBaseUpdate,s=a.shared.pending;if(null!==s){a.shared.pending=null;var l=s,u=l.next;l.next=null,null===i?o=u:i.next=u,i=l;var c=e.alternate;null!==c&&((s=(c=c.updateQueue).lastBaseUpdate)!==i&&(null===s?c.firstBaseUpdate=u:s.next=u,c.lastBaseUpdate=l))}if(null!==o){var d=a.baseState;for(i=0,c=u=l=null,s=o;;){var p=s.lane,f=s.eventTime;if((r&p)===p){null!==c&&(c=c.next={eventTime:f,lane:0,tag:s.tag,payload:s.payload,callback:s.callback,next:null});e:{var m=e,h=s;switch(p=t,f=n,h.tag){case 1:if("function"===typeof(m=h.payload)){d=m.call(f,d,p);break e}d=m;break e;case 3:m.flags=-65537&m.flags|128;case 0:if(null===(p="function"===typeof(m=h.payload)?m.call(f,d,p):m)||void 0===p)break e;d=z({},d,p);break e;case 2:Fo=!0}}null!==s.callback&&0!==s.lane&&(e.flags|=64,null===(p=a.effects)?a.effects=[s]:p.push(s))}else f={eventTime:f,lane:p,tag:s.tag,payload:s.payload,callback:s.callback,next:null},null===c?(u=c=f,l=d):c=c.next=f,i|=p;if(null===(s=s.next)){if(null===(s=a.shared.pending))break;s=(p=s).next,p.next=null,a.lastBaseUpdate=p,a.shared.pending=null}}if(null===c&&(l=d),a.baseState=l,a.firstBaseUpdate=u,a.lastBaseUpdate=c,null!==(t=a.shared.interleaved)){a=t;do{i|=a.lane,a=a.next}while(a!==t)}else null===o&&(a.shared.lanes=0);Il|=i,e.lanes=i,e.memoizedState=d}}function Zo(e,t,n){if(e=t.effects,t.effects=null,null!==e)for(t=0;t<e.length;t++){var r=e[t],a=r.callback;if(null!==a){if(r.callback=null,r=n,"function"!==typeof a)throw Error(o(191,a));a.call(r)}}}var jo=(new r.Component).refs;function Bo(e,t,n,r){n=null===(n=n(r,t=e.memoizedState))||void 0===n?t:z({},t,n),e.memoizedState=n,0===e.lanes&&(e.updateQueue.baseState=n)}var Wo={isMounted:function(e){return!!(e=e._reactInternals)&&We(e)===e},enqueueSetState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Do(r,a);o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Mo(e,o,a))&&(nu(t,e,a,r),Io(t,e,a))},enqueueReplaceState:function(e,t,n){e=e._reactInternals;var r=eu(),a=tu(e),o=Do(r,a);o.tag=1,o.payload=t,void 0!==n&&null!==n&&(o.callback=n),null!==(t=Mo(e,o,a))&&(nu(t,e,a,r),Io(t,e,a))},enqueueForceUpdate:function(e,t){e=e._reactInternals;var n=eu(),r=tu(e),a=Do(n,r);a.tag=2,void 0!==t&&null!==t&&(a.callback=t),null!==(t=Mo(e,a,r))&&(nu(t,e,r,n),Io(t,e,r))}};function Jo(e,t,n,r,a,o,i){return"function"===typeof(e=e.stateNode).shouldComponentUpdate?e.shouldComponentUpdate(r,o,i):!t.prototype||!t.prototype.isPureReactComponent||(!lr(n,r)||!lr(a,o))}function Vo(e,t,n){var r=!1,a=Pa,o=t.contextType;return"object"===typeof o&&null!==o?o=xo(o):(a=Oa(t)?Na:Ea.current,o=(r=null!==(r=t.contextTypes)&&void 0!==r)?Fa(e,a):Pa),t=new t(n,o),e.memoizedState=null!==t.state&&void 0!==t.state?t.state:null,t.updater=Wo,e.stateNode=t,t._reactInternals=e,r&&((e=e.stateNode).__reactInternalMemoizedUnmaskedChildContext=a,e.__reactInternalMemoizedMaskedChildContext=o),t}function Uo(e,t,n,r){e=t.state,"function"===typeof t.componentWillReceiveProps&&t.componentWillReceiveProps(n,r),"function"===typeof t.UNSAFE_componentWillReceiveProps&&t.UNSAFE_componentWillReceiveProps(n,r),t.state!==e&&Wo.enqueueReplaceState(t,t.state,null)}function $o(e,t,n,r){var a=e.stateNode;a.props=n,a.state=e.memoizedState,a.refs=jo,Oo(e);var o=t.contextType;"object"===typeof o&&null!==o?a.context=xo(o):(o=Oa(t)?Na:Ea.current,a.context=Fa(e,o)),a.state=e.memoizedState,"function"===typeof(o=t.getDerivedStateFromProps)&&(Bo(e,t,o,n),a.state=e.memoizedState),"function"===typeof t.getDerivedStateFromProps||"function"===typeof a.getSnapshotBeforeUpdate||"function"!==typeof a.UNSAFE_componentWillMount&&"function"!==typeof a.componentWillMount||(t=a.state,"function"===typeof a.componentWillMount&&a.componentWillMount(),"function"===typeof a.UNSAFE_componentWillMount&&a.UNSAFE_componentWillMount(),t!==a.state&&Wo.enqueueReplaceState(a,a.state,null),Lo(e,n,a,r),a.state=e.memoizedState),"function"===typeof a.componentDidMount&&(e.flags|=4194308)}function Go(e,t,n){if(null!==(e=n.ref)&&"function"!==typeof e&&"object"!==typeof e){if(n._owner){if(n=n._owner){if(1!==n.tag)throw Error(o(309));var r=n.stateNode}if(!r)throw Error(o(147,e));var a=r,i=""+e;return null!==t&&null!==t.ref&&"function"===typeof t.ref&&t.ref._stringRef===i?t.ref:(t=function(e){var t=a.refs;t===jo&&(t=a.refs={}),null===e?delete t[i]:t[i]=e},t._stringRef=i,t)}if("string"!==typeof e)throw Error(o(284));if(!n._owner)throw Error(o(290,e))}return e}function Ho(e,t){throw e=Object.prototype.toString.call(t),Error(o(31,"[object Object]"===e?"object with keys {"+Object.keys(t).join(", ")+"}":e))}function qo(e){return(0,e._init)(e._payload)}function Ko(e){function t(t,n){if(e){var r=t.deletions;null===r?(t.deletions=[n],t.flags|=16):r.push(n)}}function n(n,r){if(!e)return null;for(;null!==r;)t(n,r),r=r.sibling;return null}function r(e,t){for(e=new Map;null!==t;)null!==t.key?e.set(t.key,t):e.set(t.index,t),t=t.sibling;return e}function a(e,t){return(e=Ru(e,t)).index=0,e.sibling=null,e}function i(t,n,r){return t.index=r,e?null!==(r=t.alternate)?(r=r.index)<n?(t.flags|=2,n):r:(t.flags|=2,n):(t.flags|=1048576,n)}function s(t){return e&&null===t.alternate&&(t.flags|=2),t}function l(e,t,n,r){return null===t||6!==t.tag?((t=zu(n,e.mode,r)).return=e,t):((t=a(t,n)).return=e,t)}function u(e,t,n,r){var o=n.type;return o===k?d(e,t,n.props.children,r,n.key):null!==t&&(t.elementType===o||"object"===typeof o&&null!==o&&o.$$typeof===O&&qo(o)===t.type)?((r=a(t,n.props)).ref=Go(e,t,n),r.return=e,r):((r=Du(n.type,n.key,n.props,null,e.mode,r)).ref=Go(e,t,n),r.return=e,r)}function c(e,t,n,r){return null===t||4!==t.tag||t.stateNode.containerInfo!==n.containerInfo||t.stateNode.implementation!==n.implementation?((t=Lu(n,e.mode,r)).return=e,t):((t=a(t,n.children||[])).return=e,t)}function d(e,t,n,r,o){return null===t||7!==t.tag?((t=Mu(n,e.mode,r,o)).return=e,t):((t=a(t,n)).return=e,t)}function p(e,t,n){if("string"===typeof t&&""!==t||"number"===typeof t)return(t=zu(""+t,e.mode,n)).return=e,t;if("object"===typeof t&&null!==t){switch(t.$$typeof){case w:return(n=Du(t.type,t.key,t.props,null,e.mode,n)).ref=Go(e,null,t),n.return=e,n;case S:return(t=Lu(t,e.mode,n)).return=e,t;case O:return p(e,(0,t._init)(t._payload),n)}if(te(t)||M(t))return(t=Mu(t,e.mode,n,null)).return=e,t;Ho(e,t)}return null}function f(e,t,n,r){var a=null!==t?t.key:null;if("string"===typeof n&&""!==n||"number"===typeof n)return null!==a?null:l(e,t,""+n,r);if("object"===typeof n&&null!==n){switch(n.$$typeof){case w:return n.key===a?u(e,t,n,r):null;case S:return n.key===a?c(e,t,n,r):null;case O:return f(e,t,(a=n._init)(n._payload),r)}if(te(n)||M(n))return null!==a?null:d(e,t,n,r,null);Ho(e,n)}return null}function m(e,t,n,r,a){if("string"===typeof r&&""!==r||"number"===typeof r)return l(t,e=e.get(n)||null,""+r,a);if("object"===typeof r&&null!==r){switch(r.$$typeof){case w:return u(t,e=e.get(null===r.key?n:r.key)||null,r,a);case S:return c(t,e=e.get(null===r.key?n:r.key)||null,r,a);case O:return m(e,t,n,(0,r._init)(r._payload),a)}if(te(r)||M(r))return d(t,e=e.get(n)||null,r,a,null);Ho(t,r)}return null}function h(a,o,s,l){for(var u=null,c=null,d=o,h=o=0,v=null;null!==d&&h<s.length;h++){d.index>h?(v=d,d=null):v=d.sibling;var y=f(a,d,s[h],l);if(null===y){null===d&&(d=v);break}e&&d&&null===y.alternate&&t(a,d),o=i(y,o,h),null===c?u=y:c.sibling=y,c=y,d=v}if(h===s.length)return n(a,d),ao&&Ya(a,h),u;if(null===d){for(;h<s.length;h++)null!==(d=p(a,s[h],l))&&(o=i(d,o,h),null===c?u=d:c.sibling=d,c=d);return ao&&Ya(a,h),u}for(d=r(a,d);h<s.length;h++)null!==(v=m(d,a,h,s[h],l))&&(e&&null!==v.alternate&&d.delete(null===v.key?h:v.key),o=i(v,o,h),null===c?u=v:c.sibling=v,c=v);return e&&d.forEach((function(e){return t(a,e)})),ao&&Ya(a,h),u}function v(a,s,l,u){var c=M(l);if("function"!==typeof c)throw Error(o(150));if(null==(l=c.call(l)))throw Error(o(151));for(var d=c=null,h=s,v=s=0,y=null,b=l.next();null!==h&&!b.done;v++,b=l.next()){h.index>v?(y=h,h=null):y=h.sibling;var g=f(a,h,b.value,u);if(null===g){null===h&&(h=y);break}e&&h&&null===g.alternate&&t(a,h),s=i(g,s,v),null===d?c=g:d.sibling=g,d=g,h=y}if(b.done)return n(a,h),ao&&Ya(a,v),c;if(null===h){for(;!b.done;v++,b=l.next())null!==(b=p(a,b.value,u))&&(s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return ao&&Ya(a,v),c}for(h=r(a,h);!b.done;v++,b=l.next())null!==(b=m(h,a,v,b.value,u))&&(e&&null!==b.alternate&&h.delete(null===b.key?v:b.key),s=i(b,s,v),null===d?c=b:d.sibling=b,d=b);return e&&h.forEach((function(e){return t(a,e)})),ao&&Ya(a,v),c}return function e(r,o,i,l){if("object"===typeof i&&null!==i&&i.type===k&&null===i.key&&(i=i.props.children),"object"===typeof i&&null!==i){switch(i.$$typeof){case w:e:{for(var u=i.key,c=o;null!==c;){if(c.key===u){if((u=i.type)===k){if(7===c.tag){n(r,c.sibling),(o=a(c,i.props.children)).return=r,r=o;break e}}else if(c.elementType===u||"object"===typeof u&&null!==u&&u.$$typeof===O&&qo(u)===c.type){n(r,c.sibling),(o=a(c,i.props)).ref=Go(r,c,i),o.return=r,r=o;break e}n(r,c);break}t(r,c),c=c.sibling}i.type===k?((o=Mu(i.props.children,r.mode,l,i.key)).return=r,r=o):((l=Du(i.type,i.key,i.props,null,r.mode,l)).ref=Go(r,o,i),l.return=r,r=l)}return s(r);case S:e:{for(c=i.key;null!==o;){if(o.key===c){if(4===o.tag&&o.stateNode.containerInfo===i.containerInfo&&o.stateNode.implementation===i.implementation){n(r,o.sibling),(o=a(o,i.children||[])).return=r,r=o;break e}n(r,o);break}t(r,o),o=o.sibling}(o=Lu(i,r.mode,l)).return=r,r=o}return s(r);case O:return e(r,o,(c=i._init)(i._payload),l)}if(te(i))return h(r,o,i,l);if(M(i))return v(r,o,i,l);Ho(r,i)}return"string"===typeof i&&""!==i||"number"===typeof i?(i=""+i,null!==o&&6===o.tag?(n(r,o.sibling),(o=a(o,i)).return=r,r=o):(n(r,o),(o=zu(i,r.mode,l)).return=r,r=o),s(r)):n(r,o)}}var Qo=Ko(!0),Yo=Ko(!1),Xo={},ei=Ca(Xo),ti=Ca(Xo),ni=Ca(Xo);function ri(e){if(e===Xo)throw Error(o(174));return e}function ai(e,t){switch(xa(ni,t),xa(ti,e),xa(ei,Xo),e=t.nodeType){case 9:case 11:t=(t=t.documentElement)?t.namespaceURI:le(null,"");break;default:t=le(t=(e=8===e?t.parentNode:t).namespaceURI||null,e=e.tagName)}Ta(ei),xa(ei,t)}function oi(){Ta(ei),Ta(ti),Ta(ni)}function ii(e){ri(ni.current);var t=ri(ei.current),n=le(t,e.type);t!==n&&(xa(ti,e),xa(ei,n))}function si(e){ti.current===e&&(Ta(ei),Ta(ti))}var li=Ca(0);function ui(e){for(var t=e;null!==t;){if(13===t.tag){var n=t.memoizedState;if(null!==n&&(null===(n=n.dehydrated)||"$?"===n.data||"$!"===n.data))return t}else if(19===t.tag&&void 0!==t.memoizedProps.revealOrder){if(0!==(128&t.flags))return t}else if(null!==t.child){t.child.return=t,t=t.child;continue}if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ci=[];function di(){for(var e=0;e<ci.length;e++)ci[e]._workInProgressVersionPrimary=null;ci.length=0}var pi=_.ReactCurrentDispatcher,fi=_.ReactCurrentBatchConfig,mi=0,hi=null,vi=null,yi=null,bi=!1,gi=!1,_i=0,wi=0;function Si(){throw Error(o(321))}function ki(e,t){if(null===t)return!1;for(var n=0;n<t.length&&n<e.length;n++)if(!sr(e[n],t[n]))return!1;return!0}function Ci(e,t,n,r,a,i){if(mi=i,hi=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,pi.current=null===e||null===e.memoizedState?ss:ls,e=n(r,a),gi){i=0;do{if(gi=!1,_i=0,25<=i)throw Error(o(301));i+=1,yi=vi=null,t.updateQueue=null,pi.current=us,e=n(r,a)}while(gi)}if(pi.current=is,t=null!==vi&&null!==vi.next,mi=0,yi=vi=hi=null,bi=!1,t)throw Error(o(300));return e}function Ti(){var e=0!==_i;return _i=0,e}function xi(){var e={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return null===yi?hi.memoizedState=yi=e:yi=yi.next=e,yi}function Pi(){if(null===vi){var e=hi.alternate;e=null!==e?e.memoizedState:null}else e=vi.next;var t=null===yi?hi.memoizedState:yi.next;if(null!==t)yi=t,vi=e;else{if(null===e)throw Error(o(310));e={memoizedState:(vi=e).memoizedState,baseState:vi.baseState,baseQueue:vi.baseQueue,queue:vi.queue,next:null},null===yi?hi.memoizedState=yi=e:yi=yi.next=e}return yi}function Ei(e,t){return"function"===typeof t?t(e):t}function Ai(e){var t=Pi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=vi,a=r.baseQueue,i=n.pending;if(null!==i){if(null!==a){var s=a.next;a.next=i.next,i.next=s}r.baseQueue=a=i,n.pending=null}if(null!==a){i=a.next,r=r.baseState;var l=s=null,u=null,c=i;do{var d=c.lane;if((mi&d)===d)null!==u&&(u=u.next={lane:0,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null}),r=c.hasEagerState?c.eagerState:e(r,c.action);else{var p={lane:d,action:c.action,hasEagerState:c.hasEagerState,eagerState:c.eagerState,next:null};null===u?(l=u=p,s=r):u=u.next=p,hi.lanes|=d,Il|=d}c=c.next}while(null!==c&&c!==i);null===u?s=r:u.next=l,sr(r,t.memoizedState)||(_s=!0),t.memoizedState=r,t.baseState=s,t.baseQueue=u,n.lastRenderedState=r}if(null!==(e=n.interleaved)){a=e;do{i=a.lane,hi.lanes|=i,Il|=i,a=a.next}while(a!==e)}else null===a&&(n.lanes=0);return[t.memoizedState,n.dispatch]}function Ni(e){var t=Pi(),n=t.queue;if(null===n)throw Error(o(311));n.lastRenderedReducer=e;var r=n.dispatch,a=n.pending,i=t.memoizedState;if(null!==a){n.pending=null;var s=a=a.next;do{i=e(i,s.action),s=s.next}while(s!==a);sr(i,t.memoizedState)||(_s=!0),t.memoizedState=i,null===t.baseQueue&&(t.baseState=i),n.lastRenderedState=i}return[i,r]}function Fi(){}function Oi(e,t){var n=hi,r=Pi(),a=t(),i=!sr(r.memoizedState,a);if(i&&(r.memoizedState=a,_s=!0),r=r.queue,Vi(Mi.bind(null,n,r,e),[e]),r.getSnapshot!==t||i||null!==yi&&1&yi.memoizedState.tag){if(n.flags|=2048,Zi(9,Di.bind(null,n,r,a,t),void 0,null),null===Al)throw Error(o(349));0!==(30&mi)||Ri(n,t,a)}return a}function Ri(e,t,n){e.flags|=16384,e={getSnapshot:t,value:n},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.stores=[e]):null===(n=t.stores)?t.stores=[e]:n.push(e)}function Di(e,t,n,r){t.value=n,t.getSnapshot=r,Ii(t)&&zi(e)}function Mi(e,t,n){return n((function(){Ii(t)&&zi(e)}))}function Ii(e){var t=e.getSnapshot;e=e.value;try{var n=t();return!sr(e,n)}catch(r){return!0}}function zi(e){var t=No(e,1);null!==t&&nu(t,e,1,-1)}function Li(e){var t=xi();return"function"===typeof e&&(e=e()),t.memoizedState=t.baseState=e,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:Ei,lastRenderedState:e},t.queue=e,e=e.dispatch=ns.bind(null,hi,e),[t.memoizedState,e]}function Zi(e,t,n,r){return e={tag:e,create:t,destroy:n,deps:r,next:null},null===(t=hi.updateQueue)?(t={lastEffect:null,stores:null},hi.updateQueue=t,t.lastEffect=e.next=e):null===(n=t.lastEffect)?t.lastEffect=e.next=e:(r=n.next,n.next=e,e.next=r,t.lastEffect=e),e}function ji(){return Pi().memoizedState}function Bi(e,t,n,r){var a=xi();hi.flags|=e,a.memoizedState=Zi(1|t,n,void 0,void 0===r?null:r)}function Wi(e,t,n,r){var a=Pi();r=void 0===r?null:r;var o=void 0;if(null!==vi){var i=vi.memoizedState;if(o=i.destroy,null!==r&&ki(r,i.deps))return void(a.memoizedState=Zi(t,n,o,r))}hi.flags|=e,a.memoizedState=Zi(1|t,n,o,r)}function Ji(e,t){return Bi(8390656,8,e,t)}function Vi(e,t){return Wi(2048,8,e,t)}function Ui(e,t){return Wi(4,2,e,t)}function $i(e,t){return Wi(4,4,e,t)}function Gi(e,t){return"function"===typeof t?(e=e(),t(e),function(){t(null)}):null!==t&&void 0!==t?(e=e(),t.current=e,function(){t.current=null}):void 0}function Hi(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Wi(4,4,Gi.bind(null,t,e),n)}function qi(){}function Ki(e,t){var n=Pi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(n.memoizedState=[e,t],e)}function Qi(e,t){var n=Pi();t=void 0===t?null:t;var r=n.memoizedState;return null!==r&&null!==t&&ki(t,r[1])?r[0]:(e=e(),n.memoizedState=[e,t],e)}function Yi(e,t,n){return 0===(21&mi)?(e.baseState&&(e.baseState=!1,_s=!0),e.memoizedState=n):(sr(n,t)||(n=ht(),hi.lanes|=n,Il|=n,e.baseState=!0),t)}function Xi(e,t){var n=gt;gt=0!==n&&4>n?n:4,e(!0);var r=fi.transition;fi.transition={};try{e(!1),t()}finally{gt=n,fi.transition=r}}function es(){return Pi().memoizedState}function ts(e,t,n){var r=tu(e);if(n={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null},rs(e))as(t,n);else if(null!==(n=Ao(e,t,n,r))){nu(n,e,r,eu()),os(n,t,r)}}function ns(e,t,n){var r=tu(e),a={lane:r,action:n,hasEagerState:!1,eagerState:null,next:null};if(rs(e))as(t,a);else{var o=e.alternate;if(0===e.lanes&&(null===o||0===o.lanes)&&null!==(o=t.lastRenderedReducer))try{var i=t.lastRenderedState,s=o(i,n);if(a.hasEagerState=!0,a.eagerState=s,sr(s,i)){var l=t.interleaved;return null===l?(a.next=a,Eo(t)):(a.next=l.next,l.next=a),void(t.interleaved=a)}}catch(u){}null!==(n=Ao(e,t,a,r))&&(nu(n,e,r,a=eu()),os(n,t,r))}}function rs(e){var t=e.alternate;return e===hi||null!==t&&t===hi}function as(e,t){gi=bi=!0;var n=e.pending;null===n?t.next=t:(t.next=n.next,n.next=t),e.pending=t}function os(e,t,n){if(0!==(4194240&n)){var r=t.lanes;n|=r&=e.pendingLanes,t.lanes=n,bt(e,n)}}var is={readContext:xo,useCallback:Si,useContext:Si,useEffect:Si,useImperativeHandle:Si,useInsertionEffect:Si,useLayoutEffect:Si,useMemo:Si,useReducer:Si,useRef:Si,useState:Si,useDebugValue:Si,useDeferredValue:Si,useTransition:Si,useMutableSource:Si,useSyncExternalStore:Si,useId:Si,unstable_isNewReconciler:!1},ss={readContext:xo,useCallback:function(e,t){return xi().memoizedState=[e,void 0===t?null:t],e},useContext:xo,useEffect:Ji,useImperativeHandle:function(e,t,n){return n=null!==n&&void 0!==n?n.concat([e]):null,Bi(4194308,4,Gi.bind(null,t,e),n)},useLayoutEffect:function(e,t){return Bi(4194308,4,e,t)},useInsertionEffect:function(e,t){return Bi(4,2,e,t)},useMemo:function(e,t){var n=xi();return t=void 0===t?null:t,e=e(),n.memoizedState=[e,t],e},useReducer:function(e,t,n){var r=xi();return t=void 0!==n?n(t):t,r.memoizedState=r.baseState=t,e={pending:null,interleaved:null,lanes:0,dispatch:null,lastRenderedReducer:e,lastRenderedState:t},r.queue=e,e=e.dispatch=ts.bind(null,hi,e),[r.memoizedState,e]},useRef:function(e){return e={current:e},xi().memoizedState=e},useState:Li,useDebugValue:qi,useDeferredValue:function(e){return xi().memoizedState=e},useTransition:function(){var e=Li(!1),t=e[0];return e=Xi.bind(null,e[1]),xi().memoizedState=e,[t,e]},useMutableSource:function(){},useSyncExternalStore:function(e,t,n){var r=hi,a=xi();if(ao){if(void 0===n)throw Error(o(407));n=n()}else{if(n=t(),null===Al)throw Error(o(349));0!==(30&mi)||Ri(r,t,n)}a.memoizedState=n;var i={value:n,getSnapshot:t};return a.queue=i,Ji(Mi.bind(null,r,i,e),[e]),r.flags|=2048,Zi(9,Di.bind(null,r,i,n,t),void 0,null),n},useId:function(){var e=xi(),t=Al.identifierPrefix;if(ao){var n=Qa;t=":"+t+"R"+(n=(Ka&~(1<<32-it(Ka)-1)).toString(32)+n),0<(n=_i++)&&(t+="H"+n.toString(32)),t+=":"}else t=":"+t+"r"+(n=wi++).toString(32)+":";return e.memoizedState=t},unstable_isNewReconciler:!1},ls={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Vi,useImperativeHandle:Hi,useInsertionEffect:Ui,useLayoutEffect:$i,useMemo:Qi,useReducer:Ai,useRef:ji,useState:function(){return Ai(Ei)},useDebugValue:qi,useDeferredValue:function(e){return Yi(Pi(),vi.memoizedState,e)},useTransition:function(){return[Ai(Ei)[0],Pi().memoizedState]},useMutableSource:Fi,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1},us={readContext:xo,useCallback:Ki,useContext:xo,useEffect:Vi,useImperativeHandle:Hi,useInsertionEffect:Ui,useLayoutEffect:$i,useMemo:Qi,useReducer:Ni,useRef:ji,useState:function(){return Ni(Ei)},useDebugValue:qi,useDeferredValue:function(e){var t=Pi();return null===vi?t.memoizedState=e:Yi(t,vi.memoizedState,e)},useTransition:function(){return[Ni(Ei)[0],Pi().memoizedState]},useMutableSource:Fi,useSyncExternalStore:Oi,useId:es,unstable_isNewReconciler:!1};function cs(e,t){try{var n="",r=t;do{n+=B(r),r=r.return}while(r);var a=n}catch(o){a="\nError generating stack: "+o.message+"\n"+o.stack}return{value:e,source:t,stack:a,digest:null}}function ds(e,t,n){return{value:e,source:null,stack:null!=n?n:null,digest:null!=t?t:null}}function ps(e,t){try{console.error(t.value)}catch(n){setTimeout((function(){throw n}))}}var fs="function"===typeof WeakMap?WeakMap:Map;function ms(e,t,n){(n=Do(-1,n)).tag=3,n.payload={element:null};var r=t.value;return n.callback=function(){Vl||(Vl=!0,Ul=r),ps(0,t)},n}function hs(e,t,n){(n=Do(-1,n)).tag=3;var r=e.type.getDerivedStateFromError;if("function"===typeof r){var a=t.value;n.payload=function(){return r(a)},n.callback=function(){ps(0,t)}}var o=e.stateNode;return null!==o&&"function"===typeof o.componentDidCatch&&(n.callback=function(){ps(0,t),"function"!==typeof r&&(null===$l?$l=new Set([this]):$l.add(this));var e=t.stack;this.componentDidCatch(t.value,{componentStack:null!==e?e:""})}),n}function vs(e,t,n){var r=e.pingCache;if(null===r){r=e.pingCache=new fs;var a=new Set;r.set(t,a)}else void 0===(a=r.get(t))&&(a=new Set,r.set(t,a));a.has(n)||(a.add(n),e=Tu.bind(null,e,t,n),t.then(e,e))}function ys(e){do{var t;if((t=13===e.tag)&&(t=null===(t=e.memoizedState)||null!==t.dehydrated),t)return e;e=e.return}while(null!==e);return null}function bs(e,t,n,r,a){return 0===(1&e.mode)?(e===t?e.flags|=65536:(e.flags|=128,n.flags|=131072,n.flags&=-52805,1===n.tag&&(null===n.alternate?n.tag=17:((t=Do(-1,1)).tag=2,Mo(n,t,1))),n.lanes|=1),e):(e.flags|=65536,e.lanes=a,e)}var gs=_.ReactCurrentOwner,_s=!1;function ws(e,t,n,r){t.child=null===e?Yo(t,null,n,r):Qo(t,e.child,n,r)}function Ss(e,t,n,r,a){n=n.render;var o=t.ref;return To(t,a),r=Ci(e,t,n,r,o,a),n=Ti(),null===e||_s?(ao&&n&&eo(t),t.flags|=1,ws(e,t,r,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function ks(e,t,n,r,a){if(null===e){var o=n.type;return"function"!==typeof o||Ou(o)||void 0!==o.defaultProps||null!==n.compare||void 0!==n.defaultProps?((e=Du(n.type,null,r,t,t.mode,a)).ref=t.ref,e.return=t,t.child=e):(t.tag=15,t.type=o,Cs(e,t,o,r,a))}if(o=e.child,0===(e.lanes&a)){var i=o.memoizedProps;if((n=null!==(n=n.compare)?n:lr)(i,r)&&e.ref===t.ref)return Vs(e,t,a)}return t.flags|=1,(e=Ru(o,r)).ref=t.ref,e.return=t,t.child=e}function Cs(e,t,n,r,a){if(null!==e){var o=e.memoizedProps;if(lr(o,r)&&e.ref===t.ref){if(_s=!1,t.pendingProps=r=o,0===(e.lanes&a))return t.lanes=e.lanes,Vs(e,t,a);0!==(131072&e.flags)&&(_s=!0)}}return Ps(e,t,n,r,a)}function Ts(e,t,n){var r=t.pendingProps,a=r.children,o=null!==e?e.memoizedState:null;if("hidden"===r.mode)if(0===(1&t.mode))t.memoizedState={baseLanes:0,cachePool:null,transitions:null},xa(Rl,Ol),Ol|=n;else{if(0===(1073741824&n))return e=null!==o?o.baseLanes|n:n,t.lanes=t.childLanes=1073741824,t.memoizedState={baseLanes:e,cachePool:null,transitions:null},t.updateQueue=null,xa(Rl,Ol),Ol|=e,null;t.memoizedState={baseLanes:0,cachePool:null,transitions:null},r=null!==o?o.baseLanes:n,xa(Rl,Ol),Ol|=r}else null!==o?(r=o.baseLanes|n,t.memoizedState=null):r=n,xa(Rl,Ol),Ol|=r;return ws(e,t,a,n),t.child}function xs(e,t){var n=t.ref;(null===e&&null!==n||null!==e&&e.ref!==n)&&(t.flags|=512,t.flags|=2097152)}function Ps(e,t,n,r,a){var o=Oa(n)?Na:Ea.current;return o=Fa(t,o),To(t,a),n=Ci(e,t,n,r,o,a),r=Ti(),null===e||_s?(ao&&r&&eo(t),t.flags|=1,ws(e,t,n,a),t.child):(t.updateQueue=e.updateQueue,t.flags&=-2053,e.lanes&=~a,Vs(e,t,a))}function Es(e,t,n,r,a){if(Oa(n)){var o=!0;Ia(t)}else o=!1;if(To(t,a),null===t.stateNode)Js(e,t),Vo(t,n,r),$o(t,n,r,a),r=!0;else if(null===e){var i=t.stateNode,s=t.memoizedProps;i.props=s;var l=i.context,u=n.contextType;"object"===typeof u&&null!==u?u=xo(u):u=Fa(t,u=Oa(n)?Na:Ea.current);var c=n.getDerivedStateFromProps,d="function"===typeof c||"function"===typeof i.getSnapshotBeforeUpdate;d||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==r||l!==u)&&Uo(t,i,r,u),Fo=!1;var p=t.memoizedState;i.state=p,Lo(t,r,i,a),l=t.memoizedState,s!==r||p!==l||Aa.current||Fo?("function"===typeof c&&(Bo(t,n,c,r),l=t.memoizedState),(s=Fo||Jo(t,n,s,r,p,l,u))?(d||"function"!==typeof i.UNSAFE_componentWillMount&&"function"!==typeof i.componentWillMount||("function"===typeof i.componentWillMount&&i.componentWillMount(),"function"===typeof i.UNSAFE_componentWillMount&&i.UNSAFE_componentWillMount()),"function"===typeof i.componentDidMount&&(t.flags|=4194308)):("function"===typeof i.componentDidMount&&(t.flags|=4194308),t.memoizedProps=r,t.memoizedState=l),i.props=r,i.state=l,i.context=u,r=s):("function"===typeof i.componentDidMount&&(t.flags|=4194308),r=!1)}else{i=t.stateNode,Ro(e,t),s=t.memoizedProps,u=t.type===t.elementType?s:yo(t.type,s),i.props=u,d=t.pendingProps,p=i.context,"object"===typeof(l=n.contextType)&&null!==l?l=xo(l):l=Fa(t,l=Oa(n)?Na:Ea.current);var f=n.getDerivedStateFromProps;(c="function"===typeof f||"function"===typeof i.getSnapshotBeforeUpdate)||"function"!==typeof i.UNSAFE_componentWillReceiveProps&&"function"!==typeof i.componentWillReceiveProps||(s!==d||p!==l)&&Uo(t,i,r,l),Fo=!1,p=t.memoizedState,i.state=p,Lo(t,r,i,a);var m=t.memoizedState;s!==d||p!==m||Aa.current||Fo?("function"===typeof f&&(Bo(t,n,f,r),m=t.memoizedState),(u=Fo||Jo(t,n,u,r,p,m,l)||!1)?(c||"function"!==typeof i.UNSAFE_componentWillUpdate&&"function"!==typeof i.componentWillUpdate||("function"===typeof i.componentWillUpdate&&i.componentWillUpdate(r,m,l),"function"===typeof i.UNSAFE_componentWillUpdate&&i.UNSAFE_componentWillUpdate(r,m,l)),"function"===typeof i.componentDidUpdate&&(t.flags|=4),"function"===typeof i.getSnapshotBeforeUpdate&&(t.flags|=1024)):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),t.memoizedProps=r,t.memoizedState=m),i.props=r,i.state=m,i.context=l,r=u):("function"!==typeof i.componentDidUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=4),"function"!==typeof i.getSnapshotBeforeUpdate||s===e.memoizedProps&&p===e.memoizedState||(t.flags|=1024),r=!1)}return As(e,t,n,r,o,a)}function As(e,t,n,r,a,o){xs(e,t);var i=0!==(128&t.flags);if(!r&&!i)return a&&za(t,n,!1),Vs(e,t,o);r=t.stateNode,gs.current=t;var s=i&&"function"!==typeof n.getDerivedStateFromError?null:r.render();return t.flags|=1,null!==e&&i?(t.child=Qo(t,e.child,null,o),t.child=Qo(t,null,s,o)):ws(e,t,s,o),t.memoizedState=r.state,a&&za(t,n,!0),t.child}function Ns(e){var t=e.stateNode;t.pendingContext?Da(0,t.pendingContext,t.pendingContext!==t.context):t.context&&Da(0,t.context,!1),ai(e,t.containerInfo)}function Fs(e,t,n,r,a){return mo(),ho(a),t.flags|=256,ws(e,t,n,r),t.child}var Os,Rs,Ds,Ms={dehydrated:null,treeContext:null,retryLane:0};function Is(e){return{baseLanes:e,cachePool:null,transitions:null}}function zs(e,t,n){var r,a=t.pendingProps,i=li.current,s=!1,l=0!==(128&t.flags);if((r=l)||(r=(null===e||null!==e.memoizedState)&&0!==(2&i)),r?(s=!0,t.flags&=-129):null!==e&&null===e.memoizedState||(i|=1),xa(li,1&i),null===e)return uo(t),null!==(e=t.memoizedState)&&null!==(e=e.dehydrated)?(0===(1&t.mode)?t.lanes=1:"$!"===e.data?t.lanes=8:t.lanes=1073741824,null):(l=a.children,e=a.fallback,s?(a=t.mode,s=t.child,l={mode:"hidden",children:l},0===(1&a)&&null!==s?(s.childLanes=0,s.pendingProps=l):s=Iu(l,a,0,null),e=Mu(e,a,n,null),s.return=t,e.return=t,s.sibling=e,t.child=s,t.child.memoizedState=Is(n),t.memoizedState=Ms,e):Ls(t,l));if(null!==(i=e.memoizedState)&&null!==(r=i.dehydrated))return function(e,t,n,r,a,i,s){if(n)return 256&t.flags?(t.flags&=-257,Zs(e,t,s,r=ds(Error(o(422))))):null!==t.memoizedState?(t.child=e.child,t.flags|=128,null):(i=r.fallback,a=t.mode,r=Iu({mode:"visible",children:r.children},a,0,null),(i=Mu(i,a,s,null)).flags|=2,r.return=t,i.return=t,r.sibling=i,t.child=r,0!==(1&t.mode)&&Qo(t,e.child,null,s),t.child.memoizedState=Is(s),t.memoizedState=Ms,i);if(0===(1&t.mode))return Zs(e,t,s,null);if("$!"===a.data){if(r=a.nextSibling&&a.nextSibling.dataset)var l=r.dgst;return r=l,Zs(e,t,s,r=ds(i=Error(o(419)),r,void 0))}if(l=0!==(s&e.childLanes),_s||l){if(null!==(r=Al)){switch(s&-s){case 4:a=2;break;case 16:a=8;break;case 64:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:case 67108864:a=32;break;case 536870912:a=268435456;break;default:a=0}0!==(a=0!==(a&(r.suspendedLanes|s))?0:a)&&a!==i.retryLane&&(i.retryLane=a,No(e,a),nu(r,e,a,-1))}return hu(),Zs(e,t,s,r=ds(Error(o(421))))}return"$?"===a.data?(t.flags|=128,t.child=e.child,t=Pu.bind(null,e),a._reactRetry=t,null):(e=i.treeContext,ro=ua(a.nextSibling),no=t,ao=!0,oo=null,null!==e&&(Ga[Ha++]=Ka,Ga[Ha++]=Qa,Ga[Ha++]=qa,Ka=e.id,Qa=e.overflow,qa=t),(t=Ls(t,r.children)).flags|=4096,t)}(e,t,l,a,r,i,n);if(s){s=a.fallback,l=t.mode,r=(i=e.child).sibling;var u={mode:"hidden",children:a.children};return 0===(1&l)&&t.child!==i?((a=t.child).childLanes=0,a.pendingProps=u,t.deletions=null):(a=Ru(i,u)).subtreeFlags=14680064&i.subtreeFlags,null!==r?s=Ru(r,s):(s=Mu(s,l,n,null)).flags|=2,s.return=t,a.return=t,a.sibling=s,t.child=a,a=s,s=t.child,l=null===(l=e.child.memoizedState)?Is(n):{baseLanes:l.baseLanes|n,cachePool:null,transitions:l.transitions},s.memoizedState=l,s.childLanes=e.childLanes&~n,t.memoizedState=Ms,a}return e=(s=e.child).sibling,a=Ru(s,{mode:"visible",children:a.children}),0===(1&t.mode)&&(a.lanes=n),a.return=t,a.sibling=null,null!==e&&(null===(n=t.deletions)?(t.deletions=[e],t.flags|=16):n.push(e)),t.child=a,t.memoizedState=null,a}function Ls(e,t){return(t=Iu({mode:"visible",children:t},e.mode,0,null)).return=e,e.child=t}function Zs(e,t,n,r){return null!==r&&ho(r),Qo(t,e.child,null,n),(e=Ls(t,t.pendingProps.children)).flags|=2,t.memoizedState=null,e}function js(e,t,n){e.lanes|=t;var r=e.alternate;null!==r&&(r.lanes|=t),Co(e.return,t,n)}function Bs(e,t,n,r,a){var o=e.memoizedState;null===o?e.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:r,tail:n,tailMode:a}:(o.isBackwards=t,o.rendering=null,o.renderingStartTime=0,o.last=r,o.tail=n,o.tailMode=a)}function Ws(e,t,n){var r=t.pendingProps,a=r.revealOrder,o=r.tail;if(ws(e,t,r.children,n),0!==(2&(r=li.current)))r=1&r|2,t.flags|=128;else{if(null!==e&&0!==(128&e.flags))e:for(e=t.child;null!==e;){if(13===e.tag)null!==e.memoizedState&&js(e,n,t);else if(19===e.tag)js(e,n,t);else if(null!==e.child){e.child.return=e,e=e.child;continue}if(e===t)break e;for(;null===e.sibling;){if(null===e.return||e.return===t)break e;e=e.return}e.sibling.return=e.return,e=e.sibling}r&=1}if(xa(li,r),0===(1&t.mode))t.memoizedState=null;else switch(a){case"forwards":for(n=t.child,a=null;null!==n;)null!==(e=n.alternate)&&null===ui(e)&&(a=n),n=n.sibling;null===(n=a)?(a=t.child,t.child=null):(a=n.sibling,n.sibling=null),Bs(t,!1,a,n,o);break;case"backwards":for(n=null,a=t.child,t.child=null;null!==a;){if(null!==(e=a.alternate)&&null===ui(e)){t.child=a;break}e=a.sibling,a.sibling=n,n=a,a=e}Bs(t,!0,n,null,o);break;case"together":Bs(t,!1,null,null,void 0);break;default:t.memoizedState=null}return t.child}function Js(e,t){0===(1&t.mode)&&null!==e&&(e.alternate=null,t.alternate=null,t.flags|=2)}function Vs(e,t,n){if(null!==e&&(t.dependencies=e.dependencies),Il|=t.lanes,0===(n&t.childLanes))return null;if(null!==e&&t.child!==e.child)throw Error(o(153));if(null!==t.child){for(n=Ru(e=t.child,e.pendingProps),t.child=n,n.return=t;null!==e.sibling;)e=e.sibling,(n=n.sibling=Ru(e,e.pendingProps)).return=t;n.sibling=null}return t.child}function Us(e,t){if(!ao)switch(e.tailMode){case"hidden":t=e.tail;for(var n=null;null!==t;)null!==t.alternate&&(n=t),t=t.sibling;null===n?e.tail=null:n.sibling=null;break;case"collapsed":n=e.tail;for(var r=null;null!==n;)null!==n.alternate&&(r=n),n=n.sibling;null===r?t||null===e.tail?e.tail=null:e.tail.sibling=null:r.sibling=null}}function $s(e){var t=null!==e.alternate&&e.alternate.child===e.child,n=0,r=0;if(t)for(var a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=14680064&a.subtreeFlags,r|=14680064&a.flags,a.return=e,a=a.sibling;else for(a=e.child;null!==a;)n|=a.lanes|a.childLanes,r|=a.subtreeFlags,r|=a.flags,a.return=e,a=a.sibling;return e.subtreeFlags|=r,e.childLanes=n,t}function Gs(e,t,n){var r=t.pendingProps;switch(to(t),t.tag){case 2:case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return $s(t),null;case 1:case 17:return Oa(t.type)&&Ra(),$s(t),null;case 3:return r=t.stateNode,oi(),Ta(Aa),Ta(Ea),di(),r.pendingContext&&(r.context=r.pendingContext,r.pendingContext=null),null!==e&&null!==e.child||(po(t)?t.flags|=4:null===e||e.memoizedState.isDehydrated&&0===(256&t.flags)||(t.flags|=1024,null!==oo&&(iu(oo),oo=null))),$s(t),null;case 5:si(t);var a=ri(ni.current);if(n=t.type,null!==e&&null!=t.stateNode)Rs(e,t,n,r),e.ref!==t.ref&&(t.flags|=512,t.flags|=2097152);else{if(!r){if(null===t.stateNode)throw Error(o(166));return $s(t),null}if(e=ri(ei.current),po(t)){r=t.stateNode,n=t.type;var i=t.memoizedProps;switch(r[pa]=t,r[fa]=i,e=0!==(1&t.mode),n){case"dialog":Zr("cancel",r),Zr("close",r);break;case"iframe":case"object":case"embed":Zr("load",r);break;case"video":case"audio":for(a=0;a<Mr.length;a++)Zr(Mr[a],r);break;case"source":Zr("error",r);break;case"img":case"image":case"link":Zr("error",r),Zr("load",r);break;case"details":Zr("toggle",r);break;case"input":K(r,i),Zr("invalid",r);break;case"select":r._wrapperState={wasMultiple:!!i.multiple},Zr("invalid",r);break;case"textarea":ae(r,i),Zr("invalid",r)}for(var l in be(n,i),a=null,i)if(i.hasOwnProperty(l)){var u=i[l];"children"===l?"string"===typeof u?r.textContent!==u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",u]):"number"===typeof u&&r.textContent!==""+u&&(!0!==i.suppressHydrationWarning&&Yr(r.textContent,u,e),a=["children",""+u]):s.hasOwnProperty(l)&&null!=u&&"onScroll"===l&&Zr("scroll",r)}switch(n){case"input":$(r),X(r,i,!0);break;case"textarea":$(r),ie(r);break;case"select":case"option":break;default:"function"===typeof i.onClick&&(r.onclick=Xr)}r=a,t.updateQueue=r,null!==r&&(t.flags|=4)}else{l=9===a.nodeType?a:a.ownerDocument,"http://www.w3.org/1999/xhtml"===e&&(e=se(n)),"http://www.w3.org/1999/xhtml"===e?"script"===n?((e=l.createElement("div")).innerHTML="<script><\/script>",e=e.removeChild(e.firstChild)):"string"===typeof r.is?e=l.createElement(n,{is:r.is}):(e=l.createElement(n),"select"===n&&(l=e,r.multiple?l.multiple=!0:r.size&&(l.size=r.size))):e=l.createElementNS(e,n),e[pa]=t,e[fa]=r,Os(e,t),t.stateNode=e;e:{switch(l=ge(n,r),n){case"dialog":Zr("cancel",e),Zr("close",e),a=r;break;case"iframe":case"object":case"embed":Zr("load",e),a=r;break;case"video":case"audio":for(a=0;a<Mr.length;a++)Zr(Mr[a],e);a=r;break;case"source":Zr("error",e),a=r;break;case"img":case"image":case"link":Zr("error",e),Zr("load",e),a=r;break;case"details":Zr("toggle",e),a=r;break;case"input":K(e,r),a=q(e,r),Zr("invalid",e);break;case"option":default:a=r;break;case"select":e._wrapperState={wasMultiple:!!r.multiple},a=z({},r,{value:void 0}),Zr("invalid",e);break;case"textarea":ae(e,r),a=re(e,r),Zr("invalid",e)}for(i in be(n,a),u=a)if(u.hasOwnProperty(i)){var c=u[i];"style"===i?ve(e,c):"dangerouslySetInnerHTML"===i?null!=(c=c?c.__html:void 0)&&de(e,c):"children"===i?"string"===typeof c?("textarea"!==n||""!==c)&&pe(e,c):"number"===typeof c&&pe(e,""+c):"suppressContentEditableWarning"!==i&&"suppressHydrationWarning"!==i&&"autoFocus"!==i&&(s.hasOwnProperty(i)?null!=c&&"onScroll"===i&&Zr("scroll",e):null!=c&&g(e,i,c,l))}switch(n){case"input":$(e),X(e,r,!1);break;case"textarea":$(e),ie(e);break;case"option":null!=r.value&&e.setAttribute("value",""+V(r.value));break;case"select":e.multiple=!!r.multiple,null!=(i=r.value)?ne(e,!!r.multiple,i,!1):null!=r.defaultValue&&ne(e,!!r.multiple,r.defaultValue,!0);break;default:"function"===typeof a.onClick&&(e.onclick=Xr)}switch(n){case"button":case"input":case"select":case"textarea":r=!!r.autoFocus;break e;case"img":r=!0;break e;default:r=!1}}r&&(t.flags|=4)}null!==t.ref&&(t.flags|=512,t.flags|=2097152)}return $s(t),null;case 6:if(e&&null!=t.stateNode)Ds(0,t,e.memoizedProps,r);else{if("string"!==typeof r&&null===t.stateNode)throw Error(o(166));if(n=ri(ni.current),ri(ei.current),po(t)){if(r=t.stateNode,n=t.memoizedProps,r[pa]=t,(i=r.nodeValue!==n)&&null!==(e=no))switch(e.tag){case 3:Yr(r.nodeValue,n,0!==(1&e.mode));break;case 5:!0!==e.memoizedProps.suppressHydrationWarning&&Yr(r.nodeValue,n,0!==(1&e.mode))}i&&(t.flags|=4)}else(r=(9===n.nodeType?n:n.ownerDocument).createTextNode(r))[pa]=t,t.stateNode=r}return $s(t),null;case 13:if(Ta(li),r=t.memoizedState,null===e||null!==e.memoizedState&&null!==e.memoizedState.dehydrated){if(ao&&null!==ro&&0!==(1&t.mode)&&0===(128&t.flags))fo(),mo(),t.flags|=98560,i=!1;else if(i=po(t),null!==r&&null!==r.dehydrated){if(null===e){if(!i)throw Error(o(318));if(!(i=null!==(i=t.memoizedState)?i.dehydrated:null))throw Error(o(317));i[pa]=t}else mo(),0===(128&t.flags)&&(t.memoizedState=null),t.flags|=4;$s(t),i=!1}else null!==oo&&(iu(oo),oo=null),i=!0;if(!i)return 65536&t.flags?t:null}return 0!==(128&t.flags)?(t.lanes=n,t):((r=null!==r)!==(null!==e&&null!==e.memoizedState)&&r&&(t.child.flags|=8192,0!==(1&t.mode)&&(null===e||0!==(1&li.current)?0===Dl&&(Dl=3):hu())),null!==t.updateQueue&&(t.flags|=4),$s(t),null);case 4:return oi(),null===e&&Wr(t.stateNode.containerInfo),$s(t),null;case 10:return ko(t.type._context),$s(t),null;case 19:if(Ta(li),null===(i=t.memoizedState))return $s(t),null;if(r=0!==(128&t.flags),null===(l=i.rendering))if(r)Us(i,!1);else{if(0!==Dl||null!==e&&0!==(128&e.flags))for(e=t.child;null!==e;){if(null!==(l=ui(e))){for(t.flags|=128,Us(i,!1),null!==(r=l.updateQueue)&&(t.updateQueue=r,t.flags|=4),t.subtreeFlags=0,r=n,n=t.child;null!==n;)e=r,(i=n).flags&=14680066,null===(l=i.alternate)?(i.childLanes=0,i.lanes=e,i.child=null,i.subtreeFlags=0,i.memoizedProps=null,i.memoizedState=null,i.updateQueue=null,i.dependencies=null,i.stateNode=null):(i.childLanes=l.childLanes,i.lanes=l.lanes,i.child=l.child,i.subtreeFlags=0,i.deletions=null,i.memoizedProps=l.memoizedProps,i.memoizedState=l.memoizedState,i.updateQueue=l.updateQueue,i.type=l.type,e=l.dependencies,i.dependencies=null===e?null:{lanes:e.lanes,firstContext:e.firstContext}),n=n.sibling;return xa(li,1&li.current|2),t.child}e=e.sibling}null!==i.tail&&Qe()>Wl&&(t.flags|=128,r=!0,Us(i,!1),t.lanes=4194304)}else{if(!r)if(null!==(e=ui(l))){if(t.flags|=128,r=!0,null!==(n=e.updateQueue)&&(t.updateQueue=n,t.flags|=4),Us(i,!0),null===i.tail&&"hidden"===i.tailMode&&!l.alternate&&!ao)return $s(t),null}else 2*Qe()-i.renderingStartTime>Wl&&1073741824!==n&&(t.flags|=128,r=!0,Us(i,!1),t.lanes=4194304);i.isBackwards?(l.sibling=t.child,t.child=l):(null!==(n=i.last)?n.sibling=l:t.child=l,i.last=l)}return null!==i.tail?(t=i.tail,i.rendering=t,i.tail=t.sibling,i.renderingStartTime=Qe(),t.sibling=null,n=li.current,xa(li,r?1&n|2:1&n),t):($s(t),null);case 22:case 23:return du(),r=null!==t.memoizedState,null!==e&&null!==e.memoizedState!==r&&(t.flags|=8192),r&&0!==(1&t.mode)?0!==(1073741824&Ol)&&($s(t),6&t.subtreeFlags&&(t.flags|=8192)):$s(t),null;case 24:case 25:return null}throw Error(o(156,t.tag))}function Hs(e,t){switch(to(t),t.tag){case 1:return Oa(t.type)&&Ra(),65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 3:return oi(),Ta(Aa),Ta(Ea),di(),0!==(65536&(e=t.flags))&&0===(128&e)?(t.flags=-65537&e|128,t):null;case 5:return si(t),null;case 13:if(Ta(li),null!==(e=t.memoizedState)&&null!==e.dehydrated){if(null===t.alternate)throw Error(o(340));mo()}return 65536&(e=t.flags)?(t.flags=-65537&e|128,t):null;case 19:return Ta(li),null;case 4:return oi(),null;case 10:return ko(t.type._context),null;case 22:case 23:return du(),null;default:return null}}Os=function(e,t){for(var n=t.child;null!==n;){if(5===n.tag||6===n.tag)e.appendChild(n.stateNode);else if(4!==n.tag&&null!==n.child){n.child.return=n,n=n.child;continue}if(n===t)break;for(;null===n.sibling;){if(null===n.return||n.return===t)return;n=n.return}n.sibling.return=n.return,n=n.sibling}},Rs=function(e,t,n,r){var a=e.memoizedProps;if(a!==r){e=t.stateNode,ri(ei.current);var o,i=null;switch(n){case"input":a=q(e,a),r=q(e,r),i=[];break;case"select":a=z({},a,{value:void 0}),r=z({},r,{value:void 0}),i=[];break;case"textarea":a=re(e,a),r=re(e,r),i=[];break;default:"function"!==typeof a.onClick&&"function"===typeof r.onClick&&(e.onclick=Xr)}for(c in be(n,r),n=null,a)if(!r.hasOwnProperty(c)&&a.hasOwnProperty(c)&&null!=a[c])if("style"===c){var l=a[c];for(o in l)l.hasOwnProperty(o)&&(n||(n={}),n[o]="")}else"dangerouslySetInnerHTML"!==c&&"children"!==c&&"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&"autoFocus"!==c&&(s.hasOwnProperty(c)?i||(i=[]):(i=i||[]).push(c,null));for(c in r){var u=r[c];if(l=null!=a?a[c]:void 0,r.hasOwnProperty(c)&&u!==l&&(null!=u||null!=l))if("style"===c)if(l){for(o in l)!l.hasOwnProperty(o)||u&&u.hasOwnProperty(o)||(n||(n={}),n[o]="");for(o in u)u.hasOwnProperty(o)&&l[o]!==u[o]&&(n||(n={}),n[o]=u[o])}else n||(i||(i=[]),i.push(c,n)),n=u;else"dangerouslySetInnerHTML"===c?(u=u?u.__html:void 0,l=l?l.__html:void 0,null!=u&&l!==u&&(i=i||[]).push(c,u)):"children"===c?"string"!==typeof u&&"number"!==typeof u||(i=i||[]).push(c,""+u):"suppressContentEditableWarning"!==c&&"suppressHydrationWarning"!==c&&(s.hasOwnProperty(c)?(null!=u&&"onScroll"===c&&Zr("scroll",e),i||l===u||(i=[])):(i=i||[]).push(c,u))}n&&(i=i||[]).push("style",n);var c=i;(t.updateQueue=c)&&(t.flags|=4)}},Ds=function(e,t,n,r){n!==r&&(t.flags|=4)};var qs=!1,Ks=!1,Qs="function"===typeof WeakSet?WeakSet:Set,Ys=null;function Xs(e,t){var n=e.ref;if(null!==n)if("function"===typeof n)try{n(null)}catch(r){Cu(e,t,r)}else n.current=null}function el(e,t,n){try{n()}catch(r){Cu(e,t,r)}}var tl=!1;function nl(e,t,n){var r=t.updateQueue;if(null!==(r=null!==r?r.lastEffect:null)){var a=r=r.next;do{if((a.tag&e)===e){var o=a.destroy;a.destroy=void 0,void 0!==o&&el(t,n,o)}a=a.next}while(a!==r)}}function rl(e,t){if(null!==(t=null!==(t=t.updateQueue)?t.lastEffect:null)){var n=t=t.next;do{if((n.tag&e)===e){var r=n.create;n.destroy=r()}n=n.next}while(n!==t)}}function al(e){var t=e.ref;if(null!==t){var n=e.stateNode;e.tag,e=n,"function"===typeof t?t(e):t.current=e}}function ol(e){var t=e.alternate;null!==t&&(e.alternate=null,ol(t)),e.child=null,e.deletions=null,e.sibling=null,5===e.tag&&(null!==(t=e.stateNode)&&(delete t[pa],delete t[fa],delete t[ha],delete t[va],delete t[ya])),e.stateNode=null,e.return=null,e.dependencies=null,e.memoizedProps=null,e.memoizedState=null,e.pendingProps=null,e.stateNode=null,e.updateQueue=null}function il(e){return 5===e.tag||3===e.tag||4===e.tag}function sl(e){e:for(;;){for(;null===e.sibling;){if(null===e.return||il(e.return))return null;e=e.return}for(e.sibling.return=e.return,e=e.sibling;5!==e.tag&&6!==e.tag&&18!==e.tag;){if(2&e.flags)continue e;if(null===e.child||4===e.tag)continue e;e.child.return=e,e=e.child}if(!(2&e.flags))return e.stateNode}}function ll(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?8===n.nodeType?n.parentNode.insertBefore(e,t):n.insertBefore(e,t):(8===n.nodeType?(t=n.parentNode).insertBefore(e,n):(t=n).appendChild(e),null!==(n=n._reactRootContainer)&&void 0!==n||null!==t.onclick||(t.onclick=Xr));else if(4!==r&&null!==(e=e.child))for(ll(e,t,n),e=e.sibling;null!==e;)ll(e,t,n),e=e.sibling}function ul(e,t,n){var r=e.tag;if(5===r||6===r)e=e.stateNode,t?n.insertBefore(e,t):n.appendChild(e);else if(4!==r&&null!==(e=e.child))for(ul(e,t,n),e=e.sibling;null!==e;)ul(e,t,n),e=e.sibling}var cl=null,dl=!1;function pl(e,t,n){for(n=n.child;null!==n;)fl(e,t,n),n=n.sibling}function fl(e,t,n){if(ot&&"function"===typeof ot.onCommitFiberUnmount)try{ot.onCommitFiberUnmount(at,n)}catch(s){}switch(n.tag){case 5:Ks||Xs(n,t);case 6:var r=cl,a=dl;cl=null,pl(e,t,n),dl=a,null!==(cl=r)&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?e.parentNode.removeChild(n):e.removeChild(n)):cl.removeChild(n.stateNode));break;case 18:null!==cl&&(dl?(e=cl,n=n.stateNode,8===e.nodeType?la(e.parentNode,n):1===e.nodeType&&la(e,n),Wt(e)):la(cl,n.stateNode));break;case 4:r=cl,a=dl,cl=n.stateNode.containerInfo,dl=!0,pl(e,t,n),cl=r,dl=a;break;case 0:case 11:case 14:case 15:if(!Ks&&(null!==(r=n.updateQueue)&&null!==(r=r.lastEffect))){a=r=r.next;do{var o=a,i=o.destroy;o=o.tag,void 0!==i&&(0!==(2&o)||0!==(4&o))&&el(n,t,i),a=a.next}while(a!==r)}pl(e,t,n);break;case 1:if(!Ks&&(Xs(n,t),"function"===typeof(r=n.stateNode).componentWillUnmount))try{r.props=n.memoizedProps,r.state=n.memoizedState,r.componentWillUnmount()}catch(s){Cu(n,t,s)}pl(e,t,n);break;case 21:pl(e,t,n);break;case 22:1&n.mode?(Ks=(r=Ks)||null!==n.memoizedState,pl(e,t,n),Ks=r):pl(e,t,n);break;default:pl(e,t,n)}}function ml(e){var t=e.updateQueue;if(null!==t){e.updateQueue=null;var n=e.stateNode;null===n&&(n=e.stateNode=new Qs),t.forEach((function(t){var r=Eu.bind(null,e,t);n.has(t)||(n.add(t),t.then(r,r))}))}}function hl(e,t){var n=t.deletions;if(null!==n)for(var r=0;r<n.length;r++){var a=n[r];try{var i=e,s=t,l=s;e:for(;null!==l;){switch(l.tag){case 5:cl=l.stateNode,dl=!1;break e;case 3:case 4:cl=l.stateNode.containerInfo,dl=!0;break e}l=l.return}if(null===cl)throw Error(o(160));fl(i,s,a),cl=null,dl=!1;var u=a.alternate;null!==u&&(u.return=null),a.return=null}catch(c){Cu(a,t,c)}}if(12854&t.subtreeFlags)for(t=t.child;null!==t;)vl(t,e),t=t.sibling}function vl(e,t){var n=e.alternate,r=e.flags;switch(e.tag){case 0:case 11:case 14:case 15:if(hl(t,e),yl(e),4&r){try{nl(3,e,e.return),rl(3,e)}catch(v){Cu(e,e.return,v)}try{nl(5,e,e.return)}catch(v){Cu(e,e.return,v)}}break;case 1:hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return);break;case 5:if(hl(t,e),yl(e),512&r&&null!==n&&Xs(n,n.return),32&e.flags){var a=e.stateNode;try{pe(a,"")}catch(v){Cu(e,e.return,v)}}if(4&r&&null!=(a=e.stateNode)){var i=e.memoizedProps,s=null!==n?n.memoizedProps:i,l=e.type,u=e.updateQueue;if(e.updateQueue=null,null!==u)try{"input"===l&&"radio"===i.type&&null!=i.name&&Q(a,i),ge(l,s);var c=ge(l,i);for(s=0;s<u.length;s+=2){var d=u[s],p=u[s+1];"style"===d?ve(a,p):"dangerouslySetInnerHTML"===d?de(a,p):"children"===d?pe(a,p):g(a,d,p,c)}switch(l){case"input":Y(a,i);break;case"textarea":oe(a,i);break;case"select":var f=a._wrapperState.wasMultiple;a._wrapperState.wasMultiple=!!i.multiple;var m=i.value;null!=m?ne(a,!!i.multiple,m,!1):f!==!!i.multiple&&(null!=i.defaultValue?ne(a,!!i.multiple,i.defaultValue,!0):ne(a,!!i.multiple,i.multiple?[]:"",!1))}a[fa]=i}catch(v){Cu(e,e.return,v)}}break;case 6:if(hl(t,e),yl(e),4&r){if(null===e.stateNode)throw Error(o(162));a=e.stateNode,i=e.memoizedProps;try{a.nodeValue=i}catch(v){Cu(e,e.return,v)}}break;case 3:if(hl(t,e),yl(e),4&r&&null!==n&&n.memoizedState.isDehydrated)try{Wt(t.containerInfo)}catch(v){Cu(e,e.return,v)}break;case 4:default:hl(t,e),yl(e);break;case 13:hl(t,e),yl(e),8192&(a=e.child).flags&&(i=null!==a.memoizedState,a.stateNode.isHidden=i,!i||null!==a.alternate&&null!==a.alternate.memoizedState||(Bl=Qe())),4&r&&ml(e);break;case 22:if(d=null!==n&&null!==n.memoizedState,1&e.mode?(Ks=(c=Ks)||d,hl(t,e),Ks=c):hl(t,e),yl(e),8192&r){if(c=null!==e.memoizedState,(e.stateNode.isHidden=c)&&!d&&0!==(1&e.mode))for(Ys=e,d=e.child;null!==d;){for(p=Ys=d;null!==Ys;){switch(m=(f=Ys).child,f.tag){case 0:case 11:case 14:case 15:nl(4,f,f.return);break;case 1:Xs(f,f.return);var h=f.stateNode;if("function"===typeof h.componentWillUnmount){r=f,n=f.return;try{t=r,h.props=t.memoizedProps,h.state=t.memoizedState,h.componentWillUnmount()}catch(v){Cu(r,n,v)}}break;case 5:Xs(f,f.return);break;case 22:if(null!==f.memoizedState){wl(p);continue}}null!==m?(m.return=f,Ys=m):wl(p)}d=d.sibling}e:for(d=null,p=e;;){if(5===p.tag){if(null===d){d=p;try{a=p.stateNode,c?"function"===typeof(i=a.style).setProperty?i.setProperty("display","none","important"):i.display="none":(l=p.stateNode,s=void 0!==(u=p.memoizedProps.style)&&null!==u&&u.hasOwnProperty("display")?u.display:null,l.style.display=he("display",s))}catch(v){Cu(e,e.return,v)}}}else if(6===p.tag){if(null===d)try{p.stateNode.nodeValue=c?"":p.memoizedProps}catch(v){Cu(e,e.return,v)}}else if((22!==p.tag&&23!==p.tag||null===p.memoizedState||p===e)&&null!==p.child){p.child.return=p,p=p.child;continue}if(p===e)break e;for(;null===p.sibling;){if(null===p.return||p.return===e)break e;d===p&&(d=null),p=p.return}d===p&&(d=null),p.sibling.return=p.return,p=p.sibling}}break;case 19:hl(t,e),yl(e),4&r&&ml(e);case 21:}}function yl(e){var t=e.flags;if(2&t){try{e:{for(var n=e.return;null!==n;){if(il(n)){var r=n;break e}n=n.return}throw Error(o(160))}switch(r.tag){case 5:var a=r.stateNode;32&r.flags&&(pe(a,""),r.flags&=-33),ul(e,sl(e),a);break;case 3:case 4:var i=r.stateNode.containerInfo;ll(e,sl(e),i);break;default:throw Error(o(161))}}catch(s){Cu(e,e.return,s)}e.flags&=-3}4096&t&&(e.flags&=-4097)}function bl(e,t,n){Ys=e,gl(e,t,n)}function gl(e,t,n){for(var r=0!==(1&e.mode);null!==Ys;){var a=Ys,o=a.child;if(22===a.tag&&r){var i=null!==a.memoizedState||qs;if(!i){var s=a.alternate,l=null!==s&&null!==s.memoizedState||Ks;s=qs;var u=Ks;if(qs=i,(Ks=l)&&!u)for(Ys=a;null!==Ys;)l=(i=Ys).child,22===i.tag&&null!==i.memoizedState?Sl(a):null!==l?(l.return=i,Ys=l):Sl(a);for(;null!==o;)Ys=o,gl(o,t,n),o=o.sibling;Ys=a,qs=s,Ks=u}_l(e)}else 0!==(8772&a.subtreeFlags)&&null!==o?(o.return=a,Ys=o):_l(e)}}function _l(e){for(;null!==Ys;){var t=Ys;if(0!==(8772&t.flags)){var n=t.alternate;try{if(0!==(8772&t.flags))switch(t.tag){case 0:case 11:case 15:Ks||rl(5,t);break;case 1:var r=t.stateNode;if(4&t.flags&&!Ks)if(null===n)r.componentDidMount();else{var a=t.elementType===t.type?n.memoizedProps:yo(t.type,n.memoizedProps);r.componentDidUpdate(a,n.memoizedState,r.__reactInternalSnapshotBeforeUpdate)}var i=t.updateQueue;null!==i&&Zo(t,i,r);break;case 3:var s=t.updateQueue;if(null!==s){if(n=null,null!==t.child)switch(t.child.tag){case 5:case 1:n=t.child.stateNode}Zo(t,s,n)}break;case 5:var l=t.stateNode;if(null===n&&4&t.flags){n=l;var u=t.memoizedProps;switch(t.type){case"button":case"input":case"select":case"textarea":u.autoFocus&&n.focus();break;case"img":u.src&&(n.src=u.src)}}break;case 6:case 4:case 12:case 19:case 17:case 21:case 22:case 23:case 25:break;case 13:if(null===t.memoizedState){var c=t.alternate;if(null!==c){var d=c.memoizedState;if(null!==d){var p=d.dehydrated;null!==p&&Wt(p)}}}break;default:throw Error(o(163))}Ks||512&t.flags&&al(t)}catch(f){Cu(t,t.return,f)}}if(t===e){Ys=null;break}if(null!==(n=t.sibling)){n.return=t.return,Ys=n;break}Ys=t.return}}function wl(e){for(;null!==Ys;){var t=Ys;if(t===e){Ys=null;break}var n=t.sibling;if(null!==n){n.return=t.return,Ys=n;break}Ys=t.return}}function Sl(e){for(;null!==Ys;){var t=Ys;try{switch(t.tag){case 0:case 11:case 15:var n=t.return;try{rl(4,t)}catch(l){Cu(t,n,l)}break;case 1:var r=t.stateNode;if("function"===typeof r.componentDidMount){var a=t.return;try{r.componentDidMount()}catch(l){Cu(t,a,l)}}var o=t.return;try{al(t)}catch(l){Cu(t,o,l)}break;case 5:var i=t.return;try{al(t)}catch(l){Cu(t,i,l)}}}catch(l){Cu(t,t.return,l)}if(t===e){Ys=null;break}var s=t.sibling;if(null!==s){s.return=t.return,Ys=s;break}Ys=t.return}}var kl,Cl=Math.ceil,Tl=_.ReactCurrentDispatcher,xl=_.ReactCurrentOwner,Pl=_.ReactCurrentBatchConfig,El=0,Al=null,Nl=null,Fl=0,Ol=0,Rl=Ca(0),Dl=0,Ml=null,Il=0,zl=0,Ll=0,Zl=null,jl=null,Bl=0,Wl=1/0,Jl=null,Vl=!1,Ul=null,$l=null,Gl=!1,Hl=null,ql=0,Kl=0,Ql=null,Yl=-1,Xl=0;function eu(){return 0!==(6&El)?Qe():-1!==Yl?Yl:Yl=Qe()}function tu(e){return 0===(1&e.mode)?1:0!==(2&El)&&0!==Fl?Fl&-Fl:null!==vo.transition?(0===Xl&&(Xl=ht()),Xl):0!==(e=gt)?e:e=void 0===(e=window.event)?16:Kt(e.type)}function nu(e,t,n,r){if(50<Kl)throw Kl=0,Ql=null,Error(o(185));yt(e,n,r),0!==(2&El)&&e===Al||(e===Al&&(0===(2&El)&&(zl|=n),4===Dl&&su(e,Fl)),ru(e,r),1===n&&0===El&&0===(1&t.mode)&&(Wl=Qe()+500,Za&&Wa()))}function ru(e,t){var n=e.callbackNode;!function(e,t){for(var n=e.suspendedLanes,r=e.pingedLanes,a=e.expirationTimes,o=e.pendingLanes;0<o;){var i=31-it(o),s=1<<i,l=a[i];-1===l?0!==(s&n)&&0===(s&r)||(a[i]=ft(s,t)):l<=t&&(e.expiredLanes|=s),o&=~s}}(e,t);var r=pt(e,e===Al?Fl:0);if(0===r)null!==n&&He(n),e.callbackNode=null,e.callbackPriority=0;else if(t=r&-r,e.callbackPriority!==t){if(null!=n&&He(n),1===t)0===e.tag?function(e){Za=!0,Ba(e)}(lu.bind(null,e)):Ba(lu.bind(null,e)),ia((function(){0===(6&El)&&Wa()})),n=null;else{switch(_t(r)){case 1:n=Xe;break;case 4:n=et;break;case 16:default:n=tt;break;case 536870912:n=rt}n=Au(n,au.bind(null,e))}e.callbackPriority=t,e.callbackNode=n}}function au(e,t){if(Yl=-1,Xl=0,0!==(6&El))throw Error(o(327));var n=e.callbackNode;if(Su()&&e.callbackNode!==n)return null;var r=pt(e,e===Al?Fl:0);if(0===r)return null;if(0!==(30&r)||0!==(r&e.expiredLanes)||t)t=vu(e,r);else{t=r;var a=El;El|=2;var i=mu();for(Al===e&&Fl===t||(Jl=null,Wl=Qe()+500,pu(e,t));;)try{bu();break}catch(l){fu(e,l)}So(),Tl.current=i,El=a,null!==Nl?t=0:(Al=null,Fl=0,t=Dl)}if(0!==t){if(2===t&&(0!==(a=mt(e))&&(r=a,t=ou(e,a))),1===t)throw n=Ml,pu(e,0),su(e,r),ru(e,Qe()),n;if(6===t)su(e,r);else{if(a=e.current.alternate,0===(30&r)&&!function(e){for(var t=e;;){if(16384&t.flags){var n=t.updateQueue;if(null!==n&&null!==(n=n.stores))for(var r=0;r<n.length;r++){var a=n[r],o=a.getSnapshot;a=a.value;try{if(!sr(o(),a))return!1}catch(s){return!1}}}if(n=t.child,16384&t.subtreeFlags&&null!==n)n.return=t,t=n;else{if(t===e)break;for(;null===t.sibling;){if(null===t.return||t.return===e)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}(a)&&(2===(t=vu(e,r))&&(0!==(i=mt(e))&&(r=i,t=ou(e,i))),1===t))throw n=Ml,pu(e,0),su(e,r),ru(e,Qe()),n;switch(e.finishedWork=a,e.finishedLanes=r,t){case 0:case 1:throw Error(o(345));case 2:case 5:wu(e,jl,Jl);break;case 3:if(su(e,r),(130023424&r)===r&&10<(t=Bl+500-Qe())){if(0!==pt(e,0))break;if(((a=e.suspendedLanes)&r)!==r){eu(),e.pingedLanes|=e.suspendedLanes&a;break}e.timeoutHandle=ra(wu.bind(null,e,jl,Jl),t);break}wu(e,jl,Jl);break;case 4:if(su(e,r),(4194240&r)===r)break;for(t=e.eventTimes,a=-1;0<r;){var s=31-it(r);i=1<<s,(s=t[s])>a&&(a=s),r&=~i}if(r=a,10<(r=(120>(r=Qe()-r)?120:480>r?480:1080>r?1080:1920>r?1920:3e3>r?3e3:4320>r?4320:1960*Cl(r/1960))-r)){e.timeoutHandle=ra(wu.bind(null,e,jl,Jl),r);break}wu(e,jl,Jl);break;default:throw Error(o(329))}}}return ru(e,Qe()),e.callbackNode===n?au.bind(null,e):null}function ou(e,t){var n=Zl;return e.current.memoizedState.isDehydrated&&(pu(e,t).flags|=256),2!==(e=vu(e,t))&&(t=jl,jl=n,null!==t&&iu(t)),e}function iu(e){null===jl?jl=e:jl.push.apply(jl,e)}function su(e,t){for(t&=~Ll,t&=~zl,e.suspendedLanes|=t,e.pingedLanes&=~t,e=e.expirationTimes;0<t;){var n=31-it(t),r=1<<n;e[n]=-1,t&=~r}}function lu(e){if(0!==(6&El))throw Error(o(327));Su();var t=pt(e,0);if(0===(1&t))return ru(e,Qe()),null;var n=vu(e,t);if(0!==e.tag&&2===n){var r=mt(e);0!==r&&(t=r,n=ou(e,r))}if(1===n)throw n=Ml,pu(e,0),su(e,t),ru(e,Qe()),n;if(6===n)throw Error(o(345));return e.finishedWork=e.current.alternate,e.finishedLanes=t,wu(e,jl,Jl),ru(e,Qe()),null}function uu(e,t){var n=El;El|=1;try{return e(t)}finally{0===(El=n)&&(Wl=Qe()+500,Za&&Wa())}}function cu(e){null!==Hl&&0===Hl.tag&&0===(6&El)&&Su();var t=El;El|=1;var n=Pl.transition,r=gt;try{if(Pl.transition=null,gt=1,e)return e()}finally{gt=r,Pl.transition=n,0===(6&(El=t))&&Wa()}}function du(){Ol=Rl.current,Ta(Rl)}function pu(e,t){e.finishedWork=null,e.finishedLanes=0;var n=e.timeoutHandle;if(-1!==n&&(e.timeoutHandle=-1,aa(n)),null!==Nl)for(n=Nl.return;null!==n;){var r=n;switch(to(r),r.tag){case 1:null!==(r=r.type.childContextTypes)&&void 0!==r&&Ra();break;case 3:oi(),Ta(Aa),Ta(Ea),di();break;case 5:si(r);break;case 4:oi();break;case 13:case 19:Ta(li);break;case 10:ko(r.type._context);break;case 22:case 23:du()}n=n.return}if(Al=e,Nl=e=Ru(e.current,null),Fl=Ol=t,Dl=0,Ml=null,Ll=zl=Il=0,jl=Zl=null,null!==Po){for(t=0;t<Po.length;t++)if(null!==(r=(n=Po[t]).interleaved)){n.interleaved=null;var a=r.next,o=n.pending;if(null!==o){var i=o.next;o.next=a,r.next=i}n.pending=r}Po=null}return e}function fu(e,t){for(;;){var n=Nl;try{if(So(),pi.current=is,bi){for(var r=hi.memoizedState;null!==r;){var a=r.queue;null!==a&&(a.pending=null),r=r.next}bi=!1}if(mi=0,yi=vi=hi=null,gi=!1,_i=0,xl.current=null,null===n||null===n.return){Dl=1,Ml=t,Nl=null;break}e:{var i=e,s=n.return,l=n,u=t;if(t=Fl,l.flags|=32768,null!==u&&"object"===typeof u&&"function"===typeof u.then){var c=u,d=l,p=d.tag;if(0===(1&d.mode)&&(0===p||11===p||15===p)){var f=d.alternate;f?(d.updateQueue=f.updateQueue,d.memoizedState=f.memoizedState,d.lanes=f.lanes):(d.updateQueue=null,d.memoizedState=null)}var m=ys(s);if(null!==m){m.flags&=-257,bs(m,s,l,0,t),1&m.mode&&vs(i,c,t),u=c;var h=(t=m).updateQueue;if(null===h){var v=new Set;v.add(u),t.updateQueue=v}else h.add(u);break e}if(0===(1&t)){vs(i,c,t),hu();break e}u=Error(o(426))}else if(ao&&1&l.mode){var y=ys(s);if(null!==y){0===(65536&y.flags)&&(y.flags|=256),bs(y,s,l,0,t),ho(cs(u,l));break e}}i=u=cs(u,l),4!==Dl&&(Dl=2),null===Zl?Zl=[i]:Zl.push(i),i=s;do{switch(i.tag){case 3:i.flags|=65536,t&=-t,i.lanes|=t,zo(i,ms(0,u,t));break e;case 1:l=u;var b=i.type,g=i.stateNode;if(0===(128&i.flags)&&("function"===typeof b.getDerivedStateFromError||null!==g&&"function"===typeof g.componentDidCatch&&(null===$l||!$l.has(g)))){i.flags|=65536,t&=-t,i.lanes|=t,zo(i,hs(i,l,t));break e}}i=i.return}while(null!==i)}_u(n)}catch(_){t=_,Nl===n&&null!==n&&(Nl=n=n.return);continue}break}}function mu(){var e=Tl.current;return Tl.current=is,null===e?is:e}function hu(){0!==Dl&&3!==Dl&&2!==Dl||(Dl=4),null===Al||0===(268435455&Il)&&0===(268435455&zl)||su(Al,Fl)}function vu(e,t){var n=El;El|=2;var r=mu();for(Al===e&&Fl===t||(Jl=null,pu(e,t));;)try{yu();break}catch(a){fu(e,a)}if(So(),El=n,Tl.current=r,null!==Nl)throw Error(o(261));return Al=null,Fl=0,Dl}function yu(){for(;null!==Nl;)gu(Nl)}function bu(){for(;null!==Nl&&!qe();)gu(Nl)}function gu(e){var t=kl(e.alternate,e,Ol);e.memoizedProps=e.pendingProps,null===t?_u(e):Nl=t,xl.current=null}function _u(e){var t=e;do{var n=t.alternate;if(e=t.return,0===(32768&t.flags)){if(null!==(n=Gs(n,t,Ol)))return void(Nl=n)}else{if(null!==(n=Hs(n,t)))return n.flags&=32767,void(Nl=n);if(null===e)return Dl=6,void(Nl=null);e.flags|=32768,e.subtreeFlags=0,e.deletions=null}if(null!==(t=t.sibling))return void(Nl=t);Nl=t=e}while(null!==t);0===Dl&&(Dl=5)}function wu(e,t,n){var r=gt,a=Pl.transition;try{Pl.transition=null,gt=1,function(e,t,n,r){do{Su()}while(null!==Hl);if(0!==(6&El))throw Error(o(327));n=e.finishedWork;var a=e.finishedLanes;if(null===n)return null;if(e.finishedWork=null,e.finishedLanes=0,n===e.current)throw Error(o(177));e.callbackNode=null,e.callbackPriority=0;var i=n.lanes|n.childLanes;if(function(e,t){var n=e.pendingLanes&~t;e.pendingLanes=t,e.suspendedLanes=0,e.pingedLanes=0,e.expiredLanes&=t,e.mutableReadLanes&=t,e.entangledLanes&=t,t=e.entanglements;var r=e.eventTimes;for(e=e.expirationTimes;0<n;){var a=31-it(n),o=1<<a;t[a]=0,r[a]=-1,e[a]=-1,n&=~o}}(e,i),e===Al&&(Nl=Al=null,Fl=0),0===(2064&n.subtreeFlags)&&0===(2064&n.flags)||Gl||(Gl=!0,Au(tt,(function(){return Su(),null}))),i=0!==(15990&n.flags),0!==(15990&n.subtreeFlags)||i){i=Pl.transition,Pl.transition=null;var s=gt;gt=1;var l=El;El|=4,xl.current=null,function(e,t){if(ea=Vt,fr(e=pr())){if("selectionStart"in e)var n={start:e.selectionStart,end:e.selectionEnd};else e:{var r=(n=(n=e.ownerDocument)&&n.defaultView||window).getSelection&&n.getSelection();if(r&&0!==r.rangeCount){n=r.anchorNode;var a=r.anchorOffset,i=r.focusNode;r=r.focusOffset;try{n.nodeType,i.nodeType}catch(w){n=null;break e}var s=0,l=-1,u=-1,c=0,d=0,p=e,f=null;t:for(;;){for(var m;p!==n||0!==a&&3!==p.nodeType||(l=s+a),p!==i||0!==r&&3!==p.nodeType||(u=s+r),3===p.nodeType&&(s+=p.nodeValue.length),null!==(m=p.firstChild);)f=p,p=m;for(;;){if(p===e)break t;if(f===n&&++c===a&&(l=s),f===i&&++d===r&&(u=s),null!==(m=p.nextSibling))break;f=(p=f).parentNode}p=m}n=-1===l||-1===u?null:{start:l,end:u}}else n=null}n=n||{start:0,end:0}}else n=null;for(ta={focusedElem:e,selectionRange:n},Vt=!1,Ys=t;null!==Ys;)if(e=(t=Ys).child,0!==(1028&t.subtreeFlags)&&null!==e)e.return=t,Ys=e;else for(;null!==Ys;){t=Ys;try{var h=t.alternate;if(0!==(1024&t.flags))switch(t.tag){case 0:case 11:case 15:case 5:case 6:case 4:case 17:break;case 1:if(null!==h){var v=h.memoizedProps,y=h.memoizedState,b=t.stateNode,g=b.getSnapshotBeforeUpdate(t.elementType===t.type?v:yo(t.type,v),y);b.__reactInternalSnapshotBeforeUpdate=g}break;case 3:var _=t.stateNode.containerInfo;1===_.nodeType?_.textContent="":9===_.nodeType&&_.documentElement&&_.removeChild(_.documentElement);break;default:throw Error(o(163))}}catch(w){Cu(t,t.return,w)}if(null!==(e=t.sibling)){e.return=t.return,Ys=e;break}Ys=t.return}h=tl,tl=!1}(e,n),vl(n,e),mr(ta),Vt=!!ea,ta=ea=null,e.current=n,bl(n,e,a),Ke(),El=l,gt=s,Pl.transition=i}else e.current=n;if(Gl&&(Gl=!1,Hl=e,ql=a),0===(i=e.pendingLanes)&&($l=null),function(e){if(ot&&"function"===typeof ot.onCommitFiberRoot)try{ot.onCommitFiberRoot(at,e,void 0,128===(128&e.current.flags))}catch(t){}}(n.stateNode),ru(e,Qe()),null!==t)for(r=e.onRecoverableError,n=0;n<t.length;n++)r((a=t[n]).value,{componentStack:a.stack,digest:a.digest});if(Vl)throw Vl=!1,e=Ul,Ul=null,e;0!==(1&ql)&&0!==e.tag&&Su(),0!==(1&(i=e.pendingLanes))?e===Ql?Kl++:(Kl=0,Ql=e):Kl=0,Wa()}(e,t,n,r)}finally{Pl.transition=a,gt=r}return null}function Su(){if(null!==Hl){var e=_t(ql),t=Pl.transition,n=gt;try{if(Pl.transition=null,gt=16>e?16:e,null===Hl)var r=!1;else{if(e=Hl,Hl=null,ql=0,0!==(6&El))throw Error(o(331));var a=El;for(El|=4,Ys=e.current;null!==Ys;){var i=Ys,s=i.child;if(0!==(16&Ys.flags)){var l=i.deletions;if(null!==l){for(var u=0;u<l.length;u++){var c=l[u];for(Ys=c;null!==Ys;){var d=Ys;switch(d.tag){case 0:case 11:case 15:nl(8,d,i)}var p=d.child;if(null!==p)p.return=d,Ys=p;else for(;null!==Ys;){var f=(d=Ys).sibling,m=d.return;if(ol(d),d===c){Ys=null;break}if(null!==f){f.return=m,Ys=f;break}Ys=m}}}var h=i.alternate;if(null!==h){var v=h.child;if(null!==v){h.child=null;do{var y=v.sibling;v.sibling=null,v=y}while(null!==v)}}Ys=i}}if(0!==(2064&i.subtreeFlags)&&null!==s)s.return=i,Ys=s;else e:for(;null!==Ys;){if(0!==(2048&(i=Ys).flags))switch(i.tag){case 0:case 11:case 15:nl(9,i,i.return)}var b=i.sibling;if(null!==b){b.return=i.return,Ys=b;break e}Ys=i.return}}var g=e.current;for(Ys=g;null!==Ys;){var _=(s=Ys).child;if(0!==(2064&s.subtreeFlags)&&null!==_)_.return=s,Ys=_;else e:for(s=g;null!==Ys;){if(0!==(2048&(l=Ys).flags))try{switch(l.tag){case 0:case 11:case 15:rl(9,l)}}catch(S){Cu(l,l.return,S)}if(l===s){Ys=null;break e}var w=l.sibling;if(null!==w){w.return=l.return,Ys=w;break e}Ys=l.return}}if(El=a,Wa(),ot&&"function"===typeof ot.onPostCommitFiberRoot)try{ot.onPostCommitFiberRoot(at,e)}catch(S){}r=!0}return r}finally{gt=n,Pl.transition=t}}return!1}function ku(e,t,n){e=Mo(e,t=ms(0,t=cs(n,t),1),1),t=eu(),null!==e&&(yt(e,1,t),ru(e,t))}function Cu(e,t,n){if(3===e.tag)ku(e,e,n);else for(;null!==t;){if(3===t.tag){ku(t,e,n);break}if(1===t.tag){var r=t.stateNode;if("function"===typeof t.type.getDerivedStateFromError||"function"===typeof r.componentDidCatch&&(null===$l||!$l.has(r))){t=Mo(t,e=hs(t,e=cs(n,e),1),1),e=eu(),null!==t&&(yt(t,1,e),ru(t,e));break}}t=t.return}}function Tu(e,t,n){var r=e.pingCache;null!==r&&r.delete(t),t=eu(),e.pingedLanes|=e.suspendedLanes&n,Al===e&&(Fl&n)===n&&(4===Dl||3===Dl&&(130023424&Fl)===Fl&&500>Qe()-Bl?pu(e,0):Ll|=n),ru(e,t)}function xu(e,t){0===t&&(0===(1&e.mode)?t=1:(t=ct,0===(130023424&(ct<<=1))&&(ct=4194304)));var n=eu();null!==(e=No(e,t))&&(yt(e,t,n),ru(e,n))}function Pu(e){var t=e.memoizedState,n=0;null!==t&&(n=t.retryLane),xu(e,n)}function Eu(e,t){var n=0;switch(e.tag){case 13:var r=e.stateNode,a=e.memoizedState;null!==a&&(n=a.retryLane);break;case 19:r=e.stateNode;break;default:throw Error(o(314))}null!==r&&r.delete(t),xu(e,n)}function Au(e,t){return Ge(e,t)}function Nu(e,t,n,r){this.tag=e,this.key=n,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=r,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Fu(e,t,n,r){return new Nu(e,t,n,r)}function Ou(e){return!(!(e=e.prototype)||!e.isReactComponent)}function Ru(e,t){var n=e.alternate;return null===n?((n=Fu(e.tag,t,e.key,e.mode)).elementType=e.elementType,n.type=e.type,n.stateNode=e.stateNode,n.alternate=e,e.alternate=n):(n.pendingProps=t,n.type=e.type,n.flags=0,n.subtreeFlags=0,n.deletions=null),n.flags=14680064&e.flags,n.childLanes=e.childLanes,n.lanes=e.lanes,n.child=e.child,n.memoizedProps=e.memoizedProps,n.memoizedState=e.memoizedState,n.updateQueue=e.updateQueue,t=e.dependencies,n.dependencies=null===t?null:{lanes:t.lanes,firstContext:t.firstContext},n.sibling=e.sibling,n.index=e.index,n.ref=e.ref,n}function Du(e,t,n,r,a,i){var s=2;if(r=e,"function"===typeof e)Ou(e)&&(s=1);else if("string"===typeof e)s=5;else e:switch(e){case k:return Mu(n.children,a,i,t);case C:s=8,a|=8;break;case T:return(e=Fu(12,n,t,2|a)).elementType=T,e.lanes=i,e;case A:return(e=Fu(13,n,t,a)).elementType=A,e.lanes=i,e;case N:return(e=Fu(19,n,t,a)).elementType=N,e.lanes=i,e;case R:return Iu(n,a,i,t);default:if("object"===typeof e&&null!==e)switch(e.$$typeof){case x:s=10;break e;case P:s=9;break e;case E:s=11;break e;case F:s=14;break e;case O:s=16,r=null;break e}throw Error(o(130,null==e?e:typeof e,""))}return(t=Fu(s,n,t,a)).elementType=e,t.type=r,t.lanes=i,t}function Mu(e,t,n,r){return(e=Fu(7,e,r,t)).lanes=n,e}function Iu(e,t,n,r){return(e=Fu(22,e,r,t)).elementType=R,e.lanes=n,e.stateNode={isHidden:!1},e}function zu(e,t,n){return(e=Fu(6,e,null,t)).lanes=n,e}function Lu(e,t,n){return(t=Fu(4,null!==e.children?e.children:[],e.key,t)).lanes=n,t.stateNode={containerInfo:e.containerInfo,pendingChildren:null,implementation:e.implementation},t}function Zu(e,t,n,r,a){this.tag=t,this.containerInfo=e,this.finishedWork=this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.pendingContext=this.context=null,this.callbackPriority=0,this.eventTimes=vt(0),this.expirationTimes=vt(-1),this.entangledLanes=this.finishedLanes=this.mutableReadLanes=this.expiredLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=vt(0),this.identifierPrefix=r,this.onRecoverableError=a,this.mutableSourceEagerHydrationData=null}function ju(e,t,n,r,a,o,i,s,l){return e=new Zu(e,t,n,s,l),1===t?(t=1,!0===o&&(t|=8)):t=0,o=Fu(3,null,null,t),e.current=o,o.stateNode=e,o.memoizedState={element:r,isDehydrated:n,cache:null,transitions:null,pendingSuspenseBoundaries:null},Oo(o),e}function Bu(e,t,n){var r=3<arguments.length&&void 0!==arguments[3]?arguments[3]:null;return{$$typeof:S,key:null==r?null:""+r,children:e,containerInfo:t,implementation:n}}function Wu(e){if(!e)return Pa;e:{if(We(e=e._reactInternals)!==e||1!==e.tag)throw Error(o(170));var t=e;do{switch(t.tag){case 3:t=t.stateNode.context;break e;case 1:if(Oa(t.type)){t=t.stateNode.__reactInternalMemoizedMergedChildContext;break e}}t=t.return}while(null!==t);throw Error(o(171))}if(1===e.tag){var n=e.type;if(Oa(n))return Ma(e,n,t)}return t}function Ju(e,t,n,r,a,o,i,s,l){return(e=ju(n,r,!0,e,0,o,0,s,l)).context=Wu(null),n=e.current,(o=Do(r=eu(),a=tu(n))).callback=void 0!==t&&null!==t?t:null,Mo(n,o,a),e.current.lanes=a,yt(e,a,r),ru(e,r),e}function Vu(e,t,n,r){var a=t.current,o=eu(),i=tu(a);return n=Wu(n),null===t.context?t.context=n:t.pendingContext=n,(t=Do(o,i)).payload={element:e},null!==(r=void 0===r?null:r)&&(t.callback=r),null!==(e=Mo(a,t,i))&&(nu(e,a,i,o),Io(e,a,i)),i}function Uu(e){return(e=e.current).child?(e.child.tag,e.child.stateNode):null}function $u(e,t){if(null!==(e=e.memoizedState)&&null!==e.dehydrated){var n=e.retryLane;e.retryLane=0!==n&&n<t?n:t}}function Gu(e,t){$u(e,t),(e=e.alternate)&&$u(e,t)}kl=function(e,t,n){if(null!==e)if(e.memoizedProps!==t.pendingProps||Aa.current)_s=!0;else{if(0===(e.lanes&n)&&0===(128&t.flags))return _s=!1,function(e,t,n){switch(t.tag){case 3:Ns(t),mo();break;case 5:ii(t);break;case 1:Oa(t.type)&&Ia(t);break;case 4:ai(t,t.stateNode.containerInfo);break;case 10:var r=t.type._context,a=t.memoizedProps.value;xa(bo,r._currentValue),r._currentValue=a;break;case 13:if(null!==(r=t.memoizedState))return null!==r.dehydrated?(xa(li,1&li.current),t.flags|=128,null):0!==(n&t.child.childLanes)?zs(e,t,n):(xa(li,1&li.current),null!==(e=Vs(e,t,n))?e.sibling:null);xa(li,1&li.current);break;case 19:if(r=0!==(n&t.childLanes),0!==(128&e.flags)){if(r)return Ws(e,t,n);t.flags|=128}if(null!==(a=t.memoizedState)&&(a.rendering=null,a.tail=null,a.lastEffect=null),xa(li,li.current),r)break;return null;case 22:case 23:return t.lanes=0,Ts(e,t,n)}return Vs(e,t,n)}(e,t,n);_s=0!==(131072&e.flags)}else _s=!1,ao&&0!==(1048576&t.flags)&&Xa(t,$a,t.index);switch(t.lanes=0,t.tag){case 2:var r=t.type;Js(e,t),e=t.pendingProps;var a=Fa(t,Ea.current);To(t,n),a=Ci(null,t,r,e,a,n);var i=Ti();return t.flags|=1,"object"===typeof a&&null!==a&&"function"===typeof a.render&&void 0===a.$$typeof?(t.tag=1,t.memoizedState=null,t.updateQueue=null,Oa(r)?(i=!0,Ia(t)):i=!1,t.memoizedState=null!==a.state&&void 0!==a.state?a.state:null,Oo(t),a.updater=Wo,t.stateNode=a,a._reactInternals=t,$o(t,r,e,n),t=As(null,t,r,!0,i,n)):(t.tag=0,ao&&i&&eo(t),ws(null,t,a,n),t=t.child),t;case 16:r=t.elementType;e:{switch(Js(e,t),e=t.pendingProps,r=(a=r._init)(r._payload),t.type=r,a=t.tag=function(e){if("function"===typeof e)return Ou(e)?1:0;if(void 0!==e&&null!==e){if((e=e.$$typeof)===E)return 11;if(e===F)return 14}return 2}(r),e=yo(r,e),a){case 0:t=Ps(null,t,r,e,n);break e;case 1:t=Es(null,t,r,e,n);break e;case 11:t=Ss(null,t,r,e,n);break e;case 14:t=ks(null,t,r,yo(r.type,e),n);break e}throw Error(o(306,r,""))}return t;case 0:return r=t.type,a=t.pendingProps,Ps(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 1:return r=t.type,a=t.pendingProps,Es(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 3:e:{if(Ns(t),null===e)throw Error(o(387));r=t.pendingProps,a=(i=t.memoizedState).element,Ro(e,t),Lo(t,r,null,n);var s=t.memoizedState;if(r=s.element,i.isDehydrated){if(i={element:r,isDehydrated:!1,cache:s.cache,pendingSuspenseBoundaries:s.pendingSuspenseBoundaries,transitions:s.transitions},t.updateQueue.baseState=i,t.memoizedState=i,256&t.flags){t=Fs(e,t,r,n,a=cs(Error(o(423)),t));break e}if(r!==a){t=Fs(e,t,r,n,a=cs(Error(o(424)),t));break e}for(ro=ua(t.stateNode.containerInfo.firstChild),no=t,ao=!0,oo=null,n=Yo(t,null,r,n),t.child=n;n;)n.flags=-3&n.flags|4096,n=n.sibling}else{if(mo(),r===a){t=Vs(e,t,n);break e}ws(e,t,r,n)}t=t.child}return t;case 5:return ii(t),null===e&&uo(t),r=t.type,a=t.pendingProps,i=null!==e?e.memoizedProps:null,s=a.children,na(r,a)?s=null:null!==i&&na(r,i)&&(t.flags|=32),xs(e,t),ws(e,t,s,n),t.child;case 6:return null===e&&uo(t),null;case 13:return zs(e,t,n);case 4:return ai(t,t.stateNode.containerInfo),r=t.pendingProps,null===e?t.child=Qo(t,null,r,n):ws(e,t,r,n),t.child;case 11:return r=t.type,a=t.pendingProps,Ss(e,t,r,a=t.elementType===r?a:yo(r,a),n);case 7:return ws(e,t,t.pendingProps,n),t.child;case 8:case 12:return ws(e,t,t.pendingProps.children,n),t.child;case 10:e:{if(r=t.type._context,a=t.pendingProps,i=t.memoizedProps,s=a.value,xa(bo,r._currentValue),r._currentValue=s,null!==i)if(sr(i.value,s)){if(i.children===a.children&&!Aa.current){t=Vs(e,t,n);break e}}else for(null!==(i=t.child)&&(i.return=t);null!==i;){var l=i.dependencies;if(null!==l){s=i.child;for(var u=l.firstContext;null!==u;){if(u.context===r){if(1===i.tag){(u=Do(-1,n&-n)).tag=2;var c=i.updateQueue;if(null!==c){var d=(c=c.shared).pending;null===d?u.next=u:(u.next=d.next,d.next=u),c.pending=u}}i.lanes|=n,null!==(u=i.alternate)&&(u.lanes|=n),Co(i.return,n,t),l.lanes|=n;break}u=u.next}}else if(10===i.tag)s=i.type===t.type?null:i.child;else if(18===i.tag){if(null===(s=i.return))throw Error(o(341));s.lanes|=n,null!==(l=s.alternate)&&(l.lanes|=n),Co(s,n,t),s=i.sibling}else s=i.child;if(null!==s)s.return=i;else for(s=i;null!==s;){if(s===t){s=null;break}if(null!==(i=s.sibling)){i.return=s.return,s=i;break}s=s.return}i=s}ws(e,t,a.children,n),t=t.child}return t;case 9:return a=t.type,r=t.pendingProps.children,To(t,n),r=r(a=xo(a)),t.flags|=1,ws(e,t,r,n),t.child;case 14:return a=yo(r=t.type,t.pendingProps),ks(e,t,r,a=yo(r.type,a),n);case 15:return Cs(e,t,t.type,t.pendingProps,n);case 17:return r=t.type,a=t.pendingProps,a=t.elementType===r?a:yo(r,a),Js(e,t),t.tag=1,Oa(r)?(e=!0,Ia(t)):e=!1,To(t,n),Vo(t,r,a),$o(t,r,a,n),As(null,t,r,!0,e,n);case 19:return Ws(e,t,n);case 22:return Ts(e,t,n)}throw Error(o(156,t.tag))};var Hu="function"===typeof reportError?reportError:function(e){console.error(e)};function qu(e){this._internalRoot=e}function Ku(e){this._internalRoot=e}function Qu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType)}function Yu(e){return!(!e||1!==e.nodeType&&9!==e.nodeType&&11!==e.nodeType&&(8!==e.nodeType||" react-mount-point-unstable "!==e.nodeValue))}function Xu(){}function ec(e,t,n,r,a){var o=n._reactRootContainer;if(o){var i=o;if("function"===typeof a){var s=a;a=function(){var e=Uu(i);s.call(e)}}Vu(t,i,e,a)}else i=function(e,t,n,r,a){if(a){if("function"===typeof r){var o=r;r=function(){var e=Uu(i);o.call(e)}}var i=Ju(t,r,e,0,null,!1,0,"",Xu);return e._reactRootContainer=i,e[ma]=i.current,Wr(8===e.nodeType?e.parentNode:e),cu(),i}for(;a=e.lastChild;)e.removeChild(a);if("function"===typeof r){var s=r;r=function(){var e=Uu(l);s.call(e)}}var l=ju(e,0,!1,null,0,!1,0,"",Xu);return e._reactRootContainer=l,e[ma]=l.current,Wr(8===e.nodeType?e.parentNode:e),cu((function(){Vu(t,l,n,r)})),l}(n,t,e,a,r);return Uu(i)}Ku.prototype.render=qu.prototype.render=function(e){var t=this._internalRoot;if(null===t)throw Error(o(409));Vu(e,t,null,null)},Ku.prototype.unmount=qu.prototype.unmount=function(){var e=this._internalRoot;if(null!==e){this._internalRoot=null;var t=e.containerInfo;cu((function(){Vu(null,e,null,null)})),t[ma]=null}},Ku.prototype.unstable_scheduleHydration=function(e){if(e){var t=Ct();e={blockedOn:null,target:e,priority:t};for(var n=0;n<Rt.length&&0!==t&&t<Rt[n].priority;n++);Rt.splice(n,0,e),0===n&&zt(e)}},wt=function(e){switch(e.tag){case 3:var t=e.stateNode;if(t.current.memoizedState.isDehydrated){var n=dt(t.pendingLanes);0!==n&&(bt(t,1|n),ru(t,Qe()),0===(6&El)&&(Wl=Qe()+500,Wa()))}break;case 13:cu((function(){var t=No(e,1);if(null!==t){var n=eu();nu(t,e,1,n)}})),Gu(e,1)}},St=function(e){if(13===e.tag){var t=No(e,134217728);if(null!==t)nu(t,e,134217728,eu());Gu(e,134217728)}},kt=function(e){if(13===e.tag){var t=tu(e),n=No(e,t);if(null!==n)nu(n,e,t,eu());Gu(e,t)}},Ct=function(){return gt},Tt=function(e,t){var n=gt;try{return gt=e,t()}finally{gt=n}},Se=function(e,t,n){switch(t){case"input":if(Y(e,n),t=n.name,"radio"===n.type&&null!=t){for(n=e;n.parentNode;)n=n.parentNode;for(n=n.querySelectorAll("input[name="+JSON.stringify(""+t)+'][type="radio"]'),t=0;t<n.length;t++){var r=n[t];if(r!==e&&r.form===e.form){var a=wa(r);if(!a)throw Error(o(90));G(r),Y(r,a)}}}break;case"textarea":oe(e,n);break;case"select":null!=(t=n.value)&&ne(e,!!n.multiple,t,!1)}},Ee=uu,Ae=cu;var tc={usingClientEntryPoint:!1,Events:[ga,_a,wa,xe,Pe,uu]},nc={findFiberByHostInstance:ba,bundleType:0,version:"18.2.0",rendererPackageName:"react-dom"},rc={bundleType:nc.bundleType,version:nc.version,rendererPackageName:nc.rendererPackageName,rendererConfig:nc.rendererConfig,overrideHookState:null,overrideHookStateDeletePath:null,overrideHookStateRenamePath:null,overrideProps:null,overridePropsDeletePath:null,overridePropsRenamePath:null,setErrorHandler:null,setSuspenseHandler:null,scheduleUpdate:null,currentDispatcherRef:_.ReactCurrentDispatcher,findHostInstanceByFiber:function(e){return null===(e=Ue(e))?null:e.stateNode},findFiberByHostInstance:nc.findFiberByHostInstance||function(){return null},findHostInstancesForRefresh:null,scheduleRefresh:null,scheduleRoot:null,setRefreshHandler:null,getCurrentFiber:null,reconcilerVersion:"18.2.0-next-9e3b772b8-20220608"};if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__){var ac=__REACT_DEVTOOLS_GLOBAL_HOOK__;if(!ac.isDisabled&&ac.supportsFiber)try{at=ac.inject(rc),ot=ac}catch(ce){}}t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=tc,t.createPortal=function(e,t){var n=2<arguments.length&&void 0!==arguments[2]?arguments[2]:null;if(!Qu(t))throw Error(o(200));return Bu(e,t,null,n)},t.createRoot=function(e,t){if(!Qu(e))throw Error(o(299));var n=!1,r="",a=Hu;return null!==t&&void 0!==t&&(!0===t.unstable_strictMode&&(n=!0),void 0!==t.identifierPrefix&&(r=t.identifierPrefix),void 0!==t.onRecoverableError&&(a=t.onRecoverableError)),t=ju(e,1,!1,null,0,n,0,r,a),e[ma]=t.current,Wr(8===e.nodeType?e.parentNode:e),new qu(t)},t.findDOMNode=function(e){if(null==e)return null;if(1===e.nodeType)return e;var t=e._reactInternals;if(void 0===t){if("function"===typeof e.render)throw Error(o(188));throw e=Object.keys(e).join(","),Error(o(268,e))}return e=null===(e=Ue(t))?null:e.stateNode},t.flushSync=function(e){return cu(e)},t.hydrate=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!0,n)},t.hydrateRoot=function(e,t,n){if(!Qu(e))throw Error(o(405));var r=null!=n&&n.hydratedSources||null,a=!1,i="",s=Hu;if(null!==n&&void 0!==n&&(!0===n.unstable_strictMode&&(a=!0),void 0!==n.identifierPrefix&&(i=n.identifierPrefix),void 0!==n.onRecoverableError&&(s=n.onRecoverableError)),t=Ju(t,null,e,1,null!=n?n:null,a,0,i,s),e[ma]=t.current,Wr(e),r)for(e=0;e<r.length;e++)a=(a=(n=r[e])._getVersion)(n._source),null==t.mutableSourceEagerHydrationData?t.mutableSourceEagerHydrationData=[n,a]:t.mutableSourceEagerHydrationData.push(n,a);return new Ku(t)},t.render=function(e,t,n){if(!Yu(t))throw Error(o(200));return ec(null,e,t,!1,n)},t.unmountComponentAtNode=function(e){if(!Yu(e))throw Error(o(40));return!!e._reactRootContainer&&(cu((function(){ec(null,null,e,!1,(function(){e._reactRootContainer=null,e[ma]=null}))})),!0)},t.unstable_batchedUpdates=uu,t.unstable_renderSubtreeIntoContainer=function(e,t,n,r){if(!Yu(n))throw Error(o(200));if(null==e||void 0===e._reactInternals)throw Error(o(38));return ec(e,t,n,!1,r)},t.version="18.2.0-next-9e3b772b8-20220608"},1250:function(e,t,n){"use strict";var r=n(4164);t.createRoot=r.createRoot,t.hydrateRoot=r.hydrateRoot},4164:function(e,t,n){"use strict";!function e(){if("undefined"!==typeof __REACT_DEVTOOLS_GLOBAL_HOOK__&&"function"===typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE)try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(e)}catch(t){console.error(t)}}(),e.exports=n(4463)},6374:function(e,t,n){"use strict";var r=n(2791),a=Symbol.for("react.element"),o=Symbol.for("react.fragment"),i=Object.prototype.hasOwnProperty,s=r.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED.ReactCurrentOwner,l={key:!0,ref:!0,__self:!0,__source:!0};function u(e,t,n){var r,o={},u=null,c=null;for(r in void 0!==n&&(u=""+n),void 0!==t.key&&(u=""+t.key),void 0!==t.ref&&(c=t.ref),t)i.call(t,r)&&!l.hasOwnProperty(r)&&(o[r]=t[r]);if(e&&e.defaultProps)for(r in t=e.defaultProps)void 0===o[r]&&(o[r]=t[r]);return{$$typeof:a,type:e,key:u,ref:c,props:o,_owner:s.current}}t.Fragment=o,t.jsx=u,t.jsxs=u},9117:function(e,t){"use strict";var n=Symbol.for("react.element"),r=Symbol.for("react.portal"),a=Symbol.for("react.fragment"),o=Symbol.for("react.strict_mode"),i=Symbol.for("react.profiler"),s=Symbol.for("react.provider"),l=Symbol.for("react.context"),u=Symbol.for("react.forward_ref"),c=Symbol.for("react.suspense"),d=Symbol.for("react.memo"),p=Symbol.for("react.lazy"),f=Symbol.iterator;var m={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},h=Object.assign,v={};function y(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}function b(){}function g(e,t,n){this.props=e,this.context=t,this.refs=v,this.updater=n||m}y.prototype.isReactComponent={},y.prototype.setState=function(e,t){if("object"!==typeof e&&"function"!==typeof e&&null!=e)throw Error("setState(...): takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,e,t,"setState")},y.prototype.forceUpdate=function(e){this.updater.enqueueForceUpdate(this,e,"forceUpdate")},b.prototype=y.prototype;var _=g.prototype=new b;_.constructor=g,h(_,y.prototype),_.isPureReactComponent=!0;var w=Array.isArray,S=Object.prototype.hasOwnProperty,k={current:null},C={key:!0,ref:!0,__self:!0,__source:!0};function T(e,t,r){var a,o={},i=null,s=null;if(null!=t)for(a in void 0!==t.ref&&(s=t.ref),void 0!==t.key&&(i=""+t.key),t)S.call(t,a)&&!C.hasOwnProperty(a)&&(o[a]=t[a]);var l=arguments.length-2;if(1===l)o.children=r;else if(1<l){for(var u=Array(l),c=0;c<l;c++)u[c]=arguments[c+2];o.children=u}if(e&&e.defaultProps)for(a in l=e.defaultProps)void 0===o[a]&&(o[a]=l[a]);return{$$typeof:n,type:e,key:i,ref:s,props:o,_owner:k.current}}function x(e){return"object"===typeof e&&null!==e&&e.$$typeof===n}var P=/\/+/g;function E(e,t){return"object"===typeof e&&null!==e&&null!=e.key?function(e){var t={"=":"=0",":":"=2"};return"$"+e.replace(/[=:]/g,(function(e){return t[e]}))}(""+e.key):t.toString(36)}function A(e,t,a,o,i){var s=typeof e;"undefined"!==s&&"boolean"!==s||(e=null);var l=!1;if(null===e)l=!0;else switch(s){case"string":case"number":l=!0;break;case"object":switch(e.$$typeof){case n:case r:l=!0}}if(l)return i=i(l=e),e=""===o?"."+E(l,0):o,w(i)?(a="",null!=e&&(a=e.replace(P,"$&/")+"/"),A(i,t,a,"",(function(e){return e}))):null!=i&&(x(i)&&(i=function(e,t){return{$$typeof:n,type:e.type,key:t,ref:e.ref,props:e.props,_owner:e._owner}}(i,a+(!i.key||l&&l.key===i.key?"":(""+i.key).replace(P,"$&/")+"/")+e)),t.push(i)),1;if(l=0,o=""===o?".":o+":",w(e))for(var u=0;u<e.length;u++){var c=o+E(s=e[u],u);l+=A(s,t,a,c,i)}else if(c=function(e){return null===e||"object"!==typeof e?null:"function"===typeof(e=f&&e[f]||e["@@iterator"])?e:null}(e),"function"===typeof c)for(e=c.call(e),u=0;!(s=e.next()).done;)l+=A(s=s.value,t,a,c=o+E(s,u++),i);else if("object"===s)throw t=String(e),Error("Objects are not valid as a React child (found: "+("[object Object]"===t?"object with keys {"+Object.keys(e).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.");return l}function N(e,t,n){if(null==e)return e;var r=[],a=0;return A(e,r,"","",(function(e){return t.call(n,e,a++)})),r}function F(e){if(-1===e._status){var t=e._result;(t=t()).then((function(t){0!==e._status&&-1!==e._status||(e._status=1,e._result=t)}),(function(t){0!==e._status&&-1!==e._status||(e._status=2,e._result=t)})),-1===e._status&&(e._status=0,e._result=t)}if(1===e._status)return e._result.default;throw e._result}var O={current:null},R={transition:null},D={ReactCurrentDispatcher:O,ReactCurrentBatchConfig:R,ReactCurrentOwner:k};t.Children={map:N,forEach:function(e,t,n){N(e,(function(){t.apply(this,arguments)}),n)},count:function(e){var t=0;return N(e,(function(){t++})),t},toArray:function(e){return N(e,(function(e){return e}))||[]},only:function(e){if(!x(e))throw Error("React.Children.only expected to receive a single React element child.");return e}},t.Component=y,t.Fragment=a,t.Profiler=i,t.PureComponent=g,t.StrictMode=o,t.Suspense=c,t.__SECRET_INTERNALS_DO_NOT_USE_OR_YOU_WILL_BE_FIRED=D,t.cloneElement=function(e,t,r){if(null===e||void 0===e)throw Error("React.cloneElement(...): The argument must be a React element, but you passed "+e+".");var a=h({},e.props),o=e.key,i=e.ref,s=e._owner;if(null!=t){if(void 0!==t.ref&&(i=t.ref,s=k.current),void 0!==t.key&&(o=""+t.key),e.type&&e.type.defaultProps)var l=e.type.defaultProps;for(u in t)S.call(t,u)&&!C.hasOwnProperty(u)&&(a[u]=void 0===t[u]&&void 0!==l?l[u]:t[u])}var u=arguments.length-2;if(1===u)a.children=r;else if(1<u){l=Array(u);for(var c=0;c<u;c++)l[c]=arguments[c+2];a.children=l}return{$$typeof:n,type:e.type,key:o,ref:i,props:a,_owner:s}},t.createContext=function(e){return(e={$$typeof:l,_currentValue:e,_currentValue2:e,_threadCount:0,Provider:null,Consumer:null,_defaultValue:null,_globalName:null}).Provider={$$typeof:s,_context:e},e.Consumer=e},t.createElement=T,t.createFactory=function(e){var t=T.bind(null,e);return t.type=e,t},t.createRef=function(){return{current:null}},t.forwardRef=function(e){return{$$typeof:u,render:e}},t.isValidElement=x,t.lazy=function(e){return{$$typeof:p,_payload:{_status:-1,_result:e},_init:F}},t.memo=function(e,t){return{$$typeof:d,type:e,compare:void 0===t?null:t}},t.startTransition=function(e){var t=R.transition;R.transition={};try{e()}finally{R.transition=t}},t.unstable_act=function(){throw Error("act(...) is not supported in production builds of React.")},t.useCallback=function(e,t){return O.current.useCallback(e,t)},t.useContext=function(e){return O.current.useContext(e)},t.useDebugValue=function(){},t.useDeferredValue=function(e){return O.current.useDeferredValue(e)},t.useEffect=function(e,t){return O.current.useEffect(e,t)},t.useId=function(){return O.current.useId()},t.useImperativeHandle=function(e,t,n){return O.current.useImperativeHandle(e,t,n)},t.useInsertionEffect=function(e,t){return O.current.useInsertionEffect(e,t)},t.useLayoutEffect=function(e,t){return O.current.useLayoutEffect(e,t)},t.useMemo=function(e,t){return O.current.useMemo(e,t)},t.useReducer=function(e,t,n){return O.current.useReducer(e,t,n)},t.useRef=function(e){return O.current.useRef(e)},t.useState=function(e){return O.current.useState(e)},t.useSyncExternalStore=function(e,t,n){return O.current.useSyncExternalStore(e,t,n)},t.useTransition=function(){return O.current.useTransition()},t.version="18.2.0"},2791:function(e,t,n){"use strict";e.exports=n(9117)},184:function(e,t,n){"use strict";e.exports=n(6374)},6813:function(e,t){"use strict";function n(e,t){var n=e.length;e.push(t);e:for(;0<n;){var r=n-1>>>1,a=e[r];if(!(0<o(a,t)))break e;e[r]=t,e[n]=a,n=r}}function r(e){return 0===e.length?null:e[0]}function a(e){if(0===e.length)return null;var t=e[0],n=e.pop();if(n!==t){e[0]=n;e:for(var r=0,a=e.length,i=a>>>1;r<i;){var s=2*(r+1)-1,l=e[s],u=s+1,c=e[u];if(0>o(l,n))u<a&&0>o(c,l)?(e[r]=c,e[u]=n,r=u):(e[r]=l,e[s]=n,r=s);else{if(!(u<a&&0>o(c,n)))break e;e[r]=c,e[u]=n,r=u}}}return t}function o(e,t){var n=e.sortIndex-t.sortIndex;return 0!==n?n:e.id-t.id}if("object"===typeof performance&&"function"===typeof performance.now){var i=performance;t.unstable_now=function(){return i.now()}}else{var s=Date,l=s.now();t.unstable_now=function(){return s.now()-l}}var u=[],c=[],d=1,p=null,f=3,m=!1,h=!1,v=!1,y="function"===typeof setTimeout?setTimeout:null,b="function"===typeof clearTimeout?clearTimeout:null,g="undefined"!==typeof setImmediate?setImmediate:null;function _(e){for(var t=r(c);null!==t;){if(null===t.callback)a(c);else{if(!(t.startTime<=e))break;a(c),t.sortIndex=t.expirationTime,n(u,t)}t=r(c)}}function w(e){if(v=!1,_(e),!h)if(null!==r(u))h=!0,R(S);else{var t=r(c);null!==t&&D(w,t.startTime-e)}}function S(e,n){h=!1,v&&(v=!1,b(x),x=-1),m=!0;var o=f;try{for(_(n),p=r(u);null!==p&&(!(p.expirationTime>n)||e&&!A());){var i=p.callback;if("function"===typeof i){p.callback=null,f=p.priorityLevel;var s=i(p.expirationTime<=n);n=t.unstable_now(),"function"===typeof s?p.callback=s:p===r(u)&&a(u),_(n)}else a(u);p=r(u)}if(null!==p)var l=!0;else{var d=r(c);null!==d&&D(w,d.startTime-n),l=!1}return l}finally{p=null,f=o,m=!1}}"undefined"!==typeof navigator&&void 0!==navigator.scheduling&&void 0!==navigator.scheduling.isInputPending&&navigator.scheduling.isInputPending.bind(navigator.scheduling);var k,C=!1,T=null,x=-1,P=5,E=-1;function A(){return!(t.unstable_now()-E<P)}function N(){if(null!==T){var e=t.unstable_now();E=e;var n=!0;try{n=T(!0,e)}finally{n?k():(C=!1,T=null)}}else C=!1}if("function"===typeof g)k=function(){g(N)};else if("undefined"!==typeof MessageChannel){var F=new MessageChannel,O=F.port2;F.port1.onmessage=N,k=function(){O.postMessage(null)}}else k=function(){y(N,0)};function R(e){T=e,C||(C=!0,k())}function D(e,n){x=y((function(){e(t.unstable_now())}),n)}t.unstable_IdlePriority=5,t.unstable_ImmediatePriority=1,t.unstable_LowPriority=4,t.unstable_NormalPriority=3,t.unstable_Profiling=null,t.unstable_UserBlockingPriority=2,t.unstable_cancelCallback=function(e){e.callback=null},t.unstable_continueExecution=function(){h||m||(h=!0,R(S))},t.unstable_forceFrameRate=function(e){0>e||125<e?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):P=0<e?Math.floor(1e3/e):5},t.unstable_getCurrentPriorityLevel=function(){return f},t.unstable_getFirstCallbackNode=function(){return r(u)},t.unstable_next=function(e){switch(f){case 1:case 2:case 3:var t=3;break;default:t=f}var n=f;f=t;try{return e()}finally{f=n}},t.unstable_pauseExecution=function(){},t.unstable_requestPaint=function(){},t.unstable_runWithPriority=function(e,t){switch(e){case 1:case 2:case 3:case 4:case 5:break;default:e=3}var n=f;f=e;try{return t()}finally{f=n}},t.unstable_scheduleCallback=function(e,a,o){var i=t.unstable_now();switch("object"===typeof o&&null!==o?o="number"===typeof(o=o.delay)&&0<o?i+o:i:o=i,e){case 1:var s=-1;break;case 2:s=250;break;case 5:s=1073741823;break;case 4:s=1e4;break;default:s=5e3}return e={id:d++,callback:a,priorityLevel:e,startTime:o,expirationTime:s=o+s,sortIndex:-1},o>i?(e.sortIndex=o,n(c,e),null===r(u)&&e===r(c)&&(v?(b(x),x=-1):v=!0,D(w,o-i))):(e.sortIndex=s,n(u,e),h||m||(h=!0,R(S))),e},t.unstable_shouldYield=A,t.unstable_wrapCallback=function(e){var t=f;return function(){var n=f;f=t;try{return e.apply(this,arguments)}finally{f=n}}}},5296:function(e,t,n){"use strict";e.exports=n(6813)},4836:function(e){e.exports=function(e){return e&&e.__esModule?e:{default:e}},e.exports.__esModule=!0,e.exports.default=e.exports},907:function(e,t,n){"use strict";function r(e,t){(null==t||t>e.length)&&(t=e.length);for(var n=0,r=new Array(t);n<t;n++)r[n]=e[n];return r}n.d(t,{Z:function(){return r}})},4942:function(e,t,n){"use strict";function r(e,t,n){return t in e?Object.defineProperty(e,t,{value:n,enumerable:!0,configurable:!0,writable:!0}):e[t]=n,e}n.d(t,{Z:function(){return r}})},7462:function(e,t,n){"use strict";function r(){return r=Object.assign?Object.assign.bind():function(e){for(var t=1;t<arguments.length;t++){var n=arguments[t];for(var r in n)Object.prototype.hasOwnProperty.call(n,r)&&(e[r]=n[r])}return e},r.apply(this,arguments)}n.d(t,{Z:function(){return r}})},3366:function(e,t,n){"use strict";function r(e,t){if(null==e)return{};var n,r,a={},o=Object.keys(e);for(r=0;r<o.length;r++)n=o[r],t.indexOf(n)>=0||(a[n]=e[n]);return a}n.d(t,{Z:function(){return r}})},885:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(181);function a(e,t){return function(e){if(Array.isArray(e))return e}(e)||function(e,t){var n=null==e?null:"undefined"!==typeof Symbol&&e[Symbol.iterator]||e["@@iterator"];if(null!=n){var r,a,o=[],i=!0,s=!1;try{for(n=n.call(e);!(i=(r=n.next()).done)&&(o.push(r.value),!t||o.length!==t);i=!0);}catch(l){s=!0,a=l}finally{try{i||null==n.return||n.return()}finally{if(s)throw a}}return o}}(e,t)||(0,r.Z)(e,t)||function(){throw new TypeError("Invalid attempt to destructure non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},2982:function(e,t,n){"use strict";n.d(t,{Z:function(){return o}});var r=n(907);var a=n(181);function o(e){return function(e){if(Array.isArray(e))return(0,r.Z)(e)}(e)||function(e){if("undefined"!==typeof Symbol&&null!=e[Symbol.iterator]||null!=e["@@iterator"])return Array.from(e)}(e)||(0,a.Z)(e)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}},181:function(e,t,n){"use strict";n.d(t,{Z:function(){return a}});var r=n(907);function a(e,t){if(e){if("string"===typeof e)return(0,r.Z)(e,t);var n=Object.prototype.toString.call(e).slice(8,-1);return"Object"===n&&e.constructor&&(n=e.constructor.name),"Map"===n||"Set"===n?Array.from(e):"Arguments"===n||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(n)?(0,r.Z)(e,t):void 0}}}},t={};function n(r){var a=t[r];if(void 0!==a)return a.exports;var o=t[r]={exports:{}};return e[r].call(o.exports,o,o.exports,n),o.exports}n.n=function(e){var t=e&&e.__esModule?function(){return e.default}:function(){return e};return n.d(t,{a:t}),t},function(){var e,t=Object.getPrototypeOf?function(e){return Object.getPrototypeOf(e)}:function(e){return e.__proto__};n.t=function(r,a){if(1&a&&(r=this(r)),8&a)return r;if("object"===typeof r&&r){if(4&a&&r.__esModule)return r;if(16&a&&"function"===typeof r.then)return r}var o=Object.create(null);n.r(o);var i={};e=e||[null,t({}),t([]),t(t)];for(var s=2&a&&r;"object"==typeof s&&!~e.indexOf(s);s=t(s))Object.getOwnPropertyNames(s).forEach((function(e){i[e]=function(){return r[e]}}));return i.default=function(){return r},n.d(o,i),o}}(),n.d=function(e,t){for(var r in t)n.o(t,r)&&!n.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},n.o=function(e,t){return Object.prototype.hasOwnProperty.call(e,t)},n.r=function(e){"undefined"!==typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},function(){"use strict";var e=n(2791),t=n(1250),r=n(7462),a=n(5513),o=(n(76),n(9886)),i=(n(2110),n(5438)),s=n(9140),l=n(2561),u=(0,o.w)((function(t,n){var r=t.styles,a=(0,s.O)([r],void 0,(0,e.useContext)(o.T)),u=(0,e.useRef)();return(0,l.j)((function(){var e=n.key+"-global",t=new n.sheet.constructor({key:e,nonce:n.sheet.nonce,container:n.sheet.container,speedy:n.sheet.isSpeedy}),r=!1,o=document.querySelector('style[data-emotion="'+e+" "+a.name+'"]');return n.sheet.tags.length&&(t.before=n.sheet.tags[0]),null!==o&&(r=!0,o.setAttribute("data-emotion",e),t.hydrate([o])),u.current=[t,r],function(){t.flush()}}),[n]),(0,l.j)((function(){var e=u.current,t=e[0];if(e[1])e[1]=!1;else{if(void 0!==a.next&&(0,i.My)(n,a.next,!0),t.tags.length){var r=t.tags[t.tags.length-1].nextElementSibling;t.before=r,t.flush()}n.insert("",a,t,!1)}}),[n,a.name]),null}));function c(){for(var e=arguments.length,t=new Array(e),n=0;n<e;n++)t[n]=arguments[n];return(0,s.O)(t)}var d=function(){var e=c.apply(void 0,arguments),t="animation-"+e.name;return{name:t,styles:"@keyframes "+t+"{"+e.styles+"}",anim:1,toString:function(){return"_EMO_"+this.name+"_"+this.styles+"_EMO_"}}};var p=n(184);function f(e){var t=e.styles,n=e.defaultTheme,r=void 0===n?{}:n,a="function"===typeof t?function(e){return t(void 0===(n=e)||null===n||0===Object.keys(n).length?r:e);var n}:t;return(0,p.jsx)(u,{styles:a})}var m=n(4205);var h=function(e){return(0,p.jsx)(f,(0,r.Z)({},e,{defaultTheme:m.Z}))},v=function(e,t){return(0,r.Z)({WebkitFontSmoothing:"antialiased",MozOsxFontSmoothing:"grayscale",boxSizing:"border-box",WebkitTextSizeAdjust:"100%"},t&&{colorScheme:e.palette.mode})},y=function(e){return(0,r.Z)({color:(e.vars||e).palette.text.primary},e.typography.body1,{backgroundColor:(e.vars||e).palette.background.default,"@media print":{backgroundColor:(e.vars||e).palette.common.white}})};var b=function(t){var n=(0,a.Z)({props:t,name:"MuiCssBaseline"}),o=n.children,i=n.enableColorScheme,s=void 0!==i&&i;return(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(h,{styles:function(e){return function(e){var t,n,a={html:v(e,arguments.length>1&&void 0!==arguments[1]&&arguments[1]),"*, *::before, *::after":{boxSizing:"inherit"},"strong, b":{fontWeight:e.typography.fontWeightBold},body:(0,r.Z)({margin:0},y(e),{"&::backdrop":{backgroundColor:(e.vars||e).palette.background.default}})},o=null==(t=e.components)||null==(n=t.MuiCssBaseline)?void 0:n.styleOverrides;return o&&(a=[a,o]),a}(e,s)}}),o]})},g=n(885),_=n(4942),w=n(3366),S=n(8182),k=n(7312),C=n(1217),T=n(4419),x=n(8691),P=(0,n(4046).ZP)(),E=n(5080),A=["className","component","disableGutters","fixed","maxWidth","classes"],N=(0,E.Z)(),F=P("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,k.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),O=function(e){return(0,x.Z)({props:e,name:"MuiContainer",defaultTheme:N})},R=function(e,t){var n=e.classes,r=e.fixed,a=e.disableGutters,o=e.maxWidth,i={root:["root",o&&"maxWidth".concat((0,k.Z)(String(o))),r&&"fixed",a&&"disableGutters"]};return(0,T.Z)(i,(function(e){return(0,C.Z)(t,e)}),n)};var D=n(9853),M=n(277),I=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.createStyledComponent,a=void 0===n?F:n,o=t.useThemeProps,i=void 0===o?O:o,s=t.componentName,l=void 0===s?"MuiContainer":s,u=a((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({width:"100%",marginLeft:"auto",boxSizing:"border-box",marginRight:"auto",display:"block"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}))}),(function(e){var t=e.theme;return e.ownerState.fixed&&Object.keys(t.breakpoints.values).reduce((function(e,n){var r=n,a=t.breakpoints.values[r];return 0!==a&&(e[t.breakpoints.up(r)]={maxWidth:"".concat(a).concat(t.breakpoints.unit)}),e}),{})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"xs"===n.maxWidth&&(0,_.Z)({},t.breakpoints.up("xs"),{maxWidth:Math.max(t.breakpoints.values.xs,444)}),n.maxWidth&&"xs"!==n.maxWidth&&(0,_.Z)({},t.breakpoints.up(n.maxWidth),{maxWidth:"".concat(t.breakpoints.values[n.maxWidth]).concat(t.breakpoints.unit)}))})),c=e.forwardRef((function(e,t){var n=i(e),a=n.className,o=n.component,s=void 0===o?"div":o,c=n.disableGutters,d=void 0!==c&&c,f=n.fixed,m=void 0!==f&&f,h=n.maxWidth,v=void 0===h?"lg":h,y=(0,w.Z)(n,A),b=(0,r.Z)({},n,{component:s,disableGutters:d,fixed:m,maxWidth:v}),g=R(b,l);return(0,p.jsx)(u,(0,r.Z)({as:s,ownerState:b,className:(0,S.Z)(g.root,a),ref:t},y))}));return c}({createStyledComponent:(0,M.ZP)("div",{name:"MuiContainer",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["maxWidth".concat((0,D.Z)(String(n.maxWidth)))],n.fixed&&t.fixed,n.disableGutters&&t.disableGutters]}}),useThemeProps:function(e){return(0,a.Z)({props:e,name:"MuiContainer"})}}),z=I,L=n(2421),Z=n(104),j=n(2982),B=n(2466),W=n(114),J=["sx"];function V(e){var t,n=e.sx,a=function(e){var t={systemProps:{},otherProps:{}};return Object.keys(e).forEach((function(n){W.Gc[n]?t.systemProps[n]=e[n]:t.otherProps[n]=e[n]})),t}((0,w.Z)(e,J)),o=a.systemProps,i=a.otherProps;return t=Array.isArray(n)?[o].concat((0,j.Z)(n)):"function"===typeof n?function(){var e=n.apply(void 0,arguments);return(0,B.P)(e)?(0,r.Z)({},o,e):o}:(0,r.Z)({},o,n),(0,r.Z)({},i,{sx:t})}var U=n(886),$=["className","component"];var G=n(5902),H=n(4360),q=function(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},n=t.defaultTheme,a=t.defaultClassName,o=void 0===a?"MuiBox-root":a,i=t.generateClassName,s=t.styleFunctionSx,l=void 0===s?Z.Z:s,u=(0,L.ZP)("div",{shouldForwardProp:function(e){return"theme"!==e&&"sx"!==e&&"as"!==e}})(l),c=e.forwardRef((function(e,t){var a=(0,U.Z)(n),s=V(e),l=s.className,c=s.component,d=void 0===c?"div":c,f=(0,w.Z)(s,$);return(0,p.jsx)(u,(0,r.Z)({as:d,ref:t,className:(0,S.Z)(l,i?i(o):o),theme:a},f))}));return c}({defaultTheme:(0,H.Z)(),defaultClassName:"MuiBox-root",generateClassName:G.Z.generate}),K=q,Q=JSON.parse('{"e":5,"C":[{"nctid":"NCT03244384","version_a":53,"version_b":54,"version_a_date":"2018-03-01","version_b_date":"2018-03-02","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: From randomization to the first metastatic recurrence (presence of any recurrent disease), or death, whichever occurs first, assessed up to 5 years ]The stratified proportional hazards model will be the primary analysis. The hazard ratio and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The unstratified hazard ratio will also be presented."},{"label":"2.","content":"Overall survival[ Time Frame: From randomization to the date of death from any cause, assessed up to 5 years ]The stratified proportional hazards model will be the primary analysis. The hazard ratio and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The unstratified hazard ratio will also be presented."}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: From randomization to the date of death from any cause, assessed up to 5 years ]The stratified proportional hazards model will be the primary analysis. The hazard ratio and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The unstratified hazard ratio will also be presented."},{"label":"2.","content":"Disease-free survival[ Time Frame: From randomization to the first metastatic recurrence (presence of any recurrent disease), or death, whichever occurs first, assessed up to 5 years ]The stratified proportional hazards model will be the primary analysis. The hazard ratio and its 95% confidence interval from the stratified Cox model with a single treatment covariate will be reported. The unstratified hazard ratio will also be presented."}],"start_date":"September 21, 2017","primary_completion_date":"June 1, 2025","completion_date":"June 1, 2025","first_posted":"August 9, 2017","last_update_posted":"August 31, 2022"},{"nctid":"NCT00335595","version_a":2,"version_b":3,"version_a_date":"2006-08-10","version_b_date":"2006-11-17","pom_a":[{"label":"1.","content":"Determinate the free time to disease progression"}],"pom_b":[{"label":"1.","content":"Determine the free time to disease progression"}],"start_date":"July 2006","primary_completion_date":"June 2012","completion_date":"June 2012","first_posted":"June 12, 2006","last_update_posted":"February 20, 2013"},{"nctid":"NCT00335595","version_a":5,"version_b":6,"version_a_date":"2007-05-04","version_b_date":"2008-08-12","pom_a":[{"label":"1.","content":"Determine the free time to disease progression"}],"pom_b":[{"label":"1.","content":"Determine the free time to disease progression[ Time Frame: within study period ]"}],"start_date":"July 2006","primary_completion_date":"June 2012","completion_date":"June 2012","first_posted":"June 12, 2006","last_update_posted":"February 20, 2013"},{"nctid":"NCT00335595","version_a":7,"version_b":8,"version_a_date":"2009-03-30","version_b_date":"2010-02-18","pom_a":[{"label":"1.","content":"Determine the free time to disease progression[ Time Frame: within study period ]"}],"pom_b":[{"label":"1.","content":"Determine the free time to disease progression[ Time Frame: 2006-2010 ]"}],"start_date":"July 2006","primary_completion_date":"June 2012","completion_date":"June 2012","first_posted":"June 12, 2006","last_update_posted":"February 20, 2013"},{"nctid":"NCT00335595","version_a":11,"version_b":12,"version_a_date":"2012-02-06","version_b_date":"2012-03-22","pom_a":[{"label":"1.","content":"Determine the free time to disease progression[ Time Frame: 2006-2010 ]"}],"pom_b":[{"label":"1.","content":"Determine the free time to disease progression[ Time Frame: 2006-2012 ]"}],"start_date":"July 2006","primary_completion_date":"June 2012","completion_date":"June 2012","first_posted":"June 12, 2006","last_update_posted":"February 20, 2013"},{"nctid":"NCT02811978","version_a":8,"version_b":9,"version_a_date":"2017-03-10","version_b_date":"2017-04-14","pom_a":[{"label":"1.","content":"Overall Response Rate at the end of 4 cycles of Velcade treatment[ Time Frame: 12 weeks (at the end of 4 cycle; each cycle is of 3 weeks) ]ORR defined as the proportion of participants who achieve either complete response [CR], very good partial response [VGPR], or partial response [PR], according to the International Myeloma Working Group (IMWG) criteria. Participants with CR, VGPR, or PR that is unconfirmed in Cycle 4 but confirmed in the next response assessment will be included as CR, VGPR or PR, respectively."}],"pom_b":[{"label":"1.","content":"Overall Response Rate After 4 Cycles of Velcade Treatment[ Time Frame: 12 weeks (after 4 cycles; each cycle is of 3 weeks) ]ORR defined as the proportion of participants who achieve either complete response [CR], very good partial response [VGPR], or partial response [PR], according to the International Myeloma Working Group (IMWG) criteria. Participants with CR, VGPR, or PR that is unconfirmed in Cycle 4 but confirmed in the next response assessment will be included as CR, VGPR or PR, respectively."}],"start_date":"September 27, 2016","primary_completion_date":"May 7, 2018","completion_date":"November 10, 2018","first_posted":"June 23, 2016","last_update_posted":"November 8, 2019"},{"nctid":"NCT01980498","version_a":2,"version_b":3,"version_a_date":"2013-11-28","version_b_date":"2014-06-05","pom_a":[{"label":"1.","content":"Difference in the mean intensity of IP-BTP related to swallowing from the baseline to 20 minutes after taking FPNS/PC-UC (PID20).[ Time Frame: up to 6 days ]"}],"pom_b":[{"label":"1.","content":"Difference in the mean intensity of predictable BTP at swallowing from the baseline to 20 minutes after taking FPNS/PC-UC (PID20).[ Time Frame: up to 6 (-1,+2) days ]"}],"start_date":"September 2014","primary_completion_date":"September 2015","completion_date":"September 2015","first_posted":"November 11, 2013","last_update_posted":"October 7, 2015"},{"nctid":"NCT00085098","version_a":20,"version_b":21,"version_a_date":"2007-05-03","version_b_date":"2007-05-16","pom_a":[],"pom_b":[{"label":"1.","content":"Event-free survival"},{"label":"2.","content":"Response"},{"label":"3.","content":"Toxicity"},{"label":"4.","content":"Quality of life"}],"start_date":"January 2007","primary_completion_date":"May 2009","completion_date":"May 2009","first_posted":"June 11, 2004","results_first_posted":"November 6, 2013","last_update_posted":"September 7, 2018"},{"nctid":"NCT00085098","version_a":197,"version_b":198,"version_a_date":"2010-11-20","version_b_date":"2012-12-30","pom_a":[{"label":"1.","content":"Event-free survival"},{"label":"2.","content":"Response"},{"label":"3.","content":"Toxicity"},{"label":"4.","content":"Quality of life"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Six years after enrollment ]"}],"start_date":"January 2007","primary_completion_date":"May 2009","completion_date":"May 2009","first_posted":"June 11, 2004","results_first_posted":"November 6, 2013","last_update_posted":"September 7, 2018"},{"nctid":"NCT00085098","version_a":198,"version_b":199,"version_a_date":"2012-12-30","version_b_date":"2013-06-03","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Six years after enrollment ]"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Time from study entry to disease progression, disease recurrence or the development of new lesions, the occurrence of the second malignant neoplasm, or death from any cause, assessed up to 5 years ]There is a potential for an early time lag in the discovery of treatment failure events in patients on regimen B. Although it is unlikely that the bias that is introduced will be large enough to noticeably influence the properties of the usual logrank test in this case, a partially-grouped logrank test 34 with grouping time of 6 months will be employed to minimize this bias."}],"start_date":"January 2007","primary_completion_date":"May 2009","completion_date":"May 2009","first_posted":"June 11, 2004","results_first_posted":"November 6, 2013","last_update_posted":"September 7, 2018"},{"nctid":"NCT00085098","version_a":200,"version_b":201,"version_a_date":"2013-06-06","version_b_date":"2013-08-30","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Time from study entry to disease progression, disease recurrence or the development of new lesions, the occurrence of the second malignant neoplasm, or death from any cause, assessed up to 5 years ]There is a potential for an early time lag in the discovery of treatment failure events in patients on regimen B. Although it is unlikely that the bias that is introduced will be large enough to noticeably influence the properties of the usual logrank test in this case, a partially-grouped logrank test 34 with grouping time of 6 months will be employed to minimize this bias."}],"pom_b":[{"label":"1.","content":"Event-free Survival[ Time Frame: Study enrollment until date of earliest qualifying event (QE), date last known to be QE-free if the patient is followed for less than three years and is QE-free at the time of analysis, or 3 years if the patient is QE-free at 3 years ]Data will be summarized as number of patients in the following categories at the time of data cutoff for analyses of 3-year EFS: 1)Experienced a qualifying event (QE) (see below);2)Event-free through 3 years of follow-up;3)Event-free until data cutoff (if less than 3 years of follow-up);4)Withdrew from study;5)Lost to follow-up.QEs: 1)disease progression, defined as increase >= 40% in tumor volume or >= 25% in tumor area of target lesions;2)development of new lesions;3)occurrence of a second malignant neoplasm, defined as a malignancy with different histological type from trial-qualifying diagnosis;4)death from any cause.Stat. analyses will be based on time from enrollment to the earliest of: 1)occurrence of any of the QEs;2)withdrawal from study or lost to follow-up;3)completion of three years of follow-up event-free;4)data cutoff for completion of the statistical analyses for the protocol\'s primary objective.NOTE: Reported data are through May 2009 (see Caveats section)."}],"start_date":"January 2007","primary_completion_date":"May 2009","completion_date":"May 2009","first_posted":"June 11, 2004","results_first_posted":"November 6, 2013","last_update_posted":"September 7, 2018"},{"nctid":"NCT00733122","version_a":17,"version_b":18,"version_a_date":"2009-06-03","version_b_date":"2009-06-18","pom_a":[{"label":"1.","content":"The endpoint that will be used to evaluate the immunogenicity of GARDASIL is the percentage of subjects who seroconvert to each of HPV 6, 11, 16, 18 at Week 4 Postdose 3 (Month 7), Month 24 and Month 36. The Geometric Mean Titers (GMTs) will also be sum[ Time Frame: Week 4 Postdose 3 (Month 7), Month 24 and Month 36 ]"}],"pom_b":[{"label":"1.","content":"The percentage of subjects who seroconvert to each of HPV 6, 11, 16, 18 at Week 4 Post dose 3 (Month 7), Month 24 and Month 36.[ Time Frame: Week 4 Post dose 3 (Month 7), Month 24 and Month 36 ]"}],"start_date":"October 2009","primary_completion_date":"October 2013","completion_date":"October 2013","first_posted":"August 12, 2008","last_update_posted":"January 14, 2011"},{"nctid":"NCT03897127","version_a":47,"version_b":48,"version_a_date":"2021-11-10","version_b_date":"2021-12-03","pom_a":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: 2 years ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) in the restricted set of de novo patients[ Time Frame: 2 years ]"}],"start_date":"September 4, 2019","primary_completion_date":"March 2024","completion_date":"March 2024","first_posted":"April 1, 2019","last_update_posted":"June 24, 2022"},{"nctid":"NCT00944918","version_a":1,"version_b":2,"version_a_date":"2009-07-22","version_b_date":"2009-07-23","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: Per RECIST schedule ]"}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: every 3 months during treatment and, at time of discontinuation from treatment ]"}],"start_date":"December 2008","primary_completion_date":"June 2011","completion_date":"June 2011","first_posted":"July 23, 2009","last_update_posted":"August 29, 2011"},{"nctid":"NCT01047345","version_a":18,"version_b":19,"version_a_date":"2013-08-09","version_b_date":"2014-02-04","pom_a":[{"label":"1.","content":"Number of participants who experience serious or non-serious adverse events[ Time Frame: Day 1 to Month 7 ]"}],"pom_b":[{"label":"1.","content":"Number of participants who experience serious or non-serious adverse events[ Time Frame: Day 1 to Month 7 of the Base Study ]"}],"start_date":"February 24, 2010","primary_completion_date":"June 10, 2011","completion_date":"November 28, 2015","first_posted":"January 12, 2010","results_first_posted":"December 22, 2014","last_update_posted":"November 27, 2018"},{"nctid":"NCT01047345","version_a":19,"version_b":20,"version_a_date":"2014-02-04","version_b_date":"2014-12-12","pom_a":[{"label":"1.","content":"Number of participants who experience serious or non-serious adverse events[ Time Frame: Day 1 to Month 7 of the Base Study ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized."},{"label":"2.","content":"Percentage of Participants With Body Temperature \u2265100.0\xb0F (\u226537.8\xbaC) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded."},{"label":"3.","content":"Percentage of Participants Who Experience a Systemic AE - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs."},{"label":"4.","content":"Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention."},{"label":"5.","content":"Percentage of Participants Who Experience a Vaccine-related SAE Within 15 Days of Any Vaccination - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be \\"definitely related,\\" \\"probably related,\\" or \\"possibly related\\" is defined as a vaccine-related SAE."},{"label":"6.","content":"Percentage of Participants Who Experience a Severe Injection-site AE - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter >2 inches was recorded as severe. All AEs associated with the injection site and reported as severe were summarized."}],"start_date":"February 24, 2010","primary_completion_date":"June 10, 2011","completion_date":"November 28, 2015","first_posted":"January 12, 2010","results_first_posted":"December 22, 2014","last_update_posted":"November 27, 2018"},{"nctid":"NCT01047345","version_a":26,"version_b":27,"version_a_date":"2016-08-25","version_b_date":"2016-10-31","pom_a":[{"label":"1.","content":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized."},{"label":"2.","content":"Percentage of Participants With Body Temperature \u2265100.0\xb0F (\u226537.8\xbaC) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded."},{"label":"3.","content":"Percentage of Participants Who Experience a Systemic AE - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs."},{"label":"4.","content":"Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention."},{"label":"5.","content":"Percentage of Participants Who Experience a Vaccine-related SAE Within 15 Days of Any Vaccination - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be \\"definitely related,\\" \\"probably related,\\" or \\"possibly related\\" is defined as a vaccine-related SAE."},{"label":"6.","content":"Percentage of Participants Who Experience a Severe Injection-site AE - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter >2 inches was recorded as severe. All AEs associated with the injection site and reported as severe were summarized."}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Experience an Injection-site Adverse Event (AE) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. The percentage of participants who reported an AE that was associated with the injection site such as redness, swelling, and pain/tenderness/soreness was summarized."},{"label":"2.","content":"Percentage of Participants With Body Temperature \u2265100.0\xb0F (\u226537.8\xbaC) - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded."},{"label":"3.","content":"Percentage of Participants Who Experience a Systemic AE - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Systemic AEs were those not categorized as injection-site AEs."},{"label":"4.","content":"Percentage of Participants Who Experience a Serious Adverse Event (SAE) Within 15 Days of Any Vaccination - Base Study[ Time Frame: up to 14 days after any vaccination - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention."},{"label":"5.","content":"Percentage of Participants Who Experience a Vaccine-related SAE Any Time During Study- Base Study[ Time Frame: Up to 7 months - Base Study ]An SAE is one that results in death, disability/incapacity, or hospitalization or is life threatening, a congenital anomaly or birth defect, cancer, an overdose, or otherwise jeopardizes the participant and may require medical intervention. An SAE that is judged by the Investigator to be \\"definitely related,\\" \\"probably related,\\" or \\"possibly related\\" is defined as a vaccine-related SAE."},{"label":"6.","content":"Percentage of Participants Who Experience a Severe Injection-site AE - Base Study[ Time Frame: up to 5 days after any vaccination - Base Study ]An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the vaccine. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Participants were instructed to estimate the severity of AEs such as pain at injection site as mild (awareness of symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). Additionally, participants were instructed to measure any swelling and/or erythema at its greatest width. Swelling or erythema with diameter >2 inches (>5 cm) was recorded as severe. All AEs associated with the injection site and reported as severe were summarized."}],"start_date":"February 24, 2010","primary_completion_date":"June 10, 2011","completion_date":"November 28, 2015","first_posted":"January 12, 2010","results_first_posted":"December 22, 2014","last_update_posted":"November 27, 2018"},{"nctid":"NCT02264574","version_a":7,"version_b":8,"version_a_date":"2015-10-28","version_b_date":"2017-01-04","pom_a":[{"label":"1.","content":"The primary endpoint of this study is Progressive Free Survival[ Time Frame: Up to 3 years after last subject is randomized ]The efficacy of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab based on the IRC assessment compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression-free survival (PFS) in subjects with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)by independent central radiologists, findings from physical examinations and hematology results"}],"pom_b":[{"label":"1.","content":"The primary endpoint of this study is Progressive Free Survival[ Time Frame: 5 years after last subject is randomized ]The efficacy of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab based on the IRC assessment compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression-free survival (PFS) in subjects with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)by independent central radiologists, findings from physical examinations and hematology results"}],"start_date":"October 6, 2014","primary_completion_date":"March 26, 2018","completion_date":"September 3, 2019","first_posted":"October 15, 2014","results_first_posted":"April 16, 2019","last_update_posted":"September 21, 2020"},{"nctid":"NCT02264574","version_a":9,"version_b":10,"version_a_date":"2019-01-31","version_b_date":"2019-03-25","pom_a":[{"label":"1.","content":"The primary endpoint of this study is Progressive Free Survival[ Time Frame: 5 years after last subject is randomized ]The efficacy of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab based on the IRC assessment compared to chlorambucil in combination with obinutuzumab based on the Independent Review Committee (IRC) assessment of progression-free survival (PFS) in subjects with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)by independent central radiologists, findings from physical examinations and hematology results"}],"pom_b":[{"label":"1.","content":"The Primary Endpoint of This Study is Progression Free Survival (PFS)[ Time Frame: The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. The median follow-up time was 31.3 months at the time of the analysis. ]PFS is defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the experimental (Ibr+Ob) arm at the time of the analysis, Kaplan Meier point estimates of the PFS rate at 30 months are presented."}],"start_date":"October 6, 2014","primary_completion_date":"March 26, 2018","completion_date":"September 3, 2019","first_posted":"October 15, 2014","results_first_posted":"April 16, 2019","last_update_posted":"September 21, 2020"},{"nctid":"NCT02264574","version_a":10,"version_b":11,"version_a_date":"2019-03-25","version_b_date":"2019-04-30","pom_a":[{"label":"1.","content":"The Primary Endpoint of This Study is Progression Free Survival (PFS)[ Time Frame: The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. The median follow-up time was 31.3 months at the time of the analysis. ]PFS is defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. As the median PFS was not reached in the experimental (Ibr+Ob) arm at the time of the analysis, Kaplan Meier point estimates of the PFS rate at 30 months are presented."}],"pom_b":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. The median follow-up time was 31.3 months at the time of the analysis. ]PFS is defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of disease progression was conducted in accordance with the IWCLL 2008 criteria with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression will not be considered progressive disease. As the median PFS was not reached in the experimental (Ibr+Ob) arm at the time of the analysis, Kaplan Meier point estimates of the PFS rate at 30 months are presented."}],"start_date":"October 6, 2014","primary_completion_date":"March 26, 2018","completion_date":"September 3, 2019","first_posted":"October 15, 2014","results_first_posted":"April 16, 2019","last_update_posted":"September 21, 2020"},{"nctid":"NCT02264574","version_a":12,"version_b":13,"version_a_date":"2019-11-10","version_b_date":"2020-08-27","pom_a":[{"label":"1.","content":"Progression Free Survival (PFS)[ Time Frame: The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. The median follow-up time was 31.3 months at the time of the analysis. ]PFS is defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurs first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of disease progression was conducted in accordance with the IWCLL 2008 criteria with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression will not be considered progressive disease. As the median PFS was not reached in the experimental (Ibr+Ob) arm at the time of the analysis, Kaplan Meier point estimates of the PFS rate at 30 months are presented."}],"pom_b":[{"label":"1.","content":"Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30[ Time Frame: Month 30 (Median follow-up time was 31.3 months at the time of the primary analysis [data cutoff date: 26 March 2018]). ]PFS was defined as time from the date randomization to the date of first IRC-confirmed disease progression (PD) or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.The primary analysis was performed after observing 94 PFS events as pre-specified in the study protocol. As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 30 months (that is, the estimated percentage of participants with progression-free survival at Month 30) are presented."},{"label":"2.","content":"Final Analysis: PFS Based on Investigator Assessment - Kaplan Meier Landmark Estimates at Month 48[ Time Frame: Month 48 (Median follow-up time was 44.6 months at the time of the final analysis [data cutoff date: 17 October 2019]). ]PFS was defined as time from the date randomization to the date of first investigator-confirmed PD or date of death due to any cause, whichever occurred first, regardless of the use of subsequent antineoplastic therapy prior to documented PD or death. Assessment of PD was conducted in accordance with the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 criteria (Halleck et al) with the modification that treatment-related lymphocytosis in the absence of other signs or symptoms of disease progression was not considered progressive disease.As the median PFS was not reached in the experimental (IBR+OB) arm at the time of the analysis, Kaplan Meier landmark estimates of the PFS rate at 48 months (that is, the estimated percentage of participants with progression-free survival at Month 48) are presented."}],"start_date":"October 6, 2014","primary_completion_date":"March 26, 2018","completion_date":"September 3, 2019","first_posted":"October 15, 2014","results_first_posted":"April 16, 2019","last_update_posted":"September 21, 2020"},{"nctid":"NCT00300885","version_a":13,"version_b":14,"version_a_date":"2007-05-14","version_b_date":"2007-06-26","pom_a":[],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: 10 month ]"}],"start_date":"February 2006","primary_completion_date":"October 2007","completion_date":"February 2009","first_posted":"March 10, 2006","results_first_posted":"September 20, 2010","last_update_posted":"November 4, 2014"},{"nctid":"NCT00300885","version_a":14,"version_b":15,"version_a_date":"2007-06-26","version_b_date":"2007-12-31","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: 10 month ]"}],"pom_b":[{"label":"1.","content":"overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month, Nov 2008 ]"}],"start_date":"February 2006","primary_completion_date":"October 2007","completion_date":"February 2009","first_posted":"March 10, 2006","results_first_posted":"September 20, 2010","last_update_posted":"November 4, 2014"},{"nctid":"NCT00300885","version_a":16,"version_b":17,"version_a_date":"2008-09-26","version_b_date":"2008-10-20","pom_a":[{"label":"1.","content":"overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month, Nov 2008 ]"}],"pom_b":[{"label":"1.","content":"overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month ]"}],"start_date":"February 2006","primary_completion_date":"October 2007","completion_date":"February 2009","first_posted":"March 10, 2006","results_first_posted":"September 20, 2010","last_update_posted":"November 4, 2014"},{"nctid":"NCT00300885","version_a":19,"version_b":20,"version_a_date":"2009-02-04","version_b_date":"2009-02-13","pom_a":[{"label":"1.","content":"overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month ]"}],"start_date":"February 2006","primary_completion_date":"October 2007","completion_date":"February 2009","first_posted":"March 10, 2006","results_first_posted":"September 20, 2010","last_update_posted":"November 4, 2014"},{"nctid":"NCT00300885","version_a":20,"version_b":21,"version_a_date":"2009-02-13","version_b_date":"2010-08-26","pom_a":[{"label":"1.","content":"Overall survival (OS) in patients treated with carboplatin, paclitaxel and sorafenib to OS in patients treated with carboplatin, paclitaxel and placebo.[ Time Frame: 10 month ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in Patients Treated With Carboplatin, Paclitaxel and Sorafenib to OS in Patients Treated With Carboplatin, Paclitaxel and Placebo[ Time Frame: Outcome measure was assessed every 3 weeks starting from randomization, during treatment period and every 3 months during follow-up period until death was recorded or up to data cutoff (1Oct2007) used for planned formal interim analysis ]Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment."}],"start_date":"February 2006","primary_completion_date":"October 2007","completion_date":"February 2009","first_posted":"March 10, 2006","results_first_posted":"September 20, 2010","last_update_posted":"November 4, 2014"},{"nctid":"NCT04237584","version_a":7,"version_b":8,"version_a_date":"2022-03-30","version_b_date":"2022-05-23","pom_a":[{"label":"1.","content":"Symptomatic skeletal event-free survival (SSE-FS)[ Time Frame: through study completion, an average of 5 years ]SSE-FS is a composite endpoint, composed of 4 events that indicate disease progression:the first use of external-beam radiation therapy to relieve skeletal tumor-related symptomsthe occurrence of new symptomatic pathologic bone fractures.the occurrence of new symptomatic spinal cord compressiona tumor-related orthopedic surgical intervention"}],"pom_b":[{"label":"1.","content":"Symptomatic Skeletal Event-free Survival (SSE-FS)[ Time Frame: through study completion, an average of 5 years ]SSE-FS is a composite endpoint, composed of 4 events that indicate disease progression:the first use of external-beam radiation therapy to relieve skeletal tumor-related symptomsthe occurrence of new symptomatic pathologic bone fractures.the occurrence of new symptomatic spinal cord compressiona tumor-related orthopedic surgical intervention"},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame appears inconsistent with information provided here or in other parts of the record."}],"start_date":"June 30, 2020","primary_completion_date":"March 7, 2022","completion_date":"March 7, 2022","first_posted":"January 23, 2020","last_update_posted":"April 8, 2022"},{"nctid":"NCT04237584","version_a":8,"version_b":9,"version_a_date":"2022-05-23","version_b_date":"2022-07-22","pom_a":[{"label":"1.","content":"Symptomatic Skeletal Event-free Survival (SSE-FS)[ Time Frame: through study completion, an average of 5 years ]SSE-FS is a composite endpoint, composed of 4 events that indicate disease progression:the first use of external-beam radiation therapy to relieve skeletal tumor-related symptomsthe occurrence of new symptomatic pathologic bone fractures.the occurrence of new symptomatic spinal cord compressiona tumor-related orthopedic surgical intervention"},{"label":"Quality Control Review Comment provided by the National Library of Medicine:","content":"The Time Frame appears inconsistent with information provided here or in other parts of the record."}],"pom_b":[{"label":"1.","content":"Symptomatic Skeletal Event-free Survival (SSE-FS)[ Time Frame: approximately 1 year and 8 months ]SSE-FS is a composite endpoint, composed of 4 events that indicate disease progression:the first use of external-beam radiation therapy to relieve skeletal tumor-related symptomsthe occurrence of new symptomatic pathologic bone fractures.the occurrence of new symptomatic spinal cord compressiona tumor-related orthopedic surgical intervention"}],"start_date":"June 30, 2020","primary_completion_date":"March 7, 2022","completion_date":"March 7, 2022","first_posted":"January 23, 2020","last_update_posted":"April 8, 2022"},{"nctid":"NCT00063141","version_a":2,"version_b":3,"version_a_date":"2006-07-13","version_b_date":"2006-07-18","pom_a":[],"pom_b":[{"label":"1.","content":"To determine if overall survival is extended using the compound in combination with chemotherapy as second line treatment."}],"start_date":"April 2003","primary_completion_date":"June 2006","completion_date":"October 2007","first_posted":"June 25, 2003","last_update_posted":"April 12, 2010"},{"nctid":"NCT00063141","version_a":3,"version_b":4,"version_a_date":"2006-07-18","version_b_date":"2007-02-07","pom_a":[{"label":"1.","content":"To determine if overall survival is extended using the compound in combination with chemotherapy as second line treatment."}],"pom_b":[{"label":"1.","content":"To determine if overall survival is extended using the compound in combination with chemotherapy as second line treatment"}],"start_date":"April 2003","primary_completion_date":"June 2006","completion_date":"October 2007","first_posted":"June 25, 2003","last_update_posted":"April 12, 2010"},{"nctid":"NCT00063141","version_a":5,"version_b":6,"version_a_date":"2008-01-03","version_b_date":"2008-10-27","pom_a":[{"label":"1.","content":"To determine if overall survival is extended using the compound in combination with chemotherapy as second line treatment"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: Every 3 months after subject off-treatment ]"}],"start_date":"April 2003","primary_completion_date":"June 2006","completion_date":"October 2007","first_posted":"June 25, 2003","last_update_posted":"April 12, 2010"},{"nctid":"NCT00039780","version_a":4,"version_b":5,"version_a_date":"2006-08-22","version_b_date":"2008-04-22","pom_a":[],"pom_b":[{"label":"1.","content":"1)Incidence of PNQ Grade D or Grade E neurosensory symptoms (Item 1 of the PNQ) with duration of at least 4 weks; 2) Objective tumor response rate[ Time Frame: baseline to disease progression or discontinuation from study ]"}],"start_date":"September 2001","primary_completion_date":"October 2006","completion_date":"September 2014","first_posted":"June 13, 2002","last_update_posted":"July 13, 2022"},{"nctid":"NCT00372710","version_a":1,"version_b":2,"version_a_date":"2006-09-06","version_b_date":"2006-09-13","pom_a":[],"pom_b":[{"label":"1.","content":"Efficacy of a switch over from pamidronate therapy (2 infusions) to a treatment with zoledronic acid 4mg every 4 weeks (10 infusions) for 44 weeks in patients with breast cancer-related bone lesions"}],"start_date":"August 2002","first_posted":"September 7, 2006","last_update_posted":"November 23, 2009"},{"nctid":"NCT00003593","version_a":18,"version_b":19,"version_a_date":"2012-03-09","version_b_date":"2013-06-26","pom_a":[],"pom_b":[{"label":"1.","content":"Event Free Survival[ Time Frame: Length of study ]"}],"start_date":"June 1999","primary_completion_date":"March 2007","completion_date":"April 2012","first_posted":"January 27, 2003","last_update_posted":"June 27, 2013"},{"nctid":"NCT02393859","version_a":35,"version_b":36,"version_a_date":"2018-02-28","version_b_date":"2018-03-26","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: 36 months ]Event-free survival (EFS) after blinatumomab when compared to standard of care (SOC) chemotherapy"}],"pom_b":[{"label":"1.","content":"Event-free survival[ Time Frame: Minimum 36 months ]Event-free survival (EFS) after blinatumomab when compared to standard of care (SOC) chemotherapy"}],"start_date":"November 10, 2015","primary_completion_date":"July 17, 2019","completion_date":"November 14, 2022","first_posted":"March 20, 2015","results_first_posted":"July 13, 2020","last_update_posted":"July 22, 2022"},{"nctid":"NCT02393859","version_a":55,"version_b":56,"version_a_date":"2019-10-31","version_b_date":"2020-06-24","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Minimum 36 months ]Event-free survival (EFS) after blinatumomab when compared to standard of care (SOC) chemotherapy"}],"pom_b":[{"label":"1.","content":"Kaplan Meier Estimate: Event-Free Survival (EFS)[ Time Frame: As of the data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months. ]EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with \u2265 5% and < 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date.Participants were said to be in CR when they had the following:M1 marrowPeripheral blood without blastsAbsence of extramedullary leukemic involvementMonths are calculated as days from randomization date to event/censor date, divided by 30.5."}],"start_date":"November 10, 2015","primary_completion_date":"July 17, 2019","completion_date":"November 14, 2022","first_posted":"March 20, 2015","results_first_posted":"July 13, 2020","last_update_posted":"July 22, 2022"},{"nctid":"NCT04170283","version_a":4,"version_b":5,"version_a_date":"2020-04-23","version_b_date":"2020-08-03","pom_a":[{"label":"1.","content":"Incidence of Adverse Events (AEs)[ Time Frame: Up to 5 years ]Safety as assessed by incidence of treatment-emergent adverse events (AEs) according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, and serious AEs (SAEs)"},{"label":"2.","content":"Incidence of Serious Adverse Events (SAEs)[ Time Frame: Up to 5 years ]Safety as assessed by incidence of treatment-emergent adverse events (AEs) according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0, and serious AEs (SAEs)"}],"pom_b":[{"label":"1.","content":"Incidence of Adverse Events (AEs)[ Time Frame: Up to 5 years ]Safety as assessed by incidence of all treatment-emergent adverse events (TEAEs) and serious AEs (SAEs)"}],"start_date":"January 21, 2020","primary_completion_date":"December 2024","completion_date":"December 2025","first_posted":"November 20, 2019","last_update_posted":"July 29, 2022"},{"nctid":"NCT03200236","version_a":2,"version_b":3,"version_a_date":"2017-06-27","version_b_date":"2017-07-17","pom_a":[{"label":"1.","content":"Smoking cessation rate at 3-months post-randomization[ Time Frame: Self-report measured at 3-months post-randomization; biochemical verification measured at 3-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"2.","content":"Smoking cessation rate at 6-months post-randomization[ Time Frame: Self-report measured at 6-months post-randomization; biochemical verification measured at 6-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"3.","content":"Smoking cessation rate at 12-months post-randomization[ Time Frame: Self-report measured at 12-months post-randomization; ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."}],"pom_b":[{"label":"1.","content":"Smoking cessation rate at 3-months post-randomization[ Time Frame: Self-report measured at 3-months post-randomization; biochemical verification measured at 3-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"2.","content":"Smoking cessation rate at 6-months post-randomization[ Time Frame: Self-report measured at 6-months post-randomization; biochemical verification measured at 6-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"3.","content":"Smoking cessation rate at 12-months post-randomization[ Time Frame: Self-report measured at 12-months post-randomization; ]Comparison between study arms of 7-day and 30-day point prevalence cessation. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."}],"start_date":"May 3, 2017","primary_completion_date":"March 2022","completion_date":"June 2022","first_posted":"June 27, 2017","last_update_posted":"June 9, 2021"},{"nctid":"NCT03200236","version_a":4,"version_b":5,"version_a_date":"2018-04-14","version_b_date":"2018-07-31","pom_a":[{"label":"1.","content":"Smoking cessation rate at 3-months post-randomization[ Time Frame: Self-report measured at 3-months post-randomization; biochemical verification measured at 3-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"2.","content":"Smoking cessation rate at 6-months post-randomization[ Time Frame: Self-report measured at 6-months post-randomization; biochemical verification measured at 6-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"3.","content":"Smoking cessation rate at 12-months post-randomization[ Time Frame: Self-report measured at 12-months post-randomization; ]Comparison between study arms of 7-day and 30-day point prevalence cessation. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."}],"pom_b":[{"label":"1.","content":"Smoking cessation rate at 3-months post-randomization[ Time Frame: Self-report measured at 3-months post-randomization; biochemical verification measured at 3-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"2.","content":"Smoking cessation rate at 6-months post-randomization[ Time Frame: Self-report measured at 6-months post-randomization; biochemical verification measured at 6-months. ]Comparison between study arms of 7-day and 30-day point prevalence cessation with biochemical verification. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."},{"label":"3.","content":"Smoking cessation rate at 12-months post-randomization[ Time Frame: Self-report measured at 12-months post-randomization; biochemical verification measured at 12-month assessment; ]Comparison between study arms of 7-day and 30-day point prevalence cessation. The investigators will also assess quit rates among subgroups (gender, age, nicotine dependence, site)."}],"start_date":"May 3, 2017","primary_completion_date":"March 2022","completion_date":"June 2022","first_posted":"June 27, 2017","last_update_posted":"June 9, 2021"},{"nctid":"NCT03158220","version_a":15,"version_b":16,"version_a_date":"2018-11-28","version_b_date":"2019-11-04","pom_a":[{"label":"1.","content":"Anti-HPV Geometric Mean Titers[ Time Frame: 4 weeks postdose 3 (Month 7) ]Antibodies to the HPV types contained in V503 are measured using a competitive Luminex immunoassay. Antibody titers are expressed as milli Merck units/mL (mMU/mL)."}],"pom_b":[{"label":"1.","content":"Anti-HPV Geometric Mean Titers (GMTs) for Each Anti-HPV Type[ Time Frame: 4 weeks post vaccination 3 (Month 7) ]Antibodies to the HPV types contained in V503 were measured using a competitive luminex immunoassay. Antibody titers were expressed as milli Merck units/mL (mMU/mL). Statistical comparisons between arms was performed for the HPV types considered oncogenic (HPV Types 16/18/31/33/45/52/58)."}],"start_date":"September 20, 2017","primary_completion_date":"November 19, 2018","completion_date":"November 19, 2018","first_posted":"May 18, 2017","results_first_posted":"November 21, 2019","last_update_posted":"November 21, 2019"},{"nctid":"NCT00097981","version_a":1,"version_b":2,"version_a_date":"2005-06-23","version_b_date":"2006-02-28","pom_a":[],"pom_b":[{"label":"1.","content":"Complete response rate defined as the proportion of patients who achieve a complete response. This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks."}],"start_date":"January 2005","primary_completion_date":"October 2007","completion_date":"October 2009","first_posted":"December 2, 2004","results_first_posted":"November 27, 2008","last_update_posted":"April 7, 2017"},{"nctid":"NCT00097981","version_a":29,"version_b":30,"version_a_date":"2008-02-28","version_b_date":"2008-09-27","pom_a":[{"label":"1.","content":"Complete response rate defined as the proportion of patients who achieve a complete response. This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks."}],"pom_b":[{"label":"1.","content":"Complete response rate defined as the proportion of patients who achieve a complete response. This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks.[ Time Frame: Cycle 2 until 28 days following completion of treatment ]"}],"start_date":"January 2005","primary_completion_date":"October 2007","completion_date":"October 2009","first_posted":"December 2, 2004","results_first_posted":"November 27, 2008","last_update_posted":"April 7, 2017"},{"nctid":"NCT00097981","version_a":30,"version_b":31,"version_a_date":"2008-09-27","version_b_date":"2008-11-26","pom_a":[{"label":"1.","content":"Complete response rate defined as the proportion of patients who achieve a complete response. This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks.[ Time Frame: Cycle 2 until 28 days following completion of treatment ]"}],"pom_b":[{"label":"1.","content":"Complete Response Rate Defined as the Number of Participants Who Achieve a Complete Response[ Time Frame: Cycle 2 until 28 days following completion of treatment ]This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks."}],"start_date":"January 2005","primary_completion_date":"October 2007","completion_date":"October 2009","first_posted":"December 2, 2004","results_first_posted":"November 27, 2008","last_update_posted":"April 7, 2017"},{"nctid":"NCT00097981","version_a":35,"version_b":36,"version_a_date":"2010-10-18","version_b_date":"2013-06-27","pom_a":[{"label":"1.","content":"Complete Response Rate Defined as the Number of Participants Who Achieve a Complete Response[ Time Frame: Cycle 2 until 28 days following completion of treatment ]This is assessed at the beginning of every treatment cycle prior to treatment starting at Cycle 2. Complete response must be maintained for at least 6 weeks."}],"pom_b":[{"label":"1.","content":"Complete Response Rate: Number of Participants Who Achieved a Complete Response[ Time Frame: From Cycle 2 until 28 days following completion of treatment ]Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2."}],"start_date":"January 2005","primary_completion_date":"October 2007","completion_date":"October 2009","first_posted":"December 2, 2004","results_first_posted":"November 27, 2008","last_update_posted":"April 7, 2017"},{"nctid":"NCT03349333","version_a":2,"version_b":3,"version_a_date":"2017-11-22","version_b_date":"2019-08-06","pom_a":[{"label":"1.","content":"Objective Response Rate(ORR) by International Working Group Criteria[ Time Frame: 2 years ]ORR defined as the proportion of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months.Response will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review."}],"pom_b":[{"label":"1.","content":"Objective Response Rate(ORR) by International Working Group Criteria[ Time Frame: 2 years ]ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months.Response will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review."}],"start_date":"September 10, 2015","primary_completion_date":"July 21, 2017","completion_date":"May 21, 2018","first_posted":"November 21, 2017","results_first_posted":"September 12, 2019","last_update_posted":"October 1, 2019"},{"nctid":"NCT00508274","version_a":1,"version_b":2,"version_a_date":"2007-07-26","version_b_date":"2008-02-14","pom_a":[{"label":"1.","content":"To evaluate clinical benefit rate (CR+ PPR + SD for at least 24 weeks)[ Time Frame: 24 Weeks ]"}],"pom_b":[{"label":"1.","content":"To evaluate clinical benefit rate (CR+ PPR + SD for at least 24 weeks)"}],"start_date":"July 18, 2007","primary_completion_date":"December 2, 2015","completion_date":"July 1, 2020","first_posted":"July 27, 2007","results_first_posted":"September 3, 2009","last_update_posted":"September 21, 2021"},{"nctid":"NCT00508274","version_a":7,"version_b":8,"version_a_date":"2008-10-15","version_b_date":"2009-07-24","pom_a":[{"label":"1.","content":"To evaluate clinical benefit rate (CR+ PPR + SD for at least 24 weeks)"}],"pom_b":[{"label":"1.","content":"Clinical Benefit Rate (CBR), as Defined by the Percentage of Participants Achieving Either a Confirmed Tumor Response or Stable Disease (SD) for at Least 24 Weeks[ Time Frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression ]Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A \\"partial response\\" requires a decrease of 30% or more, \\"Progression\\" requires an increase of at least 20%, and \\"Stable disease\\" falls in between these two. All responses have a repeat assessment to confirm the response."}],"start_date":"July 18, 2007","primary_completion_date":"December 2, 2015","completion_date":"July 1, 2020","first_posted":"July 27, 2007","results_first_posted":"September 3, 2009","last_update_posted":"September 21, 2021"},{"nctid":"NCT00508274","version_a":8,"version_b":9,"version_a_date":"2009-07-24","version_b_date":"2009-10-22","pom_a":[{"label":"1.","content":"Clinical Benefit Rate (CBR), as Defined by the Percentage of Participants Achieving Either a Confirmed Tumor Response or Stable Disease (SD) for at Least 24 Weeks[ Time Frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression ]Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A \\"partial response\\" requires a decrease of 30% or more, \\"Progression\\" requires an increase of at least 20%, and \\"Stable disease\\" falls in between these two. All responses have a repeat assessment to confirm the response."}],"pom_b":[{"label":"1.","content":"Clinical Benefit Rate (CBR)[ Time Frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 11.07 months. ]CBR is defined by the percentage of participants achieving either a confirmed tumor reponse or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A \\"partial response\\" requires a decrease of 30% or more, \\"Progression\\" requires an increase of at least 20%, and \\"Stable disease\\" falls in between these two. All responses have a repeat assessment to confirm the response."}],"start_date":"July 18, 2007","primary_completion_date":"December 2, 2015","completion_date":"July 1, 2020","first_posted":"July 27, 2007","results_first_posted":"September 3, 2009","last_update_posted":"September 21, 2021"},{"nctid":"NCT00508274","version_a":28,"version_b":29,"version_a_date":"2021-05-11","version_b_date":"2021-08-26","pom_a":[{"label":"1.","content":"Clinical Benefit Rate (CBR)[ Time Frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 11.07 months. ]CBR is defined by the percentage of participants achieving either a confirmed tumor reponse or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A \\"partial response\\" requires a decrease of 30% or more, \\"Progression\\" requires an increase of at least 20%, and \\"Stable disease\\" falls in between these two. All responses have a repeat assessment to confirm the response."}],"pom_b":[{"label":"1.","content":"Clinical Benefit Rate (CBR)[ Time Frame: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months ]CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A \\"partial response\\" requires a decrease of 30% or more, \\"complete response\\" requires all target lesions disappear, \\"Progression\\" requires an increase of at least 20%, and \\"Stable disease\\" falls in between these two. All responses have a repeat assessment to confirm the response."}],"start_date":"July 18, 2007","primary_completion_date":"December 2, 2015","completion_date":"July 1, 2020","first_posted":"July 27, 2007","results_first_posted":"September 3, 2009","last_update_posted":"September 21, 2021"},{"nctid":"NCT04607421","version_a":20,"version_b":21,"version_a_date":"2022-03-07","version_b_date":"2022-03-14","pom_a":[{"label":"1.","content":"Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs)[ Time Frame: After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months ]Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment"},{"label":"2.","content":"Phase 3: Progression free survival, by blinded independent review[ Time Frame: Duration of Phase 3, approximately 34 months ]Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + (Arm A) vs Control Arm (Arm C) and encorafenib and cetuximab + mFOLFOX6 or encorafenib + cetuximab + FOLFIRI (Arm B) vs the Control Arm (Arm C)"}],"pom_b":[{"label":"1.","content":"Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs)[ Time Frame: After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months ]Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment"},{"label":"2.","content":"Phase 3: Progression free survival, by blinded independent review[ Time Frame: Duration of Phase 3, approximately 34 months ]Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + mFOLFOX6 (Arm B) vs the Control Arm (Arm C)"}],"start_date":"December 21, 2020","primary_completion_date":"September 16, 2024","completion_date":"November 15, 2026","first_posted":"October 29, 2020","last_update_posted":"September 14, 2022"},{"nctid":"NCT01566695","version_a":54,"version_b":55,"version_a_date":"2018-02-23","version_b_date":"2018-04-11","pom_a":[{"label":"1.","content":"Red blood cell (RBC) transfusion independence[ Time Frame: Up to 60 months ]Red blood cell (RBC) transfusion independence"}],"pom_b":[{"label":"1.","content":"Red blood cell (RBC) transfusion independence[ Time Frame: Up to 122 months ]Red blood cell (RBC) transfusion independence"}],"start_date":"April 26, 2013","primary_completion_date":"January 25, 2019","completion_date":"December 30, 2022","first_posted":"March 29, 2012","results_first_posted":"February 26, 2020","last_update_posted":"August 2, 2022"},{"nctid":"NCT01566695","version_a":58,"version_b":59,"version_a_date":"2018-08-20","version_b_date":"2019-01-09","pom_a":[{"label":"1.","content":"Red blood cell (RBC) transfusion independence[ Time Frame: Up to 122 months ]Red blood cell (RBC) transfusion independence"}],"pom_b":[{"label":"1.","content":"Red blood cell (RBC) transfusion independence[ Time Frame: Up to 134 months ]Red blood cell (RBC) transfusion independence"}],"start_date":"April 26, 2013","primary_completion_date":"January 25, 2019","completion_date":"December 30, 2022","first_posted":"March 29, 2012","results_first_posted":"February 26, 2020","last_update_posted":"August 2, 2022"},{"nctid":"NCT01566695","version_a":64,"version_b":65,"version_a_date":"2019-09-29","version_b_date":"2020-02-12","pom_a":[{"label":"1.","content":"Red blood cell (RBC) transfusion independence[ Time Frame: Up to 134 months ]Red blood cell (RBC) transfusion independence"}],"pom_b":[{"label":"1.","content":"Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for \u2265 56 Days[ Time Frame: Each participant was assessed for at least 56 days or more; from the date of randomization of study drug up to the data cut-off date of 25 January 2019, approximately 5 months. ]RBC transfusion (tfx) independence was defined as the absence of any RBC transfusion during any consecutive \\"rolling\\" 56 days within the treatment period. Participants who did not receive any RBC transfusion during a consecutive rolling 56 days (i.e., day 1 to day 56, day 2 to day 57) were considered as a 56-day RBC transfusion independent responder."}],"start_date":"April 26, 2013","primary_completion_date":"January 25, 2019","completion_date":"December 30, 2022","first_posted":"March 29, 2012","results_first_posted":"February 26, 2020","last_update_posted":"August 2, 2022"},{"nctid":"NCT00257205","version_a":29,"version_b":30,"version_a_date":"2007-05-29","version_b_date":"2007-06-12","pom_a":[{"label":"1.","content":"overall survival"}],"pom_b":[{"label":"1.","content":"Overall survival"}],"start_date":"March 2006","primary_completion_date":"August 2010","completion_date":"August 2010","first_posted":"November 22, 2005","last_update_posted":"July 2, 2012"},{"nctid":"NCT00257205","version_a":30,"version_b":31,"version_a_date":"2007-06-12","version_b_date":"2007-06-25","pom_a":[{"label":"1.","content":"Overall survival"}],"pom_b":[{"label":"1.","content":"overall survival"}],"start_date":"March 2006","primary_completion_date":"August 2010","completion_date":"August 2010","first_posted":"November 22, 2005","last_update_posted":"July 2, 2012"},{"nctid":"NCT00257205","version_a":35,"version_b":36,"version_a_date":"2007-12-13","version_b_date":"2008-01-06","pom_a":[{"label":"1.","content":"overall survival"}],"pom_b":[{"label":"1.","content":"overall survival[ Time Frame: unlimited ]"}],"start_date":"March 2006","primary_completion_date":"August 2010","completion_date":"August 2010","first_posted":"November 22, 2005","last_update_posted":"July 2, 2012"},{"nctid":"NCT00257205","version_a":74,"version_b":75,"version_a_date":"2010-11-15","version_b_date":"2011-04-26","pom_a":[{"label":"1.","content":"overall survival[ Time Frame: unlimited ]"}],"pom_b":[{"label":"1.","content":"overall survival[ Time Frame: August 2010 ]"}],"start_date":"March 2006","primary_completion_date":"August 2010","completion_date":"August 2010","first_posted":"November 22, 2005","last_update_posted":"July 2, 2012"},{"nctid":"NCT00785291","version_a":358,"version_b":359,"version_a_date":"2011-04-07","version_b_date":"2012-11-08","pom_a":[{"label":"1.","content":"Progression-free survival"}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) of each experimental arm to the PFS of the control arm[ Time Frame: Time from randomization to progression or death due to any cause, whichever occurs first, assessed up to 5 years ]The primary analysis will use the stratified log-rank tests to identify differences in PFS for each experimental arm as compared to control arm (based upon the trial\'s stratification factors: prior adjuvant taxanes, hormone receptor status, and concomitant bevacizumab). Any efficacy claim will be based solely on this primary statistical analysis. As a secondary analysis we will use the stratified log-rank test to test for a difference between arms after adjusting for disease-free interval and visceral metastases versus bone/soft tissue metastases."}],"start_date":"October 13, 2008","primary_completion_date":"December 31, 2013","completion_date":"June 15, 2017","first_posted":"November 5, 2008","results_first_posted":"July 2, 2015","last_update_posted":"August 5, 2022"},{"nctid":"NCT00785291","version_a":378,"version_b":379,"version_a_date":"2014-07-30","version_b_date":"2014-08-11","pom_a":[{"label":"1.","content":"Progression-free survival (PFS) of each experimental arm to the PFS of the control arm[ Time Frame: Time from randomization to progression or death due to any cause, whichever occurs first, assessed up to 5 years ]The primary analysis will use the stratified log-rank tests to identify differences in PFS for each experimental arm as compared to control arm (based upon the trial\'s stratification factors: prior adjuvant taxanes, hormone receptor status, and concomitant bevacizumab). Any efficacy claim will be based solely on this primary statistical analysis. As a secondary analysis we will use the stratified log-rank test to test for a difference between arms after adjusting for disease-free interval and visceral metastases versus bone/soft tissue metastases."}],"pom_b":[{"label":"1.","content":"PFS[ Time Frame: Time from randomization to progression or death due to any cause, whichever occurs first, assessed up to 5 years ]The primary analysis will use the stratified log-rank tests to identify differences in PFS for each experimental arm as compared to control arm (based upon the trial\'s stratification factors: prior adjuvant taxanes, hormone receptor status, and concomitant bevacizumab). Any efficacy claim will be based solely on this primary statistical analysis."}],"start_date":"October 13, 2008","primary_completion_date":"December 31, 2013","completion_date":"June 15, 2017","first_posted":"November 5, 2008","results_first_posted":"July 2, 2015","last_update_posted":"August 5, 2022"},{"nctid":"NCT00785291","version_a":395,"version_b":396,"version_a_date":"2014-10-01","version_b_date":"2015-03-04","pom_a":[{"label":"1.","content":"PFS[ Time Frame: Time from randomization to progression or death due to any cause, whichever occurs first, assessed up to 5 years ]The primary analysis will use the stratified log-rank tests to identify differences in PFS for each experimental arm as compared to control arm (based upon the trial\'s stratification factors: prior adjuvant taxanes, hormone receptor status, and concomitant bevacizumab). Any efficacy claim will be based solely on this primary statistical analysis."}],"pom_b":[{"label":"1.","content":"Progression Free Survival[ Time Frame: Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years) ]Progression-free survival (PFS) is defined as the interval from registration until first disease progression, regardless of site, or death resulting from any cause, which ever occurred first. Distribution was estimated using the Kaplan Meier product-limit method. Progression is defined as a 20% increase in the sum of longest diameter of target lesions (per Response Evaluation Criteria in Solid Tumors [RECIST] criteria)."}],"start_date":"October 13, 2008","primary_completion_date":"December 31, 2013","completion_date":"June 15, 2017","first_posted":"November 5, 2008","results_first_posted":"July 2, 2015","last_update_posted":"August 5, 2022"},{"nctid":"NCT03906071","version_a":1,"version_b":2,"version_a_date":"2019-04-04","version_b_date":"2019-04-05","pom_a":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 36 Months ]"}],"pom_b":[{"label":"1.","content":"Overall Survival (OS)[ Time Frame: 36 Months ]OS is defined as time from date of randomization to date of death due to any cause"}],"start_date":"July 15, 2019","primary_completion_date":"September 2022","completion_date":"July 2023","first_posted":"April 8, 2019","last_update_posted":"May 6, 2022"},{"nctid":"NCT00929240","version_a":71,"version_b":72,"version_a_date":"2015-01-06","version_b_date":"2015-03-02","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: assessed every 9 weeks (after every 3rd cycle) until progression ]"}],"pom_b":[{"label":"1.","content":"Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)[ Time Frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years ]Progression Free Survival (PFS) was defined as the time from first study drug dosing (during the maintenance treatment phase) to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST). Progressive Disease (PD) was defined as a 20 percent (%) or greater increase in the sum of the Longest Diameter (LD) of the target lesions taking as reference the smallest sum LD recorded or appearance of new lesions."},{"label":"2.","content":"Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)[ Time Frame: Randomization, at the end of every third cycle (every 9 weeks) until the end of maintenance phase and every 3 months until disease progression or death until data cutoff on October 4, 2013, up to 4 years ]PFS was defined as the time from first study drug dosing to the first documented disease progression or death, whichever occurred first.Time to progression was defined as the time from randomization to the first documented disease progression defined per RECIST 1.0 criteria. Participants without an event at data cut-off or who were withdrawn from the study without documented progression were censored at the date of the last tumor assessment when the participant was known to be progression free. Participants who took other non-protocol anti-cancer drugs while being on study medication, and who were still event free were censored on the date of first dose of the anti-cancer drug. Participants without post-randomization tumor assessments but alive were censored at the time of randomization. Participants without post-randomization assessments, who died after randomization were considered to have the PFS event at date of death. Kaplan-Meier estimation was used for median time to PFS"}],"start_date":"July 2009","primary_completion_date":"June 2014","completion_date":"June 2014","first_posted":"June 26, 2009","results_first_posted":"March 3, 2015","last_update_posted":"March 3, 2015"},{"nctid":"NCT01998906","version_a":2,"version_b":3,"version_a_date":"2013-12-03","version_b_date":"2014-10-24","pom_a":[{"label":"1.","content":"Event-free survival[ Time Frame: Approximately 9 years ]"}],"pom_b":[{"label":"1.","content":"Event-Free Survival (EFS) - Percentage of Participants With an Event[ Time Frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter ]EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause."},{"label":"2.","content":"Event-Free Survival[ Time Frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter ]The median time, in months, between randomization and date of documented occurrence of an EFS event."},{"label":"3.","content":"Percentage of Participants Event Free at 1 Year[ Time Frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter ]"},{"label":"4.","content":"Percentage of Participants Event Free at 2 Years[ Time Frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter ]"},{"label":"5.","content":"Percentage of Participants Event Free at 3 Years[ Time Frame: BL, Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter ]"}],"start_date":"May 2002","primary_completion_date":"July 2012","completion_date":"July 2012","first_posted":"December 2, 2013","results_first_posted":"October 28, 2014","last_update_posted":"October 28, 2014"},{"nctid":"NCT01980888","version_a":9,"version_b":10,"version_a_date":"2014-08-15","version_b_date":"2014-09-25","pom_a":[{"label":"1.","content":"Minimal residual disease negativity rate[ Time Frame: Week 36 ]Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD < 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date."},{"label":"2.","content":"Progression-free survival[ Time Frame: Baseline to Year 8 ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone."}],"pom_b":[{"label":"1.","content":"Minimal residual disease negativity rate[ Time Frame: Week 36 ]Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD < 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date."},{"label":"2.","content":"Progression-free survival[ Time Frame: Up to 8 years ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone."}],"start_date":"February 5, 2014","primary_completion_date":"May 30, 2016","completion_date":"June 16, 2016","first_posted":"November 11, 2013","results_first_posted":"October 11, 2017","last_update_posted":"November 19, 2018"},{"nctid":"NCT01980888","version_a":11,"version_b":12,"version_a_date":"2014-10-31","version_b_date":"2014-11-21","pom_a":[{"label":"1.","content":"Minimal residual disease negativity rate[ Time Frame: Week 36 ]Minimal residual disease (MRD) negativity rate is defined as the proportion of subjects with MRD < 10^-4 assessed by flow cytometry in bone marrow at Week 36 after therapy initiation or at least 12 weeks after the last dose of rituximab for participants receiving the final dose of rituximab after the original scheduled date."},{"label":"2.","content":"Progression-free survival[ Time Frame: Up to 8 years ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone."}],"pom_b":[{"label":"1.","content":"Progression-free survival[ Time Frame: Up to 56 months ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone."}],"start_date":"February 5, 2014","primary_completion_date":"May 30, 2016","completion_date":"June 16, 2016","first_posted":"November 11, 2013","results_first_posted":"October 11, 2017","last_update_posted":"November 19, 2018"},{"nctid":"NCT01980888","version_a":18,"version_b":19,"version_a_date":"2016-06-24","version_b_date":"2017-09-11","pom_a":[{"label":"1.","content":"Progression-free survival[ Time Frame: Up to 56 months ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival[ Time Frame: Up to 22 months ]Progression-free survival (PFS) is defined as the interval from randomization to the first documentation of definitive disease progression or death from any cause. Definitive disease progression is CLL progression based on standard criteria, excluding lymphocytosis alone. PFS was to be assessed by an independent review committee (IRC)."}],"start_date":"February 5, 2014","primary_completion_date":"May 30, 2016","completion_date":"June 16, 2016","first_posted":"November 11, 2013","results_first_posted":"October 11, 2017","last_update_posted":"November 19, 2018"},{"nctid":"NCT01096368","version_a":142,"version_b":143,"version_a_date":"2012-11-13","version_b_date":"2013-06-10","pom_a":[{"label":"1.","content":"Event-free survival (EFS)"},{"label":"2.","content":"Overall survival (OS)"}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS) defined as time to the first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause[ Time Frame: Up to 5 years ]Using Kaplan-Meier curves to estimate the observed EFS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed EFS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: From the time of randomization to death, assessed up to 5 years ]Using Kaplan-Meier curves to estimate the observed OS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed OS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups."}],"start_date":"March 29, 2010","primary_completion_date":"December 31, 2021","completion_date":"February 17, 2023","first_posted":"March 31, 2010","last_update_posted":"March 21, 2022"},{"nctid":"NCT01096368","version_a":150,"version_b":151,"version_a_date":"2017-09-08","version_b_date":"2018-10-17","pom_a":[{"label":"1.","content":"Event-free survival (EFS) defined as time to the first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause[ Time Frame: Up to 5 years ]Using Kaplan-Meier curves to estimate the observed EFS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed EFS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: From the time of randomization to death, assessed up to 5 years ]Using Kaplan-Meier curves to estimate the observed OS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed OS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups."}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS)[ Time Frame: From first occurrence of disease progression, disease recurrence, second malignant neoplasm, or death from any cause, assessed up to 5 years ]Using Kaplan-Meier curves to estimate the observed EFS for the two randomization arms (post-radiation maintenance arm and post-radiation observation only arm). Log rank tests will be used to compare the observed EFS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups. If outcome data on ACNS0121 or this study suggest a difference or a different pattern in outcome between the 2 randomization strata, the primary analyses will be supplemented with log-rank tests performed separately in each stratum in order not to confound the overall conclusions of the study with respect to the effect of maintenance therapy."},{"label":"2.","content":"Overall survival (OS)[ Time Frame: From the time of randomization to death, assessed up to 5 years ]Using Kaplan-Meier curves to estimate the observed OS for the two randomization arms (post-radiation Maintenance arm and post-radiation Observation only arm). Log rank tests will be used to compare the observed OS between the two randomization arms. Stratified log rank test will also be performed to examine the treatment difference with consideration and adjustment for the randomization groups. If outcome data on ACNS0121 or this study suggest a difference or a different pattern in outcome between the 2 randomization strata, the primary analyses will be supplemented with log-rank tests performed separately in each stratum in order not to confound the overall conclusions of the study with respect to the effect of maintenance therapy."}],"start_date":"March 29, 2010","primary_completion_date":"December 31, 2021","completion_date":"February 17, 2023","first_posted":"March 31, 2010","last_update_posted":"March 21, 2022"},{"nctid":"NCT01205126","version_a":16,"version_b":17,"version_a_date":"2013-02-18","version_b_date":"2013-09-13","pom_a":[{"label":"1.","content":"Patient assessment of pain at its worst in the last 24 hours, included as an item in the Brief Pain Inventory (BPI) Short Form, where 0=no pain and 10=pain as bad as you can imagine.[ Time Frame: At endpoint (the last recorded value obtained up to the end of the study (Day 29 +/-1 day) ]"}],"pom_b":[{"label":"1.","content":"Change From Baseline in Worst Pain in the Past 24 Hours in Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29[ Time Frame: Baseline and Day 29 ]The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines. Change in worst pain in the past 24 hours in BPI score was reported. The total score ranges from 0 to 10, wherein 0 indicates no pain and 10 indicates pain as bad as participants could imagine."}],"start_date":"December 2009","primary_completion_date":"February 2011","completion_date":"February 2011","first_posted":"September 20, 2010","results_first_posted":"November 25, 2013","last_update_posted":"February 3, 2014"},{"nctid":"NCT01205126","version_a":17,"version_b":18,"version_a_date":"2013-09-13","version_b_date":"2013-12-31","pom_a":[{"label":"1.","content":"Change From Baseline in Worst Pain in the Past 24 Hours in Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29[ Time Frame: Baseline and Day 29 ]The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines. Change in worst pain in the past 24 hours in BPI score was reported. The total score ranges from 0 to 10, wherein 0 indicates no pain and 10 indicates pain as bad as participants could imagine."}],"pom_b":[{"label":"1.","content":"Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29[ Time Frame: Baseline and Day 29 ]The BPI is questionnaire for evaluating the degree of pain severity and the impact of pain in performing daily routines. Change in worst pain in the past 24 hours in BPI score was reported. The total score ranges from 0 to 10, wherein 0 indicates no pain and 10 indicates pain as bad as participants could imagine."}],"start_date":"December 2009","primary_completion_date":"February 2011","completion_date":"February 2011","first_posted":"September 20, 2010","results_first_posted":"November 25, 2013","last_update_posted":"February 3, 2014"},{"nctid":"NCT03103321","version_a":17,"version_b":18,"version_a_date":"2020-10-09","version_b_date":"2022-01-02","pom_a":[{"label":"1.","content":"Knowledge assessed by Prostate Cancer Treatment questionnaire[ Time Frame: Up to 12 months ]A mixed effects regression model (also known as random effects model or multi-level model) will be utilized to examine the effects of the during-consultation Prostate Choice and the pre-consultation Knowing Your Options decision aids. Specifically, this model will contain a fixed intercept, a fixed effect for having received Prostate Choice, a fixed effect for having received Knowing Your Options, and a random, site-specific intercept to allow patients within the same site to be correlated. Baseline patient-level characteristics including race, ethnicity, severity of disease and site-level characteristics may be incorporated in this model if deemed appropriate. A similar approach will be utilized in the statistical analysis of secondary endpoints. Furthermore, descriptive statistics will be reported after incorporating cluster information, in particular, the empirical cluster size, and the observed intra-cluster correlation."}],"pom_b":[{"label":"1.","content":"Knowledge Assessed by Prostate Cancer Treatment Questionnaire[ Time Frame: 12 months ]The primary outcome, knowledge, will be assessed by a standardized questionnaire (i.e., Prostate Cancer Treatment Questionnaire) administered once, immediately after the clinical consultation while the patient is still at the study site. The number correct from this 12-item measure will be reduced to a percentage of total number correct. With 100%(12 out of 12 item average) being the best possible outcome and 0%(0 out of 12 item average) the worst possible outcome"}],"start_date":"July 14, 2017","primary_completion_date":"December 5, 2019","completion_date":"November 25, 2020","first_posted":"April 6, 2017","results_first_posted":"January 13, 2022","last_update_posted":"January 13, 2022"},{"nctid":"NCT00085644","version_a":2,"version_b":3,"version_a_date":"2006-02-16","version_b_date":"2006-02-24","pom_a":[],"pom_b":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20) at Week 12."}],"start_date":"January 2004","primary_completion_date":"December 2004","completion_date":"July 2009","first_posted":"June 16, 2004","results_first_posted":"March 11, 2010","last_update_posted":"April 21, 2011"},{"nctid":"NCT00085644","version_a":4,"version_b":5,"version_a_date":"2006-08-13","version_b_date":"2007-08-28","pom_a":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20) at Week 12."}],"pom_b":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20)[ Time Frame: Week 12 ]"}],"start_date":"January 2004","primary_completion_date":"December 2004","completion_date":"July 2009","first_posted":"June 16, 2004","results_first_posted":"March 11, 2010","last_update_posted":"April 21, 2011"},{"nctid":"NCT00085644","version_a":5,"version_b":6,"version_a_date":"2007-08-28","version_b_date":"2007-12-22","pom_a":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20)[ Time Frame: Week 12 ]"}],"pom_b":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20)[ Time Frame: Week 12 ]"},{"label":"2.","content":"Inhibition of progression of structural damage in spine as measured by modified SASSS[ Time Frame: Week 104 ]"}],"start_date":"January 2004","primary_completion_date":"December 2004","completion_date":"July 2009","first_posted":"June 16, 2004","results_first_posted":"March 11, 2010","last_update_posted":"April 21, 2011"},{"nctid":"NCT00085644","version_a":11,"version_b":12,"version_a_date":"2009-07-24","version_b_date":"2010-02-12","pom_a":[{"label":"1.","content":"Reduction of signs and symptoms as measured with Assessments in Ankylosing Spondylitis (ASAS) Working Group response criterion (ASAS 20)[ Time Frame: Week 12 ]"},{"label":"2.","content":"Inhibition of progression of structural damage in spine as measured by modified SASSS[ Time Frame: Week 104 ]"}],"pom_b":[{"label":"1.","content":"Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20).[ Time Frame: Week 12 ]Interim results through Week 12 are reported and included the placebo-controlled, blinded portion of the study. The reduction of signs and symptoms of AS was measured according to Assessments in Ankylosing Spondylitis (ASAS) Working Group criterion response at Week 12 (ASAS 20). Responders had improvements in 3 of 4 categories by Week 12 - 1) total back pain 2) global assessment of disease activity 3) inflammation measured with a visual analog scale from 0 (worst) to 100 (best) for categories 1-3, and 4) Bath ankylosing spondylitis functional index with a scale of 0 (worst) to 100 (best)."},{"label":"2.","content":"Inhibition of Progression of Structural Damage in Spine as Measured by Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)[ Time Frame: Baseline to Week 104 ]This outcome measure could not be reported within the 24-week time frame for these interim results."}],"start_date":"January 2004","primary_completion_date":"December 2004","completion_date":"July 2009","first_posted":"June 16, 2004","results_first_posted":"March 11, 2010","last_update_posted":"April 21, 2011"},{"nctid":"NCT00085644","version_a":13,"version_b":14,"version_a_date":"2010-03-18","version_b_date":"2010-07-22","pom_a":[{"label":"1.","content":"Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20).[ Time Frame: Week 12 ]Interim results through Week 12 are reported and included the placebo-controlled, blinded portion of the study. The reduction of signs and symptoms of AS was measured according to Assessments in Ankylosing Spondylitis (ASAS) Working Group criterion response at Week 12 (ASAS 20). Responders had improvements in 3 of 4 categories by Week 12 - 1) total back pain 2) global assessment of disease activity 3) inflammation measured with a visual analog scale from 0 (worst) to 100 (best) for categories 1-3, and 4) Bath ankylosing spondylitis functional index with a scale of 0 (worst) to 100 (best)."},{"label":"2.","content":"Inhibition of Progression of Structural Damage in Spine as Measured by Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)[ Time Frame: Baseline to Week 104 ]This outcome measure could not be reported within the 24-week time frame for these interim results."}],"pom_b":[{"label":"1.","content":"Number of Responders With a Reduction of Signs and Symptoms of Ankylosing Spondylitis (AS) as Measured With ASAS International Working Group Response Criteria (ASAS 20).[ Time Frame: Week 12 ]ASAS 20 responders - improvement of >=20% and absolute improvement of >=10 units from Baseline in a visual analog scale (VAS) for >=3 of 4 domains; Patient\'s Global Assessment of disease activity VAS (0 [none]-100 [severe]), Total Back Pain VAS (0 [no pain]-100 [severe]), BASFI VAS (0 [easy]-100[impossible]); and Inflammation VAS (0 [none]-10 [very severe]) and absence of deterioration in the potential remaining domain, defined as a worsening of >=20% and a net worsening of >=10 units. Applied to each scale and not to an overall global scale."},{"label":"2.","content":"Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score[ Time Frame: Week 104 ]Radiographic progression was based on change in mSASSS scoring (comparison of the means) from double-blind Baseline visit to Week 104. The mSASSS is the sum of the lumbar and cervical spine score ( 0 [no change] to 72 [progression]), derived from scoring the anterior site of the lumbar spine (T12 to S1) and the cervical spine (C2 to T1) as either 0 (normal), 1 (erosion, sclerosis, or squaring), 2 (syndesmophyte), 3 (bridging syndesmophyte), or N (vertebral body not evaluable). Data from NCT00195819 was compared with data from AS patients in OASIS."}],"start_date":"January 2004","primary_completion_date":"December 2004","completion_date":"July 2009","first_posted":"June 16, 2004","results_first_posted":"March 11, 2010","last_update_posted":"April 21, 2011"},{"nctid":"NCT04585490","version_a":1,"version_b":2,"version_a_date":"2020-10-06","version_b_date":"2020-10-19","pom_a":[{"label":"1.","content":"Decrease in ctDNA Level Following Chemotherapy[ Time Frame: 12 weeks ]Participants in Cohort 1 MRD+ will be assessed for ctDNA levels at baseline and end of treatment, expected to be 4 cycles of 3 weeks per cycle (defined as ctDNA evaluable set or ctDES). The outcome will be assessed as the number of participants with a \u2265 3 fold decrease in ctDNA level, a number without dispersion."}],"pom_b":[{"label":"1.","content":"Change in ctDNA Level Following Chemotherapy[ Time Frame: 12 weeks ]Participants in Cohort 1 MRD+ will be assessed for ctDNA levels at baseline and end of treatment, expected to be 4 cycles of 3 weeks per cycle (defined as ctDNA evaluable set or ctDES). The outcome will be assessed as the number of participants with a \u2265 3 fold decrease in ctDNA level, a number without dispersion."}],"start_date":"August 25, 2021","primary_completion_date":"March 2024","completion_date":"March 2026","first_posted":"October 14, 2020","last_update_posted":"September 8, 2021"},{"nctid":"NCT00256776","version_a":2,"version_b":3,"version_a_date":"2006-01-26","version_b_date":"2006-01-30","pom_a":[{"label":"1.","content":"Time to progression, the interval between the date of randomization & date of disease progression (death without progression is a competing risk)"}],"pom_b":[{"label":"1.","content":"Time to progression, the interval between the date of randomization and date of disease progression (death without progression is a competing risk)"}],"start_date":"July 2005","primary_completion_date":"December 2013","completion_date":"December 2015","first_posted":"November 22, 2005","results_first_posted":"October 18, 2021","last_update_posted":"October 18, 2021"},{"nctid":"NCT00256776","version_a":4,"version_b":5,"version_a_date":"2006-01-31","version_b_date":"2007-05-09","pom_a":[{"label":"1.","content":"Time to progression, the interval between the date of randomization and date of disease progression (death without progression is a competing risk)"}],"pom_b":[{"label":"1.","content":"Time to progression, the interval between the date of randomization and date of disease progression (death without progression is a competing risk)[ Time Frame: 1 year ]"}],"start_date":"July 2005","primary_completion_date":"December 2013","completion_date":"December 2015","first_posted":"November 22, 2005","results_first_posted":"October 18, 2021","last_update_posted":"October 18, 2021"},{"nctid":"NCT00256776","version_a":8,"version_b":9,"version_a_date":"2020-12-21","version_b_date":"2021-09-21","pom_a":[{"label":"1.","content":"Time to progression, the interval between the date of randomization and date of disease progression (death without progression is a competing risk)[ Time Frame: 1 year ]"}],"pom_b":[{"label":"1.","content":"Median Time to Progression (TTP)[ Time Frame: 3 year ]"}],"start_date":"July 2005","primary_completion_date":"December 2013","completion_date":"December 2015","first_posted":"November 22, 2005","results_first_posted":"October 18, 2021","last_update_posted":"October 18, 2021"},{"nctid":"NCT00430001","version_a":1,"version_b":2,"version_a_date":"2007-01-31","version_b_date":"2007-10-30","pom_a":[],"pom_b":[{"label":"1.","content":"Disease free survival[ Time Frame: median ]"}],"start_date":"May 2005","completion_date":"December 2008","first_posted":"February 1, 2007","last_update_posted":"May 9, 2008"},{"nctid":"NCT03286842","version_a":8,"version_b":9,"version_a_date":"2018-06-21","version_b_date":"2018-08-13","pom_a":[{"label":"1.","content":"Progression-free survival in real-world setting[ Time Frame: At every visit until the earliest of disease progression, death or end of study for up to 3 years. ]Progression-free survival is defined as the time from the first dose of olaparib to physician-defined progression or death from any cause (in the absence of progression). Physician-defined progression can be RECIST progression, symptomatic progression, or clear progression of non measurable disease, as long as there is some manner of documenting all of them."}],"pom_b":[{"label":"1.","content":"Progression-free survival (PFS) in real-world setting in germline BRCA mutated patients[ Time Frame: At every visit until the earliest of disease progression, death or end of study for up to 3 years. ]PFS is defined as the time from the first dose of olaparib to physician-defined progression or death from any cause (in the absence of progression). Physician-defined progression can be RECIST progression, symptomatic progression, or clear progression of non measurable disease, as long as there is some manner of documenting all of them."}],"start_date":"January 17, 2018","primary_completion_date":"October 8, 2021","completion_date":"October 8, 2021","first_posted":"September 19, 2017","last_update_posted":"November 3, 2021"},{"nctid":"NCT00129389","version_a":1,"version_b":2,"version_a_date":"2005-08-10","version_b_date":"2005-09-06","pom_a":[{"label":"1.","content":"Disease-free survival."}],"pom_b":[{"label":"1.","content":"Disease-free survival"}],"start_date":"September 19, 2003","primary_completion_date":"October 1, 2013","completion_date":"October 1, 2013","first_posted":"August 11, 2005","results_first_posted":"July 12, 2019","last_update_posted":"July 12, 2019"},{"nctid":"NCT00129389","version_a":5,"version_b":6,"version_a_date":"2007-09-04","version_b_date":"2009-04-20","pom_a":[{"label":"1.","content":"Disease-free survival"}],"pom_b":[{"label":"1.","content":"Disease-free survival[ Time Frame: 5 years ]"}],"start_date":"September 19, 2003","primary_completion_date":"October 1, 2013","completion_date":"October 1, 2013","first_posted":"August 11, 2005","results_first_posted":"July 12, 2019","last_update_posted":"July 12, 2019"},{"nctid":"NCT00129389","version_a":8,"version_b":9,"version_a_date":"2012-11-21","version_b_date":"2019-04-26","pom_a":[{"label":"1.","content":"Disease-free survival[ Time Frame: 5 years ]"}],"pom_b":[{"label":"1.","content":"Disease-free Survival (DFS) Event[ Time Frame: Up to 5 years ]DFS is defined as the evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason."}],"start_date":"September 19, 2003","primary_completion_date":"October 1, 2013","completion_date":"October 1, 2013","first_posted":"August 11, 2005","results_first_posted":"July 12, 2019","last_update_posted":"July 12, 2019"},{"nctid":"NCT00118222","version_a":10,"version_b":11,"version_a_date":"2006-08-25","version_b_date":"2007-02-20","pom_a":[],"pom_b":[{"label":"1.","content":"Survival measured at 4-6 weeks post-operatively and then every 3-4 months thereafter"},{"label":"2.","content":"Time to progression measured at 4-6 weeks post-operatively and then every 3-4 months"}],"start_date":"March 2005","primary_completion_date":"March 2006","completion_date":"March 2006","first_posted":"July 11, 2005","last_update_posted":"June 11, 2010"},{"nctid":"NCT00118222","version_a":17,"version_b":18,"version_a_date":"2009-02-06","version_b_date":"2010-02-25","pom_a":[{"label":"1.","content":"Survival measured at 4-6 weeks post-operatively and then every 3-4 months thereafter"},{"label":"2.","content":"Time to progression measured at 4-6 weeks post-operatively and then every 3-4 months"}],"pom_b":[{"label":"1.","content":"Time to progression and survival measured[ Time Frame: at 4-6 weeks post-operatively and then every 3-4 months thereafter ]"}],"start_date":"March 2005","primary_completion_date":"March 2006","completion_date":"March 2006","first_posted":"July 11, 2005","last_update_posted":"June 11, 2010"},{"nctid":"NCT01354717","version_a":2,"version_b":3,"version_a_date":"2011-06-03","version_b_date":"2014-10-09","pom_a":[{"label":"1.","content":"Percent of patients with 100% clearing[ Time Frame: 6 weeks ]"}],"pom_b":[{"label":"1.","content":"Percent of patients with clearing[ Time Frame: August 28, 2010 to March 17, 2011 ]"},{"label":"2.","content":"Clearing of actinic keratosis[ Time Frame: 42 days ]"}],"start_date":"September 2010","primary_completion_date":"March 2011","completion_date":"March 2011","first_posted":"May 17, 2011","last_update_posted":"October 20, 2014"},{"nctid":"NCT02973789","version_a":9,"version_b":10,"version_a_date":"2017-11-16","version_b_date":"2017-12-03","pom_a":[{"label":"1.","content":"Overall survival of patients treated with TTFields + docetaxel or PD-1 inhibitors vs. docetaxel or PD-1 alone (superiority)[ Time Frame: 4 years ]"},{"label":"2.","content":"Co-primary outcome (will be tested only if the primary endpoint fails): Overall survival of patients treated with TTFields + docetaxel vs. PD-1 inhibitors alone (non-inferiority)[ Time Frame: 4 years ]"}],"pom_b":[{"label":"1.","content":"Overall survival of patients treated with TTFields + docetaxel or immune checkpoint inhibitors vs. docetaxel or immune checkpoint inhibitors alone (superiority analysis)[ Time Frame: 4 years ]"}],"start_date":"December 2016","primary_completion_date":"September 2023","completion_date":"September 2023","first_posted":"November 25, 2016","last_update_posted":"September 13, 2022"},{"nctid":"NCT02026063","version_a":18,"version_b":19,"version_a_date":"2016-06-02","version_b_date":"2017-07-12","pom_a":[{"label":"1.","content":"Incidence of treatment-emergent adverse events[ Time Frame: 50 weeks ]"}],"pom_b":[{"label":"1.","content":"Incidence of Treatment-Emergent Adverse Events[ Time Frame: Baseline up to Week 86 ]"}],"start_date":"January 14, 2014","primary_completion_date":"September 12, 2018","completion_date":"September 12, 2018","first_posted":"January 1, 2014","results_first_posted":"September 17, 2019","last_update_posted":"September 17, 2019"},{"nctid":"NCT02026063","version_a":21,"version_b":22,"version_a_date":"2019-03-12","version_b_date":"2019-08-22","pom_a":[{"label":"1.","content":"Incidence of Treatment-Emergent Adverse Events[ Time Frame: Baseline up to Week 86 ]"}],"pom_b":[{"label":"1.","content":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)[ Time Frame: First dose of study drug (Day 1) up to 15 days post last dose (approximately up to 236 weeks) ]An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE includes any noxious, pathological, or unintended change in anatomical, physiological, or metabolic functions as indicated by physical signs or symptoms occurring in any phase of the clinical study whether or not considered related to the study medication. A TEAE is an AE that occurs or worsens after receiving study drug."}],"start_date":"January 14, 2014","primary_completion_date":"September 12, 2018","completion_date":"September 12, 2018","first_posted":"January 1, 2014","results_first_posted":"September 17, 2019","last_update_posted":"September 17, 2019"},{"nctid":"NCT00130494","version_a":1,"version_b":2,"version_a_date":"2005-08-12","version_b_date":"2005-09-28","pom_a":[{"label":"1.","content":"Time to first bone metastases symptom."}],"pom_b":[{"label":"1.","content":"Time to first bone metastases symptom"}],"start_date":"August 29, 2002","primary_completion_date":"November 20, 2006","completion_date":"October 22, 2007","first_posted":"August 15, 2005","last_update_posted":"April 16, 2019"},{"nctid":"NCT00130494","version_a":4,"version_b":5,"version_a_date":"2007-02-06","version_b_date":"2019-04-11","pom_a":[{"label":"1.","content":"Time to first bone metastases symptom"}],"pom_b":[{"label":"1.","content":"Time to first bone metastases[ Time Frame: Up to disease progression ]The main variable of evaluation is the time until the appearance of first bone metastases."}],"start_date":"August 29, 2002","primary_completion_date":"November 20, 2006","completion_date":"October 22, 2007","first_posted":"August 15, 2005","last_update_posted":"April 16, 2019"},{"nctid":"NCT00494299","version_a":1,"version_b":2,"version_a_date":"2007-06-28","version_b_date":"2007-12-21","pom_a":[{"label":"1.","content":"Time to progression (TTP) in patients treated with BAY 43-9006 400 mg bid will be compared with that in patients treated with placebo[ Time Frame: Measure: radiological progression/recurrence, Study period: four years ]"}],"pom_b":[{"label":"1.","content":"Time to progression (TTP) in patients treated with BAY 43-9006 400 mg bid will be compared with that in patients treated with placebo[ Time Frame: 31. Dec. 2009 ]"}],"start_date":"April 2006","primary_completion_date":"July 2009","completion_date":"November 2010","first_posted":"June 29, 2007","results_first_posted":"January 20, 2011","last_update_posted":"December 20, 2013"},{"nctid":"NCT00494299","version_a":12,"version_b":13,"version_a_date":"2010-01-22","version_b_date":"2010-02-05","pom_a":[{"label":"1.","content":"Time to progression (TTP) in patients treated with BAY 43-9006 400 mg bid will be compared with that in patients treated with placebo[ Time Frame: 31. Dec. 2009 ]"}],"pom_b":[{"label":"1.","content":"Time to progression (TTP) in patients treated with BAY 43-9006 400 mg bid will be compared with that in patients treated with placebo[ Time Frame: TTP is defined as the time from randomization to radiological progression/recurrence. ]"}],"start_date":"April 2006","primary_completion_date":"July 2009","completion_date":"November 2010","first_posted":"June 29, 2007","results_first_posted":"January 20, 2011","last_update_posted":"December 20, 2013"},{"nctid":"NCT00494299","version_a":15,"version_b":16,"version_a_date":"2010-09-21","version_b_date":"2010-11-22","pom_a":[{"label":"1.","content":"Time to progression (TTP) in patients treated with BAY 43-9006 400 mg bid will be compared with that in patients treated with placebo[ Time Frame: TTP is defined as the time from randomization to radiological progression/recurrence. ]"}],"pom_b":[{"label":"1.","content":"Time to Progression (TTP)[ Time Frame: From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months ]"}],"start_date":"April 2006","primary_completion_date":"July 2009","completion_date":"November 2010","first_posted":"June 29, 2007","results_first_posted":"January 20, 2011","last_update_posted":"December 20, 2013"},{"nctid":"NCT00494299","version_a":16,"version_b":17,"version_a_date":"2010-11-22","version_b_date":"2010-12-21","pom_a":[{"label":"1.","content":"Time to Progression (TTP)[ Time Frame: From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months ]"}],"pom_b":[{"label":"1.","content":"Time to Progression (TTP)[ Time Frame: From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months. ]Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation."}],"start_date":"April 2006","primary_completion_date":"July 2009","completion_date":"November 2010","first_posted":"June 29, 2007","results_first_posted":"January 20, 2011","last_update_posted":"December 20, 2013"},{"nctid":"NCT00946712","version_a":352,"version_b":353,"version_a_date":"2012-05-09","version_b_date":"2013-02-12","pom_a":[{"label":"1.","content":"Overall survival (OS)"},{"label":"2.","content":"Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From date of registration to 3 years or death, whichever comes first ]"},{"label":"2.","content":"Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review[ Time Frame: From date of registration to 3 years or death, whichever comes first ]"}],"start_date":"July 15, 2009","primary_completion_date":"August 31, 2017","completion_date":"December 31, 2022","first_posted":"July 27, 2009","results_first_posted":"March 7, 2019","last_update_posted":"July 12, 2021"},{"nctid":"NCT00946712","version_a":356,"version_b":357,"version_a_date":"2015-02-05","version_b_date":"2015-09-01","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: From date of registration to 3 years or death, whichever comes first ]"},{"label":"2.","content":"Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review[ Time Frame: From date of registration to 3 years or death, whichever comes first ]"}],"pom_b":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Up to 3 years ]"},{"label":"2.","content":"Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review[ Time Frame: Up to 3 years ]A stratified log-rank test will be used."}],"start_date":"July 15, 2009","primary_completion_date":"August 31, 2017","completion_date":"December 31, 2022","first_posted":"July 27, 2009","results_first_posted":"March 7, 2019","last_update_posted":"July 12, 2021"},{"nctid":"NCT00946712","version_a":361,"version_b":362,"version_a_date":"2018-10-10","version_b_date":"2019-02-13","pom_a":[{"label":"1.","content":"Overall survival (OS)[ Time Frame: Up to 3 years ]"},{"label":"2.","content":"Progression-free survival (PFS) of EGFR FISH-positive patients by institutional review[ Time Frame: Up to 3 years ]A stratified log-rank test will be used."}],"pom_b":[{"label":"1.","content":"Overall Survival (OS) in the Entire Study Population[ Time Frame: Patients will be followed every 3 weeks while on protocol treatment. Once off all protocol treatment, patients will be followed every 6 months until death or up to 3 years ]From date of randomization to date of death due to any cause. Patients last known to be alive are censored at date of last contact."},{"label":"2.","content":"Progression-free Survival (PFS) of EGFR FISH-positive Patients by Institutional Review[ Time Frame: Disease assessment will be repeated every 6 weeks for the first 9 months and every 3 months thereafter, until disease progression. ]From date of randomization to date of first documentation of progression or symptomatic deterioration, or death due to any cause, whichever comes first by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as assessed by the treating investigator.Patients last known to be alive and progression-free are censored at date of last contact. Progression is defined using RECIST 1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions."}],"start_date":"July 15, 2009","primary_completion_date":"August 31, 2017","completion_date":"December 31, 2022","first_posted":"July 27, 2009","results_first_posted":"March 7, 2019","last_update_posted":"July 12, 2021"},{"nctid":"NCT00262990","version_a":14,"version_b":15,"version_a_date":"2006-05-22","version_b_date":"2006-05-23","pom_a":[],"pom_b":[{"label":"1.","content":"Survival"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":17,"version_b":18,"version_a_date":"2006-05-31","version_b_date":"2006-06-01","pom_a":[{"label":"1.","content":"Survival"}],"pom_b":[],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":21,"version_b":22,"version_a_date":"2006-08-03","version_b_date":"2006-08-15","pom_a":[],"pom_b":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":48,"version_b":49,"version_a_date":"2007-06-26","version_b_date":"2007-07-06","pom_a":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)"}],"pom_b":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)and CA-125"},{"label":"2.","content":"Overall survival, to show superiority of patupilone in overall survival to pegylated liposomal doxorubicin"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":75,"version_b":76,"version_a_date":"2008-10-28","version_b_date":"2008-11-21","pom_a":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)and CA-125"},{"label":"2.","content":"Overall survival, to show superiority of patupilone in overall survival to pegylated liposomal doxorubicin"}],"pom_b":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)and CA-125[ Time Frame: every 8 weeks ]"},{"label":"2.","content":"Overall survival, to show superiority of patupilone in overall survival to pegylated liposomal doxorubicin[ Time Frame: once every 4 week ]"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":76,"version_b":77,"version_a_date":"2008-11-21","version_b_date":"2008-12-15","pom_a":[{"label":"1.","content":"Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)and CA-125[ Time Frame: every 8 weeks ]"},{"label":"2.","content":"Overall survival, to show superiority of patupilone in overall survival to pegylated liposomal doxorubicin[ Time Frame: once every 4 week ]"}],"pom_b":[{"label":"1.","content":"To show superiority of patupilone in overall survival compared to Doxil in taxane/platinum resistant patients with ovarian cancer[ Time Frame: every 8 weeks ]"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00262990","version_a":88,"version_b":89,"version_a_date":"2012-05-01","version_b_date":"2012-05-02","pom_a":[{"label":"1.","content":"To show superiority of patupilone in overall survival compared to Doxil in taxane/platinum resistant patients with ovarian cancer[ Time Frame: every 8 weeks ]"}],"pom_b":[{"label":"1.","content":"To show superiority of patupilone in overall survival compared to doxorubicin in taxane/platinum resistant patients with ovarian cancer[ Time Frame: every 8 weeks ]"}],"start_date":"November 2005","primary_completion_date":"February 2010","first_posted":"December 7, 2005","last_update_posted":"December 17, 2020"},{"nctid":"NCT00008385","version_a":69,"version_b":70,"version_a_date":"2006-12-06","version_b_date":"2006-12-11","pom_a":[],"pom_b":[{"label":"1.","content":"Incidence second of primary lung tumors"},{"label":"2.","content":"Toxicity"},{"label":"3.","content":"Incidence of specific cancers, mortality from cancer, and overall survival"}],"start_date":"October 2000","primary_completion_date":"June 2011","completion_date":"November 2019","first_posted":"January 27, 2003","results_first_posted":"May 4, 2016","last_update_posted":"November 17, 2020"},{"nctid":"NCT00008385","version_a":471,"version_b":472,"version_a_date":"2015-05-15","version_b_date":"2016-03-31","pom_a":[{"label":"1.","content":"Incidence second of primary lung tumors"},{"label":"2.","content":"Toxicity"},{"label":"3.","content":"Incidence of specific cancers, mortality from cancer, and overall survival"}],"pom_b":[{"label":"1.","content":"Incidence Rate of Second Primary Lung Tumor[ Time Frame: Assessed annually for 10 years after randomization ]Incidence rate of second primary lung tumor was defined as the number of new second primary lung tumors per 100 population at risk in a year."}],"start_date":"October 2000","primary_completion_date":"June 2011","completion_date":"November 2019","first_posted":"January 27, 2003","results_first_posted":"May 4, 2016","last_update_posted":"November 17, 2020"},{"nctid":"NCT04307576","version_a":13,"version_b":14,"version_a_date":"2020-10-08","version_b_date":"2020-11-02","pom_a":[{"label":"1.","content":"Event-free survival (EFS) for the whole protocol[ Time Frame: 5 year estimates from the time of diagnosis will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up. ]The primary endpoint for the whole protocol (compared with the legacy protocols of the participating study-groups forming the consortium) is event-free survival (EFS) - as defined in the protocol."},{"label":"2.","content":"Event-free survival (EFS) for the TKI intervention[ Time Frame: From the start of TKI (day 15 or day 30), 5 year estimates will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up for all interventions except Inotuzumab-randomisation (minimum 2-year follow-up). ]The primary endpoint for the TKI intervention is event-free survival (EFS) - as defined in the protocol, from the start of TKI until event or end of follow-up"},{"label":"3.","content":"Disease-free survival (DFS) R1 + R2[ Time Frame: 5 and 8 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up. ]The primary endpoint for Randomisation 1 and 2 is disease-free survival (DFS) - as defined in the protocol counting from the time of randomisation"},{"label":"4.","content":"Disease-free survival (DFS) R3[ Time Frame: 5 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 2-year follow-up ]The primary endpoint for Randomisation 3 and the ABL-class fusion intervention is disease-free survival (DFS) - as defined in the protocol counting from the time of randomisation."}],"pom_b":[{"label":"1.","content":"Event-free survival (EFS) for the whole protocol[ Time Frame: 5 year estimates from the time of diagnosis will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up. ]The primary endpoint for the whole protocol (compared with the legacy protocols of the participating study-groups forming the consortium) is event-free survival (EFS) - as defined in the protocol."},{"label":"2.","content":"Event-free survival (EFS) for the TKI intervention[ Time Frame: From the start of TKI (day 15 or day 30), 5 year estimates will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up for all interventions except Inotuzumab-randomisation (minimum 2-year follow-up). ]The primary endpoint for the TKI intervention is event-free survival (EFS) - as defined in the protocol, from the start of TKI until event or end of follow-up"},{"label":"3.","content":"Disease-free survival (DFS) R1 + R2[ Time Frame: 5 and 8 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 5 years follow-up. ]The primary endpoint for Randomisation 1 and 2 is disease-free survival (DFS) - as defined in the protocol counting from the time of randomisation"},{"label":"4.","content":"Disease-free survival (DFS) R3[ Time Frame: 5 year estimates from the time of randomisation will be measured but adequate follow-up for these estimates will be ensured: at least 2-year follow-up ]The primary endpoint for Randomisation 3 and the ABL-class fusion intervention is disease-free survival (DFS) - as defined in the protocol counting from the time of randomisation (R3) and the start of TKI-therapy (ABL-class fusion intervention)."},{"label":"5.","content":"MRD response after 1 cycle of Blinatumomab[ Time Frame: End of first Blinatumomab infusion +/- 1 week ]Fraction of patients with undetectable MRD (\\"Complete MRD response\\") at the end of one cycle of Blinatumomab (+/- 1 week)"}],"start_date":"July 13, 2020","primary_completion_date":"June 30, 2027","completion_date":"June 30, 2032","first_posted":"March 13, 2020","last_update_posted":"August 19, 2022"},{"nctid":"NCT02136134","version_a":31,"version_b":32,"version_a_date":"2016-12-09","version_b_date":"2016-12-20","pom_a":[{"label":"1.","content":"Percentage of participants with progression-free survival (PFS)[ Time Frame: Baseline, up to the end of the study, an expected average of 3 years ]PFS is defined as a duration from the date of randomization to either progressive disease or death, whichever occurs first."}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From the date of randomization to either progressive disease or death, whichever occurs first (approximately 3 years) ]PFS was defined as duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD was defined as meeting any one of following criteria: Increase of greater than equal to (>=)25 percent (%) in level of serum M-protein from lowest response value and absolute increase must be >=0.5 gram per deciliter (g/dL); Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be >10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to PC proliferative disorder."}],"start_date":"August 2014","primary_completion_date":"January 2016","completion_date":"June 2024","first_posted":"May 12, 2014","results_first_posted":"February 10, 2017","last_update_posted":"September 7, 2022"},{"nctid":"NCT00949650","version_a":47,"version_b":48,"version_a_date":"2013-01-09","version_b_date":"2013-10-25","pom_a":[{"label":"1.","content":"The primary endpoint will be progression free survival, as determined by RECIST 1.1.[ Time Frame: 2 years ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS) Time[ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks or until death ]PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates. Only data collected until the primary endpoint analysis cut-off date (09 February 2012) were considered."}],"start_date":"August 14, 2009","primary_completion_date":"February 9, 2012","completion_date":"March 16, 2017","first_posted":"July 30, 2009","results_first_posted":"November 19, 2013","last_update_posted":"April 6, 2018"},{"nctid":"NCT00949650","version_a":56,"version_b":57,"version_a_date":"2017-03-27","version_b_date":"2018-03-09","pom_a":[{"label":"1.","content":"Progression-free Survival (PFS) Time[ Time Frame: Tumour assessments were performed at screening, Week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks or until death ]PFS is defined as time from randomisation to disease progression or death whichever occurs first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates. Only data collected until the primary endpoint analysis cut-off date (09 February 2012) were considered."}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) Time[ Time Frame: Tumour assessments were performed at Screening, Week 6, Week 12, Week 18 and then every 12-18 weeks until disease progression ]PFS was defined as time from randomisation to disease progression or death whichever occured first. Assessed by central independent review according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1). Median time results from unstratified Kaplan-Meier estimates."}],"start_date":"August 14, 2009","primary_completion_date":"February 9, 2012","completion_date":"March 16, 2017","first_posted":"July 30, 2009","results_first_posted":"November 19, 2013","last_update_posted":"April 6, 2018"},{"nctid":"NCT04512235","version_a":22,"version_b":23,"version_a_date":"2021-07-30","version_b_date":"2021-11-11","pom_a":[{"label":"1.","content":"Time from the first dose of study drug until death or end of study[ Time Frame: 50 weeks ]"},{"label":"2.","content":"Number of patients with treatment emergent adverse events as assessed by CTCAE v5.0[ Time Frame: 50 weeks ]"}],"pom_b":[{"label":"1.","content":"Time from the date of randomization to date of death or end of study[ Time Frame: 50 weeks ]"},{"label":"2.","content":"Number of patients with treatment emergent adverse events as assessed by CTCAE v5.0[ Time Frame: 50 weeks ]"}],"start_date":"November 12, 2020","primary_completion_date":"March 15, 2025","completion_date":"March 15, 2025","first_posted":"August 13, 2020","last_update_posted":"August 8, 2022"},{"nctid":"NCT01064466","version_a":7,"version_b":8,"version_a_date":"2011-01-15","version_b_date":"2011-03-28","pom_a":[{"label":"1.","content":"Drug Targets SNP Genotyping[ Time Frame: 2 week ]"}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness as well as which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after 2 years used the Combined Chemotherapy including ETOPOSIDE INJECTION.Assay above every specific SCLC patient\'s Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays.Assay above every SCLC specific patient\'s Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":13,"version_b":14,"version_a_date":"2011-04-16","version_b_date":"2011-04-28","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness as well as which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after 2 years used the Combined Chemotherapy including ETOPOSIDE INJECTION.Assay above every specific SCLC patient\'s Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays.Assay above every SCLC specific patient\'s Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness and which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy including ETOPOSIDE INJECTION.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":27,"version_b":28,"version_a_date":"2012-10-16","version_b_date":"2013-01-24","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness and which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy including ETOPOSIDE INJECTION.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with (Biochips-Based) High Throughput Microarray SNP Genotyping Assays."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness and which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":30,"version_b":31,"version_a_date":"2013-01-31","version_b_date":"2013-07-11","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are relative to maximizing effectiveness and which are relative to minimizing risk.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION, like as the usual approach group.Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Single Chemotherapy on ETOPOSIDE INJECTION, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":53,"version_b":54,"version_a_date":"2016-08-06","version_b_date":"2017-01-16","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION, like as the usual approach group.Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Single Chemotherapy on ETOPOSIDE INJECTION, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION, like as the usual approach group.Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":58,"version_b":59,"version_a_date":"2017-03-02","version_b_date":"2017-05-22","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION, like as the usual approach group.Recruit 400 selected specific SCLC patients who are still surviving currently after at least 2 years used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION after local therapy with surgery, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION after local therapy with surgery, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":61,"version_b":62,"version_a_date":"2017-11-20","version_b_date":"2018-08-14","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CISPLATIN INJECTION after local therapy with surgery, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION after local therapy with surgery, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Injection plus Methotrexate Injection plus Topotecan Injection after local therapy with surgery, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after local therapy with surgery, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with Oxford precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":76,"version_b":77,"version_a_date":"2020-01-23","version_b_date":"2020-02-11","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Injection plus Methotrexate Injection plus Topotecan Injection after local therapy with surgery, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after local therapy with surgery, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with Oxford precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Injection plus Methotrexate Injection plus Topotecan Injection after lung tissue biopsy, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after lung tissue biopsy, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with Oxford precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT01064466","version_a":79,"version_b":80,"version_a_date":"2021-08-30","version_b_date":"2022-09-10","pom_a":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Injection plus Methotrexate Injection plus Topotecan Injection after lung tissue biopsy, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after lung tissue biopsy, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with Oxford precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing."}],"pom_b":[{"label":"1.","content":"Find Etoposide Drug Targets\' SNP Genotypes which are effectiveness-associated and which are risk-associated.[ Time Frame: Duration at least 180 days ]Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Injection plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after lung tissue biopsy, like as the usual approach group.Recruit 300 double blind random group separated SCLC patients currently used the Combined Chemotherapy on Etoposide Capsule plus Methotrexate Tablet plus HYCAMTIN - Topotecan Capsule after lung tissue biopsy, like as the study approach group.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (Topoisomerase II) SNP genotype in his or her SCLC cell whole genome DNA with Oxford precisely sequencing.Assay above every SCLC patient-specific Etoposide (VP-16) drug target (CYP4503A4) SNP genotype in his or her WBC cell whole genome DNA with Oxford precisely sequencing."}],"start_date":"January 2017","primary_completion_date":"November 2023","completion_date":"December 2023","first_posted":"February 8, 2010","last_update_posted":"September 14, 2022"},{"nctid":"NCT02954172","version_a":2,"version_b":3,"version_a_date":"2017-03-13","version_b_date":"2019-01-29","pom_a":[{"label":"1.","content":"objective response rate[ Time Frame: 18 months ]"}],"pom_b":[{"label":"1.","content":"objective response rate[ Time Frame: 18 weeks ]"}],"start_date":"November 28, 2016","primary_completion_date":"October 19, 2018","completion_date":"November 12, 2019","first_posted":"November 3, 2016","results_first_posted":"December 8, 2020","last_update_posted":"December 8, 2020"},{"nctid":"NCT02954172","version_a":3,"version_b":4,"version_a_date":"2019-01-29","version_b_date":"2020-11-12","pom_a":[{"label":"1.","content":"objective response rate[ Time Frame: 18 weeks ]"}],"pom_b":[{"label":"1.","content":"Objective Response Rate[ Time Frame: 18 weeks ]ORR\uff08objective response rate\uff09was defined as the percentage of participants in the analysis population who had a Complete Response or a Partial Response per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented. Overall Response (OR) = CR + PR."}],"start_date":"November 28, 2016","primary_completion_date":"October 19, 2018","completion_date":"November 12, 2019","first_posted":"November 3, 2016","results_first_posted":"December 8, 2020","last_update_posted":"December 8, 2020"},{"nctid":"NCT01931150","version_a":1,"version_b":2,"version_a_date":"2013-08-28","version_b_date":"2013-12-23","pom_a":[{"label":"1.","content":"difference in lesion counts[ Time Frame: 6 weeks ]For each side of the face and chest, lesion counts will be completed in real-time by observers blinded to the treatment status. These real-time lesion counts will be used to assess the primary endpoint."}],"pom_b":[{"label":"1.","content":"difference in lesion counts[ Time Frame: 28 \xb1 2 days ]Lesion counts at day 28 \xb1 2 days (primary endpoint)"}],"start_date":"August 2013","primary_completion_date":"September 2015","completion_date":"September 2015","first_posted":"August 29, 2013","results_first_posted":"January 13, 2017","last_update_posted":"January 13, 2017"},{"nctid":"NCT01931150","version_a":6,"version_b":7,"version_a_date":"2015-09-10","version_b_date":"2016-11-18","pom_a":[{"label":"1.","content":"difference in lesion counts[ Time Frame: 28 \xb1 2 days ]Lesion counts at day 28 \xb1 2 days (primary endpoint)"}],"pom_b":[{"label":"1.","content":"Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions[ Time Frame: 28 days ]Change from Baseline in the Number of Lesions at 28 days"}],"start_date":"August 2013","primary_completion_date":"September 2015","completion_date":"September 2015","first_posted":"August 29, 2013","results_first_posted":"January 13, 2017","last_update_posted":"January 13, 2017"},{"nctid":"NCT00418886","version_a":11,"version_b":12,"version_a_date":"2007-12-13","version_b_date":"2007-12-16","pom_a":[{"label":"1.","content":"Demonstrate an improvement in progression-free survival for the combination of ZD6474 plus pemetrexed compared with pemetrexed plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy"}],"pom_b":[{"label":"1.","content":"Demonstrate an improvement in progression-free survival for the combination of ZD6474 (vandetanib) plus pemetrexed compared with pemetrexed plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy[ Time Frame: Time until death ]"}],"start_date":"January 2007","primary_completion_date":"September 2008","completion_date":"December 31, 2022","first_posted":"January 5, 2007","results_first_posted":"March 26, 2012","last_update_posted":"November 1, 2021"},{"nctid":"NCT00418886","version_a":24,"version_b":25,"version_a_date":"2010-01-14","version_b_date":"2010-03-10","pom_a":[{"label":"1.","content":"Demonstrate an improvement in progression-free survival for the combination of ZD6474 (vandetanib) plus pemetrexed compared with pemetrexed plus placebo in patients with locally advanced or metastatic NSCLC after failure of 1st line anti-cancer therapy[ Time Frame: Time until death ]"}],"pom_b":[{"label":"1.","content":"Demonstrate an improvement in progression-free survival for ZD6474 (vandetanib) plus pemetrexed compared to pemetrexed plus placebo in patients with locally advanced/metastatic NSCLC after failure of 1st line therapy in the overall and female population[ Time Frame: Time until progression or death ]"}],"start_date":"January 2007","primary_completion_date":"September 2008","completion_date":"December 31, 2022","first_posted":"January 5, 2007","results_first_posted":"March 26, 2012","last_update_posted":"November 1, 2021"},{"nctid":"NCT00418886","version_a":25,"version_b":26,"version_a_date":"2010-03-10","version_b_date":"2012-02-22","pom_a":[{"label":"1.","content":"Demonstrate an improvement in progression-free survival for ZD6474 (vandetanib) plus pemetrexed compared to pemetrexed plus placebo in patients with locally advanced/metastatic NSCLC after failure of 1st line therapy in the overall and female population[ Time Frame: Time until progression or death ]"}],"pom_b":[{"label":"1.","content":"Progression-Free Survival (PFS) in the Overall Population[ Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression ]Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment"},{"label":"2.","content":"Progression-Free Survival (PFS) in the Female Population[ Time Frame: RECIST tumour assessments carried out every 6 weeks (+/- 3 days) from randomisation until objective progression ]Median time (in weeks) from randomisation until objective disease progression or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment"}],"start_date":"January 2007","primary_completion_date":"September 2008","completion_date":"December 31, 2022","first_posted":"January 5, 2007","results_first_posted":"March 26, 2012","last_update_posted":"November 1, 2021"},{"nctid":"NCT03504410","version_a":1,"version_b":2,"version_a_date":"2018-04-19","version_b_date":"2018-04-19","pom_a":[{"label":"1.","content":"Complete Remission (CR)[ Time Frame: 12 months ]"}],"pom_b":[{"label":"1.","content":"Complete Remission (CR)[ Time Frame: 12 months ]Complete disappearance of all clinical evidence of disease"}],"start_date":"November 12, 2018","primary_completion_date":"August 13, 2021","completion_date":"August 13, 2021","first_posted":"April 20, 2018","last_update_posted":"July 27, 2022"},{"nctid":"NCT03504410","version_a":3,"version_b":4,"version_a_date":"2018-09-07","version_b_date":"2018-10-18","pom_a":[{"label":"1.","content":"Complete Remission (CR)[ Time Frame: 12 months ]Complete disappearance of all clinical evidence of disease"}],"pom_b":[{"label":"1.","content":"Complete Remission (CR)[ Time Frame: 8 months ]Complete disappearance of all clinical evidence of disease"}],"start_date":"November 12, 2018","primary_completion_date":"August 13, 2021","completion_date":"August 13, 2021","first_posted":"April 20, 2018","last_update_posted":"July 27, 2022"},{"nctid":"NCT00753688","version_a":1,"version_b":2,"version_a_date":"2008-09-15","version_b_date":"2008-12-04","pom_a":[{"label":"1.","content":"To investigate whether treatment with pazopanib improves the outcome of patients with metastatic soft tissue sarcoma when compared to placebo."}],"pom_b":[{"label":"1.","content":"To investigate whether treatment with pazopanib improves the outcome of patients with metastatic soft tissue sarcoma when compared to placebo.[ Time Frame: during study ]"}],"start_date":"October 2008","primary_completion_date":"November 2010","completion_date":"December 2012","first_posted":"September 16, 2008","results_first_posted":"December 21, 2011","last_update_posted":"August 22, 2013"},{"nctid":"NCT00753688","version_a":78,"version_b":79,"version_a_date":"2011-10-06","version_b_date":"2011-11-17","pom_a":[{"label":"1.","content":"To investigate whether treatment with pazopanib improves the outcome of patients with metastatic soft tissue sarcoma when compared to placebo.[ Time Frame: during study ]"}],"pom_b":[{"label":"1.","content":"Progression-free Survival (PFS)[ Time Frame: From the date of randomization until the date of the first documented radiological progression or date of death from any cause, whichever came first (assessed for an average of 10 months) ]PFS was defined as the time interval between the date of randomization and the earliest date of either disease progression or death due to any cause. The diagnosis of progression was based on tumor measurements, according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0 criteria, by independent radiologic assessment. The Kaplan-Meier method was used for PFS estimates."}],"start_date":"October 2008","primary_completion_date":"November 2010","completion_date":"December 2012","first_posted":"September 16, 2008","results_first_posted":"December 21, 2011","last_update_posted":"August 22, 2013"},{"nctid":"NCT00656448","version_a":2,"version_b":3,"version_a_date":"2008-08-26","version_b_date":"2009-02-18","pom_a":[{"label":"1.","content":"To investigate whether Procrit will decrease the number and frequency of packed red blood cell transfusions in patients with AML or high-risk MDS (HR-MDS) during frontline myelosuppressive induction and/or consolidation chemotherapy.[ Time Frame: December 2009 ]"}],"pom_b":[{"label":"1.","content":"To investigate whether Procrit will decrease the number and frequency of packed red blood cell transfusions in patients with AML or high-risk MDS (HR-MDS) during frontline myelosuppressive induction and/or consolidation chemotherapy.[ Time Frame: February 2010 ]"}],"start_date":"March 2008","primary_completion_date":"June 2013","completion_date":"June 2013","first_posted":"April 11, 2008","results_first_posted":"December 23, 2013","last_update_posted":"May 30, 2018"},{"nctid":"NCT00656448","version_a":3,"version_b":4,"version_a_date":"2009-02-18","version_b_date":"2009-08-13","pom_a":[{"label":"1.","content":"To investigate whether Procrit will decrease the number and frequency of packed red blood cell transfusions in patients with AML or high-risk MDS (HR-MDS) during frontline myelosuppressive induction and/or consolidation chemotherapy.[ Time Frame: February 2010 ]"}],"pom_b":[{"label":"1.","content":"Number of transfusions (trn) required during the 12 weeks of treatment.[ Time Frame: 12 weeks ]"}],"start_date":"March 2008","primary_completion_date":"June 2013","completion_date":"June 2013","first_posted":"April 11, 2008","results_first_posted":"December 23, 2013","last_update_posted":"May 30, 2018"},{"nctid":"NCT00656448","version_a":11,"version_b":12,"version_a_date":"2013-06-24","version_b_date":"2013-11-04","pom_a":[{"label":"1.","content":"Number of transfusions (trn) required during the 12 weeks of treatment.[ Time Frame: 12 weeks ]"}],"pom_b":[{"label":"1.","content":"Median Number of Participant Transfusions Required During 12 Weeks of Treatment[ Time Frame: 12 weeks ]The number and frequency of packed red blood cells (PRBC) transfusions assessed and compared between two groups, treatment group (\\"Procrit\\") and standard care group (\\"No Procrit\\"). Participants log all PRBC transfusions. Reported are the number of transfusions in the treatment arm during induction and consolidation chemotherapy with the concomitant use of epoetin alfa during therapy, and in the standard arm those that occured during same 12 week period."}],"start_date":"March 2008","primary_completion_date":"June 2013","completion_date":"June 2013","first_posted":"April 11, 2008","results_first_posted":"December 23, 2013","last_update_posted":"May 30, 2018"},{"nctid":"NCT01368588","version_a":90,"version_b":91,"version_a_date":"2012-09-29","version_b_date":"2013-07-17","pom_a":[{"label":"1.","content":"Overall survival of patients treated with NADT and RT vs NADT and WPRT"}],"pom_b":[{"label":"1.","content":"Overall Survival[ Time Frame: From date of randomization to the date of death. ]"}],"start_date":"July 2011","primary_completion_date":"July 2027","completion_date":"July 2031","first_posted":"June 8, 2011","last_update_posted":"April 8, 2022"},{"nctid":"NCT03538171","version_a":2,"version_b":3,"version_a_date":"2018-06-04","version_b_date":"2019-05-03","pom_a":[{"label":"1.","content":"Cmax (The Open-label Part)[ Time Frame: Run-in Period Day 1, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h; Run-in Period Day 2, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h. ]Maximum Plasma Concentration"},{"label":"2.","content":"Tmax (The Open-label Part)[ Time Frame: Run-in Period Day 1, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h; Run-in Period Day 2, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h. ]Time at which maximum plasma concentration was observed."},{"label":"3.","content":"AUC 0-168h(The Open-label Part)[ Time Frame: Run-in Period Day 1, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h; Run-in Period Day 2, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h. ]area under the plasma concentration-time curve from time zero to 168h"},{"label":"4.","content":"AUC 0-inf(The Open-label Part)[ Time Frame: Run-in Period Day 1, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h; Run-in Period Day 2, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h. ]Area under the plasma concentration-time curve from time zero to infinity."},{"label":"5.","content":"T1/2(The Open-label Part)[ Time Frame: Run-in Period Day 1, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h; Run-in Period Day 2, -5min, 0.25\u30010.5\u30010.75\u30011\u30012\u30014\u30018\u300112\u300124h. ]Elimination Half-life"},{"label":"6.","content":"PFS (The Randomized Double-blinded Part)[ Time Frame: From the day of randomization, assessment will be made every 8 weeks (\xb13 days) to the earliest of documented disease progression (PD) or death caused by any reason (whichever happens first), assessed up to 40 months. ]Progression Free Survival, defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). The distribution of PFS will be estimated using the Kaplan- Meier method, with 95% confidence intervals calculated using Greenwood\'s formula. In the primary analysis of PFS, differences in treatment effect will be tested using stratified log rank tests, stratifying on the randomization stratification factors. Stratified univariate and multivariable Cox proportional-hazard models will be built to estimate the hazard ratios (HRs) for treatment effect for PFS as a supportive analysis. In all analyses, P-values will be two-sided."},{"label":"7.","content":"OS (The Randomized Double-blinded Part)[ Time Frame: From the day of randomization to the date of death from any cause,assessed up to 54 months. ]Overall Survival"}],"pom_b":[{"label":"1.","content":"PFS (The Randomized Double-blinded Part)[ Time Frame: From the day of randomization, assessment will be made every 8 weeks (\xb13 days) to the earliest of documented disease progression (PD) or death caused by any reason (whichever happens first), assessed up to 40 months. ]Progression Free Survival, defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1). The distribution of PFS will be estimated using the Kaplan- Meier method, with 95% confidence intervals calculated using Greenwood\'s formula. In the primary analysis of PFS, differences in treatment effect will be tested using stratified log rank tests, stratifying on the randomization stratification factors. Stratified univariate and multivariable Cox proportional-hazard models will be built to estimate the hazard ratios (HRs) for treatment effect for PFS as a supportive analysis. In all analyses, P-values will be two-sided."}],"start_date":"May 15, 2018","primary_completion_date":"July 2021","completion_date":"March 2023","first_posted":"May 29, 2018","last_update_posted":"July 9, 2021"},{"nctid":"NCT01170663","version_a":1,"version_b":2,"version_a_date":"2010-07-26","version_b_date":"2010-09-01","pom_a":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: 32 months ]Randomization to date of death from any cause"}],"pom_b":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: 32 months (placeholder actual timeframe driven by events) ]Overall survival time is measured as randomization to date of death from any cause."}],"start_date":"December 2010","primary_completion_date":"July 2013","completion_date":"February 2017","first_posted":"July 27, 2010","results_first_posted":"July 31, 2014","last_update_posted":"September 18, 2019"},{"nctid":"NCT01170663","version_a":2,"version_b":3,"version_a_date":"2010-09-01","version_b_date":"2010-09-10","pom_a":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: 32 months (placeholder actual timeframe driven by events) ]Overall survival time is measured as randomization to date of death from any cause."}],"pom_b":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: Approximately 32 months ]Overall survival time is measured as randomization to date of death from any cause."}],"start_date":"December 2010","primary_completion_date":"July 2013","completion_date":"February 2017","first_posted":"July 27, 2010","results_first_posted":"July 31, 2014","last_update_posted":"September 18, 2019"},{"nctid":"NCT01170663","version_a":29,"version_b":30,"version_a_date":"2013-08-14","version_b_date":"2014-07-01","pom_a":[{"label":"1.","content":"Overall survival time (OS)[ Time Frame: Approximately 32 months ]Overall survival time is measured as randomization to date of death from any cause."}],"pom_b":[{"label":"1.","content":"Overall Survival Time (OS)[ Time Frame: Randomization up to 27.5 months ]OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive."}],"start_date":"December 2010","primary_completion_date":"July 2013","completion_date":"February 2017","first_posted":"July 27, 2010","results_first_posted":"July 31, 2014","last_update_posted":"September 18, 2019"},{"nctid":"NCT04214262","version_a":252,"version_b":253,"version_a_date":"2022-07-23","version_b_date":"2022-08-09","pom_a":[{"label":"1.","content":"Overall survival[ Time Frame: 3 years ]Will compare overall survival between patients with inoperable, T1, T2, limited T3, N0M0 (early stage) non-small cell lung cancer randomized to stereotactic body radiation therapy with or without atezolizumab. Will be evaluated using the method of Kaplan-Meier. For point estimates at landmark times, the associated 95% confidence interval (CI) will be calculated using Greenwood\'s formula and based on a log-log transformation applied on the survival function. Hazard ratios for these outcomes will be estimated using a Cox Proportional Hazards regression model and estimated using a stratified Cox regression model."}],"pom_b":[{"label":"1.","content":"Overall survival[ Time Frame: From date of randomization to date of death due to any cause, assessed up to 3 years ]Will compare overall survival between patients with inoperable, T1, T2, limited T3, N0M0 (early stage) non-small cell lung cancer randomized to stereotactic body radiation therapy with or without atezolizumab. Will be evaluated using the method of Kaplan-Meier. For point estimates at landmark times, the associated 95% confidence interval (CI) will be calculated using Greenwood\'s formula and based on a log-log transformation applied on the survival function. Hazard ratios for these outcomes will be estimated using a Cox Proportional Hazards regression model and estimated using a stratified Cox regression model."}],"start_date":"March 25, 2020","primary_completion_date":"May 1, 2028","completion_date":"May 1, 2028","first_posted":"January 2, 2020","last_update_posted":"September 19, 2022"}]}'),Y=n(1184);var X=e.createContext(),ee=n(5878);function te(e){return(0,C.Z)("MuiGrid",e)}var ne=["auto",!0,1,2,3,4,5,6,7,8,9,10,11,12],re=(0,ee.Z)("MuiGrid",["root","container","item","zeroMinWidth"].concat((0,j.Z)([0,1,2,3,4,5,6,7,8,9,10].map((function(e){return"spacing-xs-".concat(e)}))),(0,j.Z)(["column-reverse","column","row-reverse","row"].map((function(e){return"direction-xs-".concat(e)}))),(0,j.Z)(["nowrap","wrap-reverse","wrap"].map((function(e){return"wrap-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xs-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-sm-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-md-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-lg-".concat(e)}))),(0,j.Z)(ne.map((function(e){return"grid-xl-".concat(e)}))))),ae=re,oe=["className","columns","columnSpacing","component","container","direction","item","rowSpacing","spacing","wrap","zeroMinWidth"];function ie(e){var t=parseFloat(e);return"".concat(t).concat(String(e).replace(String(t),"")||"px")}function se(e){var t=e.breakpoints,n=e.values,r="";Object.keys(n).forEach((function(e){""===r&&0!==n[e]&&(r=e)}));var a=Object.keys(t).sort((function(e,n){return t[e]-t[n]}));return a.slice(0,a.indexOf(r))}var le=(0,M.ZP)("div",{name:"MuiGrid",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState,r=n.container,a=n.direction,o=n.item,i=n.spacing,s=n.wrap,l=n.zeroMinWidth,u=n.breakpoints,c=[];r&&(c=function(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:{};if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return[n["spacing-xs-".concat(String(e))]];var r=[];return t.forEach((function(t){var a=e[t];Number(a)>0&&r.push(n["spacing-".concat(t,"-").concat(String(a))])})),r}(i,u,t));var d=[];return u.forEach((function(e){var r=n[e];r&&d.push(t["grid-".concat(e,"-").concat(String(r))])})),[t.root,r&&t.container,o&&t.item,l&&t.zeroMinWidth].concat((0,j.Z)(c),["row"!==a&&t["direction-xs-".concat(String(a))],"wrap"!==s&&t["wrap-xs-".concat(String(s))]],d)}})((function(e){var t=e.ownerState;return(0,r.Z)({boxSizing:"border-box"},t.container&&{display:"flex",flexWrap:"wrap",width:"100%"},t.item&&{margin:0},t.zeroMinWidth&&{minWidth:0},"wrap"!==t.wrap&&{flexWrap:t.wrap})}),(function(e){var t=e.theme,n=e.ownerState,r=(0,Y.P$)({values:n.direction,breakpoints:t.breakpoints.values});return(0,Y.k9)({theme:t},r,(function(e){var t={flexDirection:e};return 0===e.indexOf("column")&&(t["& > .".concat(ae.item)]={maxWidth:"none"}),t}))}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.rowSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({marginTop:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingTop:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({marginTop:0},"& > .".concat(ae.item),{paddingTop:0})}))}return o}),(function(e){var t=e.theme,n=e.ownerState,r=n.container,a=n.columnSpacing,o={};if(r&&0!==a){var i,s=(0,Y.P$)({values:a,breakpoints:t.breakpoints.values});"object"===typeof s&&(i=se({breakpoints:t.breakpoints.values,values:s})),o=(0,Y.k9)({theme:t},s,(function(e,n){var r,a=t.spacing(e);return"0px"!==a?(0,_.Z)({width:"calc(100% + ".concat(ie(a),")"),marginLeft:"-".concat(ie(a))},"& > .".concat(ae.item),{paddingLeft:ie(a)}):null!=(r=i)&&r.includes(n)?{}:(0,_.Z)({width:"100%",marginLeft:0},"& > .".concat(ae.item),{paddingLeft:0})}))}return o}),(function(e){var t,n=e.theme,a=e.ownerState;return n.breakpoints.keys.reduce((function(e,o){var i={};if(a[o]&&(t=a[o]),!t)return e;if(!0===t)i={flexBasis:0,flexGrow:1,maxWidth:"100%"};else if("auto"===t)i={flexBasis:"auto",flexGrow:0,flexShrink:0,maxWidth:"none",width:"auto"};else{var s=(0,Y.P$)({values:a.columns,breakpoints:n.breakpoints.values}),l="object"===typeof s?s[o]:s;if(void 0===l||null===l)return e;var u="".concat(Math.round(t/l*1e8)/1e6,"%"),c={};if(a.container&&a.item&&0!==a.columnSpacing){var d=n.spacing(a.columnSpacing);if("0px"!==d){var p="calc(".concat(u," + ").concat(ie(d),")");c={flexBasis:p,maxWidth:p}}}i=(0,r.Z)({flexBasis:u,flexGrow:0,maxWidth:u},c)}return 0===n.breakpoints.values[o]?Object.assign(e,i):e[n.breakpoints.up(o)]=i,e}),{})}));var ue=function(e){var t=e.classes,n=e.container,r=e.direction,a=e.item,o=e.spacing,i=e.wrap,s=e.zeroMinWidth,l=e.breakpoints,u=[];n&&(u=function(e,t){if(!e||e<=0)return[];if("string"===typeof e&&!Number.isNaN(Number(e))||"number"===typeof e)return["spacing-xs-".concat(String(e))];var n=[];return t.forEach((function(t){var r=e[t];if(Number(r)>0){var a="spacing-".concat(t,"-").concat(String(r));n.push(a)}})),n}(o,l));var c=[];l.forEach((function(t){var n=e[t];n&&c.push("grid-".concat(t,"-").concat(String(n)))}));var d={root:["root",n&&"container",a&&"item",s&&"zeroMinWidth"].concat((0,j.Z)(u),["row"!==r&&"direction-xs-".concat(String(r)),"wrap"!==i&&"wrap-xs-".concat(String(i))],c)};return(0,T.Z)(d,te,t)},ce=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiGrid"}),i=(0,U.Z)(m.Z).breakpoints,s=V(o),l=s.className,u=s.columns,c=s.columnSpacing,d=s.component,f=void 0===d?"div":d,h=s.container,v=void 0!==h&&h,y=s.direction,b=void 0===y?"row":y,g=s.item,_=void 0!==g&&g,k=s.rowSpacing,C=s.spacing,T=void 0===C?0:C,x=s.wrap,P=void 0===x?"wrap":x,E=s.zeroMinWidth,A=void 0!==E&&E,N=(0,w.Z)(s,oe),F=k||T,O=c||T,R=e.useContext(X),D=v?u||12:R,M={},I=(0,r.Z)({},N);i.keys.forEach((function(e){null!=N[e]&&(M[e]=N[e],delete I[e])}));var z=(0,r.Z)({},s,{columns:D,container:v,direction:b,item:_,rowSpacing:F,columnSpacing:O,wrap:P,zeroMinWidth:A,spacing:T},M,{breakpoints:i.keys}),L=ue(z);return(0,p.jsx)(X.Provider,{value:D,children:(0,p.jsx)(le,(0,r.Z)({ownerState:z,className:(0,S.Z)(L.root,l),as:f,ref:n},I))})})),de=ce,pe=n(2065);function fe(e){return(0,C.Z)("MuiPaper",e)}(0,ee.Z)("MuiPaper",["root","rounded","outlined","elevation","elevation0","elevation1","elevation2","elevation3","elevation4","elevation5","elevation6","elevation7","elevation8","elevation9","elevation10","elevation11","elevation12","elevation13","elevation14","elevation15","elevation16","elevation17","elevation18","elevation19","elevation20","elevation21","elevation22","elevation23","elevation24"]);var me=["className","component","elevation","square","variant"],he=function(e){return((e<1?5.11916*Math.pow(e,2):4.5*Math.log(e+1)+2)/100).toFixed(2)},ve=(0,M.ZP)("div",{name:"MuiPaper",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t[n.variant],!n.square&&t.rounded,"elevation"===n.variant&&t["elevation".concat(n.elevation)]]}})((function(e){var t,n=e.theme,a=e.ownerState;return(0,r.Z)({backgroundColor:(n.vars||n).palette.background.paper,color:(n.vars||n).palette.text.primary,transition:n.transitions.create("box-shadow")},!a.square&&{borderRadius:n.shape.borderRadius},"outlined"===a.variant&&{border:"1px solid ".concat((n.vars||n).palette.divider)},"elevation"===a.variant&&(0,r.Z)({boxShadow:(n.vars||n).shadows[a.elevation]},!n.vars&&"dark"===n.palette.mode&&{backgroundImage:"linear-gradient(".concat((0,pe.Fq)("#fff",he(a.elevation)),", ").concat((0,pe.Fq)("#fff",he(a.elevation)),")")},n.vars&&{backgroundImage:null==(t=n.vars.overlays)?void 0:t[a.elevation]}))})),ye=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiPaper"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.elevation,u=void 0===l?1:l,c=n.square,d=void 0!==c&&c,f=n.variant,m=void 0===f?"elevation":f,h=(0,w.Z)(n,me),v=(0,r.Z)({},n,{component:s,elevation:u,square:d,variant:m}),y=function(e){var t=e.square,n=e.elevation,r=e.variant,a=e.classes,o={root:["root",r,!t&&"rounded","elevation"===r&&"elevation".concat(n)]};return(0,T.Z)(o,fe,a)}(v);return(0,p.jsx)(ve,(0,r.Z)({as:s,ownerState:v,className:(0,S.Z)(y.root,o),ref:t},h))}));function be(e){return(0,C.Z)("MuiCard",e)}(0,ee.Z)("MuiCard",["root"]);var ge=["className","raised"],_e=(0,M.ZP)(ye,{name:"MuiCard",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{overflow:"hidden"}})),we=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCard"}),o=n.className,i=n.raised,s=void 0!==i&&i,l=(0,w.Z)(n,ge),u=(0,r.Z)({},n,{raised:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},be,t)}(u);return(0,p.jsx)(_e,(0,r.Z)({className:(0,S.Z)(c.root,o),elevation:s?8:void 0,ref:t,ownerState:u},l))}));function Se(e){return(0,C.Z)("MuiCardContent",e)}(0,ee.Z)("MuiCardContent",["root"]);var ke=["className","component"],Ce=(0,M.ZP)("div",{name:"MuiCardContent",slot:"Root",overridesResolver:function(e,t){return t.root}})((function(){return{padding:16,"&:last-child":{paddingBottom:24}}})),Te=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiCardContent"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=(0,w.Z)(n,ke),u=(0,r.Z)({},n,{component:s}),c=function(e){var t=e.classes;return(0,T.Z)({root:["root"]},Se,t)}(u);return(0,p.jsx)(Ce,(0,r.Z)({as:s,className:(0,S.Z)(c.root,o),ownerState:u,ref:t},l))}));function xe(e){return(0,C.Z)("MuiTypography",e)}(0,ee.Z)("MuiTypography",["root","h1","h2","h3","h4","h5","h6","subtitle1","subtitle2","body1","body2","inherit","button","caption","overline","alignLeft","alignRight","alignCenter","alignJustify","noWrap","gutterBottom","paragraph"]);var Pe=["align","className","component","gutterBottom","noWrap","paragraph","variant","variantMapping"],Ee=(0,M.ZP)("span",{name:"MuiTypography",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,n.variant&&t[n.variant],"inherit"!==n.align&&t["align".concat((0,D.Z)(n.align))],n.noWrap&&t.noWrap,n.gutterBottom&&t.gutterBottom,n.paragraph&&t.paragraph]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({margin:0},n.variant&&t.typography[n.variant],"inherit"!==n.align&&{textAlign:n.align},n.noWrap&&{overflow:"hidden",textOverflow:"ellipsis",whiteSpace:"nowrap"},n.gutterBottom&&{marginBottom:"0.35em"},n.paragraph&&{marginBottom:16})})),Ae={h1:"h1",h2:"h2",h3:"h3",h4:"h4",h5:"h5",h6:"h6",subtitle1:"h6",subtitle2:"h6",body1:"p",body2:"p",inherit:"p"},Ne={primary:"primary.main",textPrimary:"text.primary",secondary:"secondary.main",textSecondary:"text.secondary",error:"error.main"},Fe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiTypography"}),o=function(e){return Ne[e]||e}(n.color),i=V((0,r.Z)({},n,{color:o})),s=i.align,l=void 0===s?"inherit":s,u=i.className,c=i.component,d=i.gutterBottom,f=void 0!==d&&d,m=i.noWrap,h=void 0!==m&&m,v=i.paragraph,y=void 0!==v&&v,b=i.variant,g=void 0===b?"body1":b,_=i.variantMapping,k=void 0===_?Ae:_,C=(0,w.Z)(i,Pe),x=(0,r.Z)({},i,{align:l,color:o,className:u,component:c,gutterBottom:f,noWrap:h,paragraph:y,variant:g,variantMapping:k}),P=c||(y?"p":k[g]||Ae[g])||"span",E=function(e){var t=e.align,n=e.gutterBottom,r=e.noWrap,a=e.paragraph,o=e.variant,i=e.classes,s={root:["root",o,"inherit"!==e.align&&"align".concat((0,D.Z)(t)),n&&"gutterBottom",r&&"noWrap",a&&"paragraph"]};return(0,T.Z)(s,xe,i)}(x);return(0,p.jsx)(Ee,(0,r.Z)({as:P,ref:t,ownerState:x,className:(0,S.Z)(E.root,u)},C))})),Oe=n(5682),Re=["component","direction","spacing","divider","children"];function De(t,n){var r=e.Children.toArray(t).filter(Boolean);return r.reduce((function(t,a,o){return t.push(a),o<r.length-1&&t.push(e.cloneElement(n,{key:"separator-".concat(o)})),t}),[])}var Me=(0,M.ZP)("div",{name:"MuiStack",slot:"Root",overridesResolver:function(e,t){return[t.root]}})((function(e){var t=e.ownerState,n=e.theme,a=(0,r.Z)({display:"flex",flexDirection:"column"},(0,Y.k9)({theme:n},(0,Y.P$)({values:t.direction,breakpoints:n.breakpoints.values}),(function(e){return{flexDirection:e}})));if(t.spacing){var o=(0,Oe.hB)(n),i=Object.keys(n.breakpoints.values).reduce((function(e,n){return("object"===typeof t.spacing&&null!=t.spacing[n]||"object"===typeof t.direction&&null!=t.direction[n])&&(e[n]=!0),e}),{}),s=(0,Y.P$)({values:t.direction,base:i}),l=(0,Y.P$)({values:t.spacing,base:i});"object"===typeof s&&Object.keys(s).forEach((function(e,t,n){if(!s[e]){var r=t>0?s[n[t-1]]:"column";s[e]=r}}));a=(0,B.Z)(a,(0,Y.k9)({theme:n},l,(function(e,n){return{"& > :not(style) + :not(style)":(0,_.Z)({margin:0},"margin".concat((r=n?s[n]:t.direction,{row:"Left","row-reverse":"Right",column:"Top","column-reverse":"Bottom"}[r])),(0,Oe.NA)(o,e))};var r})))}return a=(0,Y.dt)(n.breakpoints,a)})),Ie=e.forwardRef((function(e,t){var n=V((0,a.Z)({props:e,name:"MuiStack"})),o=n.component,i=void 0===o?"div":o,s=n.direction,l=void 0===s?"column":s,u=n.spacing,c=void 0===u?0:u,d=n.divider,f=n.children,m=(0,w.Z)(n,Re),h={direction:l,spacing:c};return(0,p.jsx)(Me,(0,r.Z)({as:i,ownerState:h,ref:t},m,{children:d?De(f,d):f}))})),ze=Ie,Le=n(1774),Ze=n.n(Le);var je=function(e){var t=e.datum,n=e.datumNumber,r=e.results,a=(e.setResults,t.pom_a),o=t.pom_b,i=t.version_a_date,s=t.version_b_date;console.log({datum:t});var l=function(e,t){return e.map((function(e){return(0,p.jsx)(we,{children:(0,p.jsx)(Te,{children:(0,p.jsxs)(Fe,{children:[(0,p.jsx)("b",{children:e.label})," ",e.content]})})},e.content)}))};return(0,p.jsxs)(de,{container:!0,spacing:2,children:[(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsx)(Te,{children:(0,p.jsxs)(de,{container:!0,children:[(0,p.jsxs)(de,{item:!0,xs:4,children:[(0,p.jsxs)(Fe,{variant:"h6",children:["Comparison Number ",n+1," of ",r.length]}),(0,p.jsxs)(Fe,{variant:"h4",children:["Trial ",t.nctid]})]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.first_posted?(0,p.jsxs)(Fe,{children:["First Posted: ",t.first_posted]}):null,t.start_date?(0,p.jsxs)(Fe,{children:["Start Date: ",t.start_date]}):null]}),(0,p.jsxs)(de,{item:!0,xs:4,children:[t.primary_completion_date?(0,p.jsxs)(Fe,{children:["Primary Completion Date: ",t.primary_completion_date]}):null,t.last_update_posted?(0,p.jsxs)(Fe,{children:["Last Update Posted : ",t.last_update_posted]}):null]})]})})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsxs)(Fe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_a,": ",i]}),(0,p.jsx)(Fe,{variant:"caption"}),(0,p.jsx)(ze,{spacing:1,children:l(t.pom_a)})]})})}),(0,p.jsx)(de,{item:!0,xs:6,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsxs)(Fe,{variant:"h6",children:["Primary Outcomes for Version ",t.version_b,": ",s]}),(0,p.jsx)(ze,{spacing:1,children:l(t.pom_b)})]})})}),(0,p.jsx)(de,{item:!0,xs:12,children:(0,p.jsx)(we,{children:(0,p.jsxs)(Te,{children:[(0,p.jsx)(Fe,{variant:"h6",children:"Compare the Raw Text"}),(0,p.jsx)(Ze(),{oldValue:JSON.stringify(a,void 0,4),newValue:JSON.stringify(o,void 0,4),splitView:!0,compareMethod:Le.DiffMethod.WORDS,styles:{variables:{light:{codeFoldGutterBackground:"#6F767E",codeFoldBackground:"#E2E4E5"}}},leftTitle:"Version ".concat(t.version_a),rightTitle:"Version ".concat(t.version_b)})]})})})]})};function Be(e){return(0,C.Z)("MuiAppBar",e)}(0,ee.Z)("MuiAppBar",["root","positionFixed","positionAbsolute","positionSticky","positionStatic","positionRelative","colorDefault","colorPrimary","colorSecondary","colorInherit","colorTransparent"]);var We=["className","color","enableColorOnDark","position"],Je=function(e,t){return"".concat(null==e?void 0:e.replace(")",""),", ").concat(t,")")},Ve=(0,M.ZP)(ye,{name:"MuiAppBar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,t["position".concat((0,D.Z)(n.position))],t["color".concat((0,D.Z)(n.color))]]}})((function(e){var t=e.theme,n=e.ownerState,a="light"===t.palette.mode?t.palette.grey[100]:t.palette.grey[900];return(0,r.Z)({display:"flex",flexDirection:"column",width:"100%",boxSizing:"border-box",flexShrink:0},"fixed"===n.position&&{position:"fixed",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0,"@media print":{position:"absolute"}},"absolute"===n.position&&{position:"absolute",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"sticky"===n.position&&{position:"sticky",zIndex:(t.vars||t).zIndex.appBar,top:0,left:"auto",right:0},"static"===n.position&&{position:"static"},"relative"===n.position&&{position:"relative"},!t.vars&&(0,r.Z)({},"default"===n.color&&{backgroundColor:a,color:t.palette.getContrastText(a)},n.color&&"default"!==n.color&&"inherit"!==n.color&&"transparent"!==n.color&&{backgroundColor:t.palette[n.color].main,color:t.palette[n.color].contrastText},"inherit"===n.color&&{color:"inherit"},"dark"===t.palette.mode&&!n.enableColorOnDark&&{backgroundColor:null,color:null},"transparent"===n.color&&(0,r.Z)({backgroundColor:"transparent",color:"inherit"},"dark"===t.palette.mode&&{backgroundImage:"none"})),t.vars&&(0,r.Z)({},"default"===n.color&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette.AppBar.defaultBg:Je(t.vars.palette.AppBar.darkBg,t.vars.palette.AppBar.defaultBg),"--AppBar-color":n.enableColorOnDark?t.vars.palette.text.primary:Je(t.vars.palette.AppBar.darkColor,t.vars.palette.text.primary)},n.color&&!n.color.match(/^(default|inherit|transparent)$/)&&{"--AppBar-background":n.enableColorOnDark?t.vars.palette[n.color].main:Je(t.vars.palette.AppBar.darkBg,t.vars.palette[n.color].main),"--AppBar-color":n.enableColorOnDark?t.vars.palette[n.color].contrastText:Je(t.vars.palette.AppBar.darkColor,t.vars.palette[n.color].contrastText)},{backgroundColor:"var(--AppBar-background)",color:"inherit"===n.color?"inherit":"var(--AppBar-color)"},"transparent"===n.color&&{backgroundImage:"none",backgroundColor:"transparent",color:"inherit"}))})),Ue=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiAppBar"}),o=n.className,i=n.color,s=void 0===i?"primary":i,l=n.enableColorOnDark,u=void 0!==l&&l,c=n.position,d=void 0===c?"fixed":c,f=(0,w.Z)(n,We),m=(0,r.Z)({},n,{color:s,position:d,enableColorOnDark:u}),h=function(e){var t=e.color,n=e.position,r=e.classes,a={root:["root","color".concat((0,D.Z)(t)),"position".concat((0,D.Z)(n))]};return(0,T.Z)(a,Be,r)}(m);return(0,p.jsx)(Ve,(0,r.Z)({square:!0,component:"header",ownerState:m,elevation:4,className:(0,S.Z)(h.root,o,"fixed"===d&&"mui-fixed"),ref:t},f))}));function $e(e){return(0,C.Z)("MuiToolbar",e)}(0,ee.Z)("MuiToolbar",["root","gutters","regular","dense"]);var Ge=["className","component","disableGutters","variant"],He=(0,M.ZP)("div",{name:"MuiToolbar",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,!n.disableGutters&&t.gutters,t[n.variant]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({position:"relative",display:"flex",alignItems:"center"},!n.disableGutters&&(0,_.Z)({paddingLeft:t.spacing(2),paddingRight:t.spacing(2)},t.breakpoints.up("sm"),{paddingLeft:t.spacing(3),paddingRight:t.spacing(3)}),"dense"===n.variant&&{minHeight:48})}),(function(e){var t=e.theme;return"regular"===e.ownerState.variant&&t.mixins.toolbar})),qe=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiToolbar"}),o=n.className,i=n.component,s=void 0===i?"div":i,l=n.disableGutters,u=void 0!==l&&l,c=n.variant,d=void 0===c?"regular":c,f=(0,w.Z)(n,Ge),m=(0,r.Z)({},n,{component:s,disableGutters:u,variant:d}),h=function(e){var t=e.classes,n={root:["root",!e.disableGutters&&"gutters",e.variant]};return(0,T.Z)(n,$e,t)}(m);return(0,p.jsx)(He,(0,r.Z)({as:s,className:(0,S.Z)(h.root,o),ref:t,ownerState:m},f))})),Ke=n(792),Qe=n(6702),Ye=n(2763);function Xe(e,t){return t||(t=e.slice(0)),Object.freeze(Object.defineProperties(e,{raw:{value:Object.freeze(t)}}))}function et(e,t){return et=Object.setPrototypeOf?Object.setPrototypeOf.bind():function(e,t){return e.__proto__=t,e},et(e,t)}var tt=e.createContext(null);function nt(t,n){var r=Object.create(null);return t&&e.Children.map(t,(function(e){return e})).forEach((function(t){r[t.key]=function(t){return n&&(0,e.isValidElement)(t)?n(t):t}(t)})),r}function rt(e,t,n){return null!=n[t]?n[t]:e.props[t]}function at(t,n,r){var a=nt(t.children),o=function(e,t){function n(n){return n in t?t[n]:e[n]}e=e||{},t=t||{};var r,a=Object.create(null),o=[];for(var i in e)i in t?o.length&&(a[i]=o,o=[]):o.push(i);var s={};for(var l in t){if(a[l])for(r=0;r<a[l].length;r++){var u=a[l][r];s[a[l][r]]=n(u)}s[l]=n(l)}for(r=0;r<o.length;r++)s[o[r]]=n(o[r]);return s}(n,a);return Object.keys(o).forEach((function(i){var s=o[i];if((0,e.isValidElement)(s)){var l=i in n,u=i in a,c=n[i],d=(0,e.isValidElement)(c)&&!c.props.in;!u||l&&!d?u||!l||d?u&&l&&(0,e.isValidElement)(c)&&(o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:c.props.in,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})):o[i]=(0,e.cloneElement)(s,{in:!1}):o[i]=(0,e.cloneElement)(s,{onExited:r.bind(null,s),in:!0,exit:rt(s,"exit",t),enter:rt(s,"enter",t)})}})),o}var ot=Object.values||function(e){return Object.keys(e).map((function(t){return e[t]}))},it=function(t){var n,a;function o(e,n){var r,a=(r=t.call(this,e,n)||this).handleExited.bind(function(e){if(void 0===e)throw new ReferenceError("this hasn't been initialised - super() hasn't been called");return e}(r));return r.state={contextValue:{isMounting:!0},handleExited:a,firstRender:!0},r}a=t,(n=o).prototype=Object.create(a.prototype),n.prototype.constructor=n,et(n,a);var i=o.prototype;return i.componentDidMount=function(){this.mounted=!0,this.setState({contextValue:{isMounting:!1}})},i.componentWillUnmount=function(){this.mounted=!1},o.getDerivedStateFromProps=function(t,n){var r,a,o=n.children,i=n.handleExited;return{children:n.firstRender?(r=t,a=i,nt(r.children,(function(t){return(0,e.cloneElement)(t,{onExited:a.bind(null,t),in:!0,appear:rt(t,"appear",r),enter:rt(t,"enter",r),exit:rt(t,"exit",r)})}))):at(t,o,i),firstRender:!1}},i.handleExited=function(e,t){var n=nt(this.props.children);e.key in n||(e.props.onExited&&e.props.onExited(t),this.mounted&&this.setState((function(t){var n=(0,r.Z)({},t.children);return delete n[e.key],{children:n}})))},i.render=function(){var t=this.props,n=t.component,r=t.childFactory,a=(0,w.Z)(t,["component","childFactory"]),o=this.state.contextValue,i=ot(this.state.children).map(r);return delete a.appear,delete a.enter,delete a.exit,null===n?e.createElement(tt.Provider,{value:o},i):e.createElement(tt.Provider,{value:o},e.createElement(n,a,i))},o}(e.Component);it.propTypes={},it.defaultProps={component:"div",childFactory:function(e){return e}};var st=it;var lt=function(t){var n=t.className,r=t.classes,a=t.pulsate,o=void 0!==a&&a,i=t.rippleX,s=t.rippleY,l=t.rippleSize,u=t.in,c=t.onExited,d=t.timeout,f=e.useState(!1),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=(0,S.Z)(n,r.ripple,r.rippleVisible,o&&r.ripplePulsate),b={width:l,height:l,top:-l/2+s,left:-l/2+i},_=(0,S.Z)(r.child,h&&r.childLeaving,o&&r.childPulsate);return u||h||v(!0),e.useEffect((function(){if(!u&&null!=c){var e=setTimeout(c,d);return function(){clearTimeout(e)}}}),[c,u,d]),(0,p.jsx)("span",{className:y,style:b,children:(0,p.jsx)("span",{className:_})})};var ut,ct,dt,pt,ft,mt,ht,vt,yt=(0,ee.Z)("MuiTouchRipple",["root","ripple","rippleVisible","ripplePulsate","child","childLeaving","childPulsate"]),bt=["center","classes","className"],gt=d(ft||(ft=ut||(ut=Xe(["\n  0% {\n    transform: scale(0);\n    opacity: 0.1;\n  }\n\n  100% {\n    transform: scale(1);\n    opacity: 0.3;\n  }\n"])))),_t=d(mt||(mt=ct||(ct=Xe(["\n  0% {\n    opacity: 1;\n  }\n\n  100% {\n    opacity: 0;\n  }\n"])))),wt=d(ht||(ht=dt||(dt=Xe(["\n  0% {\n    transform: scale(1);\n  }\n\n  50% {\n    transform: scale(0.92);\n  }\n\n  100% {\n    transform: scale(1);\n  }\n"])))),St=(0,M.ZP)("span",{name:"MuiTouchRipple",slot:"Root"})({overflow:"hidden",pointerEvents:"none",position:"absolute",zIndex:0,top:0,right:0,bottom:0,left:0,borderRadius:"inherit"}),kt=(0,M.ZP)(lt,{name:"MuiTouchRipple",slot:"Ripple"})(vt||(vt=pt||(pt=Xe(["\n  opacity: 0;\n  position: absolute;\n\n  &."," {\n    opacity: 0.3;\n    transform: scale(1);\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  &."," {\n    animation-duration: ","ms;\n  }\n\n  & ."," {\n    opacity: 1;\n    display: block;\n    width: 100%;\n    height: 100%;\n    border-radius: 50%;\n    background-color: currentColor;\n  }\n\n  & ."," {\n    opacity: 0;\n    animation-name: ",";\n    animation-duration: ","ms;\n    animation-timing-function: ",";\n  }\n\n  & ."," {\n    position: absolute;\n    /* @noflip */\n    left: 0px;\n    top: 0;\n    animation-name: ",";\n    animation-duration: 2500ms;\n    animation-timing-function: ",";\n    animation-iteration-count: infinite;\n    animation-delay: 200ms;\n  }\n"]))),yt.rippleVisible,gt,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.ripplePulsate,(function(e){return e.theme.transitions.duration.shorter}),yt.child,yt.childLeaving,_t,550,(function(e){return e.theme.transitions.easing.easeInOut}),yt.childPulsate,wt,(function(e){return e.theme.transitions.easing.easeInOut})),Ct=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiTouchRipple"}),i=o.center,s=void 0!==i&&i,l=o.classes,u=void 0===l?{}:l,c=o.className,d=(0,w.Z)(o,bt),f=e.useState([]),m=(0,g.Z)(f,2),h=m[0],v=m[1],y=e.useRef(0),b=e.useRef(null);e.useEffect((function(){b.current&&(b.current(),b.current=null)}),[h]);var _=e.useRef(!1),k=e.useRef(null),C=e.useRef(null),T=e.useRef(null);e.useEffect((function(){return function(){clearTimeout(k.current)}}),[]);var x=e.useCallback((function(e){var t=e.pulsate,n=e.rippleX,r=e.rippleY,a=e.rippleSize,o=e.cb;v((function(e){return[].concat((0,j.Z)(e),[(0,p.jsx)(kt,{classes:{ripple:(0,S.Z)(u.ripple,yt.ripple),rippleVisible:(0,S.Z)(u.rippleVisible,yt.rippleVisible),ripplePulsate:(0,S.Z)(u.ripplePulsate,yt.ripplePulsate),child:(0,S.Z)(u.child,yt.child),childLeaving:(0,S.Z)(u.childLeaving,yt.childLeaving),childPulsate:(0,S.Z)(u.childPulsate,yt.childPulsate)},timeout:550,pulsate:t,rippleX:n,rippleY:r,rippleSize:a},y.current)])})),y.current+=1,b.current=o}),[u]),P=e.useCallback((function(){var e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{},t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},n=arguments.length>2?arguments[2]:void 0,r=t.pulsate,a=void 0!==r&&r,o=t.center,i=void 0===o?s||t.pulsate:o,l=t.fakeElement,u=void 0!==l&&l;if("mousedown"===(null==e?void 0:e.type)&&_.current)_.current=!1;else{"touchstart"===(null==e?void 0:e.type)&&(_.current=!0);var c,d,p,f=u?null:T.current,m=f?f.getBoundingClientRect():{width:0,height:0,left:0,top:0};if(i||void 0===e||0===e.clientX&&0===e.clientY||!e.clientX&&!e.touches)c=Math.round(m.width/2),d=Math.round(m.height/2);else{var h=e.touches&&e.touches.length>0?e.touches[0]:e,v=h.clientX,y=h.clientY;c=Math.round(v-m.left),d=Math.round(y-m.top)}if(i)(p=Math.sqrt((2*Math.pow(m.width,2)+Math.pow(m.height,2))/3))%2===0&&(p+=1);else{var b=2*Math.max(Math.abs((f?f.clientWidth:0)-c),c)+2,g=2*Math.max(Math.abs((f?f.clientHeight:0)-d),d)+2;p=Math.sqrt(Math.pow(b,2)+Math.pow(g,2))}null!=e&&e.touches?null===C.current&&(C.current=function(){x({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})},k.current=setTimeout((function(){C.current&&(C.current(),C.current=null)}),80)):x({pulsate:a,rippleX:c,rippleY:d,rippleSize:p,cb:n})}}),[s,x]),E=e.useCallback((function(){P({},{pulsate:!0})}),[P]),A=e.useCallback((function(e,t){if(clearTimeout(k.current),"touchend"===(null==e?void 0:e.type)&&C.current)return C.current(),C.current=null,void(k.current=setTimeout((function(){A(e,t)})));C.current=null,v((function(e){return e.length>0?e.slice(1):e})),b.current=t}),[]);return e.useImperativeHandle(n,(function(){return{pulsate:E,start:P,stop:A}}),[E,P,A]),(0,p.jsx)(St,(0,r.Z)({className:(0,S.Z)(yt.root,u.root,c),ref:T},d,{children:(0,p.jsx)(st,{component:null,exit:!0,children:h})}))})),Tt=Ct;function xt(e){return(0,C.Z)("MuiButtonBase",e)}var Pt,Et=(0,ee.Z)("MuiButtonBase",["root","disabled","focusVisible"]),At=["action","centerRipple","children","className","component","disabled","disableRipple","disableTouchRipple","focusRipple","focusVisibleClassName","LinkComponent","onBlur","onClick","onContextMenu","onDragLeave","onFocus","onFocusVisible","onKeyDown","onKeyUp","onMouseDown","onMouseLeave","onMouseUp","onTouchEnd","onTouchMove","onTouchStart","tabIndex","TouchRippleProps","touchRippleRef","type"],Nt=(0,M.ZP)("button",{name:"MuiButtonBase",slot:"Root",overridesResolver:function(e,t){return t.root}})((Pt={display:"inline-flex",alignItems:"center",justifyContent:"center",position:"relative",boxSizing:"border-box",WebkitTapHighlightColor:"transparent",backgroundColor:"transparent",outline:0,border:0,margin:0,borderRadius:0,padding:0,cursor:"pointer",userSelect:"none",verticalAlign:"middle",MozAppearance:"none",WebkitAppearance:"none",textDecoration:"none",color:"inherit","&::-moz-focus-inner":{borderStyle:"none"}},(0,_.Z)(Pt,"&.".concat(Et.disabled),{pointerEvents:"none",cursor:"default"}),(0,_.Z)(Pt,"@media print",{colorAdjust:"exact"}),Pt)),Ft=e.forwardRef((function(t,n){var o=(0,a.Z)({props:t,name:"MuiButtonBase"}),i=o.action,s=o.centerRipple,l=void 0!==s&&s,u=o.children,c=o.className,d=o.component,f=void 0===d?"button":d,m=o.disabled,h=void 0!==m&&m,v=o.disableRipple,y=void 0!==v&&v,b=o.disableTouchRipple,_=void 0!==b&&b,k=o.focusRipple,C=void 0!==k&&k,x=o.LinkComponent,P=void 0===x?"a":x,E=o.onBlur,A=o.onClick,N=o.onContextMenu,F=o.onDragLeave,O=o.onFocus,R=o.onFocusVisible,D=o.onKeyDown,M=o.onKeyUp,I=o.onMouseDown,z=o.onMouseLeave,L=o.onMouseUp,Z=o.onTouchEnd,j=o.onTouchMove,B=o.onTouchStart,W=o.tabIndex,J=void 0===W?0:W,V=o.TouchRippleProps,U=o.touchRippleRef,$=o.type,G=(0,w.Z)(o,At),H=e.useRef(null),q=e.useRef(null),K=(0,Ke.Z)(q,U),Q=(0,Ye.Z)(),Y=Q.isFocusVisibleRef,X=Q.onFocus,ee=Q.onBlur,te=Q.ref,ne=e.useState(!1),re=(0,g.Z)(ne,2),ae=re[0],oe=re[1];h&&ae&&oe(!1),e.useImperativeHandle(i,(function(){return{focusVisible:function(){oe(!0),H.current.focus()}}}),[]);var ie=e.useState(!1),se=(0,g.Z)(ie,2),le=se[0],ue=se[1];e.useEffect((function(){ue(!0)}),[]);var ce=le&&!y&&!h;function de(e,t){var n=arguments.length>2&&void 0!==arguments[2]?arguments[2]:_;return(0,Qe.Z)((function(r){return t&&t(r),!n&&q.current&&q.current[e](r),!0}))}e.useEffect((function(){ae&&C&&!y&&le&&q.current.pulsate()}),[y,C,ae,le]);var pe=de("start",I),fe=de("stop",N),me=de("stop",F),he=de("stop",L),ve=de("stop",(function(e){ae&&e.preventDefault(),z&&z(e)})),ye=de("start",B),be=de("stop",Z),ge=de("stop",j),_e=de("stop",(function(e){ee(e),!1===Y.current&&oe(!1),E&&E(e)}),!1),we=(0,Qe.Z)((function(e){H.current||(H.current=e.currentTarget),X(e),!0===Y.current&&(oe(!0),R&&R(e)),O&&O(e)})),Se=function(){var e=H.current;return f&&"button"!==f&&!("A"===e.tagName&&e.href)},ke=e.useRef(!1),Ce=(0,Qe.Z)((function(e){C&&!ke.current&&ae&&q.current&&" "===e.key&&(ke.current=!0,q.current.stop(e,(function(){q.current.start(e)}))),e.target===e.currentTarget&&Se()&&" "===e.key&&e.preventDefault(),D&&D(e),e.target===e.currentTarget&&Se()&&"Enter"===e.key&&!h&&(e.preventDefault(),A&&A(e))})),Te=(0,Qe.Z)((function(e){C&&" "===e.key&&q.current&&ae&&!e.defaultPrevented&&(ke.current=!1,q.current.stop(e,(function(){q.current.pulsate(e)}))),M&&M(e),A&&e.target===e.currentTarget&&Se()&&" "===e.key&&!e.defaultPrevented&&A(e)})),xe=f;"button"===xe&&(G.href||G.to)&&(xe=P);var Pe={};"button"===xe?(Pe.type=void 0===$?"button":$,Pe.disabled=h):(G.href||G.to||(Pe.role="button"),h&&(Pe["aria-disabled"]=h));var Ee=(0,Ke.Z)(te,H),Ae=(0,Ke.Z)(n,Ee);var Ne=(0,r.Z)({},o,{centerRipple:l,component:f,disabled:h,disableRipple:y,disableTouchRipple:_,focusRipple:C,tabIndex:J,focusVisible:ae}),Fe=function(e){var t=e.disabled,n=e.focusVisible,r=e.focusVisibleClassName,a=e.classes,o={root:["root",t&&"disabled",n&&"focusVisible"]},i=(0,T.Z)(o,xt,a);return n&&r&&(i.root+=" ".concat(r)),i}(Ne);return(0,p.jsxs)(Nt,(0,r.Z)({as:xe,className:(0,S.Z)(Fe.root,c),ownerState:Ne,onBlur:_e,onClick:A,onContextMenu:fe,onFocus:we,onKeyDown:Ce,onKeyUp:Te,onMouseDown:pe,onMouseLeave:ve,onMouseUp:he,onDragLeave:me,onTouchEnd:be,onTouchMove:ge,onTouchStart:ye,ref:Ae,tabIndex:h?-1:J,type:$},Pe,G,{children:[u,ce?(0,p.jsx)(Tt,(0,r.Z)({ref:K,center:l},V)):null]}))})),Ot=Ft;function Rt(e){return(0,C.Z)("MuiIconButton",e)}var Dt=(0,ee.Z)("MuiIconButton",["root","disabled","colorInherit","colorPrimary","colorSecondary","edgeStart","edgeEnd","sizeSmall","sizeMedium","sizeLarge"]),Mt=["edge","children","className","color","disabled","disableFocusRipple","size"],It=(0,M.ZP)(Ot,{name:"MuiIconButton",slot:"Root",overridesResolver:function(e,t){var n=e.ownerState;return[t.root,"default"!==n.color&&t["color".concat((0,D.Z)(n.color))],n.edge&&t["edge".concat((0,D.Z)(n.edge))],t["size".concat((0,D.Z)(n.size))]]}})((function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({textAlign:"center",flex:"0 0 auto",fontSize:t.typography.pxToRem(24),padding:8,borderRadius:"50%",overflow:"visible",color:(t.vars||t).palette.action.active,transition:t.transitions.create("background-color",{duration:t.transitions.duration.shortest})},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette.action.activeChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette.action.active,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}},"start"===n.edge&&{marginLeft:"small"===n.size?-3:-12},"end"===n.edge&&{marginRight:"small"===n.size?-3:-12})}),(function(e){var t=e.theme,n=e.ownerState;return(0,r.Z)({},"inherit"===n.color&&{color:"inherit"},"inherit"!==n.color&&"default"!==n.color&&(0,r.Z)({color:(t.vars||t).palette[n.color].main},!n.disableRipple&&{"&:hover":{backgroundColor:t.vars?"rgba(".concat(t.vars.palette[n.color].mainChannel," / ").concat(t.vars.palette.action.hoverOpacity,")"):(0,pe.Fq)(t.palette[n.color].main,t.palette.action.hoverOpacity),"@media (hover: none)":{backgroundColor:"transparent"}}}),"small"===n.size&&{padding:5,fontSize:t.typography.pxToRem(18)},"large"===n.size&&{padding:12,fontSize:t.typography.pxToRem(28)},(0,_.Z)({},"&.".concat(Dt.disabled),{backgroundColor:"transparent",color:(t.vars||t).palette.action.disabled}))})),zt=e.forwardRef((function(e,t){var n=(0,a.Z)({props:e,name:"MuiIconButton"}),o=n.edge,i=void 0!==o&&o,s=n.children,l=n.className,u=n.color,c=void 0===u?"default":u,d=n.disabled,f=void 0!==d&&d,m=n.disableFocusRipple,h=void 0!==m&&m,v=n.size,y=void 0===v?"medium":v,b=(0,w.Z)(n,Mt),g=(0,r.Z)({},n,{edge:i,color:c,disabled:f,disableFocusRipple:h,size:y}),_=function(e){var t=e.classes,n=e.disabled,r=e.color,a=e.edge,o=e.size,i={root:["root",n&&"disabled","default"!==r&&"color".concat((0,D.Z)(r)),a&&"edge".concat((0,D.Z)(a)),"size".concat((0,D.Z)(o))]};return(0,T.Z)(i,Rt,t)}(g);return(0,p.jsx)(It,(0,r.Z)({className:(0,S.Z)(_.root,l),centerRipple:!0,focusRipple:!h,disabled:f,ref:t,ownerState:g},b,{children:s}))})),Lt=n(2156),Zt=n(5129);n(8472),(0,H.Z)({palette:{neutral:{main:"#fff",contrastText:"#000"}}});function jt(e){var t=e.datumNumber,n=e.setDatumNumber,r=e.numComparisons,a=(e.outputData,e.batchNum),o=function(){n(t-1)},i=function(){n(t+1)};return(0,p.jsx)(K,{sx:{flexGrow:1},children:(0,p.jsx)(Ue,{position:"static",children:(0,p.jsxs)(qe,{children:[(0,p.jsxs)(Fe,{component:"div",variant:"h6",sx:{flexGrow:1},children:["Compare Trial Versions for Batch ",a]}),(0,p.jsxs)(Fe,{component:"div",children:[t>0?(0,p.jsx)(zt,{color:"inherit",variant:"text",onClick:o,children:(0,p.jsx)(Lt.Z,{})}):null,t<r-1?(0,p.jsx)(zt,{color:"inherit",variant:"text",onClick:i,children:(0,p.jsx)(Zt.Z,{})}):null]})]})})})}for(var Bt=JSON.parse('{"1":"Add endpoint to composite endpoint","2":"Add endpoint","3":"Change endpoint","4":"Change endpoint, add endpoint","5":"Change in endpoint in a composite endpoint","6":"Change method of analysis","7":"Change number of events","8":"Change population","9":"Change readers","10":"Change timepoint","11":"Error","12":"From nothing to something","13":"Refine definition","14":"Remove endpoint","15":"Shuffle Endpoints","16":"Syntax","":""}'),Wt=[],Jt=Q.e,Vt=Q.C,Ut=Vt.length,$t=0;$t<Ut;$t++)Wt.push("");var Gt=function(){var t=(0,e.useState)(0),n=(0,g.Z)(t,2),r=n[0],a=n[1],o=(0,e.useState)(Vt[r]),i=(0,g.Z)(o,2),s=i[0],l=i[1],u=(0,e.useState)(Wt),c=(0,g.Z)(u,2),d=c[0],f=c[1],m=(0,e.useState)([]),h=(0,g.Z)(m,2),v=h[0],y=h[1];return(0,e.useEffect)((function(){l(Vt[r])}),[r]),(0,e.useEffect)((function(){for(var e=[],t=0;t<Ut;t++){var n={};n.nctid=Vt[t].nctid,n.version_a=Vt[t].version_a,n.version_b=Vt[t].version_b,n.classification_number=d[t],n.classification_meaning=Bt[d[t]],e.push(n)}y(e)}),[d]),(0,p.jsxs)(e.Fragment,{children:[(0,p.jsx)(jt,{datumNumber:r,setDatumNumber:a,numComparisons:Ut,outputData:v,batchNum:Jt}),(0,p.jsx)(z,{children:(0,p.jsx)(K,{sx:{flexGrow:1,m:1},children:(0,p.jsx)(je,{datum:s,datumNumber:r,results:d,setResults:f})})})]})};t.createRoot(document.getElementById("root")).render((0,p.jsxs)(e.StrictMode,{children:[(0,p.jsx)(b,{}),(0,p.jsx)(Gt,{})]}))}()}();
//# sourceMappingURL=main.2d932019.js.map